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Abstract 
 
Nowadays there’s a growing interest in biologically active peptides for the 
development of new therapeutics; however in some cases, they could not directly use 
as drugs, due to their inherent limitations, such as rapid metabolism and low oral 
activity. As a result, peptides are modified into peptidomimetics with specific 
characteristics, in a rational design. 
The present PhD project is focused on the synthesis of several peptides and 
peptidomimetics, structurally different and presenting individual features, properties, 
targets and pharmaceutical applications. In particular, two are the research studies 
we’ve developed during the three years, these are the design of novel Carnosine-like 
derivatives and of new Farnesyl Transferase Inhibitors (FTIs). 
Concerning the first topic, we investigated how Carnosine (β-alanyl-L-histidine) 
structural changes influence its role as scavenger of HNE (4-hydroxy-trans-2,3-
nonenal) and other toxic aldehydes.  
For this reason we modified the carnosine structure firstly replacing the Hystidinil- 
portion with different aromatic system, secondly substituting the β-alanyl portion with 
ten different amino acids, chosen in order to cover exhaustively the available chemical 
space. Finally we rigidified the whole structure, inserting a 2-oxazolidinone; the entire 
compound underwent biological evaluation, testing their ability to quench HNE.  
As a result, some of the twenty dipeptides showed impressing scavenging activities 
and great selectivity towards toxic aldehydes, suggesting us that they can represent 
truly promising candidates for the design of improved carnosine derivatives.  
Regarding the second subject, we designed, synthesized and tested several 
peptidomimetics of the CAAX box, where CAAX is the sequence Cysteine-Valine-
Isoleucine-Methionine, able to block the farnesylation of RAS proteins and therefore 
cell proliferation.  
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The design started from a nanomolar range FTI, previously synthesized by our group, 
where the central dipeptide (AA) is replaced with a 4-amino-2-o-tolylbenzoyl spacer and 
the Cysteine (C) with the residue 2-amino-4-thiazolylacetyl. The synthesis of the novel 
FTIs followed two separate approaches; at first we kept the aromatic spacer and 
modified the N-terminal residue with other heterocycles; the unimproved 
antiproliferative activity suggested us to apply other kind of modification. Therefore we 
replaced the o-tolyl with six heteroaromatic residues, in addition the synthesized 
compounds presented, as N- terminal residue, the 2-amino-4-thiazolylacetyl itself or 
the 1,4-benzodioxan-2-ylmethyl or the 1,4-benzodioxan-2-ylformyl. In all the three 
series of compounds, the 2-thienyl, 1-naphtyl and the 3-furanyl derivatives showed the 
highest FTase inhibition, at low micromolar level. 
Taken together, our biological activities provide interesting results, confirming 
that peptides and peptidomimetics should be employed as therapeutics. 
 
 
Carnosine-like derivatives                                                                                  Introduction 
3 
 
 
Chapter 1: Carnosine 
 
 Carnosine (L-Car; β-alanyl-L-histidine) is an endogenous dipeptide widely and 
abundantly distributed in the muscle and nervous tissues of several animal species. 
It was discovered more than a century ago by the Russian scientists Gulewitsch and 
Amiradzibi: it was extracted for the first time from Liebigs in 1900, becoming the first 
ever peptide isolated from animal tissue1.  
 Carnosine is the best known representative of a series of imidazole dipeptides 
such as homocarnosine (γ-aminobutyryl-L-histidine) (Figure 2), Anserine (β-alanyl-N-π-
methyl-L-histidine) and Balenine (β-alanyl-N-τ-methyl-L-histidine), which have long been 
reported to be present at high concentrations in skeletal muscle and in the central 
nervous system of vertebrates (Figure 1). 
Specifically, the β alanyl containing peptides are mainly found in skeletal muscle, 
whereas the γ-aminobutyryl containing peptides are typical of the central nervous 
system, probably due to the availability of its precursor γ-aminobutyric acid in this 
tissue.  
 
Figure 1: Naturally occurring histidine-containing dipeptides 
 
Figure 2: Homocarnosine 
                                                            
1 Gulewitch, W., and Admiradzibi, S. , 1900, Ber. Deutsch. Chem. Ges,. 33, 1902–1903; 
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 The concentration of Carnosine in skeletal muscle of vertebrates varies 
according to the species, from 0.6 mM in mice up to 10 and 30 mM in humans and 
horses, respectively2.  
However, the dipeptide is also present at high concentrations (1–2 mM) in the 
olfactory bulb of the mammalian brain and has been detected in muscles of some 
invertebrates such as crabs, shrimp, and oysters3.  
Homocarnosine is detected at concentration of 0.3–1.5 mM in different regions of the 
human brain4.  
Anserine is abundant in rabbit leg muscle (17mM) and chicken pectoral muscle (43 
mM), whereas balenine is mainly found in muscles of marine-mammals such as 
whales and dolphins (up to 45mM). 
 Carnosine homeostasis is regulated by (1) the rate and magnitude of β-alanine 
uptake within muscle fibres, (2) serum biosynthesis and, in the absence of sufficient β-
alanine within the diet, (3) hepatic synthesis of the amino acid and its transport to 
skeletal muscle. 
Specific enzymes are involved in Carnosine synthesis and degradation; in particular 
Carnosine is known to be synthesized from β-alanine and L-histidine by an ATP-
dependent synthase (EC 6.3.2.11), which has been purified from different sources 5 
and is shown to also catalyze the synthesis of homocarnosine (Figure 2).  
 
The synthesis, here reported, consists of two different steps: 
1. β-Alanine + ATP + Enzyme + Mg2+     Enzyme-β-alanyl adenylate + pyrophosphate 
2. Enzyme-β-alanyl adenylate + L-histidine        AMP + Enzyme + L-Carnosine 
 Reaction 1 is a Mg2+-dependent α-amino acid activation, bringing to the 
intermediate β-alanyl adenylate; some support for the involvement of pyrophosphate 
was the strong inhibition produced by this compound on β-alanyl peptide synthesis 
with crude enzyme. 
                                                            
2 Crush, K. G.,1970, Comp. Biochem. Physiol., 34, 3–30; 
3 Cameron, J. N., 1989, J. Exp. Biol., 143, 543–548; Boldyrev, A. A. , 2007, Carnosine and Oxidative 
Stress in Cells and Tissues, Nova Scientific Publisher, New York; 
4 Kish, S. J., Perry, T. L., and Hansen, S., 1979, J. Neurochem., 32, 1629 –1636, 
5 Kalyankar, G. D., and Meister, A., 1959, J. Biol. Chem., 234, 3210–3218; Stenesh, J. J., and Winnick, 
T., 1960, Biochem. J., 77, 575–581; Skaper, S. D., Das, S., and Marshall, F. D., 1973, J. Neurochem., 
21, 1429–1445; Horinishi, H., Grillo, M., and Margolis, F. L., 1978, J. Neurochem., 31,909–919; Drozak 
J. Et all, 2010, J Biol Chem, 285, 9346-9356; 
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An excess of adenosine 5'-phosphate (AMP) also depressed Carnosine formation, 
moreover ADP exerted an even stronger effect. (Figure 3).  
Reaction 2, differently from Reaction1, does not require added magnesium ions. 
 
Figure 3: 
Effect of phosphate compounds on Carnosine synthase activity. The values are in terms of standard assay 
conditions, with 2 mm-ATP present. (○: Pyrophosphate; ▲: orthophosphate; □: AMP; ■: ADP). 
 
 Carnosine degradation is performed by two proteins, named carnosinases, all 
belonging to the large family of metalloproteases, identified and characterized a few 
years ago6. 
Two novel cDNAs code for two proteins of 56.8 and 52.7 kDa, named CN1 and CN2 
respectively: whereas human CN1 mRNA and protein are brain-specific, CN2 codes for 
a ubiquitous protein. 
 CN1, a pure human carnosinase, was identified as homodimeric dipeptidase (EC 
3.4.13.20) with a narrow substrate specificity for Xaa-His dipeptides, including those 
with Xaa = β-Ala (Carnosine, Km 1.2 mM), N-methyl β-Ala, Ala, Gly, and γ-aminobutyric 
acid (homocarnosine, Km 200 µM), having an isoelectric point of pH 4.5 and maximal 
activity at pH 8.5. Interestingly, deficiency of this enzyme leads to hypercarnosinemia 
and hypercarnosinuria and was associated with neurological symptoms7. 
 CN2, the cytosolic nonspecific protein, (EC 3.4.13.18) is a dipeptidase not limited 
to Xaa-His dipeptides, it requires Mn2+ for full activity, and it is sensitive to inhibition by 
bestatin (IC50 7 nM). This enzyme does not degrade homocarnosine and hydrolyzes 
Carnosine only at alkaline pH with an optimum at pH 9.5.   
                                                            
6 Teufel, M. et all, 2003, J. Biol. Chem., 278, 6521–6531; 
7 Murphey, W. H., Lindmark, D. G., Patchen, L. I., Housler, M. E., Harrod,E. K., and Mosovich, L., 1973, 
Pediatr. Res. 7, 601–606; Willi, S. M., Zhang, Y., Hill, J. B., Phelan, M. C., Michaelis, R. C., and Holden, K. 
R., 1997, Pediatr. Res. 41, 210–213 
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Carnosine roles 
 
In the latest years, thanks to a large number of works and studies, several roles of L-
Carnosine have been postulated; it is now well known that it is related to: 
 Intracellular buffering; 
 Ergogenic aid; 
 Cell senescence; 
 Neurotransmission; 
 Glycation; 
 
 
 
 
 
 
Carnosine as intracellular buffer 
Intracellular buffering is provided mainly by bicarbonate, phosphates and 
proteins, nevertheless a part may also be played by free histidine and small peptides 
containing histidine.  
Although the free histidine content in the majority of animal tissues is low, a 
variety have been found to possess substantial amounts of histidine-containing 
dipeptides, most commonly β-alanyl-L-histidine, actually L-Carnosine, either without 
substitutions or methylated at the 1-position, as in the case of Anserine, or at the 3-
position, for instance Ophidine or Balenine. At 25°C the pK of Carnosine is 6.83 
whereas that of anserine is 7.04, so the combination of appropriate pK and high 
concentration leads to significant intracellular buffer action.  
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Carnosine in ergogenic aid 
 As people exercise to voluntary failure, multiple mechanisms (psychological, 
neurological, metabolic, etc.) may undermine performance.  
Since Carnosine is an intramuscular compound, it is important to examine how 
conditions within cells, as exercise, progress to the point of fatigue. In the quest for 
sufficient ATP, perhaps the greatest exercise-induced intracellular change is the rapid 
accrual of lactate and H+ that typifies metabolic acidosis (Figure 4:).  
 
Figure 4:  
Anaerobic glycolysis and ATP hydrolysis schematic; Carnosine buffers H+ increases 
 
Lactate and acid metabolites accrue commensurate to the degree by which 
intracellular aerobic capacity is exceeded, such as when anaerobic glycolysis serves as 
the primary ATP resynthesis pathway.  
At maximal exercise rates, such bouts last from 15 to 240 s, intramuscular 
glycolytic rates may rise 1000-fold as persons go from rest to supramaximal exercise. 
With supramaximal exercise, intracellular ATP declines up to 40% and causes a near 
complete depletion of phosphocreatine as well as elevations in lactate and H+. 
Intramuscular pH, from resting values of ~7.1, may decline from supramaximal activity 
to less than 6.5, which represents a four-fold rise in H+ and an intracellular increase of 
up to 54 mmol·kg−1.  
When such increases are added to other reactions that raise the total proton load 
intracellular H+ levels exceed 100 mmol·kg−1. Concomitant lactate increases also occur 
with higher glycolytic rates; intramuscular and plasma levels for the metabolite rise by 
up to 40 and 25 mmol·L−1.  
A strong linear relationship exists between muscle pH decrements and 
intracellular lactate and pyruvate values. Thus examinations of blood lactate changes 
over time, which quantify the rate of the metabolite’s entry into and removal from the 
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vasculature, foretell concurrent intracellular H+ changes in response to, and recovery 
from, exercise.  
Upon cessation of exercise, force output and intracellular pH restoration is rapid, yet 
the former recovers at a faster rate. For each measure, recovery is slower than their 
rate of loss incurred from supramaximal exercise.  
Adverse intracellular changes from H+ accrual include phosphofructokinase inhibition, 
impaired phosphocreatine resynthesis, slower cross bridge transitions from low- to 
high-force states, losses in maximal shortening velocity, lowered glycolytic rates, 
competitive inhibition with Ca2+ at the troponin C subunit, and delayed Ca2+ reuptake 
by the sarcoplasmic reticulum. Such changes compromise exercise and recovery rates, 
which is a concern if successive bouts of supramaximal activity are to occur. If 
contractions proceed at high force outputs, which are common to supramaximal 
exercise, high H+ levels also impair intramuscular Ca2+ release and compromise Ca2+-
ATPase activity.  
To deal with such conditions, cells utilize multiple mechanisms to remove 
lactate and H+, as well as buffers to mitigate the effects of metabolic acidosis.  
Lactate and H+ efflux is facilitated by monocarboxylate transporters such as MCT1 and 
MCT4.  
Unlike Carnosine, which appears to have no ceiling with respect to its intramuscular 
concentration, other intracellular buffers such as proteins, bicarbonates, citrates and 
NAD+-dependent redox reactions, are under tight homeostatic control.  
In untrained persons, Carnosine typically adds a mere 7%–10% to their intracellular 
buffering capacity and neutralizes 2.4–10.1 mmol H+·kg−1 dry mass as intramuscular 
pH declines. Nevertheless, during exercise-induced metabolic acidosis, Carnosine is 
particularly effective as an H+ acceptor, due to its imidazole ring and a concomitant 
shift in its pKa to 6.83, which is rare for intracellular buffers and vital to maintain pH.  
Unlike most buffers, Carnosine is potent over a broad pH range in type I and II 
muscle fibres from the rapid and substantial accrual of intracellular H+ and lactate. 
Carnosine levels range from 4 to 7 and 9 to 13 mM within type I and II fibres 
respectively.  
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Since buffer capacity (β) is a quantitative index of the resistance of a buffer solution to 
change pH upon added H+, its formula is as follows: 
β= (∆n)/ (∆pH) 
where ∆n represents the incremental additions of proton equivalents to a buffered 
system and ∆pH is the observed pH changes.  
This equation is commonly known as the buffer derivative, in which pH (i.e., 
−log10[H+]) is expressed as [H+] and where the β in the presence of a neutralizing 
agent with an acid dissociation constant represented by Ka, is defined as: 
β= 2.303 ( 

[]
+ [H+] + 
	
[] 
  []
 ) 
It is important to note, for near neutral pH’s, the first (Kw/ [H+]) and second ([H+]) 
terms do not contribute significantly to Carnosine’s prowess as a buffer.  
β can be calculated at pH = 7.1 for a lower limit of 4 × 10−3 M Carnosine in type I 
fibres to have a buffer capacity of 9.1 × 10–4.  
At pH = 7.1 for Carnosine measured at the higher range found in type II fibres, i.e., at 
13 × 10−3 M, the buffer capacity rises to 2.95 × 10−3, approximately a 3.2-fold 
increase.  
At a pH of 6.5, the 4 mM Carnosine only slightly changes to 8.7 × 10−4, and for the 13 
mM Carnosine to 2.8 × 10−3. Thus as pH declines from 7.1 to 6.5 in exercising muscle, 
Carnosine’s buffer capacity is well preserved in type I and II fibres.  
Carnosine’s ability to absorb protons is well maintained over a substantial pH range 
and makes it a unique and real valuable molecule.   
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Carnosine and cell senescence 
 Carnosine has been implicated as an anti-ageing agent for different reasons8: 
(i) it can delay senescence in cultured human fibroblasts,  
(ii) it can reverse the senescent phenotype in cultured human cells and preserve a 
juvenile phenotype in cultured rodent cells;  
(iii) it is present in long-lived mammalian tissues at surprisingly high concentrations  
(up to 20 mM in human muscle) which may decline with age; 
(iv) tissue levels in mammals appear to correlate directly with the maximum life-
span of the species.  
 Many proposals have been made regarding the cellular action of Carnosine 
including a role as an anti-oxidant and oxygen free radical scavenger, a physiological 
buffer, a histidine source and an immunostimulant.  
The anti-oxidant and oxygen free radical-scavenging activities of Carnosine have been 
demonstrated in many studies9. However, other anti-oxidants do not have the anti-
ageing actions on cultured human fibroblasts described by McFarland and Holliday 
suggesting that additional properties of the dipeptide are responsible for, or contribute 
to, these effects. More recent evidences show that Carnosine can react with low-
molecular-weight aldehydes and ketones indicating that it might also act as a naturally 
occurring anti-glycating agent10.  
  
                                                            
8 (a) Hipkiss A. R., 1998, Int. J. Biochem. Cell Biol., 30, 863–868; (b) McFarland G. A. and Holliday R., 
1994, Exp. Cell Res., 212, 167–175; (c) McFarland G. A. and Holliday R., 1999, Exp. Gerontol., 34, 35–
45; (d) Kantha S. S.et all, 1996, Biochem. Biophys. Res. Commun., 223, 278–282; (e) Johnson P., 
Fedyna J. S., Schindzielorz A., Smith C. M. and Kasvinshy P. J., 1982, Biochem. Biophys. Res. Commun., 
109, 769–775; (f) Stuenenburg H. J. and Kunze K., 1999, Arch. Gerontol. Geriatrics, 29, 107–113; (g) 
Hipkiss A. R., Holliday R., McFarland G. and Michaelis J.,1993, Lifespan, 4, 1–3; (h) Munch G., Thome J., 
Foley P., Schinzel R. and Riederer P., 1997, Brain Res. Rev., 23, 134–143; (i) Quinn P. R., Boldyrev A. A. 
and Formazuyk V. E., 1992, Mol. Aspects Med. 13: 379–444; 
9 (j) Kohen R., Yamamoto Y., Cundy K. C and Ames B. N., 1988, Proc. Natl. Acad. Sci.USA, 95, 2175–
2179; (k) Boldyrev A. A., Formazyuk V. E. and Sergienko V. I., 1994, Sov. Sci. Rev. D. Physicochem. Biol., 
13, 1–60; (l) Aruoma O. I., Laughton M. J. and Halliwell B. ,1989, Biochem. J., 264, 863–869; 
10 (m)Hipkiss A. R., Michaelis J., Syrris P., Kumar S. and Lam Y., 1994, Biochem. Soc. Trans., 22, 399S; 
(n) Hipkiss A. R., Michaelis J. and Syrris P., 1995, FEBS Lett., 371, 81–85; (o) Hipkiss A. R., Michaelis J., 
Syrris P. and Dreimanis M., 1995, Hum. Biol., 1, 59–70; 
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Carnosine as neurotransmitter11 
 The detection of high levels of Carnosine in the olfactory system of several 
mammalian species, including humans, and its specific localization in the olfactory 
receptor neurons, led to the hypothesis that the dipeptide could exert a putative role in 
neurotransmission within this sensory system.  
The olfactory receptor neurons (primary olfactory neurons) are typical bipolar neurons 
located among non-neuronal supporting cells in the olfactory neuroepithelium lining 
the nasal cavity. These receptor cells send their axon to the glomerular layer of the 
olfactory bulb, where they make synapses with the dendrites of mitral, tufted and 
periglomerular cells. 
Immunocytochemical studies carried out at both the light and electron microscopical 
level clearly showed that Carnosine is contained within these axons and in their 
synaptic terminals.  
 At present, the aminoacid glutamate is the main excitatory neurotransmitter 
candidate in several sensory systems, including the primary olfactory pathway. By 
using post-embedding immunogold techniques, the coexistence of Carnosine and 
glutamate has been demonstrated in the synaptic terminals of the mouse olfactory 
neurons, as well as in hair cells of the inner ear and photoreceptors of frogs.  
These data, along with the existence of Carnosine synthetase and Carnosinase 
activities in the olfactory bulb and mucosa (higher than in other brain regions or 
tissues) and of binding sites for Carnosine in the olfactory bulb, support the hypothesis 
for an unknown role of the dipeptide Carnosine in neuromodulation in glutamatergic 
sensory neurons.  
 Nevertheless, biochemical studies indicated that Carnosine is localized in the 
cytosol of the olfactory bulb and epithelium, not associated with synaptic vesicles; 
indeed, morphological studies carried out using high resolution techniques were not 
able to clearly show a high concentration of the dipeptide in synaptic vesicles. A 
calcium-dependent depolarization stimulated release of Carnosine has been shown in 
olfactory bulb synaptosomes and inward current responses have been induced in 
olfactory bulb cultured slices after application of Carnosine; however, it is known that 
                                                            
11 Bonfanti L., Peretto P., De Machis S., Fasolo A., 1999, Progress in Neurobiology; 59, 333-353; 
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Carnosine leaks out of tissue during preparation of synaptosomes or tissue slices and 
can also be released as a slow spontaneous process which is independent of 
depolarization. 
 Definitive physiological evidence for a role of this dipeptide in 
neurotransmission is at present unavailable. Indeed, in vivo studies have provided 
conflicting results. 
Direct injection of the dipeptide into the olfactory bulb glomerular layer of rabbits 
revealed an increase in frequency of evoked potentials within the first minute after 
injection12, but Carnosine applied by microiontophoresis in the rat olfactory bulb was 
mainly with-out effect on mitral cells.  
Similarly, Nicoll et all13 found no effect using in vitro preparations of the turtle and frog 
olfactory bulb. Finally, a glutamate receptor-mediated release of Carnosine and β-
alanine, dependent on elevated intracellular Ca2+, has been recently shown to occur in 
oligodendrocytes.   
                                                            
12 Gonzalez-Estrada, M.T., Freeman, W.J., 1980, Brain Res., 202, 373-386; 
13 Nicoll, R.A., Alger, B.E., Jahr, C.E., 1980, Proc. R. Soc. Lond. (B), 210, 133-149; 
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Carnosine as glycating agent 
 Reactive carbonyl species (RCS) are electrophilic molecules which react with 
nucleophilic groups in proteins, yielding oxidative-based non-enzymatic protein 
adducts. These covalent adducts can be subdivided into two major classes, depending 
on the source of the reactive species.  
Advanced glycation end products (AGEs) are generated by sugars or sugar derivatives 
including dicarbonyl derivatives such as glyoxal (GO), methylglyoxal (MGO), 
malondialdehyde (MDA) and desoxyglucasone, while lipid-oxidation end products 
(ALEs) are formed from the oxidative reactions of lipids comprising α,β-unsaturated 
carbonyls such as 4-hydroxy-2-nonenal (HNE), 4-oxo-2-nonenal (ONE) and acrolein 
(ACR).  
AGEs and ALEs are involved in oxidative cellular damage through different 
mechanisms including protein dysfunction, protein oligomerization and fibrillogenesis, 
altered signal transduction, immune response and activation of the receptor for AGEs 
(RAGE) which is a type I transmembrane glycoprotein of the immunoglobulin 
superfamily of cell surface receptors. 
AGEs and ALEs have been widely accepted as biomarkers for oxidative-based 
diseases. Moreover, considering that AGEs and ALEs are involved in the pathogenesis 
of several diseases, including diabetes and arteriosclerosis, they are now also 
considered as promising targets for therapeutic intervention. This is promoting the 
design of carbonyl scavengers able to trap RCSs converting them into nontoxic and 
easily excretable derivatives so inhibiting protein carbonylation and all downstream 
pathways. 
 Although clinical investigations on humans are still very limited, several in vitro 
and in vivo animal studies demonstrated that Carnosine is able to detoxify RCS, 
inhibiting AGEs and ALEs formation and restraining oxidative-based diseases. The 
mechanism by which Carnosine prevents AGEs and ALEs formation is still under 
investigation and the involvement of multiple molecular mechanisms should be 
considered, given that the formation of AGEs and ALEs can involve different reactions 
and several catalysts including transition metals.  
Carnosine-like derivatives                                                                                  Introduction 
14 
Nevertheless, there is enough evidence to indicate that Carnosine acts by a direct 
quenching mechanism14; specifically, Carnosine reacts with α,β-unsaturated 
aldehydes through a multi-step mechanism involving the initial formation of a 
reversible unsaturated imino intermediate followed by the key intramolecular Michael 
addition between the histidine imidazole ring and the acceptor β-carbon atom (Figure 
5). 
 
Figure 5: Proposed reaction mechanism ofcarnosine with 4-hydroxy-trans-2,3-nonenal (HNE) 
 
 The imino intermediate acts as an intramolecular catalyst promoting a stable 
approach between the two reacting centers, this is confirmed also from the fact that a 
mixture of the two separate amino acids (βAla + L-His) does not possess a significant 
quenching activity.  
Similarly, the reversible nature of the imino intermediate can explain why Carnosine 
selectively quenches reactive α,β-unsaturated carbonyls without stably trapping 
physiological carbonyl compounds. 
 
                                                            
14 Aldini G, Carini M, Beretta G, Bradamante S, Maffei Facino R, 2002, Biochem Biophys Res Comm, 
298, 699-706; 
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Carnosine pharmacokinetics 
 
 In humans, diet represents the main source of Carnosine and histidine 
derivatives (HD), which are present in a significant amount in red and white meats.  
Following ingestion, dietary Carnosine is taken up by intestinal cells and readily 
absorbed intact.  
 The intestinal absorption is connected with H+/peptide cotransporter 1 (PEPT1) 
and human peptide/histidine transporter 1 (hPHT1). 
The high-affinity type H+/peptide cotransporter 2 (PEPT2) may be involved in the 
transport of CAR in the rat cerebellum, choroid plexus epithelial cells, astrocytes, 
cardiomyocytes and kidney. 
Moreover, PHT1, which may also mediate CAR transport, is observed throughout the 
whole brain; PEPT2 has been implicated in modulation of the disposition of exogenous 
CAR, but not in the homeostatic control of endogenous CAR levels in skeletal muscle15. 
 The enzymatic hydrolysis of the peptide bond represents the main metabolic fate 
of Carnosine, and it mainly occurs in the plasma by, as shown before, a specific serum 
hydrolase that cleaves the β-alanine–L-Histidine peptidic bond.  
The two hydrolyzed amino acids are then delivered to tissues and then again 
synthetized to Carnosine in those tissues characterized by the presence of Carnosine 
synthetase, such as skeletal muscle, heart and in some regions of the CNS16. 
 The ADME (Adsorption, Distribution, Metabolism, and Excretion) profile of 
Carnosine in humans is not fully elucidated, mainly due to the lack of specific and 
sensitive methods for their measurement in biological matrices as well as the scarcity 
of ADME studies in humans.  
Gardner17 first described the urinary and plasma profile of Carnosine and β-alanine in 
healthy volunteers, after ingesting 4 g of Carnosine, and using an ion-exchange amino 
acid analyzer with ninhydrin detection for β-alanine and Carnosine quantitation. The 
                                                            
15 Bhardwai RK, Herrera-Ruiz D, Eltoukhy N, Saad M, Knipp GT, 2006, Eur J Pharm Sci, 27, 533–542; 
Geissler S, Zwarg M, Knutter I, Markwardt F, Brandsch M , 2010, FEBS J, 277, 790–795; 
16 Aldini G, Facino RM, Beretta G, Carini M., 2005, Biofactors, 24, 77–87;  
17 Gardner ML, Illingworth KM, Kelleher J, Wood D , 1991, J Physiol, 439, 411–422; 
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amount of Carnosine recovered in urine was found to range from 1.2 to 14% of the 
ingested dose, while only small amounts of Carnosine were detected in the blood.  
In addition, it has alsobeen performed the HPLC of the plasma, studing Carnosine 
levels in healthy volunteers, following consumption of 200 g of ground beef (equivalent 
to a Carnosine dose of almost 250 mg).  
Carnosine was detected in plasma 15 min after beef consumption, and maximal 
concentration was recorded 2.5 h after consumption (Cmax 150 µM).  
More recently, the profile of histidine dipeptides in plasma and urine after ingesting 
beef, chicken, chicken broth or pure peptides in humans has been reported. 
A significant excretion of HD, and in particular of Anserine, was found in urine, despite 
the low and in many cases undetectable content of HD peptides in the serum18. 
 
                                                            
18 Park YJ, Volpe SL, Decker EA , 2005, J Agric Food Chem, 53, 4736–4739; Yeum KJ, Orioli M, 
Regazzoni L, Carini M, Rasmussen H, Russell RM, Aldini G , 2010, Amino Acids, 38, 847–858; 
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Carnosine: a novel therapeutic approach19 
 
 Many claims have been made about the therapeutic actions of Carnosine. These 
also include antihypertensive effects, as well as immunomodulating actions, wound 
healing and acting as an anti-inflammatory agent. 
It is also used in the treatment of acute spinal cord injury20; positive effects of 
Carnosine were also demonstrated on survival and learning ability of animals under 
ischemic injury21.  
In the context of neurodegenerative disorders, Carnosine has been suggested as an 
inhibitor of Amyloidβ toxicity in vitro. Moreover, it has been reported that Carnosine 
has a strong effect in restoring mitochondrial functioning and in counteracting amyloid 
pathology in triple-transgenic Alzheimer’s disease model mice.  
Very recently, a proteomic approach revealed that L-Carnosine affects tumor cell 
growth by causing an interference with protein folding/processing and HIF-1α signaling 
in gliobastomas. 
 The metal binding ability of Carnosine especially for copper (II) and zinc (II) ions 
has extensively been studied. The copper- and zinc-mediated neurotoxicity involved in 
several pathologies, such as amyotrophic lateral sclerosis, Alzheimer’s and 
Parkinson’s diseases might be reduced or prevented by endogenous metal-chelating 
agents, such as Carnosine itself.  
Recently, it has been also proven that polaprezinc, the zinc (II)–Carnosine complex, is 
effective for the recovery of ulcers and other lesions in the alimentary tract22. 
 The peptide nature of Carnosine imposes limitations in its therapeutical uses, 
mainly associated with the breakdown caused by the carnosinases.  
                                                            
19 Bellia F., Vecchio G., Rizzarelli E., 2012, Amino Acids, 43, 153-163 
20 Di Paola R, Impellizzeri D, Salinaro AT, Mazzon E, Bellia F, Cavallaro M, Cornelius C, Vecchio G, 
Calabrese V, Rizzarelli E, Cuzzocrea S, 2011, Biochem Pharmacol., doi:10.1016/j.bcp.2011.07.074; 
21 Dobrota D, Fedorova T, Stvolinsky S, Babusikova E, Likavcanova K, Drgova A, Strapkova A, Boldyrev A, 
2005, Neurochem Res, 30, 1283–1288; Gallant S, Kukley M, Stvolinsky S, Bulygina E, Boldyrev A, 
2000, Tohoku J Exp Med, 191, 85–99; 
22 Katayama S, Nishizawa K, Hirano M, Yamamura S, Momose Y, 2000, J Pharm Pharm Sci, 3, 114–
117; Matsukura T, Tanaka H., 2000, Biochemistry (Mosc), 65, 817–823; 
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 Several attempts have been made to overcome this limitation, essentially 
through the derivatization of Carnosine or the synthesis of its structural analogues23, 
but only N-acetyl Carnosine has been used as prodrug for some pharmaceutical 
applications. 
The conjugation of Carnosine with several types of organic molecules has the main 
purpose of reducing the carnosinase action on the peptide moiety, improving the 
multifunctional activity, because of the potential beneficial role of the conjugating 
moiety and the synergism with the peptide properties as well.  
Finally, the functionalized group could aim at the delivery to a specific target. 
 Another interesting consideration is that the enantiomer D-Carnosine (β-alanyl-D-
histidine, D-Car) has been reported as a very promising dipeptide, because it 
surprisingly maintains the same activity of L-enantiomer.  
In addition, D-Car is not hydrolyzed by Carnosinase, therefore an accettable 
concentration is maintained in the serum24.  
 D-Carnosine has a reasonable beneficial effect; however D-Car is less 
bioavailable than L-Car, because it is not recognized by hPepT1, a transporter 
responsible for the uptake of a broad array of small peptides in the colon.  
Nevertheless, increasing attention has been paid also on the functionalization of D-
Carnosine and several compounds have been produced with the aim of increasing 
itself bioavailability. 
 
                                                            
23 Guiotto A, Calderan A, Ruzza P, Borin G, 2005, Curr Med Chem,12, 2293–2315; 
24 Vistoli G, Orioli M, Pedretti A, Regazzoni L, Canevotti R, Negrisoli, G, Carini M, Aldini G, 2009, 
ChemMedChem, 4, 967–975; 
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Carnosine derivatives as new therapeutics: state of art 
 
The chemical modification of Carnosine is a very promising approach to realize 
therapeutic Carnosinase resistant molecules based on L-Carnosine, therefore a large 
number of Carnosine-like derivatives have been synthesized. 
Due to the way the structure has been modified, the possible derivatives could be 
classified in: 
A. Histidyl-containing Carnosine analogues bearing hydrazide or 1,2-diol moieties; 
B. Carnosine- derivatives, modified on the amino group; 
C. Carnosine-derivatives, modified at the carboxylic group; 
D. Double-functionalized Carnosine-derivatives; 
E. Ethylenic chain-modified Carnosine-derivatives; 
F. D-Carnosine derivatives. 
   
 
Histidyl-containing Carnosine analogues bearing hydrazide or 1,2-diol 
moieties25 
After the elucidation of the mechanism of Carnosine-α,β-unsaturated aldehyde adduct, 
explained before, and the consideration that the formation of the Schiff base is the 
rate-determinig step, Guiotto and co-workers decided to substitute the primary amine 
of β-alanine with different nucleophiles to produce carnosine analogues able to form 
more stable adducts with aldehydes. 
They focused on 1,2-diols, which react with carbonyls yielding cyclic acetals, and 
hydrazides, that are among the strongest aldehyde-sequestering moieties.  
                                                            
25 Guiotto A, Calderan A, Ruzza P, Borin G, 2005, Curr Med Chem,12, 2293–2315; 
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In addition, they placed the histidine residue at the C-terminus instead of the N-
terminus, in the attempt to avoid recognition by the specific enzyme Carnosinase 
(Figure 6). 
 
Figure 6:  
(2) L-histidylglycyl hydrazide, (3) N-acetyl-L-hystidylglycyl hydrazide, (4) 2-amino-N-(2,3-dihydroxypropyl)-3-(1H-
imidazol-4-yl)propionamide, (5) 2-acetylamino-N-(2,3-dihydroxypropyl)-3-(1H-imidazol-4-yl)propionamide, (6) L-
histidyl hydrazide 
 
In preliminary tests, performed using trans-2-nonenal as model (scavenger/aldehyde 
ratio 1:20), all the synthesized compounds formed stable adducts with the α,β-
unsaturated aldehyde.  
In particular, the hydrazides 2 (H-HisGly-NHNH2) and 6 (H-His-NHNH2) reacted almost 
completely, proving to be more efficient than Carnosine. 
Compounds 3 and 5 (2 and 4 N-acetyl derivatives) were far less reactive, suggesting a 
possible role as prodrugs. 
The 1,2-diol derivative 4 showed a slower reactivity, but eventually matched carnosine 
after 4 h.  
The efficacy of compound 6 was evidenced in two sets of experiments, showing that it 
is virtually nontoxic at concentrations as high as 1 mM, but has a strong cytoprotective 
activity toward SH-SY5Y neuroblastoma cells and rat hippocampal neurons treated 
with HNE.  
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Carnosine-like derivatives, modified on the amino group 
 
A wide number of Carnosine derivatives have been synthesized modifying the 
amino group of the dipeptide.  
As seen before, the presence of the primary amino group should be mandatory for the 
quenching towards RCS species. However, they could be recognized from hPepT1 
because the amino group has been tested not to be essential for the recognition of the 
transporter. 
These derivatives are reported here below (Figure 7). 
 
Figure 7: L-Carnosine derivatives at the amino group 
The amino group of carnosine has been modified, introducing: 
 Trolox, a well-known antioxidant compound (1R; 1S),  
 L-Dopa (2),  
 Cyclodextrins (3a, 3b, 3c, 4),  
 Trehalose, lactose and glucose (5, 6, 7); 
 4-Toluensulfonylureido (8).  
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The aim that has moved the synthesis of tha majority of these derivatives was the 
obtainment of Carnosinase-resistant compounds with antioxidant activity, considering 
that the antioxidant activity is generally due to carnosine moiety.  
The Carnosine derivatives with R and S-trolox, the water-soluble analog of 
alpha-tocopherol acylated derivatives [(S,S)-6-hydroxy-2,5,7,8-tetramethylchroman-2- 
carboxylic acid)], have been designed to exploit the cooperative effect of the beneficial 
activities showed by the constituents26.  
Several assays were performed in order to study the antioxidant activity of trolox 
conjugates: red blood cell hemolysis, DPPH, and lipoprotein oxidation. As a matter of 
fact, the conjugates generally show an average activity between those of trolox and 
carnosine. A higher quenching activity against the DPPH radical has been reported for 
the conjugates with respect to that of the constituents. In this assay, the 
enantioselective activity has been shown and the conjugate with R-trolox (1R) is more 
active than the epimer with S-trolox (1S). 
No hydrolysis by carnosinase in the human serum has been observed for these 
conjugates. The antioxidant effects of trolox conjugates have also been tested on the 
lifespan of the fruit fly, Drosophila melanogaster. The findings obtained in that study 
show that 1S is more active than carnosine. On the contrary, 1R is less active than the 
dipeptide. These data suggest the presence of additional cellular targets in 
comparison with simple neuronal cells to be acted upon by exposing D. Melanogaster 
to these compounds. 
L-Car has also been modified with L-Dopa (L-3,4-dihydroxyphenylalanine) with 
the aim of reducing the reactive oxygen species generated by the L-Dopa treatment in 
Parkinson’s disease27.  
The conjugate 2, designed as a potential prodrug for Parkinson’s disease, has not 
shown significant antioxidant activity in vivo. 
The third class of Carnosine derivatives are the glycoconjugates.  
Carnosine has been functionalized with β-cyclodextrin, in different positions of the 
sugar28. The pharmaceutical use of cyclodextrins is commonly used for their ability to 
                                                            
26 Stvolinsky SL, Bulygina ER, Fedorova TN, Meguro K, Sato T, Tyulina OV, Abe H, Boldyrev AA, 2010, Cell 
Mol Neurobiol,30, 395–404; 
27 Sozio P, Iannitelli A, Cerasa LS, Cacciatore I, Cornacchia C, Giorgioni G, Ricciutelli M, Nasuti C, 
Cantalamessa F, Di Stefano A, 2008, Arch Pharm (Weinheim),341, 412–417; 
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include and stabilize drugs; for this reason, several inclusion complexes are 
commercially available. This specific conjugation stabilizes the dipeptide to the 
carnosinase hydrolysis and confers a higher antioxidant activity than that of the 
natural dipeptide, as it has been found by the pulse radiolysis method. 
Other glycoconjugates with monosaccharides and disaccharides have been 
synthesized; in particular the trehalose derivative (5) has been accomplished to 
combine the properties of trehalose and Carnosine29. Trehalose is a sugar distributed 
in many living systems and used in cosmetics with protective and moisturising 
functions. Its ability to protect proteins against the denaturation process and 
conformational changes has been focused on and related to potential application in 
the treatment of Huntington’s disease. The carnosine trehalose conjugate has been 
tested in the LDL assay. 
As in the case of the cyclodextrin moiety, the trehalose increased the antioxidant 
properties and protected carnosine from the degradation by carnosinase. 
With the aim of selectively addressing Carnosine and its antioxidant function, 
glucose and lactose derivatives have been obtained (6, 7). An important physiological 
aim of the conjugation is to enhance the bioavailability of the dipeptide, by facilitating 
the site-specific transport to different tissues.  
In addition, the consideration that the animal lectins and galectins are important 
mediators in inflammatory diseases and that lectins play a key role in recognition 
processes, has prompted efforts in the syntheses of the glycoconjugates. 
As a result, these kinds of derivatives are stable to Carnosinases30. 
The conjugation of 4-Toluensulfonylureido to Carnosine has been performed, 
the resulting compound was tested as a target moiety for the delivery to tumor cells31. 
Compounds containing this aromatic moiety have been shown to act as anticancer 
agents for their ability to inhibit the carbonic anhydrase in tumor cells. 
4-Toluensulfonylureido carnosine (8) has been shown to be stable to serum 
carnosinase and to have good affinity for the hPetT1 transporter. However, its 
                                                                                                                                                                                    
28 La Mendola D, Rizzarelli E, Vecchio G, 2002, EP1176154; Bellia F, Amorini AM, La Mendola D, 
Vecchio G, Tavazzi B, Giardina B, Di Pietro V, Lazzarino G, Rizzarelli E, 2008, Eur J Med Chem, 43, 373–
380; Mineo P, Vitalini D, La Mendola D, Rizzarelli E, Scamporrino E, Vecchio G, 2004, J Inorg Biochem, 
98, 254–265; 
29 Rizzarelli E, Vecchio G, Lazzarino A, Amorini AM, Bellia F, 2007, EP1860116; 
30 Lanza V, Bellia F, D’Agata R, Grasso G, Rizzarelli E, Vecchio G, 2011, J Inorg Biochem,105, 181–188; 
31 Nielsen CU, Supuran CT, Scozzafava A, Frokjaer S, Steffansen B, Brodin B, 2002, Pharm Res, 19, 
1337–1344; 
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transepithelial transport was very low thus excluding such an application for carnosine 
tosylate. 
Nanoparticles (NPs) are a new class of carriers in nanomedicine, with special 
applications in the case of cancer. Recently, the interest for NPs has been increasing 
and also NPs based on carnosine have been obtained. 
Carnosine has been functionalized with L-lipoic acid to synthesize gold NPs32. These 
NPs have been synthesized as activators of carbonic anhydrase. The role of carnosine 
could be related to the presence of histidine, being that the activity of carnosine 
nanoparticles is very similar to that of histidine nanoparticles. 
  
                                                            
32 Saada MC, Montero JL, Vullo D, Scozzafava A, Winum JY, Supuran CT, 2011, J Med Chem, 54, 1170–
1177; 
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Carnosine-like derivatives, modified at the carboxylic group 
 
The majority of this class of derivatives are amides of Carnosine33 (Figure 8).  
 
Figure 8: L-Carnosine derivatives at the carboxylic group 
The amide functionalization seems to be a promising strategy because it deeply 
modifies the resistance of the Carnosine versus the human serum Carnosinase, it has 
been proved that the carboxylic group is important in the recognition done by the 
carnosinase enzymes; therefore the conversion of carboxyl group into amide makes 
the derivatives very stable to the carnosinase action. 
The most important Carnosine derivatives are: 
 The simple amido-Carnosine (9); 
 Other different amides (10-14); 
 The amide obtained trought conjugation with amino-β-cyclodextrin (15). 
It is interesting that the modification of the carboxyl group maintains the HNE (4-
hydroxy-trans-2-nonenal) quenching activity of the carnosine moiety, though the 
derivatives show a lower activity than that of the dipeptide. 
                                                            
33 Lanza V, Bellia F, D’Agata R, Grasso G, Rizzarelli E, Vecchio G, 2011, J Inorg Biochem,105, 181–188; 
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The activity has also been studied in cell cultures. The amido derivative 13a, which is 
moderately more hydrophobic with respect to 9, has been able to protect primary 
hippocampus neurons against HNE-induced death, showing a very significant increase 
in comparison to L-Carnosine.  
Derivative 13a is also able to cross the blood brain barrier (BBB) and to concentrate in 
the rat brain after intravenous administration. These results render 13a a very 
promising neuroprotective agent. 
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Double-functionalized Carnosine-like derivatives 
 
In addition to the Carnosine-like derivatives, modified at the aminic or carboxylic 
function, also compounds double functionalized have been prepared. 
In particular, the amide of Carnosine has also been glycoconjugated at amino 
group in order to study the metal complexing ability (Figure 9). 
 
Figure 9: Double-functionalized L-Carnosine derivatives 
As expected, these novel molecules revealed to be very promising systems that 
are able to increase Carnosine bioavailability. 
They are also potentially able to act as chelating agents in the development of clinical 
approaches for the regulation of copper (II) homeostasis in the field of medicinal 
inorganic chemistry. 
The presence of the sugar renders these derivatives capable of recognizing important 
biological systems such as the lectins. This feature should localize copper (II) chelating 
activity to the target tissue or even to the target cell compartment of interest. 
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Ethylenic chain-modified Carnosine-like derivatives34 
 
In order to investigate in more detail the effect of N-acetylation on the biochemical 
properties of Carnosine, derivatives whose side chain has been introduced on the 
ethylenic chain of beta alanine have also been synthesised. 
For this purpose, it seemed interesting to replace the residue ofβ-alanine with 
L(+)2,3-diaminopropionic acid. This chemical modification leads to a combination of a 
close structural similarity to the native model with the possibility to bear two N-
acetylamino groups or to maintain a free extra amino group.  
Hence, the two novel synthesised Carnosine analogues, containing 2,3-
diaminopropionic acid with a different degree of N-acetylation, are reported in Figure 
10. 
 
Figure 10: Carnosine derivatives modified on the ethylenic chain 
 
The compounds have been tested either as substrates or inhibitors of human 
serum carnosinase: the enzyme resistance was higher in the case of 19, while 
compound 18 showed only partial carnosinase resistance. 
In addition, interestingly enough, derivative 19 revealed to be also able to inhibit 
carnosinase. 
The antioxidant and free radical scavenger properties of these compounds have been 
also investigated by their ability to inhibit reactions induced by hydroxyl radicals and by 
peroxynitrite.  
  
                                                            
34 Cacciatore I, Cocco A, Costa M, Fontana M, Lucente G, Pecci L, Pinnen F, 2005, Amino Acids, 28, 77–
83; 
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D-Carnosine derivatives 
 
As explained before in this thesis, the design and synthesis of D-Carnosine derivatives 
prodrugs have been inspired by the promising RCS scavenger ability of D-Carnosine 
itself. 
The prodrugs of D-Car have been designed mainly based on computed lipophilicity35. 
Derivatives with both amine and carboxyl groups were synthesized (Figure 11) in order 
to study the hydrolysis mechanism in rat plasma. 
 
 
Figure 11: D-Carnosine derivatives 
 
The most stable derivatives have been excluded from an in vivo investigation. The octyl 
ester of D-Car (20) has been selected to undergo an extensive evaluation in the Zucker 
rat.  
                                                            
35 Orioli M, Vistoli G, Regazzoni L, Pedretti A, Lapolla A, Rossoni G, Canevotti R, Gamberoni L, Previtali M, 
Carini M, Aldini G, 2011, ChemMedChem, 6, 1269–1282; 
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Several protective actions have been observed: 
 the reduction of markers of carbonyl stress, such as advanced glycoxidation 
product (AGE);  
 the reduction of hyperlipidemie; 
 the prevention of renal and vascular injuries. 
These derivatives have also been synthesized in order to compare the stereochemical 
differences of the L- and D-Car conjugates.  
Cyclodextrin (21) and trehalose (22) conjugates of D-Carnosine have been structurally 
investigated and their ability to complex metal ions has been correlated to the chirality 
of the histidine ring36.  
These systems revealed to be very interesting examples in the field of stereochemistry, 
but their potentialities as therapeutic agents have not been investigated yet. 
  
                                                            
36 Grasso GI, Arena G, Bellia F, Maccarrone G, Parrinello M, Pietropaolo A, Vecchio G, Rizzarelli E, 2011 
(a), Chemistry, 17, 9448–9455; Grasso GI, Bellia F, Arena G, Vecchio G, Rizzarelli E, 2011 (b), Inorg 
Chem, 50, 4917–4924; 
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Aim of the work 
 
Considering all the possible therapeutic potentialities of Carnosine, in the present work 
several derivatives have been designed in order to: 
 increase quenching activity towards cytotoxic RCS,  
 maintain a selectivity versus cytoxic species, avoiding an activity towards 
endogenous ones; 
 ensure a satisfactory oral bioavailability by preventing carnosinase-catalyzed 
hydrolysis while preserving active absorption by hPepT1.  
A critical analysis of all reported carnosine analogues, combined with computational 
studies involving serum carnosinase and peptide transporters37, revealed that the 
carboxyl terminus and the β-alanine carbon skeleton can be largely modified to 
improve pharmacokinetic profile without detrimentally affecting quenching activity.  
As seen before, C-terminus capping is a well-known strategy to enhance plasma 
stability by hampering peptide recognition by all hydrolases, thus suggesting that such 
a modification should prevent the hydrolytic effects of both specific carnosinases and 
nonspecific peptidases.  
 On the contrary, the primary amino group should be basic enough to allow the 
Schiff-base formation with α,β-unsaturated aldehydes; also the imidazole ring is 
mandatory for quenching activity and could be modified only with other moieties able 
to form the Michael adduct, even if causing changes in efficiency and/or selectivity. 
 Starting from these simple SARs, the Carnosine structure has been modified, 
following three different approaches: 
1. replacing the Hystidinil-portion with a different nucleophilic aromatic system, 
specifically the furan, the thiophene and the p-metoxy-aniline (Figure 12); 
                                                            
37 Vistoli G, Pedretti A, Cattaneo M, Aldini G, Testa B, 2006, J Med Chem, 49, 3269-3277; Pedretti A, De 
Luca L, Marconi C, Negrisoli G, Aldini G, Vistoli G., 2008, ChemMedChem, 3, 1913-1921; Pedretti A, De 
Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G., 2011, Bioorg Med Chem., 19, 4544-4551; 
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2. substituting the β-alanyl portion with ten different aminoacids, chosen in order 
to cover exhaustively the available chemical space; the synthesized 
diastereoisomeric pairs of Histidine-containing dipeptides are shown in Figure 
14; 
3. rigidifying the whole structure, with the insertion of a 2-oxazolidinone that 
includes the amino- and the C-terminal-portion of the Histidine (Figure 15)  
 The first approach wanted to evaluate the substitution of the Histidine ring with 
other moieties, nucleophilic enough to form the Michael adduct. 
Following this idea, several aromatic rings were chosen, in order to have a balance 
between reactivity and nucleophilicity of the ring itself (Figure 13). 
 
Figure 12 
The nucleophilicity (ω-) is expressed, as we can see from the Figure 13 below, from a 
matemathic ratio. 
This nucleophilicity scale was derived by HOMO/LUMO energies (µ and η) of the two 
interacting partners (A and B) as here reported for imidazole ring with acrolein. 
Such calculations suggest that furan and tiophene could have a conformational profile 
and reactivity rather similar to those of imidazole; therefore they have been chosen as 
substituting moieties. 
 
Figure 13: Nucleophilic scale for different aromatic rings 
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 In the second approach (Figure 14), since the Carnosine carboxyl group is not 
required for carbonyl scavenging and its modifications can improve the resulting 
pharmacokinetic profile, as it has been explained above, the dipeptides were prepared 
with the C-terminus capped by a methyl ester so as to study dipeptides which should 
be still recognized by peptide transporters and resistant to proteolysis.  
Moreover, the study considered diastereoisomeric pairs of dipeptides produced by 
alternating the absolute configuration of the Histidine residue with a view to revealing 
the effect of configuration on quenching activity.  
Figure 14 
Indeed, while the two Carnosine enantiomers have almost the same quenching 
activity, a result easily explainable since two enantiomers must possess the same 
chemical reactivity, the introduction of a second chiral center should allow 
diastereoisomeric differences useful for a better understanding of the precise 
scavenging mechanism. 
The third approach (Figure 15) was performed in order to follow a new research 
line, not jet explored that is the total rigidifying of the structure. The synthetised 
molecule includes all the mandatory features explained before. 
 
Figure 15 
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Synthetic scheme 
 
The synthetic pathway has been peculiar for each of the three different classes 
of compounds.  
The Carnosine-like derivatives reported in Figure 16 were prepared starting from 
the 2- or 3- furfuryl alcohol and 2- or 3-thiophenemethanol which are commercially 
available.  
 
Reagents and conditions: (aa) PBr3, THF, -5°C; (ab) t-BuOK, diethyl acetamidomalonate, THF, Et2O, reflux; (ac) 
NaOH 4M, dioxane, reflux; (ad) CH3COOH, dioxane, reflux; (ae) NaOH 30%, reflux; HCl conc, methanol; (af) SOCl2, 
trimethylorthoformate, MeOH, 50°C; (ag) R-β-Alanine, HOBt, EDAC, DIPEA, DCM, RT; (ah) NaOH 4M, MeOH, RT; (ai) 
H2 Pd/C 5%, MeOH, RT; (aj) TFA, anisole. 
Figure 16 
The alcoholic derivative underwent firstly bromination (aa), using PBr3 in THF, 
with good yields and purity of the products, and then nucleophilic substitution (ab) 
from the diethyl acetamidomalonate, operating in THF using potassium tert-butoxide 
as base. 
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The ethylic esters hydrolysis (ac) is achieved in basic conditions, accomplishing 
the bi-carboxylic derivative, which, after treatment with acetic acid (ad), let the 
obtainment of compound IV. 
The basic hydrolysis of the acetamidic function (ae) and the esterification of the 
free carboxylic acid, achieved in Methanol using thionyl chloride (af), yielded 
compound VI. 
VI was coupled, using HOBt and EDAC as coupling reagents (ag), with β-alanine, 
differently protected for the furan- and thiophene- derivatives. In the first case, the 
aminic function is capped with benzyl chloroformate, and, after basic hydrolysis of the 
esteric function (ah), the Cbz- is easily removed by hydrogenolysis. 
On the other hand, the 2-thiophene-derivative was initially protected, one more 
time, with benzyl chloroformate; nevertheless in this case, after basic hydrolysis of the 
esteric function (ah), the Cbz removal wasn’t possible by hydrogenolysis, due to the 
poisoning action of the sulphur on the Pd/C. Therefore the final compound was 
accomplished treating the compound with Trifluoroacetic acid, in presence of anisole 
as scavenger. 
In order to avoid such difficulties, in the synthetic pathway of the 3-thiophene 
compound, the β-alanine was protected with di-tert-butyl-dicarbonate, whose removal 
was easily achieved in acidic conditions.  
The synthesis of compound 5 is here reported (Figure 17). 
 
Reagents and conditions: (ak) Cbz-beta-Alanine, HOBt, EDAC, DIPEA, DCM, RT; (al) H2 Pd/C 5%, MeOH, RT. 
Figure 17 
It started from the commercially available p-methoxy-aniline, that is coupled with Cbz-
β-alanine in dichloromethane, using HOBt and EDAC as coupling reagents (ak). The 
hydrogenolysis (al) accomplished the final product in good yield.  
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Concerning the second approach38, the dipeptides were prepared by 
maintaining the N-terminal residue in its natural L configuration and alternating the 
configuration of the Histidine residue, in order to obtain the desired diastereoisomeric 
pairs of general formula NH2-L-X-(L or D)-His-OMe.  
All dipeptides were synthesized as methyl esters to facilitate their 
physicochemical profiling, characterized by 1H NMR spectroscopy and analyzed by 
reverse-phase HPLC under conditions effective in diastereomer separation, in order to 
prove their >98% purity and, what is more, the absence of any epimer. 
The synthesis of each dipeptide started by preparing the specific L-amino acid, 
when non commercially available: the amino group is protected using benzyl 
chloroformate in basic conditions, the eventual functional groups on the lateral chain 
are suitably protected. 
The L- and D- Histidine were prepared as methyl ester dihydrochloride (X), 
treating the amino acid with thionyl chloride and trimethyl orthoformate in methanol, 
and then coupled with each L protected amino acid in DMF, using HOBt and EDAC as 
coupling reagents, yielding XI (Figure 18).  
Reagents and conditions: (am) HOBt, EDAC, DIPEA, DMF, RT; (an) H2 Pd/C 5%, MeOH, RT or TFA/anisole. 
 
Figure 18 
The resultant crude full-protected dipeptide was purified by column 
chromatography.  
The purification conditions of each single dipeptide and the respective yields 
are listed in Table 1.  
                                                            
38 Vistoli G, Straniero V, Pedretti A, Fumagalli L, Bolchi C, Pallavicini M, Valoti E, Testa B, 2012, Chirality, 
24, 566-576; 
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Table 1: Yields and elution conditions of the full protected dipeptides 
Each purified dipeptide was analyzed by HPLC at 1 ml/min flow rate (0.5 
ml/min for the dipeptides containing Asparagine or Glutamic acid) with the elution 
gradient stated in Table 2. 
 
Table 2: Elution gradient for the analysis of full-protected dipeptides by HPLC 
Under such conditions, proved to be effective in separating all the diastereoisomeric 
pairs of the dipeptides epimers at the hystidine stereocentre, each purified dipeptide 
was found exempt from its diastereisomers.  
The fully protected dipeptides, with the exception of those containing serine, 
cysteine, and methionine, were deprotected by hydrogenolisis in a mixture of dry 
methanol/ 1.25M methanolic hydrogen chloride, in the presence of 10% Pd/C.  
In the case of Serine (Figure 19-A), the Serine suitably protected was coupled 
with both the methyl ester of the Histidine dihydrochlorides, yielding the dipeptide XIII 
according to the general coupling procedure. The side chain protection was removed 
stirring the dipeptide in a mixture 7:3 DCM/ TFA, in the presence of anisole (ao). The 
crude products XIV underwent hydrogenolisis (ap), giving the final dipeptide, as 
dihydrochloride (XV). 
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Reagents and conditions: (ao) TFA/DCM= 7/3, anisole; (ap) MeOH*HCl 1,25M, MeOH; (aq) Acetone; (ar) Benzyl 
chloroformate, DIPEA, ACN; (as) HOBt, EDAC, DIPEA, DMF; (at) TFA, anisole; (au) TFA, anisole. 
 
Figure 19 
The synthesis of Cysteine containing dipeptides (Figure 19-B) started from the 
formation of the dimethyl tiazolidine (aq; XV), that is sequentially protected on the 
aminic function (ar) with benzyl chloroformate, in Acetonitrile and DIPEA (XVI). 
The isolation of the protected compound was followed by the coupling with both the 
Histidine dihydrochlorides, following the general method (as). 
The full protected dipeptides (XVII) were stirred in TFA, in the presence of anisole, 
yielding the final products (at). 
The full protected Methionine containing dipeptides (XVIII) were obtained with 
the general coupling procedure (Figure 19-C); the consecutive treatment in TFA in the 
presence of anisole (au) accomplished the final compounds, in quantitative yield. 
Each final dipeptide, methyl esterified at the C-terminal amino acid hystidine, 
was analyzed by HPLC at 1 ml/min flow rate (0.5 ml/min for the dipeptides containing 
asparagine or glutamic acid) with the elution gradient stated in Table 3.  
 
Table 3: Elution gradient for the analysis and the preparative purification of deprotected dipeptides, by HPLC 
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When purity was found lower than 98% (UV detector 220 nm), the dipeptide was 
purified and isolated as di-trifluoroacetate by reverse-phase HPLC under the same 
conditions reported previously for the analyses, but using a preparative C-18 column. 
The third approach has been the rigidifying of the whole molecule (Figure 20), 
obtained with the insertion of a 2-oxazolidinone, that includes the amino- and the C-
terminal-portion of the Histidine; the synthesis started from the Histidine monohydrate 
monochloride, which reacted with benzylchloride, in liquid NH3 and Na (av).  
The achieved solid (XIX) was then treated in Methanol with Methanolic hydrogen 
chloride (aw), giving the corresponding methyl ester. The Histidine suitably protected 
was sequentially coupled with the β-alanine (ax), having the amine function protected 
as benzyl carbamate, under the usual coupling condition.  
The hydrogenolysis (ay) and the consecutive reduction (az) of both the amide and ester 
functions, achieved heating the dipeptide in THF in the presence of Lithium aluminum 
hydride, yielded a very polar compound (XXIII), having free primary amines. 
Therefore, the two aminic functions were transformed in the corresponding benzyl 
carbamates, using benzyl chloroformate and DIPEA in THF (ba).  
The formation of the oxazolidinone (XXV) was simply obtained treating the 
resulted compound with sodium hydride in dry THF; the consecutive hydrogenolysis 
allowed the desired compound.  
 
Reagents and conditions: (av) Na, BnCl, NH3; (aw) MeOH*HCl 1,25M, MeOH; (ax) Cbz-ß-alanine, HOBt, EDAC, DIPEA, 
DMF; (ay) H2, Pd/C 10%, MeOH*HCl, MeOH; (az) LiAlH4, heating, THF; (ba) benzyl chloroformate, DIPEA, THF; (bb) 
NaH, THF; (bc) H2, Pd/C 10%, MeOH*HCl, MeOH. 
Figure 20 
This compound was analyzed by reverse phase HPLC, at 0.5 ml/min flow rate 
with the elution gradient stated in Table 3, and further purified by reverse phase 
preparative column, using the same conditions reported previously for the analyses 
but using a preparative C-18 column.   
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Physicochemical, computational and biological evaluation 
 
All the novel Carnosine-like derivatives were biologically evaluated; in addition the set 
of diastereoisomeric dipeptides underwent physicochemical profiling, computational 
studies and biological evaluation. 
Physicochemical data 
The physicochemical properties of the dipeptides were used to investigate 
configurational effects on ionization and lipophilicity, as well as to develop correlative 
models able to predict the diastereoisomeric differences. 
The amino acids, as explained before, were chosen to cover exhaustively the 
available chemical space, even though the zwitterionic character of the glutamate-
containing dipeptides impeded their accurate lipophilicity evaluation, and the 
dipeptides were synthetized as methyl esters. This choice facilitated their 
physicochemical profiling; indeed, esterification (1) reduces polarity, (2) simplifies the 
ionization scheme, and (3) abolishes the zwitterionic behavior that would prevent 
experimental log P determination.  
The attention was focused on the accurate measurement of log PN39 only 
because the log P values for most ionized states were somewhat out of the range of 
the apparatus (i.e., log PI<<-1). 
The physicochemical results are compiled in Table 4 that includes ionization constants 
(namely pK1 for the N-terminus, pK2 for the Histidine imidazole ring, and eventually, 
pK3 when the second side chain possessed an ionizable group), lipophilic data (i.e., log 
PN and logD7.4) plus the corresponding diastereoisomeric differences and some overall 
averages.  
Physicochemical data for some well-known natural histidine-containing dipeptides (i.e., 
carnosine, β-Ala-His and homocarnosine, γ-aminobutyryl-His) were also included for 
easy comparison. 
                                                            
39 Log PN: normalized partition coefficient; logD7.4: distribution coefficient at pH=7.4 (the physiological 
pH of blood serum). 
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Table 4: Determined physicochemical properties, plus the corresponding diastereoisomeric differences and some 
general mean values. 
 
pKa values  
Comparing the pK1 values of the dipeptides with those of the corresponding 
free amino acids confirms that the amino group is markedly less basic when belonging 
to a peptide. 
Indeed, although the pK1 values in free amino acids are almost always greater than 9, 
they rarely exceed 8 in the analyzed dipeptides because of the electron-withdrawing 
effect of the peptide bond. This electronic effect is particularly evident when 
considering the pK1 values of the included natural histidine-containing dipeptides. 
Indeed, the shifting of the amino group from the α to the β position (as seen in 
Carnosine) induces a pK1 increase of more than one logarithmic unit, whereas further 
shifting to the γ position (as seen in homocarnosine) has a more modest effect on pK1, 
even though it should be noted that the electron-withdrawing effect of the peptide 
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bond is still significant also in a γ position as evidenced by a comparison with the 
clearly greater basicity of alkylamines (e.g., butylamine pK = 10.77). 
Moreover, the obtained pK1 values are in line with those reported for unprotected 
dipeptides, thus indicating that the esterification of the C-terminus does not induce 
pronounced effects on the pK1 values, but it may influence differences between 
diastereoisomers. 
The pK2 values of the imidazole ring remain in a narrow range somewhat above 
that of free Histidine (pK2 = 5.97) and are rather similar to those of the reported 
endogenous dipeptides, thus being scarcely affected by the vicinal residue. 
The third ionization constant, when present, shows marked differences 
compared with the corresponding values for the free residues probably because of a 
mutual influence between adjacent ionizable side chains.  
For example, the low basicity of the second imidazole ring in the NH2-L-His- (L or D)-His-
OMe dipeptides indicates that the influence between contacting basic moieties 
destabilizes the electrical state with both protonated imidazole rings.  
Also, NH2-L-Cys- (L or D)-His-OMe dipeptides show higher pK3 values compared with 
that of the sulfhydryl group in free cysteine (pK= 8.33), whereas Lysine-containing and 
Tyrosine-containing dipeptides show pK3 values similar to those of the corresponding 
free amino acids. 
When considering the mean difference in the pK values of each diastereoisomeric pair 
(∆pKmean), there are three different behaviors that depend on conformational flexibility 
and intramolecular interactions.  
They can be schematized as follows: 
1. When the dipeptide is characterized by significant intramolecular 
interactions (mainly, but not exclusively, between side chains), it shows low 
diastereoisomeric differences (∆pKmean<0.1) because the configurational 
effects are restrained by conformational rigidity; 
2. When the dipeptide does not show relevant intramolecular interactions 
(apart from some weak hydrophobic contacts), it exhibits intermediate 
diastereoisomeric differences (0.1< ∆pKmean <0.2), thus indicating that the 
configurational effects are paralleled by a good conformational flexibility; 
3. When the dipeptide conformation is affected by relevant intramolecular 
repulsions (as in the case of NH2-L-Lys-(L or D)-His-OMe dipeptides between 
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the ammonium heads), it exhibits large diastereoisomeric differences 
(∆pKmean>0.2), thus indicating that the configurational effects are amplified 
by an extreme conformational mobility. 
Lipophilicity 
Comparing the present lipophilicity data (Table 4) with literature values 
confirms the remarkable polarity of these dipeptides, and, despite the impossibility of 
a direct comparison, suggests that hydrophilicity is only slightly reduced by methyl 
esterification.  
Specifically, most log PN values are found in the range 0<log PN<1, and only the 
Cysteine--containing and Methionine-containing dipeptides show markedly higher log 
PN values. 
The extrapolated logD7.4 values are well correlated with the log PN values (r2 = 0.93) 
and were found to be slightly lower than the latter. This may indicate that the neutral 
forms play a relevant role at pH 7.4, a result explainable by the weak basicity of the 
amino groups. 
The diastereoisomeric differences in lipophilicity values (∆log PN and ∆logD7.4) 
are well understandable considering the discussed conformational properties. The 
data reported in the table reveal that homochiral isomers are, on average, more 
lipophilic than the heterochiral isomers as confirmed by both ∆log PN and ∆logD7.4 
values. This can be explained by the greater side chain accessibility of the heterochiral 
isomers that results in more polar derivatives and suggests that the hydrophilicity 
increase due to a greater imidazole exposition is rarely counterbalanced by the second 
side chain. Only the significant apolarity of the Cysteine and Methionine side chains 
can overcome the polarity of the imidazole ring, and indeed, sulfur-containing 
dipeptides show an opposite trend, their (L, D)-isomers being more lipophilic than the 
(L, L)-isomers. 
Conversely, the accessibility of the dipeptide termini shows a reduced influence as 
demonstrated by the higher lipophilicity of the (L, L)-isomers despite the greater 
accessibility of both termini. This may imply that the hydrophilic contributions of the 
termini, and in particular that of the ionizable N-termini, are so crucial to be almost 
independent on conformational and configurational effects.  
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Collectively, lipophilicity data show significant diastereoisomeric differences 
that appear more pronounced than those observed for the ionization constants and 
also more homogeneously distributed.  
However, one can also recognize here a constraining effect of the intramolecular 
interactions as seen, for example, when comparing ∆log PN for NH2-L-Met-(L or D)-His-
OMe with that of NH2-L-Ser-(L or D)-His-OMe (1.02 vs. 0.11). 
Altogether, the lipophilicity data confirm that peptide isomerisation can have a 
remarkable impact on lipophilicity profile, essentially because of a greater exposition 
of the side chains in the heterochiral peptides. Clearly, the resulting effect depends on 
the hydrophilicity of the side chains. In our Histidine-containing dipeptides, 
isomerization almost always induced a log P decrease ascribable to the polarity of the 
imidazole moiety, whereas the heterochiral diastereoisomers of apolar peptides are 
expected to be more lipophilic (and thus more prone to amyloid deposition) as 
confirmed here for the sulfur-containing dipeptides. 
 
MD simulations 
 
The property space of the dipeptides was investigated by calculating the following 
properties for each conformer stored during the MD simulations in vacuo, in water, 
and in chloroform: 
1. Its radius of gyration, a well-known descriptor encoding molecular 
shape and size40, and whose variations can be used to estimate 
molecular flexibility41; 
2. Its conformer-dependent log PMLP value (also known as virtual log P, as 
computed here by the Molecular Lipophilicity Potential (MLP) 
approach42;  
3. Its polar surface area (PSA), which parameterizes their H-bonding 
capacity43. 
                                                            
40 Vree C, Mayr SG., 2010, New. J.Phys.,;12, 023001; 
41 Vistoli G, Pedretti A, Testa B., 2011, Future Med Chem., 3, 995–1010; 
42 Gaillard P, Carrupt PA, Testa B, Boudon A., 1994, J Comput Aided Mol Des, 8, 83–96; 
43 Clark DE., 2011, Future Med Chem., 3, 469–84; 
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For each property, the resulting space is described by the mean plus the range 
(namely, the difference between maximum and minimum values) of the computed 
values, as well as the sensitivity computed as the ratio between property range and 
number of rotatable bonds. 
.
 
Figure 21: Comparison of the overall means (upper 
plot) and ranges (lower plot) for the radius of gyration 
as calculated by molecular dynamics simulations in 
vacuo, in water, and in chloroform and computed for 
all dipeptides (light gray bars), homochiral peptides 
(dashed bars), and heterochiral peptides (dark gray 
bars). 
 
 
Figure 22: Comparison of the overall means (upper 
plot) and ranges (lower plot) for the log PMLP values as 
calculated by molecular dynamics simulations in 
vacuo, in water, and in chloroform and computed for 
all dipeptides (light gray bars), homochiral peptides 
(dashed bars), and heterochiral peptides (dark gray 
bars). 
 
 
Figure 23: Comparison of the overall means (upper plot) and ranges (lower plot) for the polar surface area (PSA) as 
calculated by molecular dynamics simulations in vacuo, in water, and in chloroform and computed for all dipeptides 
(light gray bars), homochiral peptides (dashed bars), and heterochiral peptides (dark gray bars). 
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Figure 21, Figure 22 and Figure 23 compare the overall averages and ranges as 
obtained in the simulated media for the radius of gyration (Fig. 21), lipophilicity (Fig. 
22), and the PSA (Fig. 23). 
With regard to the radius of gyration, Figure 21 shows that all simulated 
dipeptides assumed more folded conformations in vacuo because, essentially, of 
intramolecular polar interactions. 
In contrast, the monitored conformations appear largely more extended in water and 
chloroform probably because of strong solute–solvent interactions. Conceivably, the 
effect is more pronounced in water where the extended geometries are stabilized by 
strong polar contacts, whereas the effect in chloroform is mainly due to a greater 
molecular friction experienced by extended geometries. 
Conformational variability, as encoded by the ranges of values, is greater in solvents 
than in vacuum, a result that depends on the abundance of extended geometries in 
the investigated solvents. The diastereoisomeric differences are quite marginal and 
without well-defined trends for both means and ranges, thus suggesting that the 
conformation profiles of all isomers are similarly affected by the simulated media. 
The log PMLP means (Fig. 22) are in line with the polarity of the simulated 
environments. Indeed, a vacuum represents the most apolar medium, water as the 
most polar one, where as chloroform properties are intermediate. Figure 22 confirms 
that molecules tend to adapt their physicochemical properties to those of the 
environment without restraining their conformational spaces (as evidenced by the 
ranges of radius of gyration). The global log PMLP means are in encouraging agreement 
with the experimental data because the heterochiral dipeptides appear more 
hydrophilic than the homochiral ones in a vacuum and in water because of a greater 
accessibility of their side chains. 
The log PMLP means show an opposite trend in chloroform probably because the 
exposed side chains tend to collapse in an apolar solvent. 
Unlike the trends shown by the radius of gyration, the overall log PMLP ranges clearly 
decrease when the dipeptides are simulated in a solvent. This implies that the 
property adaptability is achieved by narrowing the property space while expanding the 
corresponding conformational space because the medium is able to select in each 
conformational cluster those conformers whose polarity most resembles its own. This 
confirms that conformational space and property spaces are only partly related and 
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that each cluster of conformers spans most of the property space. Albeit with minimal 
differences, the computed ranges suggest that the log PMLP variability is greater in the 
homochiral peptides presumably because of a variable exposition of their termini. The 
range differences vanish in chloroform probably because here, the polar termini tend 
to minimize their exposure regardless of configuration. 
The overall averages and ranges for PSA (Fig. 23) are in line with those of log 
PMLP, although the reported differences are far less pronounced allegedly because of 
the homogeneity in PSA values. Specifically, it is confirmed the adaptability of the 
dipeptides simulated in solvents of different polarity and the constraining effects that 
the solvents exert on property variability as seen in PSA ranges. Similar to what was 
observed for the radius of gyration, the diastereoisomeric differences are marginal and 
without defined trends. 
The investigated property spaces suggest that genuine physicochemical properties 
(namely, log PMLP) are more sensible to both environmental and configurational effects 
compared with geometrical (radius of gyration) or mixed (PSA) properties. 
 
Quenching ability 
Each Carnosine-like derivative has been biologically evaluated, studying the quenching 
activities toward 4-hydroxy-2-nonenal (HNE), chosen as representative of α,β-
unsaturated aldehydes (Table 5 and Table 6). 
 
 
 
 
 
 
 
 
Compound % HNE quenching 
Carnosine 48.20 
1 2.9 
2 2.8 
3 5.82 
4 14.49 
5 5.8 
26 12.15 
Table 5: HNE quenching activity of the synthesised Carnosine-like derivatives 
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Table 6: HNE/ PYR quenching activity of the dipeptides 
 
Dipeptide % HNE % PYR HNE/PYR 
 Quenching Std dev Quenching Std dev  
Carnosine 48.20 --- 5.57 --- 8.65 
6 8.86 2.13 7.70 0.78 1.15 
7 6.00 1.75 1.82 1.14 3.30 
∆ (His-His-OMe) -2.86 p > 0.05 -5.88 p < 0.05 +2.15 
8 16.92 1.27 3.62 4.27 4.67 
9 4.97 2.46 0.87 0.42 5.71 
∆ (Val-His-OMe) -11.95 p < 0.05 -2.75 p > 0.05 +1.04 
10 13.12 2.15 0.73 1.19 17.97 
11 12.21 4.37 0.76 0.78 16.07 
∆ (Glu-His-OMe) -0.91 p > 0.05 +0.03 p > 0.05 -1.91 
12 27.44 1.08 1.29 1.08 21.27 
13 12.53 0.78 4.02 0.29 3.12 
∆ (Tyr-His-OMe) -14.91 p < 0.05 +2.73 p < 0.05 -18.15 
14 100.00 --- 40.78 0.73 2.45 
15 100.00 --- 25.26 1.56 3.96 
∆ (Cys-His-OMe) 0.00 ND -15.52 p < 0.05 +1.51 
16 10.20 0.98 0.35 0.11 29.14 
17 31.27 1.06 1.87 0.54 16.72 
∆ (Lys-His-OMe) +21.07 p < 0.05 +1.52 p < 0.05 -12.42 
18 9.50 3.27 1.14 0.64 8.33 
19 9.59 3.08 1.00 0.44 9.59 
∆ (Asn-His-OMe) +0.09 p > 0.05 -0.14 p > 0.05 +1.26 
20 18.83 3.75 5.81 0.55 3.24 
21 11.71 2.51 4.20 0.23 2.79 
∆ (Trp-His-OMe) -7.12 p < 0.05 -1.61 p < 0.05 -0.45 
22 5.91 0.37 2.08 1.55 2.84 
23 5.18 0.14 0.10 0.65 51.80 
∆ (Ser-His-OMe) -0.73 p > 0.05 -1.98 p > 0.05 +48.96 
24 1.81 1.49 3.11 0.29 0.58 
25 0.17 0.80 2.61 0.17 0.07 
∆ (Met-His-OMe) -1.64 p > 0.05 -0.50 p < 0.05 -0.52 
Means 20.31± 28.31  5.46 ± 9.94  10.24  ± 12.64 
(L, D) Means 21.26 ± 28.59  6.66 ± 12.22  9.17 ± 10.01 
(L, L) Means 19.36 ± 29.53  4.25 ± 7.51  11.31  ± 15.32 
∆ Mean -1.90 ± 9.64  -2.41 ± 5.18  +2.15 ± 17.79 
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In addition, the dipeptides, which revealed to be promising candidates, were also 
tested towards pyridoxal (PYR), chosen as representative of endogenous carbonyl 
compounds. 
These quenching activities are expressed as percentages of quenched carbonyl 
compound after a fixed incubation time of 180 min. Table 6 reports also the 
corresponding standard deviations as well as the dipeptide selectivity calculated as 
the ratio between the quenching activities toward HNE and PYR. 
 
HNE Quenching 
The data referring to the first five Carnosine-like derivatives and the rigidified one are 
not comparable to the one of the Carnosine itself; on the other hand some of the 
twenty dipeptides possess an impressive scavenging activity since they completely 
quenched HNE during the incubation time, regardless of their capping and 
configuration.  
These data suggest that the Cysteine-containing dipeptides do not follow the 
multistep mechanism involving the amino and imidazolyl moieties as seen for 
Carnosine, while their extreme reactivity seems to be due almost exclusively to the 
marked nucleophilicity of the thiol group. Such a mechanism is indirectly confirmed by 
the virtually undetectable activity of the Methionine-containing dipeptides and 
suggests that these very reactive dipeptides cannot be considered promising scaffolds 
in the design of improved carbonyl quenchers because the remarkable thiol 
nucleophilicity renders them unsafely reactive molecules acting by nonspecific 
mechanisms. 
In addition, thiol-containing drugs could potentially toxic compounds since they 
can react with Cysteine thiol functions yielding protein-drug mixed disulfides and these 
adducts can impair the physiological functions of the modified proteins. 
What’s more, thiol-containing drugs can behave as haptens when the mixed disulfides 
become antigenic determinants and initiate an immune response which can culminate 
in hypersensitivity and, consequently, idiosyncratic reactions (IDRs) depending on the 
body’s capacity to detoxify these adducts.  
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Nevertheless, some dipeptides show remarkable quenching activities which 
deserve specific considerations.  
The significant activity of the Lysine containing peptides can be explained 
considering that they possess two primary amines, favouring the formation of the 
imino intermediate regardless of which amino group is the more reactive one.  
In general, dipeptides containing aromatic residues show marked quenching 
activities probably because the aromatic rings facilitate interactions between the 
imidazole ring and the acceptor β-carbon atom through π-π stacking with a beneficial 
effect already seen for the β-aryl amino acids44.  
Meanwhile, the dipeptides presenting the double Histidine, show modest 
activities suggesting interference between imidazole rings, causing a prevalently 
negative effect on the whole scavenging mechanism.  
Finally, the weak quenching activity of the dipeptides containing hydroxyl 
functions (specifically Serine and Tyrosine containing peptides) suggests the possibility 
to yield also hemiacetal intermediates that do not enhance the scavenging activity. 
Considering the totality of the dipeptides, the pairs of diastereoisomers show 
only marginal quenching differences since the heterochiral isomers (19.69 ± 28.07) 
are barely more active than their homochiral diastereoisomers (18.58 ± 28.52), and 
this result may by explained considering the heterogeneity of the examined dipeptides 
which prevents general trends to be uncovered.  
Nevertheless, several pairs of diastereoisomers exhibit statistically significant 
differences, which also reflect the dissimilar physicochemical features. 
Table 6 underlines that 11 diastereoisomeric pairs out of 20 show statistically 
significant differences (i.e. p < 0.05) and for 7 pairs out of 11 the heterochiral 
dipeptide is more active than the homochiral one thus substantiating the trend 
observed in the overall means. This result can be explained by the conformational 
differences between diastereoisomers, evidenced in previously, after the 
physicochemical evaluation. 
Consequently, the greater activity of heterochiral dipeptides is easily 
interpretable in terms of increased accessibility of the Histidine side chain that renders 
the imidazole ring more prone to the Michael addition, while the intramolecular 
                                                            
44 Vistoli G, Orioli M, Pedretti A, Regazzoni L, Canevotti R, Negrisoli G, Carini M, Aldini G., 2009, 
ChemMedChem., 4, 967-75;  
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interactions which characterize the homochiral isomers shield the imidazole ring 
preventing its approach to the unsaturated imine.  
For both Lysine-containing pairs of diastereoisomers, the homochiral isomers 
are conversely more active than the corresponding heterochiral ones. This finding may 
suggest that here the imino intermediate is mostly produced by the Lysine’s ε-amino 
group (rather than by the N-terminus) which is stably closer to the imidazolyl ring in the 
homochiral dipeptides thus favouring the key Michael addition.  
A closer analysis confirms that aromatic and positively charged side-chains 
have generally a significantly beneficial effect; aromatic residues promote contacts 
between the imidazolyl ring and the β-carbon atom as discussed above, while 
positively charged residues may promote the initial imino formation.  
On the contrary, negatively charged and H-bonding side-chains show an overall 
negative effect on the quenching activity: the former can stabilize ion-pairs with 
primary amine thus hampering the imino formation, while H-bonding residues may 
engage imidazole ring and imino function in intramolecular H-bonds which shield their 
nucleophilicity or preclude their contacts.  
Generally, hydrophobic residues have a modest effect on quenching activity and 
at least they can hamper the necessary approach of the reactive groups by steric 
hindrance. 
 
PYR quenching and peptide selectivity 
Considering the promising HNE quenching activity of some of the dipeptides, it has 
been also tested their scavenging ability toward an endogenous carbonyl compound 
(the Pyridoxal), in order to study their selectivity. 
The data shown in Table 6 reveal that all the considered derivatives possess 
very modest quenching activities toward pyridoxal.  
Specifically, Cysteine-containing dipeptides have the greatest quenching activity; this 
could be explained by the marked nucleophilicity of their thiol group.  
In addition, the detectable activity of some hydroxyl-containing dipeptides could 
be due to their capacity to form hemiacetal adducts.  
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The very poor activity toward PYR of the examined dipeptides confirms that they 
are unable to yield stable imino derivatives with physiological carbonyls. On average, 
all peptides show the same poor activity regardless of their capping and absolute 
configuration, which indeed have a limited impact on the reactivity of the amino group.  
Concerning the HNE/PYR selectivity, all tested dipeptides show a marked 
selectivity for HNE given their very weak quenching activity toward pyridoxal. More 
importantly, such a remarkable selectivity emphasizes that the HNE quenching of 
these dipeptides cannot be restricted to the formation of a mere imino function but 
may also involve a crucial Michael addition.  
 
In conclusion, the present PhD thesis suggests that some dipeptides show a 
quenching activity only slightly weaker than that of Carnosine; in addition this 
scavenging activity is endowed by a markedly greater selectivity, therefore they can 
represent truly promising candidates for the design of improved Carnosine derivatives. 
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Chapter 2: Ras proteins45 
 
 Cell growth, differentiation and survival are regulated by a complex combination 
of extracellular signals and intracellular signaling cascades. 
The Ras proteins, a family of monomeric G molecules (H-ras, N-ras and K-ras) act as 
‘‘molecular switches’’, as linker from extracellular signals to intracellular ones, through 
membrane receptors.  
 Ras family 
 
 H-, N- and K-ras are members of a highly homologous group of approximately 21 
kDa monomeric, membrane-localized GTPases whose structure and function has been 
extensively studied46 . The p21 Ras proteins are formed of H-, N- and K-ras, with K-ras 
existing in two alternatively spliced forms, 4A and 4B, resulting in differing C-terminal 
residues which are important for post-translational modification.  
Every single Ras protein share approximately 85% sequence homology, there’s also a 
larger Ras superfamily, which includes other proteins such as R-ras, M-ras, TC21, 
Rap1A, Rap1B, RalA and RalB, sharing 40–50% sequence homology47.  
In its totality, the Ras superfamily includes over 150 small GTPases. 
The Ras proteins length is of 188 amino acids for H-ras, N-ras and K-ras 4A, while K-
Ras4B is an amino acid longer. 
 Amino acids 1–165 are highly conserved between the four Ras proteins while 
the carboxy terminal 25 amino acids could have a considerable variation. In the 
conserved domain there are several motifs important for protein function including 
GTP binding, effector binding and Switch I and Switch II loops responsible for Guanine 
nucleotide exchange factor (GEF) and GTPase activating protein (GAP) interactions 
(Figure 24). 
                                                            
45  Friday B.B., Adjei A.A., 2005, Bioch Biophys Acta, 1756, 127-144; 
46 C.A. Ellis, G. Clark, 2000, Cell. Signal., 12, 425–434; A.A. Adjei, 2001, Curr. Pharm. Des., 7, 1581–
1594; A.A. Adjei, 2001, J. Natl. Cancer. Inst,. 93, 1062–1074; M. Barbacid, 1987, Annu. Rev. Biochem., 
56, 779–827; D.R. Lowy, B.M. Willumsen, 1993, Annu. Rev. Biochem., 62, 851–891; 
47 A. Ehrhardt, G.R.A. Ehrhardt, X. Guo, J.W. Schrader, 2002, Exp. Hematol., 30,x 1089–1106; 
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of the receptor. This process results in juxtaposition of the cytoplasmic, catalytic 
domains in a manner that allows activation of the kinase activity and 
transphosphorylation. 
 Adaptor proteins such as Grb2 are now able to recognize Sequence Homology 2 
(SH2) domains which, in turn, recruit Guanine nucleotide Exchange Factors (GEFs) like 
SOS-1 or CDC25 to the cell membrane.  
The GEF is now capable of interacting with Ras proteins at the cell membrane to 
promote a conformational change and the exchange of GDP for GTP. Subcellular 
localization of GEFs is thought to be a key event in Ras activation. Indeed, when SOS-1 
or CDC25 are constitutively targeted to the cell membrane, they have enhanced ability 
to transform NIH 3T3 cells. In addition, the interesting consideration that the pathway 
is bidirectional, whereby RAS regulates SOS activity, suggests that regulation of this 
key component of Ras signaling is a very complex mechanism. 
 Hydrolysis of the GTP to GDP terminates Ras activation; nevertheless Ras 
proteins have intrinsically low GTPase activity.  
The GTPase activity is stimulated by GAPs such as NF1-GAP/neurofibromin and p120-
GAP leading to inactivation, and consequently preventing prolonged Ras stimulated 
signaling. The importance of GAPs in regulating Ras is highlighted by the fact that 
oncogenic ras mutations almost uniformly abolish the interaction of GAPs and Ras, as 
described above. In addition, NF1-GAP is a tumor suppressor gene and dysfunction of 
this gene results in neurofibromatosis type 1, a clinical disorder that places patients at 
high risk for optic gliomas, astrocytomas, nerve sheath tumors, rhabdomyosarcomas 
and pheochromocytomas. Ras signaling is normally transient, both because of the 
intrinsic GTPase activity and the action of GAPs. 
 However, prolonged or constitutive Ras signaling as a result of ras mutations, NF-
1 dysfunction or Ras overexpression is a key event in Ras induced oncogenesis. 
 
Ras proteins effectors 
 
 Activated Ras include a large number of effectors, which serve to regulate myriad 
cell functions, including growth, survival, differentiation and angiogenesis. 
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These pathways become more complex as the number of effectors increases and the 
complexity of regulation by cross-talk between pathways is better understood. 
 The best characterized Ras effector is the Raf family of Serine/Threonine 
kinases, including Raf-1, A-Raf and B-Raf. 
Raf kinase is a key component of the mitogen-activated protein kinase (MAPK) 
pathway comprising Raf/MEK/ERK.  
Raf is recruited, following Ras activation, to the cell membrane through binding to the 
switch I domain of Ras and also by lipid binding. Full activation of Raf requires multiple 
cofactors and phosphorylation steps, and is therefore a complex event not fully 
understood.  
K-ras 4B is the best Ras isoform which most efficiently activates Raf-1, although K-ras 
4A, H-ras and N-ras are also capable of activate the pathway. Raf plays a critical role in 
Ras signaling and oncogenesis, this is due of several reasons. 
First, dominant-negative forms of Raf are capable of suppressing H-ras induced cell 
transformation. Second, constitutively active forms of Raf possess transforming 
activity comparable to Ras. Third, activating BRAF mutations are found at high 
frequency in many human cancers, including malignant melanoma (66%) and colon 
cancer (12%).  
 However, Raf is not the only effector of Ras in oncogenesis; Raf activation 
stimulates a signaling cascade by phosphorylation of MEK1 and MEK2, which 
successively phosphorylate and activate ERK1 and ERK2. Activation of ERK is critical 
for a large number of Ras-induced cellular responses. ERK1 and ERK2 phosphorylate 
and activate a variety of transcription factors and kinases, including Elk-1, c-Ets1, c- 
Ets2, p90RSK1, MNK1, MNK2, as well as other proteins such as the anti-proliferative 
protein Tob. Many of these Erk targets have been implicated in Ras induced cell 
transformation. 
 Phosphoinositide 3V-kinases (PI3-K) generate mitogenic phoshoinositol lipids by 
phosphorylating various phosphatidylinositol substrates. Of the three known classes of 
PI3- Ks, each of the three related p110 kinase subunits of class 1 are able to bind Ras 
through a Ras binding domain similar to those found in Raf and Ral-GDS.  
GTP bound Ras stimulates PI3-K activity; in NIH 3T3 cells, both Raf and PI3-K are 
necessary for cell transformation. 
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The importance of PI3-K in Ras mediated tumorigenesis likely occurs through several 
downstream targets of PI3-K. Akt/PKB is a downstream target of PI3-K that plays a 
significant role in regulation of apoptosis through proapoptotic proteins such as Bad 
and caspase 9.  
 Constitutive Akt/PKB activity was found in 16/17 NSCLC cell lines tested, and 
the activity was PI3-K dependent as treatment with PI3-K inhibitors decreased 
Akt/PKB activation and induced apoptosis. An alternative target of PI3-K is Rac, a G 
protein that can be activated by phosphatidyl 3,4,5-triphosphate, a PI3-K product. 
Rac is important in regulating cytoskeletal rearrangement, which along with membrane 
ruffling is induced by Ras mediated transformation. Ras-controlled membrane 
remodelling through Rac is dependent on PI3-K activity, therefore, PI3-K is an 
important mediator of Ras induced cell transformation. 
 The GAPs p120 and NF-1/neurofibromin function as Ras effectors in addition to 
their roles in the negative regulation of Ras through stimulation of GTP hydrolysis. 
Constitutively active Ras induces the association of p120 and syndecan-2, a complex 
that can provide docking sites for the oncogene src.  
 MEKK1 is a Serine/Threonine kinase activated in response to multiple signals 
including growth factors and cytokines to promote cell survival and apoptosis through 
a number of mediators such as JNK, SAPK, 14-3-3 and NFKB. 
MEKK1 may also regulate both Raf and ERK, providing for cross talk between multiple 
signalling pathways. Indeed, MEKK1 appears to induce apoptosis by dysregulation of a 
number of pathways including ERK, JNK and p38.  
 RalGEFs regulate the function of the G proteins RalA and RalB in the same 
manner that SOS and cdc25 regulate Ras activity, by stimulating the exchange of GDP 
for GTP. 
The RalGEF family contains at least three members with Ras binding domains, 
RalGDS, Rgl and Rgl2/Rlf. 
A dominant negative Ral protein is capable of blocking Ras induced transformation of 
mouse fibroblasts; this function is at least in part mediated by RalGDS, as RalGDS 
knock out mice demonstrate resistance to the development of skin tumors in a model 
dependent on Ras activation. 
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Ras proteins post-translational modification 
 
 Ras proteins are involved in a multi-stage post-translational modification48; their 
membrane localization is essential for function, but they are synthesised in the 
cytoplasm, as small and hydrophilic compounds.  
 Therefore they must undergo a four stage post-translational lipid modification, 
occuring at the carboxyterminal tetrapeptide, or ‘CAAX box’ (where “C” is Cysteine, “A” 
is any aliphatic residue, and “X” is any other residue), (Figure 26): 
1. Ras proteins prenylation, resulting in the addition of a farnesyl group to the 
carboxy terminus; the process is catalyzed by an isoprenyltransferase enzyme; 
2. Proteolytic cleavage of the terminal AAX motif by CAAX proteases Rce1 or Afc1;  
3. Carboxymethylation at the terminus, via sadenosyl methionine (SAM) and a 
specific transferase; 
4. Palmitoylation of the SH group of cysteine residues, close to the carboxy 
terminus, operated by a prenyl protein-specific palmitoyltransferase (PPPTase); 
 
Figure 26: Ras post-translational modification 
 
 
                                                            
48 I.M. Ghobrial, A.A. Adjei, 2002, Hematol. Oncol. Clin. N. Am., 16, 1065–1088; A.A. Adjei, 2001, 
Cancer Chemother. Biol. Response Modif., 19, 149–164; K.N. Cho, K.I. Lee, 2002, Arch. Pharm. Res., 
25, 759–769; 
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 Ras proteins and oncogenesis 
 
 The importance of Ras signaling in cell growth and survival is evidenced by the 
importance of Ras in oncogenesis. Specifically, K-ras was identified as a transforming 
protein in human tumors that was analogous to the transforming protein of the Kirsten 
murine sarcoma virus. 
 Several K-ras point mutations have been identified that result in constitutive 
activation. These mutations are found at high frequency (from 10% to 90%) in almost 
all the human tumors (Figure 27). 
 
Figure 27: Prevalence of k-ras mutations in selected human tumors 
Pancreatic tumors appear to have a particular propensity for K-ras mutations, with 
identifiable mutations in approximately 72–90% of all pancreatic tumors. 
Alternatively, some tumors have a relatively high prevalence of mutations in other ras 
genes, but only rare K-ras mutations; for instance N-ras mutations are common in both 
primary melanomas and melanoma cell lines, while K-ras mutations are rare.  
 The differential spectrum of ras mutations among the various tumor types likely 
reflects their expression levels and cell-specific roles in survival and growth.  
There are differences between the Ras proteins in their post-translational 
modifications, GEFs and effectors. 
In the absence of activating mutations, K-ras may still play a role in oncogenesis via 
Ras gene amplification, overexpression or upstream activation of the pathway. Each of 
these potential cellular alterations will produce increased activation of Ras effectors, 
thereby promoting development of tumors.  
In esophageal adenocarcinomas, 40% of the tumors were found to have amplification 
of the K-ras gene; in addition, morphologic transformation of 10T1/2 cell lines is 
associated with overexpression of wild-type K-ras.  
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Although ras mutations are rare in breast cancer, Ras is highly active in approximately 
50% of tumors compared to benign tissue, and this is associated with expression of 
epidermal growth factor and HER-2 receptors.  
In low-grade ovarian serous carcinomas, active MAPK was present in 41% of the 
tumors tested that did not have either K-ras or BRAF activating mutations. The 
importance of Ras activation in the absence of activating mutations is also suggested 
by the success of receptor tyrosine kinase targeted therapies, such as anti Her-2 
monoclonal antibody in breast cancer and anti-EGFR monoclonal antibodies in colon 
cancer. 
Ras as pharmaceutical target 
 
 Because of its crucial role in oncogenesis, various strategies have been 
developed to target K-ras for the treatment of human cancers.  
These strategies have ranged from inhibiting protein expression via anti-sense 
oligonucleotides to blocking post-translational modification, to inhibiting downstream 
effectors.  
The best results were obtained interfering with Ras post-translational 
modification, and therefore with Ras-driven cell transformation. In particular, 
prenylation, that is the first reaction of the multiple post-translational modifications, is 
the only one crucial for Ras biological activity; the others are dispensable49. 
Thus, interference with Ras prenylation (catalyzed by specific isoprenyltransferase 
enzymes) offered an interesting strategy in the interference with Ras-driven cell 
transformation. 
Prenylated proteins can be grouped into two major classes: the one containing 
the CAAX motif and the so-called CC- or CXC-containing proteins.  
The former class contains a diverse group of proteins, whereas the latter is almost 
exclusively composed of members of the Rab family; they are small GTP binding 
proteins that participate in intracellular membrane trafficking. 
                                                            
49 Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ, 1992, Proc Natl Acad Sci USA, 89, 6403–
6407; 
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Three known enzymes catalyze isoprenoid addition to proteins; these are termed 
protein famesyltransferase (FTase), protein geranylgeranyltransferase type I (GGTase-
I), and protein geranylgeranyltransferase type I1 (GGTase-II). 
FTase and GGTase-I are closely related and transfer a farnesyl group or a 
geranylgeranyl group from farnesyldiphosphate (FPP) and geranylgeranyldiphosphate 
(GGPP), respectively, to the cysteine residue of CAAX-containing proteins.  
FTase catalyzes the transfer of a 15-carbon isoprenyl group on farnesyl diphosphate 
(FPP) to its protein substrates via the formation of a covalent thioether bond. GGTase-I 
similarly transfers a 20-carbon isoprenyl group to its target proteins.  
The carboxyl-terminal residue of the CAAX motif (i.e. the “X’) in general determines 
which isoprenoid will be added to a protein50. When “X” is Serine, Methionine, or 
Glutamine, proteins are recognized by FTase whereas a Leucine at this position results 
in modification by GGTase-I. 
However, these preferences are not absolute and there is no exact rule to predict the 
CAAX specificity for prenyltransferases. All Ras proteins are preferentially farnesylated 
by FTase, but if FTase activity is inhibited K-Ras and N-Ras can be geranylgeranylated 
by GGTase.  
These biochemical data suggest that a combination of FTase and GGTase inhibitors 
may be needed to inhibit the prenylation of K-Ras or N-Ras proteins. However, FTase 
inhibitors are sufficient to achieve growth suppression in cancer cells and co-
application of GGTase inhibitors does not increase this effect. 
In addition, there was also the proof that mutated Ras proteins remain active when 
geranylgeranylated, but that normal H-Ras protein exerts growth-suppressive effects 
when geranylgeranylated. 
On the other hand, GGTase-II transfers geranylgeranyl groups from GGPP to 
both Cysteine residues of CC- or CXC- containing proteins in a process mechanistically 
distinct from that of the CAAX proteins51.   
                                                            
50 Casey PJ, Thissen JA, Moomaw JF., 1991,. Proc. Natl. Acad. Sci. USA, 88, 8631-8635; Yokoyama K, 
Goodwin GW. Ghomashchi F, Glomset JA, Gelb MH., 1991, Proc. Nuti. Acad. Sci. USA, 88, 5302-5306; 
51 Seabra MC. Goldstein JL, Sudhof TC, Brown MS., 1992, J. Biol. Chem, 267, 14497-14503; Horiuchi H, 
Kawata M, Katayama M, Yoshida Y, Musha T, et al. 1991,. J. Biol. Chem,. 266, 16981-16984; 
Farnsworth CC, Seabra MC, Ericsson LH, Gelb MH, Glomset JA. 1994,.Proc. Natl. Acad. Sci. USA, 91, 
11963-11967; 
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FTase52 
 
Mammalian protein Farnesyltransferase (FTase) was first identified and purified to 
homogeneity from rat brain cytosol.  
FTase is a heterodimer consisting of 48 kDa (αF/GGI)- and 45 kDa (βF)- subunit 
polypeptides; the nomenclature αF/GGI is chosen because the α subunit is also a 
component of GGTase-I. Substrates for FTase in mammalian cells include all known 
Ras proteins, nuclear lamins A and B, the γ subunit of the retinal trimeric G protein 
transducin, rhodopsin kinase, and a peroxisomal protein of unknown function termed 
PxF.  
The mammalian αF/GGI subunit is formed of 377 amino acid and has a 
calculated molecular weight is 44 kDa. A string of nine consecutive Proline residues 
near the amino terminus is responsible for the apparent molecular weight of 48 kDa 
observed on SDS-PAGE. 
The mammalian βF subunit consists of 437 residues with a calculated molecular 
weight of 48.6 kDa. The αF/GGI and βF subunits of mammalian FTase show about 30% 
and 37% identity with the proteins encoded by the S. Cerevisiae genes RAM2 and 
RAM1 (also known as DPR1), respectively. 
The two yeast genes were originally identified in a genetic screen of suppressors of 
RAS2val19, a mutationally activated RAS allele; RAM1 was also identified based on its 
involvement in a-factor (a S. Cerevisiae carboxymethylated pheromone) processing 
and as a suppressor of G protein function.  
Mutations in either RAM1 or RAM2 abolish FTase activity, and coexpression of the two 
genes in E. coli produces FTase activity that can farnesylate a-factor peptide and Ras 
protein substrates.  
A compelling property of FTase is that it can recognize short peptides containing 
appropriate CAAX motifs as substrates, where “C” is cysteine, “A” is any aliphatic 
                                                            
52 Zhang F.L., Casey P.J., 1996, Annu Rev. Biochem., 65, 241-269; 
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residue, and “X” is any other residue. Specificity in recognition of CA1A2X sequences by 
FTase indicates that the A1 position has a relaxed amino acid specificity, whereas 
variability at A2 and X are more restricted.  
Basic and aromatic side chains are tolerated at A1 but not at A2, whereas acidic 
residues are not well tolerated at either position. Moreover, substitution at the A2 
position by an aromatic residue in the context of a tetrapeptide creates a molecule 
which is not a substrate for FTase but rather is a competitive inhibitor53.  
FTase is a Zinc metalloenzyme. Dialysis versus chelating reagents, such as 
EDTA, is able to completely inactivate the enzyme. Neither Zn2+ nor Mg2+ alone restore 
the activity of metal-depleted FTase, on the other hand addition of both Zn2+ and Mg2+ 
fully restores it.  
The dependence on millimolar levels of Mg2+ for full activity indicates that it is probably 
not an integral component of FTase; measurement of the zinc content of recombinant 
FTase has confirmed that FTase contains one mole of zinc per mole of enzyme.  
The zinc isn’t required for FPP binding, but it is mandatory for protein substrate 
binding. Whether the zinc plays a structural role or whether it is directly involved in 
catalysis is not yet known.  
One possibility for a catalytic role of the zinc is that the metal could activate the 
sulfhydryl of the substrate protein cysteine residue and make it more nucleophilic. 
Evidence for such a “metalloactivation of cysteine” mechanism has been found in a 
DNA repair enzyme termed Ada, which catalyzes a reaction chemically similar to that of 
FTase. 
Metal substitution studies combined with spectroscopic analysis could provide 
evidence for such a mechanism. 
FTase can bind its two substrates, peptide and FPP respectively, in an 
independent manner.  
Binding of peptide substrate has been closely examined by NMR using a 
transferred NOE approach, revealing that the CAAX sequence of a peptide substrate 
adopts a Type I β-turn conformation when bound to the enzyme. A similar study of 
                                                            
53 Goldstein JL, Brown MS, Stradley SJ, Reiss Y, Gierasch LM., 1991,. J. Biol. Chem., 266, 15575-
15578; Brown MS, Goldstein JL, Paris KJ, Burnier JP, Marsters JC., 1992, Proc. Natl. Acad. Sci. USA, 89, 
8313-8316; Reiss Y, Stradley SJ, Gierasch LM, Brown MS, Goldstein JL., 1991. Proc. Natl. Acad. Sci. 
USA, 88, 732-36; 
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binding of a peptidomimetic inhibitor of FTase termed L-739,787 revealed a slightly 
different conformation most closely approximating a Type III β-turn. 
Binding of FPP by FTase is of such high affinity that the complex can be isolated 
by gel filtration. No covalent adduct is involved, however, because FPP can be released 
intact by denaturing the enzyme. Although kinetic analysis indicates that FTase has 
distinct binding sites for its two substrates, direct evidence for the formation of a 
ternary complex has not been obtained. 
The binding sites for both substrates seem to lie on the β subunit of the enzyme, and 
the binding site for the peptide substrate may be near the interface of the two 
subunits.  
The publication of the first X-ray crystallographic structure of an FTase enzyme 
in 199754 (Figure 28) was a major breakthrough in FTase research; five years later it 
was published the first X-ray structures for the FTase ternary complex (FTase–FPP–
Peptide) and product complex, added to the structure of the FTase binary complex 
(FTase–FPP).  
The publication of such a complex made available a complete series of structures 
representing the major steps along the reaction coordinate of this enzyme.  
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Figure 28: Structure of the FTase heterodimer. 
(A) Overall view of the structure. In the α-subunit, the α-helices are orange, 310 helices are magenta, and the β-
strand is red. In the β-subunit, the α-helices are cyan, 310 helices are blue, and the β strands are red. The zinc ion is 
a magenta sphere and its three amino acid ligands are yellow. The secondary structures of the-α subunit include 15 
α-helices, 3 short 310 helices, and a short β-strand. The β subunit contains 14 α -helices, 7 short 310 helices, and 3 
short β-strands.  
(B) Topology diagram. The open boxes represent α-helices, the striped boxes 310 helices, and the arrows β-strands. 
In both subunits, the residue numbers for α-helices are shown. Each of the 15 helices (1α to 15α) of the α-subunit 
are 8 to 17 residues in length, and the connecting loops are 4 to 8 residues. Helices 1β to 14β of the β-subunit 
contain between 9 and 22 residues. In the α-subunit, the three 310 helices are four to five residues in length (65α–
69α, 70α–73α, and 288α–291α). A three-residue β-strand (89α –91α) in the α-subunit interacts with a β-strand 
(87β–89β) in the β-subunit at the subunit interface. In the b-subunit, each of seven 310 helices consists of less than 
seven residues (23β–27β, 28β–34β, 91β–96β, 264β– 268β, 389β–393βb, 423β–427β, and 433β–437β) and 
the three β-strands are less than four residues in length (87β–89β, 375β–378β, and 381β–384β). The NH2-
terminal proline-rich domain (residues 1 to 54) is disordered in the crystal.  
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FTase inhibitors 
 
Starting from the prenylation mechanism and from its substrate (Figure 29), several 
different approaches were performed during the years, looking for active inhibitors of 
FTase.  
 
Figure 29: Ras proteins prenylation 
 
The main classes of Ftase inhibitors (FTIs) are: 
1. Peptidomimetics, analogues of the tetrapeptide CAAX; 
2. FPP analogues, able to interact with the binding site; 
3. Bisubstrate analogues, incorporating in their structure both a FPP moiety and a 
CAAX peptidomimetics; 
4. Natural inhibitors; 
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Peptidomimetic inhibitors 
 
Initial reports of farnesyltransferase inhibitors were based on the CAAX motif that is 
the sequence Cysteine-Valine-Isoleucine-Methionine: CVIM.  
 
The tetrapeptide itself was found to be a competitive inhibitor with Ras p21; 
consecutive modifications of the tetrapeptide at the “Ile” position, with its substitution 
with the aromatic amino acid Phenylalanine, led to a potent Ras FTase inhibitor with 
an IC50 of 25 nM against bovine FTase. 
Further modifications have also been reported, such as the introduction of 
reduced bond isosteres and homoserine for Methionine, leading to L-731,735, which 
has an IC50 of 18 nM against bovine FTase. The corresponding homoserine lactone L-
731,734 had an IC50 of 280 nM and was active in cells (Figure 30). 
 
Figure 30: Peptidomimetic inhibitors-(part I) 
 
The above-mentioned compound inhibited Ras processing in v-Ras-transformed cells 
and growth in soft agar and reduced Ras farnesylation by 50% in NIH 3T3 fibroblasts 
in culture at 50 µM. 
Both pseudopeptides were found to be selective for FTase (IC50 for GGTase-I > 10 µM). 
Indeed most groups have made an attempt to increase selectivity for FTase over 
GGTase-I due to a perceived increased incidence of potential toxicity if both enzymes 
are inhibited. It is of course possible that greater in vivo efficacy will be demonstrated 
with ‘less selective agents’, especially since K-Ras is known to be geranylgeranylated. 
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Figure 31: Peptidomimetic inhibitors-(part II) 
L-739,749, the methyl ester analogue of L-739,750 (Figure 31), is also a 
pseudopeptide based on the CAAX motif. It is a potent selective inhibitor of bovine 
FTase, with an IC50 of 240 nM. In cells, it was found to inhibit processed Ras by 50% at 
a concentration between 0.1 and 1 µM; however, it was found to also affect the 
regulation of actin stress fiber formation.  
Another CAAX mimetic, L-744,832 (Figure 32), was found to be active in an in 
vivo model. In MMTV-v-Ras mice bearing palpable tumors, daily administration of L-
744,832 caused complete tumor regression after 2 weeks of treatment (40 mg/kg). 
These in vivo results, and particularly tumor regression, with various CAAX mimetics 
are truly significant demonstrating the efficacy of FTase inhibitors as antitumor agents. 
It will be important to determine the range of tumor types that these compounds are 
active against for clinical development.  
 
Figure 32: Peptidomimetic inhibitors-(part III) 
Systematic modifications of the CVFM tetrapeptide by replacement of the 
amino-terminal amide bonds led to the inhibitor B581 (Figure 33), which has an IC50 of 
0.021 µM against bovine FTase. It was shown to inhibit Ras processing in cells with an 
IC50 of 50 µM. It was reported to be 40-fold selective toward FTase versus GGTase-I in 
vitro and in NIH 3T3 cells expressing oncogenic (Leu61) H-Ras-CVLS (for FTase) and 
oncogenic (Leu61) H-ras-CVLL (for GGTase-I). 
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Further modifications led to the inhibitor B956, which inhibits H-Ras 
farnesylation with an IC50 of 11 nM; B956 and its methyl ester, B1086 (Figure 33), 
inhibit the formation of colonies in soft agar of 14 human tumor cell lines, at 
concentrations between 0.2 and 60 µM. B956 revealed also to be more selective for 
the inhibition of farnesylation of H-Ras. B956/B1086 at 100 mg/kg inhibits tumor 
growth of EJ-1 human bladder carcinomas (oncogenic H-Ras- Val12) by about 60%. 
 
Figure 33: Peptidomimetic inhibitors- part IV 
Replacement of the Phenylalanine residue in CVFM with 1,2,3,4-
tetrahydroisoquinoline-3-carboxylate (Tic) led to increased activity against rat FTase 
with an IC50 of 1 nM for the Tic-containing tetrapeptide compared to 37 nM when 
phenylalanine was present.  
This inhibitor is one of the most potent compounds reported to date. Reduction of the 
amide bond, replacement of the isopropyl group of Valine with a tert-butyl group, and 
substitution of Metionine by Glutamine led to a compound with an IC50 of 2.8 nM 
against rat FTase and which was also 500-fold selective (IC50 against GGTase-I ) 1400 
nM) (Figure 34-a). Retaining the Methionine residue as the methyl ester also gave a 
potent Ras FTase inhibitor (IC50 = 85 nM), but it was found to be less selective (IC50 
against GGTase-I = 200 nM) (Figure 34-b).  
 
Figure 34: Peptidomimetic inhibitors-part V 
Replacement of the Cysteine residue by 4-imidazole (Figure 34-c) in the above 
class of inhibitors led to an increase in activity with an IC50 of 0.79 nM against rat 
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FTase, and in a clonogenic assay (H-Ras-transformed NIH 3T3 cells) this compound 
had an IC50 of 3.8 µM. 
Replacement of the two aliphatic amino acids by a benzodiazepine mimicking a 
peptide turn, BZA-2B (Figure 35-a), gave a potent inhibitor of FTase with an IC50 of 
0.85 nM against recombinant rat FTase. The corresponding methyl ester, BZA-5B 
(Figure 35-a), was found to be active in cells. At micromolar concentrations, it was able 
to restore normal growth to Ras-transformed cells. BZA-5B interrupts the MAP kinase 
activation pathway in H-Ras-transformed cells. Recently, it has been reportd that BZA-
5B blocks farnesylation of the lamin proteins with an IC50 comparable to that obtained 
for Ras p21. However, it did not interfere with a variety of cellular functions expected 
to be farnesylation dependent such as cell growth and viability. 
Although the above results show no interference with cellular function, the 
blockade of farnesylation of other proteins should still be of concern. As more potent 
agents are developed and tested in various in vivo models, it will become of upmost 
importance to monitor closely if indeed proteins such as lamin-B and transducin are 
post-translationally modified in the presence of Ras FTase inhibitors as well as and 
their effects on the viability of the cells. 
 
Figure 35: Peptidomimetic inhibitors-part VI 
The two aliphatic residues have also been replaced by a hydrophobic spacer, 3-
(aminomethyl)benzoic acid (3-AMBA) (Figure 35-b). Cys-3-AMBA-Met inhibits p21 Ras 
FTase from human colon carcinoma (COLO-205) and Burkett’s lymphoma (Daudi) with 
IC50 values of 60 and 120 nM, respectively. 
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Substitution of the two aliphatic residues was also carried out with 4-AMBA and 
3- and 4-aminobenzoic acid (3- and 4-ABA). Cys- 4-AMBA-Met was 17-fold less potent 
than the corresponding 3-AMBA analogue, and Cys-3-ABA-Met also showed reduced 
activity. However, Cys-4-ABA-Met had an IC50 of 50 nM. Introduction of functionality 
such as N,S-di-Cbz-Cys-3-AMBA-Met-OCH3 led to compounds which could penetrate 
NIH 3T3 cells and disrupt p21 Ras plasma membrane association. 
  Substitution at the 2-position of the 4-aminobenzoic acid moiety with a phenyl 
group led to a potent inhibitor (FTI-276) of Ras FTase with an IC50 of 0.5 nM, against 
human FTase (Figure 35-c), and it was 100-fold selective, with an IC50 of 50 nM 
against human GGTase-I. The corresponding methyl ester (FTI-277; Figure 35-c) has an 
IC50 of 50 nM against human FTase but inhibits H-Ras processing in whole cells with 
an IC50 of 100 nM and induces accumulation of cytoplasmic nonfarnesylated H-Ras 
that was able to bind Raf and form a Ras/Raf complex where Raf was not activated. 
FTI-277 did not inhibit processing of Rap by GGTase-I at concentrations as high as 10 
µM.136 The inhibitor FTI-276 blocked the growth in nude mice of a human lung 
carcinoma expressing oncogenic K-Ras (50 mg/kg, dosed ip for 36 days). FTI- 276 also 
inhibits oncogenic signaling and tumor growth of NIH 3T3 cells transformed with the 
Ras oncogene at 20 µM. 
Further design led to the replacement of the AAX tripeptide with biphenyl 
derivatives. The analogue (R)-4-[N-(3-mercapto-2-aminopropyl)amino]-3’-
carboxybiphenyl (Figure 35-d) was found to inhibit rat brain FTase with an IC50 of 50 
nM, while it inhibited GGTase-I with an IC50 of 100 µM. It disrupted H-Ras processing at 
a concentration of 50 µM (human H-Ras oncogenetransformed Balb/c 3T3 cells). 
More recently, a piperazine analogue, L-745,631, was reported to suppress 
tumor growth in nude mice (Figure 35-e). It was found to be potent against bovine 
FTase (IC50 = 5 nM) and selective (IC50 against GGTase-I = 10 µM). It was shown to 
inhibit Ras processing with an IC50 of 0.5 µM and to be noncytotoxic to NIH 3T3 cells at 
concentrations up to 100 µM. In H-Rastransfected NIH 3T3 cells, it suppresses tumor 
growth by 75% at a dose of 40 mg/kg (sc administration). 
The bioactive conformation of the CAAX-based FTase inhibitors has been 
studied by NMR spectroscopy. One study suggested that the tetrapeptide of the 
sequence KTKCVFM adopted a type I β-turn conformation in the bound state.  
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This conclusion was obtained by studying the heptapeptide by NMR spectroscopy in 
the presence of the FTase enzyme analyzing the transferred nuclear Overhauser 
effects (NOEs). However activity of the inhibitors where the two aliphatic amino acids 
have been replaced by 3- or 4-aminobenzoic acid or 3- or 4-(aminomethyl)benzoic acid 
would argue against a α-turn since, for these tetrapeptide mimetics, the flexibility of 
the aminobenzoic acid spacer is different than the two amino acids, Val-Phe. In 
particular, for the 4-aminobenzoic acid spacer, it is not possible for the molecule to 
adopt a β-turn conformation, and yet it is a potent FTase inhibitor (50 nM). These two 
different sets of results suggest that the conformation of the terminal CAAX motif 
needs to be investigated further. 
The disclosure of the structure of the FTase enzyme will hopefully further our 
understanding of the binding of specific classes of inhibitors and provide insight into 
the bioactive conformation of the CAAX peptidomimetics. Meanwhile, to investigate the 
binding sites of the substrates, there have been reports using radiolabeled FPP 
analogues suggesting that the β-subunit contributes significantly to the recognition 
and binding of the isoprenoid substrate. However, there has been no work with 
elucidating the site for the protein substrate, and at this point interaction with the R-
subunit cannot be precluded. 
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FPP analogues 
 
Since the FTase catalyzed Ras farnesylation involves two substrates, FPP and Ras, 
there has been interest in the design of molecules that can mimic the FPP substrate 
as a strategy for blocking FTase activity.  
Unlike the peptidomimetic strategy, FPP analogues have an inherent 
disadvantage in functioning as FTase inhibitors. The problem comes from inhibitor 
specificity for FTase over other FPP utilizing enzymes such as squalene synthase.  
As FPP is an important intermediate in cholesterol biosynthesis, nonspecific binding by 
FPP analogues will cause side effects 
The design of FPP analogues started by substituting the hydrolyzable 
diphosphate fragment in FPP: in the first derivative, the α-hydroxyfarnesylphosphonic 
acid (Figure 36-a), a monophosphonate replaced the pyrophosphate group in FPP.  
In the second analogue, farnesylmethylhydroxyphosphinyl methyl phosphonic acid 
(Figure 36-b), the diphosphate oxygen atom is replaced with a methylene group.  
 
Figure 36: FPP analogues (part I) 
Both the derivatives have no hydrolyzable bonds and have been shown to be 
competitive to FPP and non competitive to Ras protein in inhibiting FTase with 
inhibition constants of 5.2 and 8.30 nM, respectively55. 
The first compound was also proved to inhibit squalene synthase in vitro with an IC50 
of 630 nM. The inhibition of H-Ras processing in whole cells with this compound was 
observed at a concentration of 1 µM. 
                                                            
55 Pompliano, D. L.; Rands, E.; Schaber, M. D.; Mosser, S. D.; Anthony, N. J.; Gibbs, J. B., 1992, 
Biochemistry, 31, 3800-3807; Gibbs, J. B.; Pompliano, D. L.; Mosser, S. D.; Rands, E.; Lingham, R. B.; 
Singh, S. B.; Scolnick, E. M.; Kohl, N. E.; Oliff, A., 1993, J. Biol. Chem., 268, 7617-7620; 
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The selectivity of these analogues for FTase over GGTase-I is not known but would be 
of interest. 
Farnesyl pyrophosphate analogues that are potent and selective inhibitors of 
FTase were sequentially described, with the insertion of other functional groups on the 
backbone (Figure 37-a)56.  
 
Figure 37: FPP analogues (part II) 
Farnesyl pyrophosphate analogues I-III revealed to be selective inhibitors of FTase in 
vitro, having IC50s of 0.083, 0.075, and 2.61 µM, respectively. In particular, compound 
III, synthesized as prodrug, blocked H-Ras-mediated transformation of NIH 3T3 cells at 
concentrations of 100 µM. None showed toxicity to untransformed cells up to 
concentrations of 250 µM.  
This represents the first report of a farnesyl pyrophosphate analogue showing 
biological activity in inhibiting Ras processing in whole cells. 
Another approach was the incorporation of fluorines at the R-position of the α-
ketophosphonic acid (Figure 37-b), yielding an inhibitor with an IC50 of 0.35 µM against 
pig FTase. FPP derivatives of phenylalanine have also been reported as potent 
selective FTase inhibitors (Figure 37-c). The compound here reported was found to 
inhibit bovine FTase with an IC50 of 0.08 µM. 
Concluding, this class of inhibitors has been less potent in cells, and no in vivo 
activity has been demonstrated for any of these inhibitors. 
  
                                                            
56 Manne, V. et all, 1995, Drug Dev. Res., 34, 121-137; Kang, M. S.; Stemerick, D. M.; Zwolshen, J. H.; 
Harry, B. S.; Sunkara, P. S.; Harrison, B. L., 1995, Biochem. Biophys. Res. Commun., 217, 245-249; 
Lamothe, M.; Perrin, D.; Blotiere, D.; Leborgne, M.; Gras, S.; Bonnet, D.; Hill, B. T.; Halazy, S., 1996, 
BioOrg. Med. Chem. Lett., 6, 1291-1296. 
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Bisubstrate analogues 
 
Bisubstrate derivatives of Ras FTase incorporate the structural motifs of both FPP and 
the CAAX tetrapeptide57. 
A few examples of such compounds are here reported; in the first case the 
substitution of thiol moiety of the CAAX motif with a carboxylic acid, together with the 
binding of the farnesyl chain on this carboxylic acid through a secondary amine, yields 
a sub-micromolar range inhibitor (Figure 38), having a IC50 of 0.033 µM. 
 
Figure 38: Bisubstrate analogue 
The selectivity of this inhibitor versus FTase or GGTase-I is unknown, and it would be of 
interest to determine whether the replacement of the thiol group by a carboxylic acid 
group would favor one over the other and whether these compounds are competitive 
for FPP or the peptide or both.  
A second bisubstrate analogue is the phosphinate inhibitor BMS-186511 
(Figure 39); it was shown to inhibit Ras processing in H-Ras-transformed NIH 3T3 cells 
at concentrations as low as 0.1 µM and it showed a higher affinity for FTase versus 
GGTase-I (>2000-fold). 
 
Figure 39: BMS-186511 
                                                            
57 Bhide, R. S. et all, 1994, BioOrg. Med. Chem. Lett., 4, 2107-2112; Manne, V. et all, 1995, Oncogene, 
10, 1763-1779; 
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Similar results were obtained with K-Ras-transformed NIH 3T3 cells. BMS-186511 
inhibited [3H]mevalonate incorporation into p21 Ras proteins in a 
concentrationdependent manner. At 100 µM, the Ras farnesylation was almost 
completely inhibited in H-Ras- and K-Ras- transformed NIH 3T3 cells. This inhibitor was 
also shown to be a selective Ras FTase inhibitor (>2000-fold) and had little effect on 
normal cells.  
 
Natural inhibitors 
Several natural product inhibitors of FTase have been reported, but in general their 
potency is not so high, compared to the one of synthetic FTIs58. 
Some are competitive with farnesyl pyrophosphate (FPP), including chaetomellic acids 
(Figure 40-a), actinoplanic acid A (Figure 40-b) and manumycin analogues (Figure 40-
c). 
  
Figure 40: Chaetomellic acids (a), actonoplanic acid A (b) and manumycin analogues (c) . 
                                                            
58 Singh, S. B.et all, 1993, Tetrahedron, 49, 5917-5926; Singh, S. B., 1993, Tetrahedon Lett., 34, 
6521-6524; Lingham, R. B. et all, 1993, Appl. Microbiol. Biotechnol., 40, 370-374; Singh, S. B.; Liesch, 
J. M.; Lingham, R. B.; Goetz, M. A.; Gibbs, J. B., 1994, J. Am. Chem. Soc., 116, 11606-11607; Hara, M.; 
Akasaka, K.; Akinaga, S.; Okabe, M.; Nakano, H.; Gomez, R.; Wood, D.; Uh, M.; Tamanoi, F., 1993, Proc. 
Natl. Acad. Sci. U.S.A., 90, 2281-2285; Tamanoi, F., 1993, Trends Biochem. Sci., 18, 349-353; Shiomi, 
K. Et all, 1993, J. Antiobiot., 46, 229-234; Singh, S. B. et all, 1994, Tetrahedron Lett., 35, 4963-4696; 
Singh, S. B. et all, 1994, J. Org. Chem., 59, 6269-6302; Van der Pyl, D.; Inokoshi, J.; Shiomi, K.; Yang, H.; 
Takeshima, H.; Omura, S., 1992, J. Antibiot., 45, 1802-1805; Liu, W. C. et all, 1992, J. Antibiot., 45, 
454-457; Singh, S. B.et all, 1995, Tetrahedron Lett., 36, 4935-4938; 
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Other inhibitors, such as pepticinnamins, are competitive with the Ras peptide (Figure 
41). 
The remaining inhibitors do not refer neither to FPP nor to the CAAX tetrapeptide, and 
their mechanism of inhibition is unknown. 
Examples of such inhibitors are fusidienol (Figure 42-a), preussomerins (Figure 42-b), 
gliotoxin (Figure 42-c), 10’-desmethoxystreptonigrin (Figure 42-d) and cylindrol A 
(Figure 42-e). 
 
 
 
 
 
 
 
Figure 41: Pepticinnamins 
 
Figure 42: Non competitive natural inhibitors 
 
The potency of this class of FTIs varies from submicromolar to micromolar (Table 7: 
Activity of natural FTIs). One of the manumycin analogues, UFC1-C (Figure 40-c), was 
shown to inhibit the growth of K-Ras-transformed fibrosarcoma at a dose of 6.3 mg/kg, 
administered intraperitoneally for 5 days. 
 
Table 7: Activity of natural FTIs  
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Aim of the work 
 
The tetrapeptide CAAX, proven to be a potent FTase inhibitor in vitro, showed 
devoid of activity in vivo, therefore it inspired the design of CAAX mimetics, more 
metabolically stable and with enhanced cell permeability.  
Among these, my research group in the latest years focused its attention in the 
modification of the tetrapeptide structure.  
The first studies brought to mimetics having a biphenyl core in lieu of the 
dipeptide “AA” and, in particular, to compounds in which the biphenyl substructure, 2’-
methyl or 2’-methoxy substituted, bears a 3-pyridodioxanylmethyloxy residue replacing 
Cysteine (Figure 43).  
 
Figure 43 
It has been also demonstrated that pyridodioxane nucleus, namely 2,3-dihydro-
1,4-dioxino[2,3-b]pyridine, linked to the 2'-methyl or 2'-methoxy substituted biphenyl by 
a methyleneoxy or a methyleneaminocarbonyl bridge, can replace the 3-
pyridyloxymethyl residue maintaining, if the linker is a methyleneoxy chain, a high 
FTase inhibition and producing micromolar antiproliferative activity on human aorta 
myocytes due to Ras farnesylation inhibition59.  
Consistently with these results, docking of the whole series of pyridodioxane 
derivatives in the crystal structure of human FTase enlightens a better interaction of 
the enzyme with the pyridodioxanemethyl ethers than with the pyridodioxanemethyl 
amides and, in particular, the best interaction with the pyridodioxanemethyl ethers 2'-
                                                            
59  Bolchi C, Pallavicini M, Rusconi C, Diomede l, Ferri N, Corsini A, Fumagalli L, Pedretti A, Vistoli G, 
Valoti E, 2007, Bioorg. Med. Chem. Lett., 17, 6192-6196; 
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methoxy substituted at the biphenyl core, which are just the most potent inhibitors of 
FTase and of cell proliferation in the series. 
Successively, new Ras CAAX mimetics have been investigated, in which the 
pyridodioxane system is replaced by benzodioxane (Figure 44), thus effecting a 
simplifying isosteric modification, which could have beneficial effects in the case of 
unfavourable position of nitrogen in the pyridodioxane system.  
 
Figure 44 
In this new series of compounds, all esterified at the terminal X amino acid 
residue (Methionine, Glycine or Leucine), the best activity is shown by the derivatives 
with methyleneoxy linker between dioxane and 2’-methyl substituted biphenyl. In 
particular, the compound with terminal Methionine and S configuration at the dioxane 
C-2 proves to be a good Ras prenylation inhibitor. In addition, comparison with the 
methyl ester of the corresponding pyridodioxane analogue indicates that replacement 
of pyridodioxane with benzodioxane potentiates the activity60.  
The 2-Amino-4-thiazolyl moiety has been also considered as alternative 
heterocycle to construct systems mimicking terminal Cysteine.  
 
Figure 45 
                                                            
60
 Bolchi C, Pallavicini M, Fumagalli L, Ferri N, Corsini A, Rusconi C, Valoti E, 2009, Bioorg Med Chem 
Lett, 19, 550-5504; 
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In particular, 2-amino-4-thiazolyl is basic as pyridine and has pronounced 
complexation properties. Indeed, the CAAX mimetic, in which AA is replaced with 4-
amino-2-phenylbenzoic acid and C with 2-amino-4-thiazolylacetic acid (Figure 45) 
inhibits FTase activity in the low nanomolar range and shows antiproliferative effect on 
rat aortic smooth muscle cells (SMC) interfering with Ras farnesylation. 
These results indicate that 2-amino-4-thiazole can be regarded as an alternative to 
heterocycles, such as pyridine and imidazole, normally used in FTase inhibitors 
designed as non-thiol CAAX mimetics.  
 Considering these previous results, the present PhD project started from 
compound A, which exerts a nanomolar range FTase inhibition, substituting the 2-
amino-4-thiazolylacetyl residue with other heterocycles. 
Specifically, the chosen moieities have been the 2-mercapto-4-imidazolylacetyl-, 2-
mercapto-4-imidazolylpropionyl-, 2-mercapto-4-thiazolylacetyl-, 2-mercapto-4-
thiazolylpropionyl-, 2-methylthio-4thiazolylacetyl- and 2-methylthio-4thiazolylpropionyl- 
ones; the resulting derivatives, isopropylesters (27, 29, 31, 33, 35 and 37) and 
corresponding acids (28, 30, 32, 34, 36 and 38), are reported in Figure 4661. 
 
Figure 46 
The antiproliferative activity of the isopropyl compounds, prepared as prodrugs, 
and of the relative free carboxylic acids was evaluated using two specific tests: 
respectively a cellular and an enzymatic assay. All the resulting data confirmed their 
antiproliferative activity, even if at micromolar range, suggesting us to design further 
FTIs, differently modified. 
                                                            
61 Bolchi C, Pallavicini M, Bernini S K, Chiodini G, Corsini A, Ferri N, Fumagalli L, Straniero V, Valoti E; 
2011, Bioorg Med Chem Lett, 21, 5408-5412; 
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On these bases, starting from both compounds A and B (Figure 44 and Figure 
45) and from an interesting work by Qian and others62, there were investigated 
different aromatic substitutions.  
Therefore novel FTIs were designed; specifically the first modification occurred to the 
aromatic spacer, which mimics AA of the CAAX tetrapeptide, replacing the o-tolyl 
residue with other six heteroaromatic ones, specifically the 2-thienyl-, 3-thienyl-, 3-
furanyl-, 3-furanyl-, 4-isoquinolyn- and 1-naphtyl-. 
The accomplished comounds are shown in Figure 47 and-Figure 48. 
 
Figure 47-Figure 48 
Furthermore, starting from the structure of compound A in Figure 44, it has 
been chosen to invariably connect the aromatic spacer to the terminal heterocyclic 
system by an amide function.  
The synthesis involved all the derivatives bringing the six heteroaromatic residue 
together with the one having the o-tolyl one, so far undesigned, in order to study how 
such new modifications could influence the inhibitory activity. 
Figure 49 reports all the yielded derivatives 63-76.  
 
Figure 49 
                                                            
62 Qian Y, Marugan J J, Fossum R D, Vogt A, Sebti S M, Hamilton A D, 1999, Bioorg. Med. Chem. Lett., 7, 
3011-3024; 
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All the novel FTIs were tested with the two different assays, mentioned before: 
in particular the biological activity of the isopropyl esters were examined measuring 
the proliferation inhibition of the human aortic smooth muscle cells, as explained 
before. On the other hand, the FTase inhibition of the free acids was evaluated using 
recombinant rat FTase in a FTase fluorescent assay.  
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Synthetic scheme 
 
The synthetic pathway has been specific for each single class of novel FTIs. 
The synthesis of the FTase inhibitors 27-32, modified on the N-terminal residue 
and reported in Figure 46, is shown in Figure 50, 51 and 52; it started from the 
commercially available 2-bromo-4-nitro toluene that underwent oxidation in pyridine 
with potassium permanganate (bd)63.  
The further convertion into methyl ester, achieved in Methanol using H2SO4 as catalyst 
(be), afforded XVI, which was coupled with o-tolyl boronic acid using Suzuki conditions 
(bf) to give the biphenyl derivative XVII.  
Successive reduction of nitro to amino group (bg) accomplished XVIII, which was 
condensed with the isopropyl ester of L-Methionine (bh); the resultant N-
nitrobenzoylated methionine ester XIX underwent hydrogenolysis, yielding the 
corresponding aminobenzoylamide XX.  
 Reagents and conditions: (bd) KMnO4 ,Pyridine, water, 96h, reflux; (be) H2SO4, MeOH, trimethylorthoformate,18h, 
reflux; (bf) tolyl boronic acid, K2CO3, Pd(PPh3)4, Toluene/MeOH/Water, 18h, 80°C; (bg) NaOH, MeOH, 18h, RT; (bh) 
H-L-Met-Oi-Pr, HOBt, EDAC*HCl, DIPEA, DMF, 18h, RT; (bi) SnCl2, AcOEt, 3h, reflux; 
Figure 50 
This compound (XX) is the starting point for the condensation with all the heteroaryl 
acetic and propionic acids, that had to be prepared from ethyl 4-chloroacetoacetate 
and methyl 5-bromolevulinate (XXVIII). XXVIII is simply yielded through bromination of 
the levulinic acid (bn), as shown in Figure 51. 
                                                            
63
 Bolchi C, Pallavicini M, Bernini S K, Chiodini G, Corsini A, Ferri N, Fumagalli L, Straniero V, Valoti E; 2011, 
Bioorg Med Chem Lett, 21, 5408-5412; 
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Reagents and conditions: (bj) NaN3, water, THF, 18h, RT; (bk) H2, Pd/C 10%, TsOH, EtOH, 4h, RT; (bl) KNCS, H2O, 
2h, reflux; (bm) NaOH, MeOH, 1h, reflux; (bn) Br2, MeOH, 60h, RT; (bo) ammonium dithiocarbamate, H2O, 15h, 
reflux; (bp) NaOH, 55°C, 1h; (bq) CH3I, NaH, DME, 15h, RT. 
Figure 51 
The heteroaryl acids were accomplished as shown in Figure 51, specifically the 
mercaptoimidazolyl acetic acid (XXIII) and its propionic homologue (XXXI) were 
obtained by conversion (bj) of ethyl 4- chloroacetoacetate and of methyl 5-
bromolevulinate into the corresponding azides (XXI and XXIX), (bk) reduction to 4-
aminoacetoacetate (XXII) and 5-aminolevulinate (XXX), isolated as tosylic acid salts, 
(bl) cyclization with potassium thiocyanate giving the mercaptoimidazole ring and the 
successive (bm) ester hydrolysis. 
 Cyclization of ethyl 4-chloroacetoacetate and methyl 5-bromolevulinate with 
ammonium dithiocarbamate afforded ethyl (2-mercapto-4-thiazolyl)acetate (XXIV) and 
methyl 3-(2-mercapto-4-thiazolyl) propinate (XXXII), respectively, which were 
successively converted into acids XXV and XXIII by basic hydrolisys (bp). 
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The methylthio analogues, XXVII and XXXV, were obtained in the same manner, 
after methylation of compounds XXIV and XXXII with methyl iodide in a suspension of 
NaH in DME. 
The condensation of each single heteroaryl acetic and propionic acid with the amino 
benzoylamide XX is achieved in DMF using HOBt and EDAC as coupling reagents; the 
following hydrolysis in basic conditions yielded the final products 28, 30, 32, 34, 36 
and 38, as shown in Figure 52. 
Reagents and conditions: (br) HOBt, EDAC*HCl, DIPEA, DMF, 18h, RT; (bs) NaOH, MeOH, 2-3 h, RT. 
 
Figure 52 
Concerning the second approach, the syntheses of the two different series of 
amidic compound (Figure 47 e 49), and of the ethereal series (Figure 48) require three 
different scaffold, whose preparation is shown in Figure 53. 
The synthesis of the scaffold XXXVIII started from the 2-amino-4-thiazolyl-acetic-
acid, that is firstly esterified in Methanol using thionyl chloride (bs), then tritylated at 
the amino function (bt) and finally desesterified in basic conditions (bu). 
The compound XLI is prepared from the methylacrilate, through bromination 
(bv), condensation with the cathecol, using potassium carbonate in Isopropanol (bw), 
and hydrolysis of the methylester (bx). The treatment with pure thionyl chloride 
accomplished the 2-benzodioxanyl-acyl chloride (by). 
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The last scaffold (XLIII), that is the 2-mesiloxymethylbenzodioxane, is 
synthesised starting from the condensation of the epichlorohydrin on the cathecol (bz), 
followed by mesylation in DCM (ca), in the presence of TEA as base. These three 
scaffolds are stable and they are used for the synthesis of each final product.  
 
 
Reagents and conditions: (bt) SOCl2, MeOH, 12h, RT; (bu) TrtCl, TEA, DCM, 15h, RT; (bv) 2.5N NaOH, MeOH, 3h, 
reflux; (bw) Br2, DCM, 30 min, RT; (bx) (1) K2CO3, i-PrOH, 18h, reflux; (2) NaOH, MeOH, 2h, reflux; (by) SOCl2, 
Toluene, 3h, reflux; (bz) K2CO3 ,MeOH, 8h, reflux; (ca) MsCl, TEA, DCM, 1h, RT. 
 
Figure 53 
The synthetic pathway for the two aminic series of novel FTIs is shown in Figure 
54 and started from compound XVI, whose preparation has been explained before 
(Figure 50).  
XVI was then coupled with the six different boronic acids (cb). The Suzuki 
coupling, achieved using different boronic acids, in individual conditions (solvents and 
temperatures), was followed by hydrolysis (cc) and condensation with the isopropyl 
ester of L-methionine (cd); the consecutive reduction of the nitro group (ce), achieved 
in Ethyl Acetate with Stannous chloride, led to the aminic compound XLVII, which 
reacted either with acidic scaffold XXXVIII or scaffold XLI.  
The condensation with the 2-trytilamino-4-tiazolyl-acetic acid is achieved in DMF 
using HOBt and EDAC as coupling reagents (cf). The sequential acidic removal of the 
protective trityl group (cg) and the hydrolysis of the esteric function (ch) gave the final 
products 45-50.  
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Meanwhile the condensation with the 2-mesiloxymethyl-benzodioxane is 
accomplished in DCM with DIPEA (ci), and followed by hydrolysis in basic condition (cj), 
obtaining the second series of FTase inhibitors, as free carboxylic acid (70-76). 
 
Reagents and conditions: (cb) RB(OH)2, K2CO3, Pd(PPh3)4, DME or DMF or THf or Toluene/MeOH/Water, 18h, RT-
100°C; (cc) NaOH, MeOH, 18h, RT; (cd) H-L-Met-Oi-Pr, HOBt, EDAC*HCl, DIPEA, DCM or DMF, 18h, RT; (ce) SnCl2, 
AcOEt, 3h, reflux; (cf) HOBt, EDAC*HCl, DIPEA, DMF, 18h, RT; (cg) HCOOH, DCM, 18h, RT, (ch) NaOH, MeOH, 18h, 
RT, (ci) DIPEA, DCM, 3h, RT, (cj) NaOH, MeOH, 18h, RT. 
 
Figure 54 
As shown in Figure 55, the starting point for the synthesis of the ethereal FTIs is 
compound L, achieved, starting from XVI, through reduction (ck) and consecutive 
diazotation and replacement by hydroxyl group (cl), yielding the relative phenol.  
The hydroxyl group is sequentially condensed with scaffold XLII in DMF and potassium 
carbonate (cm), the subsequent Suzuki coupling (cn) and hydrolysis (co) let to obtain 
the free carboxylic acid, able to be condensed with the isopropyl ester of the L-
methionine (cp) and then hydrolyzed in basic conditions (cq), giving the final products 
57-62. 
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Reagents and conditions: (ck) SnCl2, AcOEt, 3h, reflux; (cl) NaNO2 ,H2SO4 20%,18h, reflux; (cm) K2CO3, DMF, 18h, 
60°C; (cn) RB(OH)2, K2CO3, Pd(PPh3)4, DME or DMF or THF or Toluene/MeOH/Water, 18h, RT-100°C; (co) NaOH, 
MeOH, 18h, RT; (cp) H-L-Met-Oi-Pr, HOBt, EDAC*HCl, DIPEA, DMF, 18h, RT; (cq) NaOH, MeOH, 18h, RT. 
 
Figure 55 
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Biological evaluation 
 
Two different assays have been performed in order to study the inhibiton ability of the 
entire novel FTis. Particularly, at first FTase inhibition of the free acids was evaluated 
using recombinant rat FTase in a FTase fluorescent assay, then the biological activity 
of the isopropyl esters were examined measuring the proliferation inhibition of the 
human aortic smooth muscle cells (SMC). 
 
 
In vitro FTase assay 
The effect on protein farnesylation was tested using a FTase fluorescent assay 
and FTI-276 (Figure 35-c) and B (Figure 45) as reference compounds  
FTI-276 and B, as explainded before, were proved to inhibit FTase with an IC50 of, 
respectively, 0.5 nM and of 49 nM. 
In this test, the substrates used were Dansyl-Gly-Cys-Val-Leu-Ser-OH peptide 
(Calbiochem) and farnesyl-pyrophosphate (FPP) (SIGMA).  
Each reaction mixture contained Dansyl peptide (final concentration 3 µM), FPP (final 
concentration 10 µM) and n-docecyl-β-D-maltoside in 25 µL of Assay buffer (MTT 5.8 
mM, MgCl2 12 mM, ZnCl2 12 mM, Tris pH 7.5 52 mM) aliquoted in a 384 wells plate.  
 The reaction was started by adding of rat recombinant FTase (0.25 µg per 
reaction) and conducted in the presence or absence of tested compounds (20 µM).  
The fluorescent signal was recorder by using the Fluoroskan Ascent Microplate 
Fluorometer (Labsystem) every 15 s for 5 min.  
The inhibitory activity (% vs control) and the IC50 values were calculated from the 
fluorescent signal at the steady state, and the respective values are listed in Table 8.  
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Compound 
FTase Assay 
(inhibition at 20 µM) 
IC50 
FTI-276 - IC50 = 0.005 µM 
B - IC50 = 0.049 µM 
28 - IC50 = 0.12 µM 
30 - n.a. 
32 - IC50 = 0.54 µM 
34 - IC50 = 0.53 µM 
36 - n.a. 
38 - IC50 = 0.41 µM 
45 53.8%  n.d. 
46 20.9% n.d. 
47 15.4% n.d. 
48 98.7% IC50 = 2.8 µM 
49 0% n.d. 
50 90.4%  n.d. 
57 90.0%  n.d. 
58 96.6%  IC50 = 5.0 µM  
59 51.5% n.d. 
60 48.7%  n.d. 
61 14.5% n.d. 
62 41.7% n.d. 
70 6.2% n.d. 
71 0% n.d. 
72 4.8% n.d. 
73 72.9% n.d. 
74 0% n.d. 
75 67.7% n.d. 
76 73.9%  n.d. 
Table 8: Inhibition of FTase activity (n.d.: not determined) 
 
Cell proliferation assay 
In order to study whether the compounds ability to interfere with FTase activity in vitro 
was maintained also in cultured cells, the Ras prenylation was investigated, by SDS–
PAGE from a total cell lysates of rat SMCs. 
Cells were incubated for 72 h, at 37°C, in the presence and in the absence of 
our compounds, at three different concentrations: 100, 250 and 500 µM; at the end 
of this incubation period the cell number was determined and the value was 
subtracted with the starting number of cells.  
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The IC50 values were then calculated by nonlinear regression curve and are 
summarized in Table 9.  
Compound 
Cell proliferation Assay (MTT) 
(IC50) 
B 28.5 µM 
27 226 µM 
29 n.a. 
31 21 µM 
33 25 µM 
35 n.a. 
37 n.a. 
39 200 µM  
40 123 µM  
41 110 µM 
42 259 µM 
43 252 µM 
44 81 µM 
51 81 µM 
52 n.a.  
53 98.9 µM 
54 61.5 µM  
55 n.a. 
56 155 µM 
63 n.a. 
64 333 µM  
65 n.a.  
66 478 µM 
67 n.a. 
68 38 µM 
69 n.a. 
Table 9: Inhibition of rat SMC proliferation (n.a.: not active) 
 
Discussion and conclusion 
The entire compounds, modified on the N-terminal residue and reported in 
Figure 46 (27-38), were biologically evaluated; the results suggest that compounds 31 
and 33 show an improved antiproliferative activity, compared to the one of compound 
B.  
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In contrast, their compelling inhibitory capacity is not confirmed by the FTase inhibition 
data of the corresponding free carboxylic acids (32 and 34); this should be related to 
the toxical events that could affect the molecule itself.  
In addition, the introduction of SH substituent, instead of NH2, into the 2- 
position of thiazole, couldn’t improve the activity due to the weak basicity of the 2-
aminothiazole opposed to the weak acidity of the 2-mercaptothiazol.  
Such a difference cannot be considered uninfluential, especially in molecules with a 
carboxylic head, and it is not accidental that the fragment mimicking Cysteine in the 
known CAAX mimetics preferably has weakly basic or neutral character rather than 
acidic.  
Moreover, the tautomeric thione-thiol equilibrium might further justify the remarkable 
decrease of activity. Obviously, this does not mean that SH methylation is sufficient to 
restore the FTase activity, as demonstrated by compounds 36 and 38, which are also 
modestly or totally inactive. 
Considering the three series of FTIs modified on the aromatic spacer, the 
interesting results coming from the substitution of the o-tolyl with a naphtalenic 
system (50 and 75) indicate that, indeed, a bicyclic system could fit the enzymatic 
cavity.  
On the other hand, such a hindrance, in addition to the introduction of a nitrogen 
atom, causes a total decrease in the inhibitory activity (49, 61 and 74)  
Further investigations should be performed on these molecules, in order to completely 
define how the isoquinoline ring could influence the FTase activity. 
Comparing the enzymatic inhibitions of the two amidic series of all the derivatives (45-
50 versus 70-76), there is clear evidence that the preservation of the 2-amino-4-
thiazolylmethyl chain causes a better FTase inhibition, confirming the activity of the 
precursor B. 
The FTase inhibition activity of the thienyl derivatives (45-46, 57-58 and 70-
71), differently substituted at the N-terminal, reveals that the introduction of the 
thiophene, a classical example of benzene isosteric substitution, results in a beneficial 
effect. Specifically, for all these compounds there is a regular trend: the enzymatic 
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inhibition is maximal for the ethereal derivatives, intermediate for the 2-amino-4-
thiazolylmethyl- amidic series and minimal for the benzodioxanyl- amidic class.  
A different outcome results from the furanyl FTIs; the 2-furanyl compounds, 
even less active than the corresponding thionyl derivatives, have the same trend 
explained before (FTase inhibition scale: 72 < 47 < 59).  
On the contrary, the most potent of the 3-furanyl FTIs is 48, belonging to the 2-
amino-4-thiazolylmethyl- amidic class. This could be due to a different arrangement of 
the furanyl ring in the FTase cavity, causing a specific interaction of the molecule with 
the enzyme; this hypothesis should be confirmed by further computational studies.  
It’s interesting to notice that there isn’t a fixed correlation between FTase 
inhibition and antiproliferative activity of the corresponding isopropyl ester; this could 
be due, as explained before, to differences in bioavailability, cell penetration and 
cellular toxicity  
 
In conclusion, it’s now pending how the aromatic spacer specifically interacts 
with the catalytic site of FTase; in particular it’s important to understand if there are 
any HBD points, able to stabilize the FTI binding and therefore the chain 
rearrangement.  
Such an accommodation could also better explain why the isoquinoline derivatives are 
totally inert, and if such an inactivity is related or not to their steric hindrance. 
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Experimental section 
 
1H-NMR spectra were performed at 300 MHz, using a Varian 300 Mercury instrument; 
the chemical shifts are reported in ppm; 
 
Thermal analyses were performed on two different instruments: 
- DCS 2010 TA INSTRUMENTS, using 1-3 mg of each sample, and a heating 
speed of 5°C/ min; 
- Büchi Melting Point B-540; 
 
TLC were performed on standard analytical silica gel layers (thickness 0.20 mm; 
Macherey-Nagel ALUGRAM SIL G/UV254) 
 
Chromatographic purifications were performed, in normal phase, using Biotage 
instruments ( Horizon or SP1) over different Biotage SNAP Ultra flash chromatography 
cartridges, filled of Merck Silica Gel 60 (0.040-0.063 µm)  
The analysis by reverse phase was accomplished using an VWR-Hitachi LaChrom 
Elite® HPLC System, with diode array detector (190–400 nm), over a Water 
XBridgeTM C18 column (5µm, 4.6x150mm); the purification by reverse phase was 
performed on VWR-Hitachi LaPrep® HPLC System, over a Water XBridgeTM Prep C18 
column (5µm, 19x150mm). 
 
The ionization constants and lipophilicity parameters of the dipeptides were 
determined at 25 °C by potentiometric titration with the GlpKa apparatus (Sirius 
Analytical Instruments Ltd., Forest, Row, East Sussex, UK).  
All experiments were carried out under a slow nitrogen flow to avoid CO2 absorption. A 
weighted sample (5–10 mg) was supplied manually, whereas the diluent and all the 
other reagents were added automatically. 
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Acronyms used: 
(NMR): s (singlet); bs (broad singlet); d (doublet); t (triplet); m (multiplet) 
(Solvents and Reactives): ACN (Acetonitrile); DCM (Dichloromethane); DIPEA (N,N-
Diisopropylethylamine); DME (1,2-dimethoxyethane); DMF (Dimethylformamide);; 
DMSO (Dimethylsulphoxide); EDAC (N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride); HOBt (1-Hydroxybenzotriazole hydrate); TFA (Trifluoroacetic acid); THF 
(Tetrahydrofurane); 
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3-((tert-butoxycarbonyl)amino)propanoic acid 
 
 
 
β-Alanine (3.0 g, 33.67 mmol) is dissolved in 20 mL of NaOH 2.5M, the solution is 
cooled to 0°C and then di-tert-butyl-dicarbonate (11.02 mL; 50.51 mmol) is added 
dropwise. 
The reaction is warmed to RT and stirred for 18 hours, monitoring the reaction 
progression by NMR.  
At completion, the mixture is washed twice with Ethyl ether, acidified with HCl 10% and 
extracted three times with Ethyl Acetate. The organic phase is dried over Na2SO4, 
filtered, and concentrated under reduced pressure, yielding 6.08 g (32.13 mmol) of 
the white solid. 
 
 
Yield: 95.5% 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 6.64 (m, 1H), 2.96 (t, 1H, J= 7.04 Hz), 2.18 (t, 2H, J=7.04 Hz), 1.21 (s, 
9H).  
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3-(((benzyloxy)carbonyl)amino)propanoic acid 
 
 
 
β-Alanine (5.0 g, 56.12 mmol) is dissolved in 28.06 mL of NaOH 2M, the solution is 
cooled to 0°C and then benzyl chloroformate (8.41 mL; 58.93 mmol) is added 
dropwise. 
The reaction is stirred at 0°C and monitored by NMR and TLC64.  
After 3 hours the mixture is washed twice with Ethyl ether, acidified with HCl 10% and 
extracted three times with Ethyl Acetate. The organic phase is dried over Na2SO4, 
filtered, and concentrated under reduced pressure, giving 10.06 g (45.06 mmol) of the 
white solid. 
 
 
Yield: 80.3% 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 12.19 (bs, 1H), 7.32 (m, 5H), 5.00 (s, 2H), 3.19 (t, 2H, J= 6.70 Hz), 2.38 (t, 
2H, J=6.70 Hz).  
                                                            
64 TLC conditions: Cyclohexane/ Ethyl Acetate= 60/40 + Acetic Acid 10% 
Rf: 0.19 
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2-(bromomethyl)furan 
 
 
 
To a solution of furan-2-methanol (10.00 g, 101.94 mmol) in 100 mL of dry THF, at -
5°C under a nitrogen atmosphere, is slowly dropped PBr3 (3.19 mL, 33.98 mmol)  
The temperature is maintained at 0°C and the reaction progression is followed by 
TLC65; at completion, the solution is poured in 240 mL of an iced mixture of Ethyl 
ether/ Water= 2/1.  
The two layers are separated; the organic phase is washed with NaHCO3 and brine, 
dried over Na2SO4, decolorized over charcoal and used for the successive reaction 
without further purification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.41 (m, 1H), 6.35 (m, 2H), 4.45 (s, 2H).  
                                                            
65 TLC conditions: Cyclohexane / Ethyl Acetate= 60/ 40 
Rf: 0.60 
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Diethyl 2-acetamido-2-(furan-2-ylmethyl)malonate 
 
 
 
A suspension of potassium tert-butoxide (9.15 g, 81.55 mmol) in 100 mL of THF, 
under a nitrogen atmosphere, is added of diethyl acetamidomalonate (17.71 g, 81.55 
mmol) and stirred for 20 minutes. Then the ethereal solution of the 2-
(bromomethyl)furan (101.94 mmol) is dropped; the ether is removed and the mixture 
is refluxed. 
After 2 hours, monitoring the progression of the reaction by TLC66, the suspension is 
concentrated under vacuum, resumed with Ethyl Acetate, washed with HCl 10%, 
NaHCO3 10% and brine.  
The organic phase is dried over Na2SO4, decolorized on carchoal, filtered and 
concentrated under reduced pressure; the crude is a sticky solid that is further 
crystallized in isopropyl ether yielding 10.91 g (36.70 mmol) of a white solid. 
 
 
Yield: 45% 
 
Melting point: 81.81°C 
 
 
 
 
1H-NMR (CDCl3): 7.27 (m, 1H), 6.65 (bs, 1H), 6.26 (dd, 1H, J= 1.92 Hz, J= 3.30 Hz), 6.03 (dd, 
1H, J= 0.55 Hz, J= 3.30 Hz), 4.28 (q, 4H, J= 7.16 Hz), 3.72 (s, 2H), 2.01 (s, 3H), 1.29 (t, 6H, J= 
7.16 Hz).  
                                                            
66 TLC conditions: Cyclohexane/ Ethyl Acetate= 60/ 40 
Rf: 0.23 
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2-acetamido-2-(furan-2-ylmethyl)malonic acid 
 
O
C10H11NO6
M.W.: 241,20
COOH
AcHN COOH
O
C14H19NO6
M.W.: 297,30
COOCH2CH3
AcHN COOCH2CH3
 
 
To a solution of diethyl 2-acetamido-2-(furan-2-ylmethyl)malonate (10.91 g, 36.70 
mmol) in 100 mL of Dioxane are added dropwise 75 mL of NaOH 4M and the mixture 
is refluxed for 3 hours. 
The reaction is monitored by NMR, at completion, the mixture is slowly poured in a 
flask, containing 300 mL of Ethyl Acetate/ HCl 10%= 1/1. 
The two layers are separated and the aqueous phase is extracted twice more with 
Ethyl Acetate; the organic phases are collected, dried over Na2SO4, filtered and 
concentrated under reduced pressure, yielding 7.44 g (30.83 mmol) of a white solid. 
 
 
Yield: 84% 
 
Melting point: 106.0 °C 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 7.81 (bs, 1H), 7.45 (dd, 1H, J= 0.55 Hz, J= 1.92 Hz), 6.32 (dd, 1H, J= 1.92 
Hz, J= 3.30 Hz), 6.03 (dd, 1H, J= 0.55 Hz, J= 3.30 Hz), 3.48 (s, 2H), 2.01 (s, 3H).  
Carnosine-like derivatives                                                                  Experimental section 
101 
2-acetamido-3-(furan-2-yl)propanoic acid 
 
 
 
A solution of 7.44 g (30.83 mmol) of 2-acetamido-2-(furan-2-ylmethyl)malonic acid in 
75 mL of Dioxane is acidified with Acetic Acid and refluxed for 2 ½ hours, monitoring 
the completion of the reaction by NMR. 
The removal of the solvents yields 4.86 g (24.66 mmol) of a pale brown solid. 
 
 
Yield: 80% 
 
Melting point: 156.78 °C 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.20 (d, 1H, J= 7.70 Hz), 7.50 (dd, 1H, J= 0.55 Hz, J= 1.92 Hz), 6.33 (dd, 
1H, J= 1.92 Hz, J= 3.07 Hz), 6.13 (d, 1H, J= 0.55 Hz, J= 3.07 Hz), 4.49 (m, 1H), 3.04 (dd, 1H, 
J= 5.27 Hz, J= 10.11 Hz), 2.91 (dd, 1H, J= 8.79 Hz, J= 10.11 Hz), 1.85 (s, 3H).  
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1-carboxy-2-(furan-2-yl)ethanaminium chloride 
 
 
 
A solution of 4.86 g (24.66 mmol) of 2-acetamido-3-(furan-2-yl)propanoic acid in 95 
mL of NaOH 4 M is refluxed for 2 ½ hours, monitoring the reaction by NMR. 
At completion, the mixture is cooled to 0°C and acidified with HCl 37%, the solvents 
are removed and the crude is resumed with Isopropanol, heated for 1 hour and 
filtered. 
The resulting solution is concentrated under vacuum, yielding 4.06 g (21.18 mmol) of 
a pale grey solid. 
 
 
Yield: 85.9 % 
 
Melting point: 222.04 °C 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.71 (bs, 3H), 7.58 (dd, 1H, J= 0.55 Hz, J= 1.92 Hz), 6.39 (dd, 1H, J= 1.92 
Hz, J= 3.30 Hz), 6.26 (d, 1H, J= 0.55 Hz, J= 3.30 Hz), 4.10 (t, 1H, J= 5.90 Hz), 3.22 (d, 2H, J= 
5.90 Hz). 
.  
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3-(furan-2-yl)-1-methoxy-1-oxopropan-2-aminium chloride 
 
 
 
Thionyl chloride (1.55 mL, 21.18 mmol) is slowly dropped to a solution of 1-carboxy-2-
(furan-2-yl)ethanaminium chloride 4.06 g (21.18 mmol) and trimethyl orthoformate 
(2.32 mL, 21.18 mmol) in anhydrous methanol (50 mL) at 0°C under a nitrogen 
atmosphere. 
The resulting mixture is warmed to RT, refluxed for 1 h, monitoring the reaction by 
NMR; at completion the solvent is removed, the crude is resumed with Methanol, 
decolorized on carchoal, filtered and concentrated under reduce pressure. 
Crystallization in Acetonitrile yields 3.00 g of a white solid (14.61 mmol). 
 
 
Yield: 69% 
 
Melting point: 152.70 °C 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.56 (bs, 3H), 7.58 (dd, 1H, J= 0.55 Hz, J= 1.92 Hz), 6.39 (dd, 1H, J= 1.92 
Hz, J= 3.30 Hz), 6.26 (d, 1H, J= 0.55 Hz, J= 3.30 Hz), 4.25 (t, 1H, J= 5.90 Hz), 3.68 (s, 3H), 
3.20 (d, 2H, J= 5.90 Hz).  
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Methyl 2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-
(furan-2-yl)propanoate 
 
 
 
A solution of EDAC (3.36 g, 17.53 mmol) and DIPEA (3.05 mL, 17.53 mmol) in 15 mL 
of DCM is added dropwise to a solution of 3-(((benzyloxy)carbonyl)amino)propanoic 
acid (3.91 g, 17.53 mmol), HOBT (2.37 g, 17.53 mmol) in 30 mL of DCM under a 
nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of 3-(furan-2-
yl)-1-methoxy-1-oxopropan-2-aminium chloride (3.00 g, 14.61 mmol) and DIPEA (2.54 
mL, 14.61 mmol) in 15 mL of DCM is added dropwise. 
The reaction mixture is stirred at RT for 2 hours and monitored by TLC67.  
At completion, the mixture is treated with DCM and HCl 10%; the organic layer is 
washed with NaHCO3 and brine, dried over Na2SO4, filtered, and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Toluene/Ethyl Acetate = 60/40 as elution solvent, to give 3.50 g (9.35 mmol) of the 
desired product, as pale yellow solid. 
 
Yield: 64 % 
 
Melting point: 89.79 °C 
 
 
1H NMR (·d6DMSO): 8.39 (d, 1H, J= 7.71 Hz), 7.50 (dd, 1H,J= 0.55 Hz; J=1.92 Hz), 7.33 (m, 
5H), 7.17 (m, 1H), 6.32 (dd, 1H, J= 1.92 Hz, J= 2.48 Hz), 6.13 (dd, 1H, J= 0.55 Hz, J= 2.48 
Hz), 5.00 (s, 2H), 4.50 (m, 1H), 3.59 (s, 3H), 3.14 (m, 2H), 3.00 (m, 2H), 2.28 (m, 2H). 
                                                            
67 TLC conditions: Chloroform/ Methanol= 95/5 + TEA 1% 
Rf= 0.56 
Carnosine-like derivatives                                                                  Experimental section 
105 
2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-(furan-
2-yl)propanoic acid 
 
 
3.50 g (9.35 mmol) of Methyl 2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-(furan-
2-yl)propanoate are dissolved in 35 mL of Methanol; 7 of NaOH 4M are dropped and 
the resulting mixture is stirred at RT for 1 hour. 
After completion of the reaction, followed by TLC68, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with HCl 10% and extracted three times with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated, 
yielding 3.27 g (9.07 mmol) of a white solid.  
 
 
Yield: 97% 
 
Melting point: 136.22 °C 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.22 (d, 1H, J=7.71 Hz), 7.50 (dd, 1H, J=0.55 Hz, J=1.92 Hz), 7.33 (m, 
5H), 7.17 (m, 1H), 6.32 (dd, 1H, J=1.92 Hz, J=3.30 Hz), 6.13 (dd, 1H, J=0.55 Hz, J=3.30 Hz), 
5.00 (s, 2H), 4.43 (m, 1H), 3.14 (m, 2H), 3.00 (m, 2H), 2.28 (m,2H).   
                                                            
68 TLC conditions: Toluene/ Ethyl Acetate= 60/40 
Rf = basal 
Carnosine-like derivatives                                                                  Experimental section 
106 
2-(3-aminopropanamido)-3-(furan-2-yl)propanoic acid 
 
 
 
3.27 g (9.07 mmol) of the 2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-(furan-2-
yl)propanoic acid undergo hydrogenolysis with Pd/C 10% in 50 mL of dry Methanol. 
The reaction is monitored by TLC69; at completion, catalyst filtration and solvent 
evaporation gives 1.31 g (5.80 mmol) of a sticky white solid. 
 
 
Yield: 64% 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 7.32 (dd, 1H, J=0.55 Hz, J=1.92 Hz), 6.28 (dd, 1H, J=1.92 Hz, J=3.30 Hz), 
6.09 (dd, 1H, J=0.55 Hz, J=3.30 Hz), 4.38 (m, 1H), 3.08 (m, 3H), 2.94 (m, 1H), 2.55 (m, 2H). 
                                                            
69 TLC conditions: Toluene/ Ethyl Acetate= 60/40 + Acetic Acid 10%  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
107 
3-(bromomethyl)furan 
 
 
 
To a solution of furan-3-methanol (10.00 g, 101.94 mmol) in 100 mL of dry THF, at -
5°C under a nitrogen atmosphere, is slowly dropped PBr3 (3.19 mL, 33.98 mmol)  
The temperature is maintained at 0°C and the reaction progression is followed by 
TLC70; at completion, the solution is poured in 250 mL of an iced mixture of Ethyl 
ether/ Water= 2/1.  
The two layers are separated; the organic phase is washed with NaHCO3 and brine, 
dried over Na2SO4, decolorized over charcoal and used for the successive reaction 
without further purification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.41 (m, 1H), 6.35 (m, 2H), 4.45 (s, 2H).  
                                                            
70 TLC conditions: Cyclohexane / Ethyl Acetate= 60/ 40 
Rf: 0.58 
Carnosine-like derivatives                                                                  Experimental section 
108 
Diethyl 2-acetamido-2-(furan-3-ylmethyl)malonate 
 
 
 
A suspension of potassium tert-butoxide (9.15 g, 81.55 mmol) in 100 mL of THF, 
under a nitrogen atmosphere, is added of diethyl acetamidomalonate (17.71 g, 81.55 
mmol) and stirred for 20 minutes. Then the ethereal solution of the 3-
(bromomethyl)furan (101.94 mmol) is dropped; the ether is removed and the mixture 
is refluxed. 
After 2 hours, monitoring the progression of the reaction by TLC71, the suspension is 
concentrated under vacuum, resumed with Ethyl Acetate, washed with HCl 10%, 
NaHCO3 10% and brine.  
The organic phase is dried over Na2SO4, decolorized on carchoal, filtered and 
concentrated under reduced pressure; the crude is a sticky solid that is further 
crystallized in Isopropyl ether yielding 11.64 g (39.14 mmol) of a white solid. 
 
 
Yield: 48% 
 
Melting point: 89.18°C 
 
 
 
 
 
1H-NMR (CDCl3): 7.81 (s, 1H), 7.53 (m, 1H), 7.35 (m, 1H), 6.18 (dd, 1H, J= 0.83 Hz, J= 1.65 
Hz), 4.28 (q, 4H, J= 7.16 Hz), 3.24 (s, 2H), 2.01 (s, 3H), 1.29 (t, 6H, J= 7.16 Hz).  
                                                            
71 TLC conditions: Cyclohexane/ Ethyl Acetate= 60/ 40 
Rf: 0.23 
Carnosine-like derivatives                                                                  Experimental section 
109 
2-acetamido-2-(furan-3-ylmethyl)malonic acid 
 
 
 
To a solution of diethyl 2-acetamido-2-(furan-3-ylmethyl)malonate 11.64 g (39.14 
mmol) in 100 mL of Dioxane are added dropwise 78 mL of NaOH 4M and the mixture 
is refluxed for 1 hour. 
The reaction is monitored by NMR, at completion, the mixture is slowly poured in a 
flask, containing 300 mL of a mixture of Ethyl Acetate/ HCl 10%= 1/ 1. 
The two layers are separated and the aqueous phase is extracted twice more with 
Ethyl Acetate; the organic phases are collected, dried over Na2SO4, filtered and 
concentrated under reduced pressure, yielding 7.84 g (32.49 mmol) of a beige solid. 
 
 
Yield: 83% 
 
Melting point: 130.07 °C 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 7.81 (bs, 1H), 7.53 (m, 1H), 7.35 (m, 1H), 6.18 (dd, 1H, J= 0.83 Hz, J= 
1.65 Hz), 3.24 (s, 2H), 1.95 (s, 3H).  
Carnosine-like derivatives                                                                  Experimental section 
110 
2-acetamido-3-(furan-3-yl)propanoic acid 
 
 
 
A solution of 7.84 g (32.49 mmol) of 2-acetamido-2-(furan-3-ylmethyl)malonic acid in 
80 mL of Dioxane is acidified with Acetic Acid and refluxed for 2 hours, monitoring the 
completion of the reaction by NMR. 
The removal of the solvents yields 5.12 g (25.99 mmol) of a orange oil. 
 
 
Yield: 80% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.14 (d, 1H, J= 7.70 Hz), 7.53 (m, 1H), 7.44 (m, 1H), 6.37 (m, 1H), 4.31 
(m, 1H), 2.70 (m, 1H), 2.81 (m, 1H), 1.90 (s, 3H).  
Carnosine-like derivatives                                                                  Experimental section 
111 
1-carboxy-2-(furan-3-yl)ethanaminium chloride 
 
 
 
A solution of 5.12 g (25.99 mmol) of 2-acetamido-3-(furan-3-yl)propanoic acid in 100 
mL of NaOH 4M is refluxed for 2 hours, monitoring the reaction by NMR. 
At completion, the mixture is cooled to 0°C and acidified with HCl 37%, the solvents 
are removed and the crude is resumed with Methanol, heated for 1 hour and filtered. 
The resulting solution is concentrated under vacuum, yielding 4.48 g (23.39 mmol) of 
beige solid. 
 
 
Yield: 90 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 7.30 (m, 1H), 7.22 (m, 1H), 6.23 (m, 1H), 3.26 (m, 1H), 2.59 (m, 2H). 
  
Carnosine-like derivatives                                                                  Experimental section 
112 
3-(furan-3-yl)-1-methoxy-1-oxopropan-2-aminium chloride 
 
 
 
Thionyl chloride (1.71 mL, 23.39 mmol) is slowly dropped to a solution of 1-carboxy-2-
(furan-3-yl)ethanaminium chloride 4.48 g (23.39 mmol) and trimethyl orthoformate 
(2.56 mL, 23.39 mmol) in anhydrous methanol (50 mL) at 0°C under a nitrogen 
atmosphere; the resulting mixture is warmed to RT and refluxed for 1 h.  
The reaction is monitored by NMR; at completion the solvent is removed, the crude is 
resumed with Methanol and decolorized on carchoal, filtered and concentrated under 
reduce pressure, yielding 4.43 g (21.52 mmol) of a brown oil. 
 
 
Yield: 92% 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 7.43 (m, 1H), 7.40 (m, 1H), 6.28 (m, 1H), 4.31 (m, 1H), 3.78 (s, 3H), 3.10 
(m, 2H).  
Carnosine-like derivatives                                                                  Experimental section 
113 
Methyl 2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-
(furan-3-yl)propanoate 
 
 
 
A solution of EDAC (4.94 g, 25.82 mmol) and DIPEA (4.50 mL, 25.82 mmol) in 20 mL 
of DCM is added dropwise to a solution of 3-(((benzyloxy)carbonyl)amino)propanoic 
acid (5.76 g, 25.82 mmol), HOBT (3.49 g, 25.82 mmol) in 50 mL of DCM under a 
nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of 3-(furan-3-
yl)-1-methoxy-1-oxopropan-2-aminium chloride (4.43 g, 21.52 mmol) and DIPEA (3.75 
mL, 21.52 mmol) in 30 mL of DCM is added dropwise. 
The reaction mixture is stirred at RT for 1 hour and monitored by TLC72.  
At completion, the mixture is treated with DCM and HCl 10%; the organic layer is 
washed with brine, dried over Na2SO4, filtered, and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Toluene/Ethyl Acetate = 60/40 as elution solvent, to give 3.55 g (9.47 mmol) of the 
desired product, as a yellow solid. 
 
Yield: 44 % 
 
Melting point: 81.03 °C 
 
 
1H NMR (·d6DMSO): 8.21 (d, 1H, J= 7.43 Hz), 7.53 (m, 1H), 7.42 (m, 1H), 7.32 (m,1H), 7.19 
(m, 1H), 6.40 (m, 1H), 5.02 (s, 2H), 4.50 (m, 1H), 3.78 (s, 3H), 3.19 (m, 2H), 2.80 (m, 2H), 
2.30 (m, 2H).  
                                                            
72 TLC conditions: Toluene/ Ethyl Acetate= 60/40 
Rf= 0.23 
Carnosine-like derivatives                                                                  Experimental section 
114 
2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-(furan-
3-yl)propanoic acid 
 
 
 
3.55 g (9.47 mmol) of Methyl 2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-(furan-
2-yl)propanoate are dissolved in 40 mL of Methanol; 7 mL of NaOH 4M are dropped 
and the resulting mixture is stirred at RT for 1 hour. 
After completion of the reaction, followed by TLC73, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with HCl 10% and extracted three times with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated, 
yielding 3.14 g (8.71 mmol) of a white solid.  
 
 
Yield: 92% 
 
Melting point: 131.98 °C 
 
 
 
 
 
1H-NMR (d6DMSO): 8.21 (d, 1H, J=7.71 Hz), 7.53 (m, 1H), 7.42 (m, 1H), 7.32 (m, 5H), 7.19 
(m, 1H), 6.40 (m, 1H), 5.02 (s, 2H), 4.33 (m, 1H), 3.19 (m, 2H), 3.00 (m, 2H), 2.90 (m, 1H), 
2.70 (m, 1H), 2.32 (m,2H).  
                                                            
73 TLC conditions: Toluene/ Ethyl Acetate= 60/40 
Rf = basal 
Carnosine-like derivatives                                                                  Experimental section 
115 
2-(3-aminopropanamido)-3-(furan-3-yl)propanoic acid 
 
 
 
3.14 g (8.71 mmol) of the 2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-(furan-2-
yl)propanoic acid undergo hydrogenolysis with Pd/C 5% in 50 mL of dry Methanol. 
The reaction is monitored by TLC74, at completion, catalyst filtration and solvent 
evaporation gives a white solid that is further crystallized from Water yielding 0.89 g 
(3.92 mmol) of the final product. 
 
 
Yield: 45% 
 
Melting point: 252.30 °C 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 7.33 (m, 1H), 7.26 (m, 1H), 6.28 (m, 1H), 4.31 (m, 1H), 3.11 (m, 2H), 3.00 
(m, 1H), 2.70 (m, 1H), 2.53 (m, 2H).  
                                                            
74 TLC conditions: Toluene/ Ethyl Acetate= 60/40 + Acetic Acid 10%  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
116 
2-(bromomethyl)thiophene 
 
 
 
To a solution of thiophen-2-methanol (10.00 g, 87.59 mmol) in 100 mL of dry THF, at -
5°C under a nitrogen atmosphere, is slowly dropped PBr3 (2.74 mL, 29.20 mmol)  
The temperature is maintained at 0°C and the reaction progression is followed by 
TLC75; at completion, the solution is poured in 250 mL of an iced mixture of Ethyl 
ether/ Water= 2/1.  
The two layers are separated; the organic phase is washed with NaHCO3 and brine, 
dried over Na2SO4, decolorized over charcoal and used for the successive reaction 
without further purification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.33 (m, 1H), 7.12 (m, 1H), 6.97 (m, 1H), 4.78 (s, 2H).  
                                                            
75 TLC conditions: Cyclohexane / Ethyl Acetate= 60/ 40 
Rf: 0.60 
Carnosine-like derivatives                                                                  Experimental section 
117 
Diethyl 2-acetamido-2-(thiophen-2-ylmethyl)malonate 
 
 
 
A suspension of potassium tert-butoxide (7.86 g, 70.07 mmol) in 80 mL of THF, under 
a nitrogen atmosphere, is added of diethyl acetamidomalonate (15.22 g, 70.07 mmol) 
and stirred for 20 minutes. Then the ethereal solution of the 2-
(bromomethyl)thiophene (87.59 mmol) is dropped; the ether is removed and the 
mixture is refluxed. 
After 2 hours, monitoring the progression of the reaction by TLC76, the suspension is 
concentrated under vacuum, resumed with Ethyl Acetate, washed with HCl 10%, 
NaHCO3 10% and brine.  
The organic phase is dried over Na2SO4, decolorized on carchoal, filtered and 
concentrated under reduced pressure; the crude is a sticky solid that is further 
crystallized in isopropyl ether yielding 9.88 g (31.53 mmol) of a white solid. 
 
 
Yield: 45% 
 
Melting point: 118.09°C 
 
 
 
 
 
1H-NMR (CDCl3): 7.18 (m, 1H), 6.91 (m, 1H), 6.70 (m, 2H), 4.25 (q, 4H, J= 7.15 Hz), 3.88 (s, 
2H), 2.06 (s, 3H), 1.29 (t, 6H, J= 7.15 Hz).  
                                                            
76 TLC conditions: Cyclohexane/ Ethyl Acetate= 60/ 40 
Rf: 0.23 
Carnosine-like derivatives                                                                  Experimental section 
118 
2-acetamido-2-(thiophen-2-ylmethyl)malonic acid 
 
 
 
To a solution of diethyl 2-acetamido-2-(thiophen-2-ylmethyl)malonate (9.88 g, 31.53 
mmol) in 100 mL of Dioxane are added dropwise 63 mL of NaOH 4M, and the mixture 
is refluxed for 1 hour. 
The reaction is monitored by NMR, at completion, the mixture is slowly poured in a 
flask, containing 150 mL of a mixture of Ethyl Acetate/ HCl 10%=1/ 1. 
The two layers are separated and the aqueous phase is extracted twice more with 
Ethyl Acetate; the organic phases are collected, dried over Na2SO4, filtered and 
concentrated under reduced pressure, yielding 6.49 g (25.22 mmol) of a beige solid. 
 
 
Yield: 80% 
 
Melting point: 117.04 °C 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 7.84 (bs, 1H), 7.33 (m, 1H), 6.91 (m, 1H), 6.74 (m, 1H), 3.64 (s, 2H), 1.95 
(s, 3H).  
Carnosine-like derivatives                                                                  Experimental section 
119 
2-acetamido-3-(thiophen-2-yl)propanoic acid 
 
 
 
A solution of 6.49 g (25.22 mmol) of 2-acetamido-2-(thiophen-2-ylmethyl)malonic acid 
in 65 mL of Dioxane is acidified with Acetic Acid and refluxed for 2 hours, monitoring 
the completion of the reaction by NMR. 
The removal of the solvents yields 4.84 g (22.70 mmol) of beige oil. 
 
 
Yield: 90% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.21 (d, 1H, J= 7.70 Hz), 7.33 (m, 1H), 6.90 (m, 2H), 4.37 (m, 1H), 3.30 
(m, 1H), 3.11 (m, 1H), 1.82 (s, 3H).  
Carnosine-like derivatives                                                                  Experimental section 
120 
1-carboxy-2-(thiophen-2-yl)ethanaminium chloride 
 
 
 
A solution of 4.84 g (22.70 mmol) of 2-acetamido-3-(thiophen-2-yl)propanoic acid in 
NaOH 2.5M is refluxed for 2 ½ hours, monitoring the reaction by NMR. 
At completion, the mixture is cooled to 0°C and acidified with HCl 37%, the solvents 
are removed and the crude is resumed with Isopropanol, heated for 1 hour and 
filtered. 
The resulting solution is concentrated under vacuum, yielding 3.58 g (17.25 mmol) of 
a pale grey solid. 
 
 
Yield: 76 % 
 
Melting point: 248.30 °C 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.65 (bs, 3H), 7.40 (m, 1H), 7.00 (m, 2H), 4.10 (m, 1H), 3.37-3.48 (m, 2H). 
  
Carnosine-like derivatives                                                                  Experimental section 
121 
3-(thiophen-2-yl)-1-methoxy-1-oxopropan-2-aminium 
chloride 
 
 
 
Thionyl chloride (1.26 mL, 17.25 mmol) is slowly dropped to a solution of 1-carboxy-2-
(thiophen-2-yl)ethanaminium chloride (3.58 g, 17.25 mmol)) and trimethyl 
orthoformate (1.89 mL, 17.25 mmol) in anhydrous methanol (40 mL) at 0°C under a 
nitrogen atmosphere; the resulting mixture is warmed to RT and refluxed for 1 h.  
The reaction is monitored by NMR; at completion the solvent is removed, yielding 3.67 
g (16.56 mmol) of sticky beige solid. 
 
 
Yield: 96% 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 7.27 (m, 1H), 6.92 (m, 2H), 4.64 (m, 1H), 3.67 (s, 3H), 3.43 (m, 2H). 
Carnosine-like derivatives                                                                  Experimental section 
122 
Methyl 2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-
(thiophen-2-yl)propanoate 
 
 
 
A solution of EDAC (3.81 g, 19.87 mmol) and DIPEA (3.46 mL, 19.87 mmol) in 12 mL 
of DCM is added dropwise to a solution of 3-(((benzyloxy)carbonyl)amino)propanoic 
acid (4.44 g, 19.87 mmol), HOBT (2.68 g, 19.87 mmol) in 20 mL of DCM under a 
nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of 3-(thiophen-
2-yl)-1-methoxy-1-oxopropan-2-aminium chloride (3.67 g, 16.56 mmol) and DIPEA 
(2.88 mL, 16.56 mmol) in 30 mL of DCM is added dropwise. 
The reaction mixture is stirred at RT for 1 hour and monitored by TLC77.  
At completion, the mixture is treated with DCM and HCl 10%; the organic layer is 
washed with brine, dried over Na2SO4, filtered, and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Toluene/Ethyl Acetate = 60/40 as elution solvent, to give 1.94 g (4.97 mmol) of the 
desired product, as a yellow solid. 
 
Yield: 36 % 
 
Melting point: 103.89 °C 
 
 
1H NMR (·d6DMSO): 8.45 (d, 1H, J= 7.43 Hz), 7.32 (m, 6H), 7.19 (m, 1H), 6.90 (m, 2H), 5.00 
(s, 2H), 4.45 (m, 1H), 3.61 (s, 3H), 3.08-3.32 (m, 4H), 2.30 (m, 2H).  
                                                            
77 TLC conditions: Toluene/ Ethyl Acetate= 60/40 
Rf= 0.31 
Carnosine-like derivatives                                                                  Experimental section 
123 
2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-
(thiophen-2-yl)propanoic acid 
 
 
 
1.94 g (4.97 mmol) of Methyl 2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-
(thiophen-2-yl)propanoate are dissolved in 25 mL of Methanol; 6 mL of NaOH 2.5M are 
dropped and the resulting mixture is stirred at RT for 1 hour. 
After completion of the reaction, followed by TLC78, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with HCl 10% and extracted three times with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated, 
yielding 1.80 g (4.77 mmol) of a white solid.  
 
 
Yield: 96% 
 
Melting point: 149.81 °C 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.29 (d, 1H, J=7.43 Hz), 7.30 (m, 6H), 7.18 (m, 1H), 6.90 (m, 2H), 5.00 (s, 
2H), 4.40 (m, 1H), 3.07-3.32 (m, 4H), 2.30 (m, 2H).  
                                                            
78 TLC conditions: Toluene/ Ethyl Acetate= 60/40 
Rf = basal 
Carnosine-like derivatives                                                                  Experimental section 
124 
2-(3-aminopropanamido)-3-(thiophen-2-yl)propanoic acid 
 
 
1.80 g (4.77 mmol) of the 2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-(thiophen-
2-yl)propanoic acid is dissolved in 20 mL of TFA, in presence of anisole (1.08 mL, 9.54 
mmol). 
The reaction is monitored by TLC79, at completion, the solvent is removed, the residue 
is treated with Ethyl Acetate and Water, the aqueous layer is concentrated under 
reduced pressure, yielding 1.12 g (3.15 mmol) of the final product, as sticky yellow 
solid. 
 
 
Yield: 66% 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.52 (d, 1H, J=7.70 Hz), 7.78 (bs, 3H), 7.32 (m, 2H), 6.90 (m, 1H), 4.42 
(m, 1H), 3.32 (m, 2H), 3.10 (m, 2H), 2.95 (m, 2H).  
                                                            
79 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.02 
Carnosine-like derivatives                                                                  Experimental section 
125 
3-(bromomethyl)thiophene 
 
 
 
To a solution of thiophen-3-methanol (10.00 g, 87.59 mmol) in 100 mL of dry THF, at -
5°C under a nitrogen atmosphere, is slowly dropped PBr3 (2.74 mL, 29.20 mmol)  
The temperature is maintained at 0°C and the reaction progression is followed by 
TLC80; at completion, the solution is poured in 200 mL of an iced mixture of Ethyl 
ether/ Water= 2/1.  
The two layers are separated; the organic phase is washed with NaHCO3 and brine, 
dried over Na2SO4, decolorized over charcoal and used for the successive reaction 
without further purification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.21 (m, 2H), 7.02 (m, 1H), 4.43 (s, 2H).  
                                                            
80 TLC conditions: Cyclohexane / Ethyl Acetate= 60/ 40 
Rf: 0.60 
Carnosine-like derivatives                                                                  Experimental section 
126 
Diethyl 2-acetamido-2-(thiophen-3-ylmethyl)malonate 
 
 
 
A suspension of potassium tert-butoxide (7.86 g, 70.07 mmol) in 80 mL of THF, under 
a nitrogen atmosphere, is added of diethyl acetamidomalonate (15.22 g, 70.07 mmol) 
and stirred for 20 minutes. Then the ethereal solution of the 3-
(bromomethyl)thiophene (87.59 mmol) is dropped; the ether is removed and the 
mixture is refluxed. 
After 2 hours, monitoring the progression of the reaction by TLC81, the suspension is 
concentrated under vacuum, resumed with Ethyl Acetate, washed with HCl 10%, 
NaHCO3 10% and brine.  
The organic phase is dried over Na2SO4, decolorized on carchoal, filtered and 
concentrated under reduced pressure; the crude is a sticky solid that is further 
crystallized in Isopropyl ether yielding 13.61 g (43.44 mmol) of a white solid. 
 
 
Yield: 62% 
 
Melting point: 66.91°C 
 
 
 
 
 
1H-NMR (CDCl3): 7.21 (m, 1H), 7.15 (m, 1H), 6.84 (m, 1H), 6.69 (bs, 1H), 4.19 (q, 4H, J= 7.04 
Hz), 3.71 (s, 2H), 1.97 (s, 3H), 1.22 (t, 6H, J= 7.04 Hz).  
                                                            
81 TLC conditions: Cyclohexane/ Ethyl Acetate= 60/ 40 
Rf: 0.23 
Carnosine-like derivatives                                                                  Experimental section 
127 
2-acetamido-2-(thiophen-3-ylmethyl)malonic acid 
 
 
 
To a solution of diethyl 2-acetamido-2-(thiophen-3-ylmethyl)malonate 13.61 g (43.44 
mmol) in 150 mL of Dioxane are added dropwise 87 mL of NaOH 4M and the mixture 
is refluxed for 1 hour. 
The reaction is monitored by NMR, at completion, the mixture is slowly poured in a 
flask, containing 300 mL of a mixture of Ethyl Acetate/ HCl 10%= 1/ 1. 
The two layers are separated and the aqueous phase is extracted twice more with 
Ethyl Acetate; the organic phases are collected, dried over Na2SO4, filtered and 
concentrated under reduced pressure, yielding 9.83 g (38.23 mmol) of a sticky beige 
solid. 
 
 
Yield: 88% 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 7.76 (bs, 1H), 7.41 (m, 1H), 7.05 (m, 1H), 6.78 (m, 1H), 3.44 (s, 2H), 1.92 
(s, 3H).  
Carnosine-like derivatives                                                                  Experimental section 
128 
2-acetamido-3-(thiophen-3-yl)propanoic acid 
 
 
 
A solution of 9.83 g (38.23 mmol) of 2-acetamido-2-(thiophen-3-ylmethyl)malonic acid 
in 100 mL of Dioxane is acidified with Acetic Acid and refluxed for 2 hours, monitoring 
the completion of the reaction by NMR. 
The removal of the solvents yields 7.10 g (33.26 mmol) of beige oil. 
 
 
Yield: 87% 
 
Melting point: 147 °C 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.17 (d, 1H, J= 7.70 Hz), 7.41 (m, 1H), 7.20 (m, 1H), 6.98 (dd, 2H, J= 1.32 
Hz, J= 4.48 Hz), 4.45 (m, 1H), 3.07 (m, 1H), 2.83 (m, 1H), 1.80 (s, 3H). 
  
Carnosine-like derivatives                                                                  Experimental section 
129 
1-carboxy-2-(thiophen-3-yl)ethanaminium chloride 
 
 
 
A solution of 7.10 g (33.26 mmol) of 2-acetamido-3-(thiophen-3-yl)propanoic acid in 
NaOH 2.5M is refluxed for 2 ½ hours, monitoring the reaction by NMR. 
At completion, the mixture is cooled to 0°C and acidified with HCl 37%, the solvents 
are removed and the crude is resumed with Methanol, heated for 1 hour and filtered. 
The resulting solution is concentrated under vacuum, yielding 6.08 g (29.27 mmol) of 
a white sticky solid. 
 
 
Yield: 88 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.55 (bs, 3H), 7.50 (dd, 1H, J= 0.55 Hz, J= 4.48 Hz), 7.34 (dd, 1H, J= 0.55 
Hz, J= 1.32 Hz), 7.03 (d, 1H, J= 1.32 Hz, J= 4.48 Hz), 4.09 (t, 1H, J= 5.77 Hz), 3.19 (d, 2H, J= 
5.77 Hz).  
Carnosine-like derivatives                                                                  Experimental section 
130 
3-(thiophen-3-yl)-1-methoxy-1-oxopropan-2-aminium 
chloride 
 
 
 
Thionyl chloride (2.14 mL, 29.27 mmol) is slowly dropped to a solution of 1-carboxy-2-
(thiophen-3-yl)ethanaminium chloride (6.08 g, 29.27 mmol) and trimethyl 
orthoformate (3.20 mL, 29.27 mmol) in anhydrous methanol (70 mL) at 0°C under a 
nitrogen atmosphere; the resulting mixture is warmed to RT and refluxed for 3 h.  
The reaction is monitored by NMR; at completion the solvent is removed, yielding 6.10 
g (27.51 mmol) of beige oil. 
 
 
Yield: 94% 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.81 (bs, 3H), 7.49 (d, 1H, J= 0.55 Hz, J= 4.48 Hz), 7.34 (m, 1H), 6.99 (d, 
1H, J= 4.48 Hz), 4.22 (m, 1H), 3.66 (s, 3H), 3.21 (m, 2H).  
Carnosine-like derivatives                                                                  Experimental section 
131 
Methyl 2-(3-((tert-butoxycarbonyl)amino)propanamido)-3-
(thiophen-3-yl)propanoate 
 
 
 
A solution of EDAC (6.32 g, 33.01 mmol) and DIPEA (5.75 mL, 33.01 mmol) in 20 mL 
of DCM is added dropwise to a solution of 3-((tert-butoxycarbonyl)amino)propanoic 
acid (6.25 g, 33.01 mmol), HOBT (4.46 g, 33.01 mmol) in 30 mL of DCM under a 
nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of 3-(thiophen-
3-yl)-1-methoxy-1-oxopropan-2-aminium chloride (6.10 g, 27.51 mmol) and DIPEA 
(4.79 mL, 27.51 mmol) in 20 mL of DCM is added dropwise. 
The reaction mixture is stirred at RT for 2 hours and monitored by TLC82.  
At completion, the mixture is treated with DCM and HCl 10%; the organic layer is 
washed with NaHCO3 and brine, dried over Na2SO4, filtered, and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Toluene/Ethyl Acetate = 60/40 as elution solvent, to give 5.55 g (15.57 mmol) of the 
desired product, as pale yellow oil. 
 
Yield: 56.6 % 
 
 
 
 
1H NMR (·d6DMSO): 8.35 (d, 1H, J= 7.42 Hz), 7.42 (d, 1H, J= 4.95 Hz), 7.20 (d, 1H, J= 1.50 
Hz), 6.97 (dd, 1H, J= 1.50 Hz, J= 4.95 Hz), 6.67 (m, 1H), 4.43 (m, 1H), 3.59 (s, 3H), 3.08 (m, 
2H), 2.88 (m, 2H), 2.24 (m, 2H), 1.36 (s, 9H).  
                                                            
82 TLC conditions: Toluene/ Ethyl Acetate= 60/40 
Rf= 0.31 
Carnosine-like derivatives                                                                  Experimental section 
132 
2-(3-((tert-butoxycarbonyl)amino)propanamido)-3-
(thiophen-3-yl)propanoic acid 
 
 
 
5.55 g (15.57 mmol) of Methyl 2-(3-(((benzyloxy)carbonyl)amino)propanamido)-3-
(thiophen-3-yl)propanoate are dissolved in 50 mL of Methanol; 12 mL of NaOH 4M are 
dropped and the resulting mixture is stirred at RT for 1 hour. 
After completion of the reaction, followed by TLC83, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with HCl 10% and extracted three times with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated, 
yielding 4.95 g (14.48 mmol) of a sticky white solid.  
 
 
Yield: 93% 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.21 (d, 1H, J=7.43 Hz), 7.42 (dd, 1H, J=0.55 Hz, J=4.95 Hz), 7.20 (d, 1H, 
J= 1.50 Hz), 6.97 (dd, 1H, J= 1.50 Hz, J= 4.95 Hz), 6.67 (bs, 1H), 4.45 (m, 1H), 3.10 (m, 2H), 
2.90 (m, 2H), 2.24 (m,2H), 1.36 (s, 9H).  
                                                            
83 TLC conditions: Toluene/ Ethyl Acetate= 60/40 
Rf = basal 
Carnosine-like derivatives                                                                  Experimental section 
133 
2-(3-aminopropanamido)-3-(thiophen-3-yl)propanoic acid 
 
 
 
A solution of 4.95 g (14.48 mmol) of the 2-(3-
(((benzyloxy)carbonyl)amino)propanamido)-3-(thiphen-3-yl)propanoic acid in 50 mL of 
Ethyl Acetate is acidified with HCl 10% and heated at 50°C . 
The reaction is monitored by TLC84, at completion, the solvent evaporation yields 3.75 
g (13.47 mmol) of a sticky white solid. 
 
 
Yield: 93% 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.21 (d, 1H, J= 7.70 Hz), 7.42 (dd, 1H, J= 0.55 Hz, J= 4.95 Hz), 7.20 (dd, 
1H, J= 0.55 Hz, J= 1.50 Hz), 6.97 (dd, 1H, J= 1.50 Hz, J= 4.95 Hz), 4.43 (m, 1H), 3.08 (m, 2H), 
2.94 (m, 2H), 2.24 (m,2H).  
                                                            
84 TLC conditions: DCM/ Methanol= 90/10   
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
134 
Benzyl (3-((4-methoxyphenyl)amino)-3-
oxopropyl)carbamate 
 
 
 
A solution of EDAC (0.86 g, 4.48 mmol) and DIPEA (0.78 mL, 4.48 mmol) in 3 mL of 
DCM is added dropwise to a solution of 3-((tert-butoxycarbonyl)amino)propanoic acid 
(1.00 g, 4.48 mmol), HOBT (0.61 g, 4.48 mmol) in 10 mL of DCM under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of 4-
metoxyaniline (0.46 g, 3.73 mmol) in 2 mL of DCM is added dropwise. 
The reaction mixture is stirred at RT for 3 hours and monitored by TLC85.  
At completion, the mixture is treated with DCM and HCl 10%; the organic layer is 
washed with NaHCO3 and brine, dried over Na2SO4, filtered, and concentrated.  
The crude product is crystallized from Isopropanol, yielding 0.69 g (2.10 mmol) of the 
desired product, as a white solid. 
 
 
Yield: 56.4 % 
 
Melting point: 163.78 °C 
 
 
 
 
1H NMR (CDCl3): 7.34-7.39 (m, 9H), 6.83 (d, 1H, J= 7.70 Hz), 5.10 (s, 2H), 3.79 (s, 3H), 3.56 
(t, 2H, J= 6.05 Hz), 2.59 (t, 2H, J= 6.05 Hz).  
                                                            
85 TLC conditions: Chloroform/ Methanol= 90/10 
Rf= 0.50 
Carnosine-like derivatives                                                                  Experimental section 
135 
3-amino-N-(4-methoxyphenyl)propanamide 
 
MeO NH
O
H
N
Cbz
MeO NH
O NH2
C18H20N2O4
M.W.: 328,36
C10H14N2O2
M.W.: 194,23
 
 
0.69 g (2.10 mmol) undergo hydrogenolysis with Pd/C 5% in 10 mL of Methanol. 
The reaction is monitored by TLC86, at completion, catalyst filtration and solvent 
evaporation gives a sticky white solid, that is further crystallized from Isopropanol/ 
isopropyl ether = 1/1, yielding 0.15 g (0.76 mmol) of the final product. 
 
 
Yield: 36% 
 
Melting point: 103.70 °C 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (D2O): 7.21 (d, 1H, J= 7.07 Hz), 6.83 (d, 1H, J= 7.07 Hz), 3.70 (s, 3H), 2.82 (t, 2H, J= 
6.05 Hz), 2.41 (t, 2H, J= 6.05 Hz).  
                                                            
86 TLC conditions: Chloroform/ Methanol= 90/10 
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
136 
(L)-Histidine-methyl ester dihydrochloride 
 
 
 
Thionyl chloride (13.84 mL, 190.81 mmol) is added dropwise to a suspension of L-
histidine monochloride monohydrate (40.0 g, 190.81 mmol) and trimethyl 
orthoformate (20.87 mL, 190.81 mmol) in anhydrous methanol (400 mL) at 0°C 
under a nitrogen atmosphere, and the resulting mixture is refluxed for 16 h.  
The reaction is monitored by NMR; at completion the mixture is cooled down to RT and 
concentrated, yielding 46.10 g (190.43 mmol) of a white solid. 
 
 
Yield: 98.8 % 
 
Melting point: 200°C 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.1 (s, 1H), 7.50 (s, 1H), 4.46 (t, 1H, J=7.15 Hz), 3.70 (s, 3H), 3.30 (d, 2H, 
J=7.15 Hz).  
Carnosine-like derivatives                                                                  Experimental section 
137 
(D)-Histidine-methyl ester dihydrochloride 
 
 
 
Thionyl chloride (13.84 mL, 190.81 mmol) is added dropwise to a suspension of D-
histidine monochloride monohydrate (40.0 g, 190.81 mmol) and trimethyl 
orthoformate (20.87 mL, 190.81 mmol) in anhydrous methanol (400 mL) at 0°C 
under a nitrogen atmosphere, and the resulting mixture is refluxed for 16 h.  
The reaction is monitored by NMR, at completion the mixture is cooled down to RT and 
concentrated, yielding 45.83 g of a white solid (189.28 mmol). 
 
 
Yield: 99.2 % 
 
Melting point: 197°C 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.05 (s, 1H), 7.50 (s, 1H), 4.46 (t, 1H, J=7.15 Hz), 3.69 (s, 3H), 3.31 (d, 
2H, J=7.15 Hz).  
Carnosine-like derivatives                                                                  Experimental section 
138 
(L)-(benzyloxy)carbonyl-Valine-(L)-Histidine-methyl ester 
 
 
 
A solution of EDAC (0.95 g, 4.96 mmol) and DIPEA (0.86 mL, 4.96 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of (benzyloxy)carbonyl-(L)Valine (1.04 g, 4.13 
mmol), HOBT (0.67 g, 4.96 mmol) in 8 mL of dry DMF under a nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (L)-Histidine 
methyl ester dihydrochloride (1.00 g, 4.13 mmol) and DIPEA (1.44 mL, 8.26 mmol) in 
5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC87.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated.  
The crude product is purified by column chromatography on silica gel, using 
DCM/Methanol = 90/10 as elution solvent, to give 1.00g (2.48 mmol) of the desired 
dipeptide. 
 
 
Yield: 60 % 
 
 
1H NMR (·d6DMSO): 11.84 (bs, 1H), 8.33 (d, 1H, J=7.15 Hz), 7.51 (s, 1H), 7.25-7.35 (m, 6H), 
6.81 (s, 1H), 5.01 (s, 2H), 4.46 (m, 1H), 3.86 (m, 1H), 3.55 (s, 3H), 2.84-2.90 (m, 2H), 1.91 
(m, 1H), 0.83 (d, 3H, J= 6.88 Hz), 0.80 (d, 3H, J= 6.88 Hz).  
                                                            
87 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.34 
Carnosine-like derivatives                                                                  Experimental section 
139 
(L)-(benzyloxy)carbonyl-Valine-(D)-Histidine-methyl ester 
 
 
 
A solution of EDAC (0.95 g, 4.96 mmol) and DIPEA (0.86 mL, 4.96 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of (benzyloxy)carbonyl-(L)Valine (1.04 g, 4.13 
mmol), HOBT (0.67 g, 4.96 mmol) in 8 mL of dry DMF under a nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (D)-
Histidine methyl ester dihydrochloride (1.00 g, 4.13 mmol) and DIPEA (1.44 mL, 8.26 
mmol) in 5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC88.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated.  
The crude product is purified by column chromatography on silica gel, using 
DCM/Methanol = 90/10 as elution solvent, to give 0.76 g (1.90 mmol) of the desired 
dipeptide. 
 
 
Yield: 46% 
 
 
 
1H NMR (·d6DMSO): 11.80 (bs, 1H), 8.33 (d, 1H, J=7.15 Hz), 7.48 (s, 1H), 7.22-7.40 (m, 6H), 
6.78 (s, 1H), 5.01 (s, 2H), 4.43 (m, 1H), 3.84 (m, 1H), 3.58 (s, 3H), 2.80-2.92 (m, 2H), 1.86 
(m, 1H), 0.76 (s, 6H).  
                                                            
88 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.30 
Carnosine-like derivatives                                                                  Experimental section 
140 
(L)-Valine-(L)-Histidine-methyl ester dihydrochloride 
 
 
 
1.00g (2.48 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 15 mL of dry Methanol and 4 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC89, at completion, achieved after stirring for 18 hours 
at RT, the solvents are evaporated giving 0.85 g of a sticky white solid in quantitative 
yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO):  9.25 (d, 1H, J= 7.15 Hz), 8.92 (s, 1H), 8.0-8.9 (bs, 5H), 7.48 (s, 1H), 4.68 
(m, 1H), 3.71 (d, 1H, J= 5.5 Hz), 3.64 (s, 3H), 3.13-3.20 (m, 2H), 2.10 (m, 1H), 0.94 (s, 3H), 
0.92 (s, 3H).  
                                                            
89 TLC conditions: DCM/ Methanol= 90/10  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
141 
(L)-Valine-(D)-Histidine-methyl ester dihydrochloride 
 
 
 
0.76 g (1.90 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 15 mL of dry Methanol and 3 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC90, at completion, achieved after stirring for 18 hours 
at RT, the solvents are evaporated giving 0.55 g of a sticky white solid in quantitative 
yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (·d6DMSO): 8.99 (d, 1H, J= 7.97 Hz), 7.77 (s, 1H), 6.93 (s, 1H), 4.62 (m, 1H), 3.63 (s, 
3H), 3.60 (d, 1H, J= 5.13 Hz), 3.01 (dd, 1H, J= 14.58 Hz, J= 4.68 Hz), 2.89 (dd, 1H), 1.96 (m, 
1H, J= 14.58 Hz, J= 9.63 Hz), 0.78 (d, 3H, J= 6.88 Hz), 0.70 (d, 3H, J= 6.78 Hz). 
                                                            
90 TLC conditions: DCM/ Methanol= 90/10  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
142 
(L)-2,2-dimethylthiazolidine-4-carboxylic acid 
hydrochloride 
 
 
 
(L)-Cysteine hydrochloride monohydrate (5.0 g, 28.47 mmol) is dissolved in 200 mL of 
Acetone and then refluxed for 2 hours; the reaction is monitored by NMR analysis. 
At completion, the mixture is cooled and concentrated, obtaining 5.06 g (25.62 mmol) 
of the desired product, as white solid.  
 
 
Yield: 90% 
 
Melting point: 168 °C 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 7.60 (bs, 3H), 3.96 (dd, 1H, J=7.15 Hz, J =8.53 Hz), 3.32 (dd, 1H, J =7.15 
Hz, J =11.17 Hz), 2.93 (dd, 1H, J =8.53 Hz, J =11.17 Hz), 1.58 (s, 3H), 1.41 (s, 3H). 
  
Carnosine-like derivatives                                                                  Experimental section 
143 
(L)-3-((benzyloxy)carbonyl)-2,2-dimethylthiazolidine-4-
carboxylic acid 
  
 
 
(L)-2,2-dimethylthiazolidine-4-carboxylic acid hydrochloride (5.06 g, 25.62 mmol) is 
dissolved in 100 mL of Acetonitrile and added of DIPEA (5.80 mL; 33.31 mmol), under 
nitrogen condition.  
The mixture is treated with benzyl chloroformate (4.75 mL; 33.31 mmol) at 0°C. 
The reaction is then warmed to RT and monitored by NMR. After 3 hours the solvent is 
removed, the residue treated with Ethyl Acetate and washed with HCl 10% and brine. 
The organic phase is dried over Na2SO4, filtered, and concentrated under reduced 
pressure, giving 7.57 g of the desired product, in quantitative yield.  
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.40 (bs, 1H), 7.22-7.46 (m, 5), 4.92-5.32 (m, 3H), 3.18-3.38 (m, 2H), 
1.92 (s, 3H), 1.83 (s, 3H). 
  
Carnosine-like derivatives                                                                  Experimental section 
144 
(L)-3-((benzyloxy)carbonyl)-2,2-dimethylthiazolidine-4-
(L)Histidine-methyl ester 
 
 
 
A solution of EDAC (0.95 g, 4.96 mmol) and DIPEA (0.86 mL, 4.96 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of (L)-3-((benzyloxy)carbonyl)-2,2-
dimethylthiazolidine-4-carboxylic acid (1.22 g, 4.13 mmol), HOBT (0.67 g, 4.96 mmol) 
in 8 mL of dry DMF under a nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (L)-Histidine 
methyl ester dihydrochloride (1.00 g, 4.13 mmol) and DIPEA (1.44 mL, 8.26 mmol) in 
5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC91.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using DCM/Methanol = 90/10 as 
elution solvent, to give 0.94 g (2.11 mmol) of the desired dipeptide. 
 
 
Yield: 51 % 
 
 
1H NMR (·d6DMSO): 11.83 (bs, 1H), 8.40 (d, 1H, J=5.57 Hz), 7.50 (s, 1H), 7.26-7.49 (m, 6H), 
6.76 (s, 1H), 5.05 (s, 2H), 4.78 (m, 1H), 4.47 (m, 1H), 3.52 (s, 3H), 3.37 (m, 2H), 2.97 (m, 2H), 
1.78 (s, 3H), 1.71 (s, 3H).  
                                                            
91 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.37 
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145 
(L)-3-((benzyloxy)carbonyl)-2,2-dimethylthiazolidine-4-
(D)Histidine-methyl ester 
 
 
 
A solution of EDAC (0.95 g, 4.96 mmol) and DIPEA (0.86 mL, 4.96 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of (L)-3-((benzyloxy)carbonyl)-2,2-
dimethylthiazolidine-4-carboxylic acid (1.22 g, 4.13 mmol), HOBT (0.67 g, 4.96 mmol) 
in 8 mL of dry DMF under a nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (D)-
Histidine methyl ester dihydrochloride (1.00 g, 4.13 mmol) and DIPEA (1.44 mL, 8.26 
mmol) in 5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC92.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using DCM/Methanol = 90/10 as 
elution solvent, to give 1.07 g (2.40 mmol) of the desired dipeptide. 
 
 
Yield: 58 % 
 
 
1H NMR (·d6DMSO): 7.69 (d, 1H, J=7.90 Hz), 7.24-7.33 (m, 6H), 7.26 (d, 1H, J=8.48 Hz), 6.66 
(s, 1H), 4.96 (s, 2H), 3.90 (m, 1H), 3.77 (m, 3H), 3.46 (m, 1H), 3.31 (m, 2H), 3.01 (m, 2H), 
2.03 (s, 3H), 1.99 (s, 3H).  
                                                            
92 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.36 
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146 
(L)-Cysteine-(L)-Histidine-methyl ester di-trifluoroacetate 
 
 
 
0.94 g (2.11 mmol) of the (L)-3-((benzyloxy)carbonyl)-2,2-dimethylthiazolidine-4-(L)-
Histidine methyl ester is stirred in TFA for 24 hours in presence of anisole (0.46 mL, 
4.22 mmol).  
At completion of the reaction, monitored by TLC93, the solvent is removed and the 
residue rinsed and washed three times with Ethyl ether. 
Simply water removal under vacuum gives 1.06 g of the final product in quantitative 
yield.  
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
1H NMR (·d6DMSO): 9.04 (d, 1H, J= 7.70 Hz), 8.99 (s, 1H), 8.26 (bs, 5H), 7.42 (s, 1H), 4.69 (m, 
1H), 4.04 (m, 1H), 3.65 (s, 3H), 2.94-3.22 (m, 4H).  
                                                            
93 TLC conditions: DCM/ Methanol= 90/10  
Rf= basal 
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147 
(L)-Cysteine-(D)-Histidine-methyl ester di-trifluoroacetate 
 
 
 
1.07 g (2.40 mmol) of the (L)-3-((benzyloxy)carbonyl)-2,2-dimethylthiazolidine-4-(L)-
Histidine methyl ester is stirred in TFA for 24 hours in presence of anisole (0.46 mL, 
4.22 mmol).  
At completion of the reaction, monitored by TLC94, the solvent is removed and the 
residue rinsed and washed three times with Ethyl ether. 
Simply water removal under vacuum gives 1.20 g of the final product in quantitative 
yield.  
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
1H NMR (·d6DMSO): 9.11 (d, 1H, J= 7.70 Hz), 8.98 (s, 1H), 8.26 (bs, 5H), 7.41 (s, 1H), 4.73 (m, 
1H), 4.03 (m, 1H), 3.66 (s, 3H), 3.20 (dd, 1H, J= 15.13 Hz, J= 4.95 Hz), 3.04 (dd, 1H, J= 15.13 
Hz, J= 9.63 Hz), 2.85 (m, 2H).  
                                                            
94 TLC conditions: DCM/ Methanol= 90/10  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
148 
(L)-(benzyloxy)carbonyl-Histidine-(L)-Histidine-methyl ester 
 
 
 
A solution of EDAC (0.95 g, 4.96 mmol) and DIPEA (0.86 mL, 4.96 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-Histidine (1.19 g, 
4.13 mmol), HOBT (0.67 g, 4.96 mmol) in 8 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (L)-Histidine 
methyl ester dihydrochloride (1.00 g, 4.13 mmol) and DIPEA (1.44 mL, 8.26 mmol) in 
5 mL of dry DMF is added dropwise.  
The reaction mixture is stirred at RT overnight and monitored by TLC95.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using Ethyl Acetate/Methanol = 95/5 
as elution solvent, to give 0.85 g (1.94 mmol) of the desired dipeptide. 
 
 
Yield: 47 % 
 
 
1H NMR (d6DMSO·): 11.81 (bs, 2H), 8.34 (d, 1H, J=6.96 Hz), 7.50 (s, 1H), 7.42 (d, 1H, J=8.43 
Hz), 7.30-7.39 (m, 6H), 6.79 (s, 1H), 6.76 (s, 1H), 4.97 (s, 2H), 4.44 (m, 1H), 4.24 (m, 1H), 
3.57 (s, 3H), 2.67-2.91 (m, 4H).  
                                                            
95 TLC conditions: Ethyl Acetate/ Methanol= 95/5  
Rf= 0.30 
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149 
(L)-(benzyloxy)carbonyl-Histidine-(D)-Histidine-methyl 
ester 
 
 
 
A solution of EDAC (0.95 g, 4.96 mmol) and DIPEA (0.86 mL, 4.96 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-Histidine (1.19 g, 
4.13 mmol), HOBT (0.67 g, 4.96 mmol) in 8 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (D)-
Histidine methyl ester dihydrochloride (1.00 g, 4.13 mmol) and DIPEA (1.44 mL, 8.26 
mmol) in 5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC96.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using Ethyl Acetate/Methanol = 95/5 
as elution solvent, to give 0.91 g (2.07 mmol) of the desired dipeptide. 
 
Yield: 50 % 
 
 
1H NMR (d6DMSO): 11.80 (bs, 2H), 8.53 (d, 1H, J=6.96 Hz), 7.49 (s, 1H), 7.41 (s, 1H), 7.29-
7.39 (m, 6H), 6.76 (s, 1H), 6.67 (s, 1H), 4.97 (s, 2H), 4.44 (m, 1H), 4.24 (m, 1H), 3.57 (s, 3H), 
2.67-2.91 (m, 4H).  
                                                            
96 TLC conditions: Ethyl Acetate/ Methanol= 95/5  
Rf= 0.28 
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150 
(L)-Histidine-(L)-Histidine-methyl ester trihydrochloride 
 
 
 
0.85 g (1.94 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 10 mL of dry Methanol and 4.7 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC97, at completion, achieved after stirring for 18 hours 
at RT, the solvents are evaporated giving 0.81 g of a sticky white solid in quantitative 
yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.43 (d, 1H, J= 7.47 Hz), 9.05 (s, 1H), 9.03 (s, 1H), 8.65 (bs, 7H), 7.54 (s, 
1H), 7.47 (s, 1H), 4.69 (m, 1H), 4.31 (m, 1H), 3.62 (s, 3H), 3.11-3.25 (m, 4H).  
                                                            
97 TLC conditions: Ethyl Acetate/ Methanol= 95/5  
Rf= basal 
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151 
(L)-Histidine-(D)-Histidine-methyl ester trihydrochloride 
 
 
 
0.91 g (2.07 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 15 mL of dry Methanol and 3 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC98, at completion, achieved after stirring for 18 hours 
at RT, the solvents are evaporated giving 0.86 g of a sticky white solid in quantitative 
yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.32 (m, 1H), 8.99 (s, 1H), 8.94 (s, 1H), 7.42 (s, 1H), 7.36 (s, 1H), 4.60 (m, 
1H), 4.20 (m, 1H), 3.62 (s, 3H), 3.03-3.17 (m, 4H).  
                                                            
98 TLC conditions: Ethyl Acetate/ Methano l= 95/5  
Rf= basal 
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152 
(L)-Glutamic acid-γ-benzyl ester 
 
 
 
(L)-Glutamic acid (5.0 g, 34.0 mmol) is added portionwise to a solution of benzyl 
alcohol (5.30 mL, 51.0 mmol) in 5 mL of Toluene. 
The mixture is heated to 45°C and sequentially 2.64 mL (40.8 mmol) of 
methanesulfonic acid are slowly dropped in. The temperature is maintained at 45°C 
for 2 hours and then at 32°C for further 3 hours. 
After 5 hours the solution is cooled to RT and 10 mL of Water are added; after 
separation of the two phases, the aqueous layer is amounted of 15 mL of Ethanol and 
20%NH3, reaching a neutral pH.  
The mixture is heated at 60°C for 2 hours and then cooled to 5°C, till the formation of 
a white precipitate. The solid is filtered and washed three times with Ethanol and twice 
with iced Water, obtaining 4.27 g (18.00 mmol) of the desired product. 
 
 
Yield: 52% 
 
 
 
 
 
 
1H NMR (d6DMSO): 7.33 (m, 5H), 5.00 (s, 2H), 4.04 (m, 1H), 2.31 (m, 1H), 2.12 (m, 2H), 1.95 
(m, 1H). 
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153 
(L)-(benzyloxy)carbonyl-Glutamic acid-γ-benzyl ester 
 
 
 
A solution of 2.70 mL (18.9 mmol) of benzyl chloroformate in 40 mL of THF is dropped, 
at 0°C, to a white suspension of (L)-Glutamic acid-γ-benzyl ester (4.27 g, 18.00 mmol) 
and NaHCO3 (3.10 g, 36.9 mmol) in 40 mL of Water.  
The mixture is then warmed to RT and monitored by TLC99; at completion the THF is 
removed and the aqueous layer is firstly washed with 30 mL of Ethyl Ether, secondly 
acidified with 10% Citric Acid and finally extracted three times with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated, 
yielding 6.48 g (17.46 mmol) of the protected amino acid, as colourless oil. 
 
 
Yield: 97%   
 
 
 
 
 
 
 
 
 
1H NMR (CDCl3): 7.31 (m, 10H), 5.51 (d, 1H, J= 7.98 Hz), 5.10 (s, 4H), 4.44 (m, 1H), 2.50 (m, 
2H), 2.27 (m, 1H), 2.02 (m, 1H).  
                                                            
99 TLC conditions: DCM/ Methanol/ Acetic acid= 90/8 /2  
Rf= 0.52 
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154 
(L)-(benzyloxy)carbonyl-Glutammate-γ-benzyl ester-(L)-
Histidine-methyl ester 
 
 
 
A solution of EDAC (2.17 g, 11.34 mmol) and DIPEA (1.97 mL, 11.34 mmol) in 4 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-Glutamic acid-γ-
benzyl ester (3.24 g, 8.72 mmol), HOBT (1.53 g, 11.34 mmol) in 16 mL of dry DMF 
under a nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (L)-Histidine 
methyl ester dihydrochloride (2.11 g, 8.72 mmol) and DIPEA (3.04 mL, 17.44 mmol) in 
5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC100.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using Ethyl Acetate/Methanol = 95/5 
as elution solvent, to give 2.23 g (4.27 mmol) of the desired dipeptide. 
 
Yield: 49 % 
 
 
1H NMR (d6DMSO): 11.81 (bs, 1H), 8.35 (d, 1H, J=7.43 Hz), 7.49 (s, 1H), 7.28-7.38 (m, 11H), 
6.81 (s, 1H), 5.07 (s, 2H), 5.00 (s, 2H), 4.46 (m, 1H), 4.04 (m, 1H), 3.58 (s, 3H), 2.87-2.90 (m, 
2H), 2.39 (m, 2H), 1.94 (m, 1H), 1.83 (m, 1H).  
                                                            
100 TLC conditions: Ethyl Acetate/ Methanol= 95/5  
Rf= 0.32 
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155 
(L)-(benzyloxy)carbonyl-Glutammate-γ-benzyl ester-(D)-
Histidine-methyl ester 
 
 
 
A solution of EDAC (2.17 g, 11.34 mmol) and DIPEA (1.97 mL, 11.34 mmol) in 4 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-Glutamic acid-γ-
benzyl ester (3.24 g, 8.72 mmol), HOBT (1.53 g, 11.34 mmol) in 16 mL of dry DMF 
under a nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (D)-
Histidine methyl ester dihydrochloride (2.11 g, 8.72 mmol) and DIPEA (3.04 mL, 17.44 
mmol) in 5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC101.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using Ethyl Acetate/Methanol = 95/5 
as elution solvent, to give 3.01 g (5.76 mmol) of the desired dipeptide. 
 
Yield: 66 % 
 
 
1H NMR (d6DMSO): 11.77 (bs, 1H), 8.34 (d, 1H, J=7.43 Hz), 7.44 (s, 1H), 7.22-7.30 (m, 11H), 
6.78 (s, 1H), 5.05 (s, 2H), 5.00 (s, 2H), 4.46 (m, 1H), 4.04 (m, 1H), 3.57 (s, 3H), 2.88 (m, 2H), 
2.30 (m, 2H), 1.64-1.96 (m, 2H).  
                                                            
101 TLC conditions: Ethyl Acetate/ Methanol= 95/5  
Rf= 0.30 
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156 
(L)-Glutammate-(L)-Histidine-methyl ester dihydrochloride 
 
 
 
2.23 g (4.27 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 25 mL of dry Methanol and 6.8 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC102, at completion, achieved after stirring for 18 hours 
at RT, the solvents are evaporated giving 1.59 g of a sticky white solid in quantitative 
yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.30 (d, 1H, J= 7.43 Hz), 9.02 (s, 1H), 8.39 (bs, 5H), 7.52 (s, 1H), 4.69 (m, 
1H), 3.92 (m, 1H), 3.65 (s, 3H), 3.20 (dd, 1H, J= 15.68 Hz, J= 5.22 Hz), 3.13 (dd, 1H, J= 15.68 
Hz, J= 6.33 Hz), 2.38 (m, 1H), 1.95 (m, 3H).  
                                                            
102 TLC conditions: Ethyl Acetate/ Methanol= 95/5  
Rf= basal 
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157 
(L)-Glutammate-(D)-Histidine-methyl ester dihydrochloride 
 
 
 
3.01 g (5.76 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 30 mL of dry Methanol and 9.2 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC103, at completion, achieved after stirring for 18 hours 
at RT, the solvents are evaporated giving 2.14 g of a sticky white solid in quantitative 
yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.39 (d, 1H, J= 7.15 Hz), 8.93 (s, 1H), 8.46 (bs, 5H), 7.49 (s, 1H), 4.52 (m, 
1H), 3.84 (m, 1H), 3.63 (s, 3H), 3.12-3.19 (m, 2H), 2.21 (m, 2H), 1.91 (m, 2H).  
                                                            
103 TLC conditions: Ethyl Acetate/ Methanol= 95/5  
Rf= basal 
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158 
(L)-Tyrosine-methyl ester 
 
 
 
Thionyl chloride (1.60 mL, 22.08 mmol) is added dropwise to a suspension of L-
tyrosine (2.0 g, 11.04 mmol) in 30 mL of anhydrous methanol at 0°C, the resulting 
mixture is warmed to RT and then refluxed for 16 h.  
The reaction is monitored by NMR, at completion the mixture is cooled down to RT and 
concentrated, yielding 2.16 g (11.04 mmol) of a white solid. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (D2O): 7.03 (d, 1H, J= 7.97 Hz), 6.97 (d, 1H, J= 7.97 Hz), 4.25 (m, 1H), 3.71 (s, 3H), 
3.05-3.12 (m, 2H). 
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159 
(L)-(benzyloxy)carbonyl-Tyrosine-methyl ester 
 
 
 
To a solution of (L)-Tyrosine-methyl ester (2.16 g, 11.04 mmol) and Na2CO3 (1.52 g, 
14.38 mmol) in 50 mL of Water/Acetone =1/1 is slowly added Benzyl chloroformate 
(1.74 mL, 12.17 mmol), at 0°C. 
The reaction mixture is then warmed to RT and stirred for 18 hours, monitoring the 
reaction progression by TLC104. 
At completion, the suspension is treated with Ethyl Acetate and Water, the organic 
phase is washed with brine, dried over Na2SO4, filtered and concentrated under 
vacuum.  
The crude is purified on silica gel, using Cyclohexane / Ethyl Acetate= 80/20 as elution 
solvent, yielding 2.65 g (8.05 mmol) of the desired product. 
 
 
Yield: 73% 
 
 
 
 
 
 
1H NMR (CDCl3): 7.38 (m, 5H), 6.96 (d, 1H, J= 7.97 Hz), 6.67 (d, 1H, J= 7.97 Hz), 5.24 (d, 1H, 
J= 7.05 Hz), 5.10 (s, 2H), 4.60 (m, 1H), 3.71 (s, 3H), 2.95-3.10 (m, 2H).  
                                                            
104 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30  
Rf= 0.33 
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160 
(L)-(benzyloxy)carbonyl-O-benzyl-Tyrosine-methyl ester 
 
 
 
A solution of (L)-(benzyloxy)carbonyl-Tyrosine-methyl ester (2.65 g, 8.05 mmol) in 25 
mL of Acetone is amounted of solid Cs2CO3 (2.75 g, 8.85 mmol) and stirred for 30 
minutes. 
To the resulting suspension, at 0°C, is dropped benzyl bromide (1.05 mL, 8.85 mmol), 
the mixture is then heated to reflux and monitored by TLC105. 
At completion, the suspension is cooled to RT and filtered over Celite; the filtrate is 
concentrated under reduced pressure. 
The crude is purified on silica gel, using Cyclohexane/ Ethyl Acetate = 80/20 as elution 
solvent, yielding 2.20 g (5.24 mmol) of a colourless oil, corresponding to the desired 
product. 
 
 
Yield: 65 % 
 
 
 
 
 
 
1H NMR (CDCl3): 7.38 (m, 10H), 7.02 (d, 1H, J= 7.97 Hz), 6.92 (d, 1H, J= 7.97 Hz), 5.24 (d, 
1H, J= 7.05 Hz), 5.10 (s, 2H), 5.00 (s, 2H), 4.61 (m, 1H), 3.71 (s, 3H), 3.00-3.14 (m, 2H). 
                                                            
105  TLC condition: Cyclohexane / Ethyl Acetate = 70/30 
Rf: 0.41 
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161 
(L)-(benzyloxy)carbonyl-O-benzyl-Tyrosine 
 
 
 
2.20 g (5.24 mmol) of (L)-(benzyloxy)carbonyl-O-benzyl-tyrosine-methyl ester are 
dissolved in 25 mL of Methanol and amounted, dropwise, of 2.5 mL of NaOH 2.5 M. 
The reaction is stirred at RT for 18 hours and monitored by TLC106; at completion, after 
solvent removal, the residue is rinse and washed with Ethyl ether, the aqueous layer is 
then acidified with HCl 10% and extraxted three times with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated, 
yielding 2.12 g of the free carboxylic acid, in quantitative yield. 
 
 
Yield: Quantitative  
 
 
 
 
 
 
 
 
 
1H NMR (CDCl3): 9.08 (bs, 1H), 7.33-7.43 (m, 10H), 7.07 (d, 1H, J= 8.53 Hz), 6.92 (d, 1H, J= 
8.53 Hz), 5.24 (d, 1H, J= 7.98 Hz), 5.10 (s, 2H), 5.02 (s, 2H), 4.78 (m, 1H), 3.08-3.14 (m, 2H). 
                                                            
106 TLC condition: Cyclohexane / Ethyl Acetate = 70/30 
Rf: 0.10 
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162 
(L)-(benzyloxy)carbonyl-O-benzyl-Tyrosine-(L)-Histidine-
methyl ester 
 
 
 
A solution of EDAC (0.65 g, 3.41 mmol) and DIPEA (0.59 mL, 3.41 mmol) in 4 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-O-benzyl-Tyrosine 
(1.06 g, 2.62 mmol), HOBT (0.46 g, 3.41 mmol) in 16 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (L)-Histidine 
methyl ester dihydrochloride (0.63 g, 2.62 mmol) and DIPEA (0.91 mL, 5.24 mmol) in 
5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC107.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using DCM/Methanol = 90/10 as 
elution solvent, to give 0.74 g (1.34 mmol) of the desired dipeptide. 
 
Yield: 51 % 
 
1H NMR (d6DMSO): 7.47 (s, 1H), 7.22-7.41 (m, 10 H), 7.21 (bs, 1H), 7.05 (d, 2H, J=8.34 Hz), 
6.85 (d, 2H, J=8.34 Hz), 6.69 (s, 1H), 5.57 (bs, 1H), 5.04 (d, 2H, J=4.68 Hz), 4.99 (s, 2H), 
4.76 (dd, 1H, J=4.98 Hz, J=12.28 Hz), 4.38 (dd, 1H, J=7.02 Hz, J=7.32 Hz), 3.67 (s, 3H), 3.10 
(m, 2H), 3.03 (dd, 1H, J=15.58 Hz, J=4.98 Hz), 2.90 (dd, 1H, J=15.58 Hz, J=12.28 Hz). 
                                                            
107 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.32 
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163 
(L)-(benzyloxy)carbonyl-O-benzyl-Tyrosine-(D)-Histidine-
methyl ester 
 
 
 
A solution of EDAC (0.65 g, 3.41 mmol) and DIPEA (0.59 mL, 3.41 mmol) in 4 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-O-benzyl-Tyrosine 
(1.06 g, 2.62 mmol), HOBT (0.46 g, 3.41 mmol) in 16 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (D)-
Histidine methyl ester dihydrochloride (0.63 g, 2.62 mmol) and DIPEA (0.91 mL, 5.24 
mmol) in 5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC108.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using DCM/Methanol = 90/10 as 
elution solvent, to give 0.71 g (1.28 mmol) of the desired dipeptide. 
 
Yield: 49 % 
 
1H NMR (d6DMSO): 11.80 (bs, 1H), 8.47 (d, 1H, J=7.33 Hz), 7.51 (s, 1H), 7.19-7.49 (m, 10 H), 
7.12 (d, 2H, J=8.80 Hz), 7.07 (d, 2H, J=8.43 Hz), 6.86 (d, 1H, J=8.80 Hz), 6.81 (s, 1H), 5.03 
(s, 2H), 4.94 (s, 2H), 4.48 (ddd, 1H, J=7.33 Hz, J=5.36 Hz, J=8.43 Hz), 4.19 (ddd, 1H, J=8.43 
Hz, J=6.97 Hz, J=8.80 Hz), 3.61 (s, 3H), 2.75-2.91 ( m, 4H).  
                                                            
108 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.30 
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164 
(L)-Tyrosine-(L)-Histidine-methyl ester dihydrochloride 
 
 
 
0.74 g (1.34 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 25 mL of dry Methanol and 2.14 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC109 , at completion, achieved after stirring for 18 
hours at RT, the solvents are evaporated giving 0.54 g of a sticky white solid in 
quantitative yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 8.45 (s, 1H), 7.07 (s, 1H), 6.96 (d, 2H, J= 7.15 Hz), 6.66 (d, 2H, J= 7.15 
Hz), 4.65 (m, 1H), 4.04 (m, 1H), 3.58 (s, 3H), 2.83-3.17 (m, 4H).  
                                                            
109 TLC conditions: DCM/ Methanol= 90/10  
Rf= basal 
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165 
(L)-Tyrosine-(D)-Histidine-methyl ester di-trifluoroacetate 
 
 
 
0.71 g (1.28 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 10 mL of dry Methanol and 2.1 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC110 , at completion, achieved after stirring for 18 
hours at RT, the solvents are evaporated. 
The residue is further purified by reverse phase preparative HPLC, according to the 
gradient reported in Table 3, giving 0.56 g (1.01 mmol) of a sticky white solid. 
 
 
Yield: 75% 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.41 (d, 1H, J= 7.70 Hz), 9.04 (s, 1H), 8.19 (bs, 5H), 7.48 (s, 1H), 6.95 (d, 
2H, J= 8.53 Hz), 6.68 (d, 2H, J= 8.53 Hz), 4.56 (m, 1H), 3.95 (m, 1H), 3.64 (s, 3H), 2.98-3.21 
(m, 2H), 2.91 (m, 1H), 2.70 (m, 1H).  
                                                            
110 TLC conditions: DCM/ Methanol= 90/10  
Rf= basal 
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166 
(L)-di-(benzyloxy)carboxyl-Lysine 
 
 
 
To a solution of (L)-Lysine hydrochloride (3.0 g, 16.42 mmol) in NaOH, at 0°C, is slowly 
dropped benzyl chloroformate (5.16 mL, 36.12 mmol). 
The reaction is warmed to RT and monitored by TLC111. 
At completion, the mixture is washed with Ethyl ether, acidified with HCl 10% and 
extracted three times with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated, 
yielding 6.80 g of a colorless oil. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
1H NMR (CDCl3): 7.35 (m, 10H), 5.58 (m, 1H), 5.09 (s, 2H), 5.06 (s, 2H), 4.93 (m, 1H), 4.38 
(m, 1H), 3.17 (m, 2H), 1.86 (m, 1H), 1.73 (m, 1H), 1 47 (m, 2H), 1.39 (m, 2H).  
                                                            
111 TLC conditions: DCM/ Methanol/ Acetic Acid= 90/9/1  
Rf= 0.15 
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167 
(L)-di-(benzyloxy)carboxyl-Lysine-(L)-Histidine-methyl ester 
 
 
 
A solution of EDAC (1.11 g, 5.79 mmol) and DIPEA (1.00 mL, 5.79 mmol) in 4 mL of 
dry DMF is added dropwise to a solution of (L)-di-(benzyloxy)carbonyl-Lysine (2.00 g, 
4.83 mmol), HOBT (0.78 g, 5.79 mmol) in 16 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (L)-Histidine 
methyl ester dihydrochloride (1.17 g, 4.83 mmol) and DIPEA (0.84 mL, 4.83 mmol) in 
5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC112.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using DCM/Methanol = 90/10 as 
elution solvent, to give 1.50 g (2.66 mmol) of the desired dipeptide. 
 
Yield: 55 % 
 
 
1H NMR (CD3OD):7.52 (s, 1H), 7.25-7.32 (m, 10 H), 6.86 (s, 1H), 5.08 (s, 2H), 5.04 (s, 2H), 
4.66 (m, 1H), 4.09 (m, 1H), 3.66 (s, 3H), 3.00-3.14 (m, 4H), 1.69 (m, 1H), 1.62 (m, 1H), 1.46 
(m, 2H), 1.38 (m, 2H).  
                                                            
112 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.34 
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168 
(L)-di-(benzyloxy)carboxyl-Lysine-(D)-Histidine-methyl ester 
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A solution of EDAC (0.65 g, 3.41 mmol) and DIPEA (0.59 mL, 3.41 mmol) in 4 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-O-benzyl-Tyrosine 
(1.06 g, 2.62 mmol), HOBT (0.46 g, 3.41 mmol) in 16 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (D)-
Histidine methyl ester dihydrochloride (1.06 g, 2.62 mmol) and DIPEA (0.91 mL, 5.24 
mmol) in 5 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC113.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using DCM/Methanol = 90/10 as 
elution solvent, to give 0.74 g (1.31 mmol) of the desired dipeptide. 
 
Yield: 50 % 
 
 
1H NMR (CDCl3): 7.42 (s, 1H), 7.24-7.32 (m, 11H), 6.73 (s, 1H), 5.80 (bs, 1H), 5.09 (s, 2H), 
5.06 (s, 2H), 4.76 (m, 1H), 4.18 (m, 1H), 3.70 (s, 3H), 3.09-3.13 (m, 4H), 1.79 (m, 1H), 1.61 
(m, 1H), 1.43 (m, 2H), 1.25 (m, 2H).  
                                                            
113 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.33 
Carnosine-like derivatives                                                                  Experimental section 
169 
(L)-Lysine-(L)-Histidine-methyl ester tri-hydrochloride 
 
 
 
1.50 g (2.66 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 25 mL of dry Methanol and 6.38 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC114 , at completion, achieved after stirring for 18 
hours at RT, the solvents are evaporated giving 1.08 g of a sticky white solid in 
quantitative yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
1H NMR (D2O): 8.53 (s, 1H), 7.24 (s, 1H), 4.78 (dd, J= 5.77 Hz, J= 8.25 Hz, 1H), 3.95 (dd, J= 
6.6 Hz, J= 6.32 Hz, 1H), 3.67 (s, 3H), 3.28 (dd, J= 15.68 Hz, J= 5.77 Hz, 1H), 3.15 (dd, J= 
15.68 Hz, J= 8.25 Hz, 1H), 2.90 (m, 2H), 1.83 (m, 2H), 1.61 (m, 2H), 1.37 (m, 2H). 
                                                            
114 TLC conditions: DCM/ Methanol= 90/10  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
170 
(L)-Lysine-(D)-Histidine-methyl ester tri-hydrochloride 
 
 
 
0.74 g (1.31 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 25 mL of dry Methanol and 3.14 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC115 , at completion, achieved after stirring for 18 
hours at RT, the solvents are evaporated giving 0.53 g of a sticky white solid in 
quantitative yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.10 (d, 1H, J= 7.69 Hz), 8.31 (s, 1H), 8.12 (bs, 8H), 7.16 (s, 1H), 4.62 (m, 
1H), 3.77 (m, 1H), 3.65 (s, 3H), 3.07 (m, 1H), 2.92 (m, 1H), 2.69 (m, 2H), 1.60 (m, 2H), 1.47 
(m, 2H), 1.19 (m, 1H), 1.03 (m, 1H).  
                                                            
115 TLC conditions: DCM/ Methanol= 90/10  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
171 
(L)-(benzyloxy)carbonyl-Asparagine 
 
 
 
2.0 g (15.14 mmol) of (L)-Asparagine are dissolved in 30 mL of 10% aqueous solution 
of Na2CO3 and 18 mL of Dioxane.  
The solution is cooled to 0°C, 2.59 mL (18.17 mmol) of benzyl chloroformate are 
slowly dropped and then the mixture is warmed to RT and monitored by NMR. 
At completion, the reaction is poured in water, washed with Ethyl ether, acidified with 
HCl 10% till the precipitation of a white solid. 
The precipitate is filtered and washed three times with Ethyl ether, obtaining 3.02 g 
(11.36 mmol) of the protected amino acid.  
 
 
Yield: 75% 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.44 (d, 1H, J= 8.19 Hz), 7.34 (m, 6H), 6.91 (bs, 1H), 5.01 (s, 2H), 4.32 (m, 
1H), 2.43-2.52 (m, 2H).  
Carnosine-like derivatives                                                                  Experimental section 
172 
(L)-(benzyloxy)carbonyl-Asparagine-(L)-Histidine-methyl 
ester 
 
 
A solution of EDAC (0.86 g, 4.51 mmol) and DIPEA (0.79 mL, 4.51 mmol) in 3 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-Asparagine (1.00 g, 
3.76 mmol), HOBT (0.61 g, 4.51 mmol) in 5 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (L)-Histidine 
methyl ester dihydrochloride (0.91 g, 3.76 mmol) and DIPEA (1.31 mL, 7.52 mmol) in 
3 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC116.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using DCM/Methanol = 96/4 as 
elution solvent, to give 0.57 g (1.35 mmol) of the desired dipeptide. 
 
 
Yield: 36 % 
 
1H NMR (d6DMSO): 11.78 (bs, 1H), 8.54 (d, 1H, J=7.33 Hz), 7.80 (d, 1H, J=8.43 Hz), 7.49 (s, 
1H), 7.21-7.42 (m, 7H), 6.81 (s, 1H), 5.05 (s, 4H), 4.44 (m, 2H), 3.57 (s, 3H), 2.90 (m, 2H), 
2.66 (m, 2H).  
                                                            
116 TLC conditions: DCM/ Methanol= 96/4  
Rf= 0.24 
Carnosine-like derivatives                                                                  Experimental section 
173 
(L)-(benzyloxy)carbonyl-Asparagine-(D)-Histidine-methyl 
ester 
 
A solution of EDAC (0.86 g, 4.51 mmol) and DIPEA (0.79 mL, 4.51 mmol) in 3 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-Asparagine (1.00 g, 
3.76 mmol), HOBT (0.61 g, 4.51 mmol) in 5 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (D)-
Histidine methyl ester dihydrochloride (0.91 g, 3.76 mmol) and DIPEA (1.31 mL, 7.52 
mmol) in 3 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC117.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using DCM/Methanol = 96/4 as 
elution solvent. 
The compound undergoes further purification by reverse phase preparative HPLC, 
according to the gradient reported in Table 2, giving 0.60 g (1.43 mmol) of the desired 
dipeptide. 
 
Yield: 38 % 
 
1H NMR (d6DMSO): 8.96 (s, 1H), 8.40 (d, 1H, J=7.98 Hz), 7.44 (d, 1H, J=7.98 Hz), 7.24-7.40 
(m, 7H), 6.90 (s, 1H), 5.01 (s, 2H), 4.99 (s, 2H), 4.56 (m, 1H), 4.28 (m, 1H), 3.62 (s, 3H), 3.12 
(dd, 1H, J= 4.68 Hz, J= 16.78 Hz), 3.07 (dd, 1H, J= 9.07 Hz, J= 16.78 Hz), 2.33-2.47 (m 2H). 
                                                            
117 TLC conditions: DCM/ Methanol= 96/4  
Rf= 0.24 
Carnosine-like derivatives                                                                  Experimental section 
174 
(L)-Asparagine-(L)-Histidine-methyl ester di-
trifluoroacetate 
 
 
 
0.57 g (1.35 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 10 mL of dry Methanol and 2.16 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC118 , at completion, achieved after stirring for 18 
hours at RT, the solvents are evaporated. 
The residue is further purified by reverse phase preparative HPLC, according to the 
gradient reported in Table 3, giving 0.69 g of a sticky white solid. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.23 (d, 1H, J= 7.43 Hz), 8.83 (s, 1H), 7.80 (s, 1H), 7.40 (s, 1H), 7.21 (s, 
1H), 4.63 (m, 1H), 4.11 (m, 1H), 3.63 (s, 3H), 3.06-3.19 (m, 2H), 2.74 (dd, 1H, J= 4.13 Hz, J= 
16.76 Hz), 2.62 (dd, 1H, J= 7.98 Hz, J= 16.76 Hz).  
                                                            
118 TLC conditions: DCM/ Methanol= 96/4  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
175 
(L)-Asparagine-(D)-Histidine-methyl ester dihydrochloride 
 
 
 
0.60 g (1.43 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 10 mL of dry Methanol and 2.3 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC119 , at completion, achieved after stirring for 18 
hours at RT, the solvents are evaporated giving 0.73 g of a sticky white solid in 
quantitative yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.13 (d, 1H, J= 8.20 Hz), 9.03 (s, 1H), 8.20 (bs, 5H), 7.76 (s, 1H), 7.46 (s, 
1H), 7.21 (s, 1H), 4.60 (m, 1H), 4.04 (m, 1H), 3.60 (s, 3H), 3.22 (m, 1H), 3.16 (m, 1H), 2.68 
(dd, 1H, J= 4.76 Hz, J= 16.87 Hz), 2.56 (dd, 1H, J= 7.68 Hz, J= 16.87 Hz).  
                                                            
119 TLC conditions: DCM/ Methanol= 96/4  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
176 
(L)-(benzyloxy)carbonyl-Tryptophan-(L)-Histidine-methyl 
ester 
 
 
A solution of EDAC (0.68 g, 3.55 mmol) and DIPEA (0.62 mL, 3.55 mmol) in 3 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-Tryptophan (1.00 g, 
2.95 mmol), HOBT (0.48 g, 3.55 mmol) in 5 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (L)-Histidine 
methyl ester dihydrochloride (0.71 g, 2.95 mmol) and DIPEA (1.03 mL, 5.90 mmol) in 
3 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC120.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using Ethyl Acetate/Methanol = 95/5 
as elution solvent, to give 1.33 g (2.71 mmol) of the desired dipeptide. 
 
Yield: 92 % 
 
 
1H NMR (d6DMSO): 11.80 (bs, 1H), 10.81 (s, 1H), 8.43 (d, 1H, J=7.52 Hz), 7.62 (d, 1H, J=7.7 
Hz), 7.51 (s, 1H), 7.22-7.35 (m, 7H), 7.08-6.95 (m, 3H), 6.81 (bs, 1H), 4.92 (s, 2H), 4.52 (m, 
1H), 4.28 (m, 1H), 3.56 (s, 3H), 2.81-3.06 (m, 4H).  
                                                            
120 TLC conditions: Ethyl Acetate/ Methanol= 90/10  
Rf= 0.28 
Carnosine-like derivatives                                                                  Experimental section 
177 
(L)-(benzyloxy)carbonyl-Tryptophan-(D)-Histidine-methyl 
ester 
 
 
A solution of EDAC (0.68 g, 3.55 mmol) and DIPEA (0.62 mL, 3.55 mmol) in 3 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-Tryptophan (1.00 g, 
2.95 mmol), HOBT (0.48 g, 3.55 mmol) in 5 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (D)-
Histidine methyl ester dihydrochloride (0.71 g, 2.95 mmol) and DIPEA (1.03 mL, 5.90 
mmol) in 3 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC121.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using Ethyl Acetate/Methanol = 95/5 
as elution solvent, to give 1.27 g (2.60 mmol) of the desired dipeptide. 
 
Yield: 88 % 
 
 
1H NMR (d6DMSO·): 11.80 (bs, 1H), 10.76 (s, 1H), 8.49 (d, 1H, J=7.7 Hz), 7.60 (d, 1H, J=7.7 
Hz), 7.49 (s, 1H), 7.22-7.35 (m, 7H), 7.03 (m, 2H), 6.95 (m, 1H), 6.82 (bs, 1H), 4.92 (s, 2H), 
4.50 (m, 1H), 4.27 (m, 1H), 3.61 (s, 3H), 2.71-2.96 (m, 4H).  
                                                            
121 TLC conditions: Ethyl Acetate/ Methanol= 90/10  
Rf= 0.30 
Carnosine-like derivatives                                                                  Experimental section 
178 
(L)-Tryptophan-(L)-Histidine-methyl ester dihydrochloride 
 
 
 
1.33 g (2.71 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 20 mL of dry Methanol and 4.34 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC122, at completion, achieved after stirring for 18 hours 
at RT, the solvents are evaporated giving 1.16 g of a sticky white solid in quantitative 
yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 11.06 (s, 1H), 9.35 (d, 1H, J= 7.62 Hz), 8.92 (s, 1H), 7.73 (d, 1H, J= 7.63 
Hz), 7.44 (s, 1H), 7.34 (d, 1H, J= 7.92 Hz), 7.21 (s, 1H), 7.06 (dd, 1H, J= 7.92 Hz, J= 7.04 Hz), 
6.96 (dd, 1H, J= 7.63 Hz, J= 7.04 Hz), 4.68 (m, 1H), 4.09 (m, 1H), 3.62 (s, 3H), 2.87-3.28 (m, 
4H).  
                                                            
122 TLC conditions: Ethyl Acetate/ Methanol= 90/10  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
179 
(L)-Tryptophan-(D)-Histidine-methyl ester dihydrochloride 
 
 
 
1.27 g (2.60 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 20 mL of dry Methanol and 4.16 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC123, at completion, achieved after stirring for 18 hours 
at RT, the solvents are evaporated giving 1.11 g of a sticky white solid in quantitative 
yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 11.02 (s, 1H), 9.26 (d, 1H, J= 7.70 Hz), 8.25 (s, 1H), 7.61 (d, 1H, J= 7.71 
Hz), 7.34 (d, 1H, J= 8.25 Hz), 7.12 (s, 2H), 7.07 (dd, 1H, J= 8.25 Hz, J= 7.15 Hz), 6.97 (dd, 1H, 
J= 7.71 Hz, J= 7.15 Hz), 4.56 (m, 1H), 4.02 (m, 1H), 3.63 (s, 3H), 2.87-3.17 (m, 4H). 
                                                            
123 TLC conditions: Ethyl Acetate/ Methanol= 90/10  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
180 
(L)-(benzyloxy)carbonyl-Methionine-methyl ester 
 
 
 
2.0 g (13.40 mmol) of (L)-Methionine are dissolved in 20 mL of 10% aqueous solution 
of NaHCO3 and cooled to 0°C.  
The solution is amounted, dropwise, of 2.10 mL (14.74 mmol) of benzyl chloroformate 
and then the mixture is warmed to RT and monitored by TLC124. 
At completion, the reaction is poured in washed with Ethyl ether, acidified with HCl 
10% and extracted three times with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduce pressure, yielding 2.39 g (8.44 mmol) of the desired product, as colourless oil. 
 
Yield: 63% 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.75 (bs, 1H), 7.37 (m, 5H), 5.44 (d, 1H, J= 7.43 Hz), 5.14 (s, 2H), 4.58 (m, 
1H), 2.58 (t, 2H, J= 6.60 Hz), 2.19 (m, 1H), 2.04 (s, 3H), 1.98 (m, 1H).  
                                                            
124 TLC conditions: DCM/ Methanol= 95/ 5 
Rf: 0.32 
Carnosine-like derivatives                                                                  Experimental section 
181 
(L)-(benzyloxy)carbonyl-Methionine-(L)-Histidine-methyl 
ester 
 
 
 
A solution of EDAC (0.97 g, 5.08 mmol) and DIPEA (0.88 mL, 5.08 mmol) in 5 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-Methionine (1.2 g, 
4.24 mmol), HOBT (0.69 g, 5.08 mmol) in 7 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (L)-Histidine 
methyl ester dihydrochloride (1.03 g, 4.24 mmol) and DIPEA (1.48 mL, 8.48 mmol) in 
3 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC125.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using DCM/Methanol = 90/10 as 
elution solvent, to give 0.92 g (2.12 mmol) of the desired dipeptide. 
 
Yield: 50 % 
 
 
1H NMR (d6DMSO): 11.80 (bs, 1H), 8.34 (d, 1H, J=7.43 Hz), 7.49 (s, 1H), 7.26-7.39 (m, 6H), 
6.81 (s, 1H), 5.01 (s, 2H), 4.44 (m, 1H), 4.08 (m, 1H), 3.56 (s, 3H), 2.88 (m, 2H), 2.48 (m, 2H), 
1.72-1.94 (m. 2H).  
                                                            
125 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.33 
Carnosine-like derivatives                                                                  Experimental section 
182 
(L)-(benzyloxy)carbonyl-Methionine-(D)-Histidine-methyl 
ester 
 
 
 
A solution of EDAC (0.97 g, 5.08 mmol) and DIPEA (0.88 mL, 5.08 mmol) in 5 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-Methionine (1.2 g, 
4.24 mmol), HOBT (0.69 g, 5.08 mmol) in 7 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (D)-
Histidine methyl ester dihydrochloride (1.03 g, 4.24 mmol) and DIPEA (1.48 mL, 8.48 
mmol) in 3 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC126.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using DCM/Methanol = 90/10 as 
elution solvent, to give 1.16 g (2.67 mmol) of the desired dipeptide. 
 
Yield: 63 % 
 
 
1H NMR (d6DMSO): 11.82 (bs, 1H), 8.32 (d, 1H, J=7.68 Hz), 7.48 (s, 1H), 7.26-7.40 (m, 6H), 
6.78 (s, 1H), 5.01 (s, 2H), 4.48 (m, 1H), 4.09 (m, 1H), 3.59 (s, 3H), 2.88 (m, 2H), 2.34 (m, 2H), 
1.72 ( m, 2H).  
                                                            
126 TLC conditions: DCM/ Methanol= 90/10  
Rf= 0.32 
Carnosine-like derivatives                                                                  Experimental section 
183 
(L)-Methionine-(L)-Histidine-methyl ester di-
trifluoroacetate 
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0.92 g (2.12 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 10 mL of dry Methanol and 3.39 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC127 , at completion, achieved after stirring for 18 
hours at RT, the solvents are evaporated. 
The residue is further purified by reverse phase preparative HPLC, according to the 
gradient reported in Table 3Errore. L'origine riferimento non è stata trovata., giving 1.12 g 
of a sticky white solid. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 8.52 (s, 1H), 7.22 (s, 1H), 4.75 (m, 1H), 4.03 (dd, 1H, J= 6.6 Hz, J= 6.32 
Hz), 3.67 (s, 3H), 3.28 (dd, 1H, J= 15.5 Hz, J= 5.4 Hz), 3.15 (dd, 1H, J= 15.5 Hz, J= 8.25 Hz), 
2.46-2.52 (m, 2H), 2.02-2.10 (m, 2H), 2.00 (s, 3H).  
                                                            
127 TLC conditions: DCM/ Methanol= 96/4  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
184 
(L)-Methionine-(D)-Histidine-methyl ester di-
trifluoroacetate 
 
N
H
COOCH3
H2N
N
H
N
O
C16H22F6N4O7S
M.W.: 528,4
S
N
H
COOCH3
H
N
Cbz
N
H
N
O
C20H26N4O5S
M.W.: 434,51
S
*2 TFA
 
 
1.16 g (2.67 mmol) of the protected dipeptide undergo hydrogenolysis with Pd/C 10% 
in a mixture of 15 mL of dry Methanol and 4.27 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC128 , at completion, achieved after stirring for 18 
hours at RT, the solvents are evaporated. 
The residue is further purified by reverse phase preparative HPLC, according to the 
gradient reported in Table 3, giving 1.41 g of a sticky white solid. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 8.53 (s, 1H), 7.22 (s, 1H), 4.75 (dd, 1H, J= 4.68 Hz, J= 10.17 Hz), 3.97 
(dd, 1H, J= 6.6 Hz, J= 6.32 Hz), 3.65 (s, 3H), 3.30 (dd, 1H, J= 15.68 Hz, J= 4.68 Hz), 3.08 (dd, 
1H, J= 15.68 Hz, J= 10.17 Hz), 2.10-2.28 (m, 2H), 1.86-1.93 (m, 2H), 1.91 (s, 3H). 
                                                            
128 TLC conditions: DCM/ Methanol= 96/4  
Rf= basal 
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185 
(L)-(benzyloxy)carbonyl O-tert-Butil Serine-(L)-Histidine-
methyl ester 
 
 
 
A solution of EDAC (0.78 g, 4.06 mmol) and DIPEA (0.71 mL, 4.06 mmol) in 5 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-O-tert-butyl-Serine 
(1.0 g, 3.39 mmol), HOBT (0.55 g, 4.06 mmol) in 8 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (L)-Histidine 
methyl ester dihydrochloride (0.82 g, 3.39 mmol) and DIPEA (1.18 mL, 6.78 mmol) in 
3 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC129.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using Ethyl Acetate/Methanol = 95/5 
as elution solvent, to give 1.10 g (2.47 mmol) of the desired dipeptide. 
 
Yield: 73 % 
 
 
 
1H NMR (·d6DMSO): 11.80 (bs, 1H), 8.26 (d, 1H, J=7.43 Hz), 7.48 (s, 1H), 7.22-7.33 (m, 6H), 
6.80 (s, 1H), 5.02 (s, 2H), 4.49 (m, 1H), 4.10 (m, 1H), 3.55 (s, 3H), 3.35-3.48 (m, 2H), 2.88 
(m, 2H), 1.07 (s, 9H).  
                                                            
129 TLC conditions: Ethyl Acetate/ Methanol= 95/5  
Rf= 0.30 
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186 
(L)-(benzyloxy)carbonyl-O-tert-Butil Serine-(D)-Histidine-
methyl ester 
 
 
 
A solution of EDAC (0.78 g, 4.06 mmol) and DIPEA (0.71 mL, 4.06 mmol) in 5 mL of 
dry DMF is added dropwise to a solution of (L)-(benzyloxy)carbonyl-O-tert-butyl-Serine 
(1.0 g, 3.39 mmol), HOBT (0.55 g, 4.06 mmol) in 8 mL of dry DMF under a nitrogen 
atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of (D)-
Histidine methyl ester dihydrochloride (0.82 g, 3.39 mmol) and DIPEA (1.18 mL, 6.78 
mmol) in 3 mL of dry DMF is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC130.  
After completion, the solvent is removed under vacuum and the residue is treated with 
Ethyl Acetate and washed first with a solution of NaHCO3 and then with brine. 
The organic phase is dried over Na2SO4, filtered, and evaporated. The crude product is 
purified by column chromatography on silica gel, using Ethyl Acetate/Methanol = 95/5 
as elution solvent, to give 1.21 g (2.71 mmol) of the desired dipeptide. 
 
Yield: 80 % 
 
 
 
1H NMR (·d6DMSO): 11.78 (bs, 1H), 8.30 (d, 1H, J=7.42 Hz), 7.49 (s, 1H), 7.17-7.37 (m, 6H), 
6.78 (s, 1H), 5.02 (s, 2H), 4.48 (m, 1H), 4.10 (m, 1H), 3.58 (s, 3H), 3.32-3.45 (m, 2H), 2.71-
2.87 (m, 2H), 1.04 (s, 9H).  
                                                            
130 TLC conditions: Ethyl Acetate/ Methanol= 95/5  
Rf= 0.30 
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(L)-Serine-(L)-Histidine-methyl ester dihydrochloride 
 
 
 
1.10 g (2.47 mmol) of the full protected dipeptide are stirred 10 mL of DCM/TFA =7/3 
for 3 hours in presence of anisole (0.54 mL, 4.94 mmol).  
The solvent is removed and the residue rinsed and washed three times with Ethyl 
ether; simply water removal under vacuum giving the (L)-(benzyloxy)carbonyl-Serine-(L)-
Histidine-methyl ester, in quantitative yield. 
The dipeptide undergoes hydrogenolysis with Pd/C 10% in a mixture of 15 mL of dry 
Methanol and 3.95 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC131 , at completion, achieved after stirring for 18 
hours at RT, the solvents are evaporated, giving 0.81 g of a sticky white solid. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.10 (d, 1H, J= 7.69 Hz), 8.99 (s, 1H), 8.22 (bs, 5H), 7.45 (s, 1H), 5.50 (bs, 
1H), 4.67 (m, 1H), 3.88 (m, 1H), 3.76 (dd, 1H, J= 3.66 Hz, J= 11.37 Hz), 3.5-3.7 (m, 1H), 3.64 
(s, 3H), 3.04-3.22 (m, 2H).  
                                                            
131 TLC conditions: DCM/ Methanol= 96/4  
Rf= basal 
Carnosine-like derivatives                                                                  Experimental section 
188 
(L)-Serine-(D)-Histidine-methyl ester dihydrochloride 
 
 
 
1.21 g (2.71 mmol) of the full protected dipeptide are stirred 10 mL of DCM/TFA =7/3 
for 3 hours in presence of anisole (0.59 mL, 5.42 mmol).  
The solvent is removed and the residue rinsed and washed three times with Ethyl 
ether; simply water removal under vacuum gives (L)-(benzyloxy)carbonyl-Serine-(D)-
Histidine-methyl ester, in quantitative yield. 
The dipeptide undergoes hydrogenolysis with Pd/C 10% in a mixture of 15 mL of dry 
Methanol and 4.34 mL of 1.25 M HCl Methanol solution. 
The reaction is monitored by TLC132 , at completion, achieved after stirring for 18 
hours at RT, the solvents are evaporated, giving 0.89 g of a sticky white solid. 
 
 
Yield: Quantitative 
 
 
 
 
 
1H NMR (d6DMSO): 9.13 (d, 1H, J= 7.69 Hz), 8.98 (s, 1H), 8.21 (bs, 5H), 7.44 (s, 1H), 5.54 (bs, 
1H),4.67 (m, 1H), 3.85 (m, 1H), 3.77 (dd, 1H, J= 4.33 Hz, J= 11.37 Hz), 3.57-3.70 (m, 1H), 
3.65 (s, 3H), 3.03-3.22 (m, 2H).  
                                                            
132 TLC conditions: DCM/ Methanol= 96/4  
Rf= basal 
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2-amino-3-(1-benzyl-1H-imidazol-4-yl)propanoic acid 
 
 
 
75 mL of dry liquid ammonia are added, at -76°C, to 10.0 g (47.40 mmol) of (L)-
Histidine monohydrochloride monohydride; the mixture is amounted of small pieces of 
Na (4.39 g, 190.80 mmol) and then benzyl chloride (5.58 mL, 52.47 mmol) is slowly 
dropped. 
The reaction is stirred for 2 hours and monitored by NMR. 
At completion, ammonia is removed, 70 mL of iced Water are added and the solution 
is washed with Ethyl ether. 
The aqueous layer is acidified with H2SO4 until precipitation begins; the filtration of 
the white solid and the further crystallization with Ethanol/ Water= 7/3 let the 
obtainment of 6.16 g (25.12 mmol) of the desired product. 
 
 
Yield: 53% 
 
Melting point: 248°C 
 
 
 
 
 
1H NMR (D2O): 7.62 (s, 1H), 7.26-7.33 (m, 5H), 6.91 (s, 1H), 5.06 (s, 2H), 3.82 (dd, 1H, J= 
4.68 Hz, J= 7.98 Hz), 3.03 (dd, 1H, J= 4.68 Hz, J= 15.40 Hz), 2.91 (dd, 1H, J= 7.98 Hz, J= 
15.40 Hz).  
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Methyl 2-amino-3-(1-benzyl-1H-imidazol-4-yl)propanoate 
hydrochloride 
 
 
 
25 mL of 1.25 M HCl Methanol solution are dropped to a solution of 6.16 g (25.12 
mmol) in 60 mL of Methanol. 
The solution is refluxed for 18 hours, monitoring the progression by NMR. 
At completion, the simply solvents removal yields 7.54 g (25.12 mmol) of a dense oil. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.31 (s, 1H), 8.88 (bs, 3H), 7.61 (s, 1H), 7.35-7.41 (m, 5H), 5.40 (s, 2H), 
4.44 (m, 1H), 3.64 (s, 3H), 3.27 (m, 2H).  
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Methyl 3-(1-benzyl-1H-imidazol-4-yl)-2-(3-
(((benzyloxy)carbonyl)amino)propanamido)propanoate 
 
 
 
A solution of EDAC (6.25 g, 32.66 mmol) and DIPEA (5.69 mL, 32.66 mmol) in 30 mL 
of DCM is added dropwise to a solution of 3-((tert-butoxycarbonyl)amino)propanoic 
acid (5.70 g, 30.14 mmol), HOBT (4.41 g, 32.66 mmol) in 30 mL of DCM under a 
nitrogen atmosphere. 
The resulting mixture is stirred for 30 minutes at RT and then a solution of Methyl 2-
amino-3-(1-benzyl-1H-imidazol-4-yl)propanoate hydrochloride (7.54 g, 25.12 mmol) 
and DIPEA (27.63 mL, 25.12 mmol) in 30 mL of DCM is added dropwise. 
The reaction mixture is stirred at RT overnight and monitored by TLC133.  
After completion, the mixture is treated with DCM and a solution of NaHCO3 and then 
the organic phase is washed with brine, dried over Na2SO4, filtered, and evaporated. 
The crude product is purified by column chromatography on silica gel, using 
DCM/Methanol = 94/4 as elution solvent, to give 6.81 g (15.82 mmol) of the dense 
oil. 
 
Yield: 63 % 
 
 
1H NMR (d6DMSO): 8.21 (d, 1H, J=7.7 Hz), 7.62 (s, 1H), 7.17-7.38 (m, 5H), 6.88 (s, 1H), 6.72 
(bs, 1H), 5.11 (s, 2H), 4.43 (m, 1H), 3.57 (s, 3H), 3.05 (dt, 1H, J= 7.15 Hz, J= 13.20 Hz), 2.70-
2.85 (m, 2H), 2.21 (t, 2H, J= 7.15 Hz), 1.35 (s, 9H).  
                                                            
133 TLC conditions: DCM/ Methanol= 95/5  
Rf= 0.17 
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192 
Methyl 2-(3-aminopropanamido)-3-(1-benzyl-1H-imidazol-
4-yl)propanoate trifluoroacetate 
 
 
 
6.81 g (15.82 mmol) of the Methyl 3-(1-benzyl-1H-imidazol-4-yl)-2-(3-
(((benzyloxy)carbonyl)amino)propanamido)propanoate are dissolved in 70 mL of DCM 
and treated with 13 mL of TFA. 
The reaction is stirred for 11/2 hours, evaluating the completion by TLC134. 
The simply removal of the solvents gives 7.03 g of a dense oil, in quantitative yield. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
 
 
 
 
1H NMR (d6DMSO): 9.18 (s, 1H), 8.68 (d, 1H, J= 7.7 Hz), 7.79 (bs, 3H), 7.50 (s, 1H), 7.34-7.42 
(m, 5H), 5.38 (s, 2H), 4.58 (m, 1H), 3.57 (s, 3H), 3.07 (m, 1H), 3.02 (m, 1H), 2.87-2.94 (m, 
2H), 2.42-2.50 (m, 2H).  
                                                            
134 TLC condition: DCM / Methanol= 90 / 10 
Rf: 0.12 
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2-((3-aminopropyl)amino)-3-(1-benzyl-1H-imidazol-4-
yl)propan-1-ol 
 
N
H
COOMe
N
N
Bn
C19H23F3N4O5
M.W.: 444,39
O
H2N N
H
N
N
Bn
C16H24N4O
M.W.: 288,39
H2N
* TFA
OH
 
 
7.03 g (15.82 mmol) of the Methyl 2-(3-aminopropanamido)-3-(1-benzyl-1H-imidazol-4-
yl)propanoate trifluoroacetate in 50 mL of dry THF are slowly dropped, at -10°C, to a 
suspension of LiH4 (4.20 g, 110.74 mmol) in 20 mL of dry THF, under a nitrogen 
atmosphere. 
The mixture is warmed to RT and then refluxed, monitoring the progression by NMR. 
At completion, the mixture is cooled to RT, 40 ml of Water are firstly added, followed by 
50 mL of Ethanol. 
The suspension is stirred at 60°C for 2 hours, cooled to RT and filtered over Celite. 
The solution is dried over Na2SO4, filtered and concentrated under vacuum, yielding 
4.11 g of the dense oil (14.34 mmol). 
 
 
Yield: 90%  
 
 
 
 
 
 
 
1H NMR (TFA+D2O): 7.65-7.80 (m, 5H), 7.64 (s, 1H), 7.49 (s, 1H), 5.49 (s, 1H), 4.20 (m, 2H), 
3.92 (m, 2H), 3.47-3.63 (m, 5H), 2.58 (m, 2H).  
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Benzyl (1-(1-benzyl-1H-imidazol-4-yl)-3-hydroxypropan-2-
yl)(3-(((benzyloxy)carbonyl)amino)propyl)carbamate 
 
 
 
A solution of 2-((3-aminopropyl)amino)-3-(1-benzyl-1H-imidazol-4-yl)propan-1-ol (4.11 
g, 14.34 mmol) and DIPEA (5.00 mL, 28.68 mmol) of in 40 mL of THF is heated at 60 
°C, under a nitrogen atmosphere. 
Benzyl chloroformate (4.09 mL, 28.68 mmol) is then slowly dropped, and the 
progression of the reaction is monitored by TLC135 
At completion, the mixture is cooled to RT, the solvent is removed and the residue is 
resumed with Ethyl Acetate; the organic layer is washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. 
Purification on silica gel, using Ethyl Acetate as elution solvent, yields 3.83 g (6.88 
mmol) of the di-protected compound, as yellow oil. 
 
 
Yield: 48 % 
 
 
 
 
1H NMR (d6DMSO): 7.63 (s, 1H), 7.14-7.34 (m, 16H), 6.77 (d, 1H, J= 13.46 Hz), 5.08 (s, 2H), 
4.99 (s, 2H), 4.97 (s, 2H), 4.35 (m, 1H), 4.19 (bs, 1H), 3.06 (m, 2H), 2.87 (m, 2H), 2.66 (m, 
2H), 1.50 (m, 4H).  
                                                            
135 TLC conditions: Ethyl Acetate 100% 
Rf: 0.30 
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Benzyl (3-(4-((1-benzyl-1H-imidazol-4-yl)methyl)-2-
oxooxazolidin-3-yl)propyl)carbamate 
 
 
 
To a suspension of NaH (0.20 g, 8.26 mmol) in 10 mL of THF, at 0°C, is dropped a 
solution of Benzyl (1-(1-benzyl-1H-imidazol-4-yl)-3-hydroxypropan-2-yl)(3-
(((benzyloxy)carbonyl)amino)propyl)carbamate (3.83 g, 6.88 mmol) in 20 mL of THF.  
The reaction is refluxed, monitoring the progression by TLC136; after 1 hour, the solvent 
is removed and the residue is treated with Ethyl Acetate and brine.  
The organic phase is dried over Na2SO4, filtered and concentrated under reduced 
pressure; the crude is purified on silica gel, using Ethyl Acetate/ Methanol= 90/10 as 
elution solvent, obtaining 2.05.g (4.59 mmol) of a pale yellow oil.. 
 
 
Yield:67% 
 
 
 
 
 
1H NMR (CDCl3): 7.45 (s, 1H), 7.26-7.39 (m, 9H), 7.14 (s, 1H), 7.11 (s, 1H), 6.67 (s, 1H), 5.57 
(m, 1H), 5.08 (s, 2H), 5.03 (s, 2H), 4.29 (m, 1H), 4.11 (m, 1H), 3.46 (m, 1H), 3.07-3.30 (m, 
3H), 2.96 (dd, 1H, J= 3.51 Hz, J = 14.33 Hz), 2.66 (dd, 1H, J= 7.60 Hz, J= 14.33 Hz), 1.71 (m, 
1H).  
                                                            
136 TLC conditions:Ethyl Acetate/ Methanol= 90/ 10 
Rf: 0.14  
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3-(3-aminopropyl)-4-((1-benzyl-1H-imidazol-4-
yl)methyl)oxazolidin-2-one di-trifluoroacetate 
 
 
 
2.05.g (4.59 mmol) of Benzyl (3-(4-((1-benzyl-1H-imidazol-4-yl)methyl)-2-oxooxazolidin-
3-yl)propyl)carbamate are dissolved in a solution of 20 mL of Methanol and 7.34 mL of 
1.25 M HCl Methanol solution.  
The mixture undergoes hydrogenolysis with Pd/C 10% at RT; the progression of the 
reaction is monitored by TLC137. 
At completion, the solvents are removed and the crude is further purified by reverse 
phase preparative HPLC, according to the gradient reported in Table 3, with a flowrate 
of 7 mL/min, yielding 1.49 g (2.75 mmol) of a sticky white solid. 
 
 
Yield: 60% 
 
 
 
 
1H NMR (D2O): 8.48 (s, 1H), 7.17 (s, 1H), 4.30 (t, 1H, J= 8.8 Hz), 4.19 (m, 1H), 4.02 (dd, 1H, 
J= 4.12 Hz, J= 8.8 Hz), 3.37 (m, 1H), 3.16 (m, 1H), 2.98 (m, 2H), 2.86 (m, 2H), 1.81 (m, 2H). 
 
13C-NMR (D2O): 160.22, 133.99, 127.44, 117.36, 67.53, 54.07, 38.91, 36.99, 26.21, 25.19. 
                                                            
137  TLC conditions: Ethyl Acetate/ Methanol = 80 /20 
Rf: basal 
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(L)-Methionine isopropyl ester 
 
 
 
125 mL of Isopropyl alcohol, at 0°C, are slowly amounted of 16.66 mL (234.0 mmol) 
of Acethylchloride; the mixture is maintained cold and stirred for 30 minutes. 
L-Metionine (10.0 g, 67.0 mmol) is sequentially added portionwise as solid, afterwards 
the reaction is warmed to RT and then refluxed for 4 hours. 
After completion of the reaction, followed by TLC138, the mixture is concentrated, 
treated with 100 mL of DCM and carefully washed with 100 mL of NaHCO3.  
The two layers are separated; the organic phase is washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure, giving 12.82 g (67.0 
mmol) of the desired product as pale yellow oil. 
 
 
Yield: quantitative 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 5.05 (m, 1H), 4.59 (bs, 1H), 3.77 (dd, 1H, J=5.22 Hz, J=7.7 Hz), 2.67 (m, 2H), 
2.10 (s, 3H), 1.97-2.16 (m, 2H).  
                                                            
138 Cyclohexane / Ethyl Acetate= 1/1 + TEA 0.25% 
Rf= 0.3  
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Methyl 2-(2-aminothiazol-4-yl)acetate hydrochloric acid 
 
 
 
10.0 g (63.22 mmol) of 2-amino-4-thiazolylacetic acid are dissolved in 100 mL of 
methanol; the solution is cooled to -15°C and slowly added of 5.04 mL (60.54 mmol) 
of SOCl2. 
The reaction is monitored by NMR analysis; at the completion of the reaction, the 
mixture is concentrated under reduce pressure, obtaining 13.19 g of the desired 
product, as a white solid. 
 
 
Yield: quantitative 
 
Melting point: 173.84 °C 
 
 
 
 
 
 
 
  
 
 
 
1H-NMR (CDCl3): 6.51 (s, 1H), 4.66 (bs, 3H), 3.64 (s, 2H), 3.60 (s, 3H).  
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Methyl 2-(2-(tritylamino)thiazol-4-yl)acetate 
 
 
 
13.19 g (63.22 mmol) of methyl 2-(2-aminothiazol-4-yl)acetate hydrochloric acid are 
dissolved in 100 mL of DCM and added of 19.39 mL (139.08 mmol) of TEA. 
The reaction mixture is cooled to -10°C, slowly amounted of 21.15 g (75.86 mmol) of 
Trityl chloride in 160 mL of DCM and then warmed to RT.  
The reaction is monitored by TLC139; after completion, the mixture is treated with 100 
mL of DCM and quenched with 300 mL of NaHCO3 10%, the organic layer is washed 
with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
The crude is crystallized by Diethyl ether, giving 23.58 g (56.90 mmol) of the desired 
product, as a white solid. 
 
 
Yield: 90% 
 
Melting point: 190.22°C 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.26-7.35 (m, 15H), 6.71 (bs, 1H), 6.17 (s, 1H), 3.70 (s, 3H), 3.54 (s, 2H). 
                                                            
139 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1  
Rf= 0.60 
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2-(2-(tritylamino)thiazol-4-yl)acetic acid 
 
 
 
A solution of 23.58 g (56.90 mmol) of the methyl 2-(2-(tritylamino)thiazol-4-yl)acetate 
in 230 mL of Methanol is treated with 21.5 mL of 2.5 M NaOH and refluxed. 
The reaction is monitored by TLC140; after completion, achieved in 2 hours, the solvent 
is removed under vacuum, the residue is resumed with 250 mL of Water and acidified 
using HCl 37%. 
The white precipitate is filtered and dried under reduce pressure, giving 21.65 g 
(54.06 mmol) of the free carboxylic acid. 
 
 
Yield: 95% 
 
Melting point: 152°C 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.25-7.34 (m, 15H), 6.05 (s, 1H), 3.58 (s, 2H). 
 
                                                            
140 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.15 
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(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol 
 
 
 
A red solution of Catechol (10.0 g, 90.82 mmol) in 100 mL of Methanol is added of 
27.61 g of K2CO3 (200 mmol) as solid, forming a suspension that is stirred for 30 
minutes. 
21.31 mL (272.46 mmol) of Epichlorohydrin are then dropped and the resulting 
mixture is refluxed for 8 hours, monitoring the completion by TLC141. 
After evaporating the solvent, the residue is resumed with 80 mL of DCM, washed with 
brine, dried over Na2SO4, filtered and concentrated under vacuum. 
The crude undergoes crystallization with Isopropyl ether, giving 8.15 g (49.0 mmol) of 
a white solid. 
 
 
Yield: 54% 
 
Melting point: 86.32°C 
 
 
 
 
 
 
  
1H-NMR (CDCl3): 6.83-6.92 (m, 4H), 4.24-4.32 (m, 2H), 4.07-4.14 (m, 1H), 3.81- 3.93 
(m, 2H), 2.03 (bs, 1H).  
                                                            
141 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.33 
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(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl 
methanesulfonate 
 
 
 
A solution of 7.51 ml of TEA (53.9 mmol) in 8 mL of DCM is dropped to the reaction 
mixture, containing (2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol (8.15 g, 49.0 mmol) 
in 32 mL of DCM, the resulting pale yellow solution is then cooled to -15°C and 
amounted of 4.17 mL of Methansulfonyl chloride (53.9 mmol), over 15 minutes. 
The reaction is monitored by TLC142; after completion, the mixture is treated with 50 
mL of DCM and quenched with 80 mL of HCl 10%, the organic layer is washed with 
brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
The crude is crystallized from Isopropanol, obtaining 10.77 g (44.1 mmol) of the 
desired product, as a white solid. 
 
 
Yield: 90% 
 
Melting point: 62.7% 
 
 
 
 
 
1H-NMR (CDCl3): 7.00 (m, 1H), 6.89-6.96 (m, 3H), 4.43-4.55 (m, 3H), 4.32 (dd, 1H, J= 
1.82 Hz, J= 11.82 Hz), 4.20 (dd, 1H, J=4.95 Hz, J= 11.82 Hz), 3.09 (s, 3H). 
 
                                                            
142 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.30 
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Methyl 2,3-dibromopropanoate 
 
 
 
A solution of methyl acrylate (10.46 mL, 116.16 mmol) in 50 mL of DCM is refluxed 
and sequentially added of bromine (5.95 mL, 116.16 mmol) in 50 mL of DCM. 
The reaction is monitored by the disappearing of the orange coloration and by NMR 
analysis; the completion is achieved after 30 minutes.  
The reaction mixture is then cooled, washed with 80 mL of 10% NaS2O5 in water, dried 
over Na2SO4, filtered and concentrated under reduced pressure, obtaining 28.01 g 
(113.93 mmol) of the desired product, ad a colourless oil. 
 
 
Yield: 98% 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 4.45 (dd, 1H, J=2.18 Hz, J=5.45 Hz), 3.93 (dd, 1H, J=4.36 Hz, J=5.45 Hz), 
3.84 (s, 3H), 3.67(dd, 1H, J=2.18 Hz, J=4.36 Hz). 
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2,3-dihydrobenzo[b][1,4]dioxine-2-carboxylic acid 
 
 
 
A suspension of K2CO3 (47.24 g, 341.79 mmol) in 125 mL of Isopropanol is slowly 
added of solid catechol (12.54g, 113.93 mmol) and then stirred for 30 minutes. 
After that period, a solution of Methyl 2,3-dibromopropanoate (28.01 g, 113.93 mmol) 
in 250 mL of Isopropanol is dropped, and all the reaction mixture is refluxed overnight. 
The mixture is concentrated, resumed with 200 mL of Methanol and then added of 
5.45 g of NaOH in pellets. The reaction is refluxed for 2 hours and monitored by 
TLC143; after evaporating the solvent, the residue is treated with water, acidified with 
HCl 10% and extracted three times with 70 mL of DCM.  
The organic layers are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure; the crude obtained is then crystallized by Toluene, giving 16.00 g 
(88.86 mmol) of the desired product, as white solid.  
 
 
Yield: 78% 
 
Melting Point: 114.69°C 
 
 
 
 
1H-NMR (CDCl3): 8.51 (bs, 1H), 7.00 (m, 1H), 6.87-6.94 (m, 3H), 4.90 (dd, 1H, J= 3.02 Hz, J= 
4.4 Hz), 4.44 (dd, 1H, J= 4.4 Hz, J= 11.28 Hz), 4.38 (dd, 1H, J=3.02 Hz, J= 11.28 Hz). 
                                                            
143 TLC conditions: DCM/ Methanol= 1/1 + 10% Acetic Acid 
Rf= 0.20 
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2,3-dihydrobenzo[b][1,4]dioxine-2-carbonyl chloride 
 
 
 
16.00 g of 2,3-dihydrobenzo[b][1,4]dioxine-2-carboxylic acid (88.86 mmol) are 
suspended in 160 mL of Toluene, cooled at -10°C and amounted of 9.67 mL (133.29 
mmol) of pure SOCl2.  
The mixture is then warmed to RT and sequentially refluxed for 3 hours, following the 
completion by NMR. 
The evaporation of the solvents let the obtainment of 17.65 g of the desired product, 
as a sticky solid, in quantitative yields.  
 
 
Yield: quantitative 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.00 (m, 1H), 6.89-6.96 (m, 3H), 5.09 (dd, 1H, J= 2.75 Hz, J= 2.82 Hz), 4.74 
(dd, 1H, J= 2.82 Hz, J= 11.82 Hz), 4.34 (dd, 1H, J=2.75 Hz, J= 11.82 Hz). 
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Ethyl 4-azido-3-oxobutanoate 
 
 
 
A solution of freshly distilled ethyl 4-chloro-3-oxo-butanoate (19.50 g, 118.48 mmol) in 
35 mL of THF is slowly dropped, at 4°C, to a mixture of NaN3 (17.72 g, 272.50 mmol) 
in Water. 
The reaction is stirred at RT for 18 hours, monitoring the progression by TLC144. 
At completion, 20 mL of Ethyl Acetate are added to the mixture, the aqueous layer is 
extracted twice more with Ethyl Acetate, the organic phases are collected, dried over 
Na2SO4, filtered and concentrated under vacuum, yielding 19.35 g (112.35 mmol) of a 
brown oil.   
 
 
Yield: 94.83 % 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 4.26 (s, 2H), 4.07 (q, 2H, J=3.58 Hz), 3.60 (s, 2H), 1.17 (t, 3H, J=3.58 Hz). 
  
                                                            
144 TLC conditions: Cyclohexane/ Ethyl Acetate= 80/20 
Rf= 0.36 
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Ethyl 4-amino-3-oxobutanoate p-toluenesulfonate 
 
 
 
A solution of ethyl 4-azido-3-oxo butanoate (19.35 g, 112.35 mmol) and p-
toluenesulfonic acid (19.23 g, 112.35 mmol) in 100 mL of Ethanol undergoes 
hydrogenolysis with Pd/C 10% at RT, the progression of the reaction is monitored by 
TLC145. 
At completion, catalyst filtration and solvent removal give a residue that is further 
crystallized from Isopropanol, yielding 10.1 g (31.82 mmol) of a white solid.  
 
 
Yield: 28.33 % 
 
Melting point: 111.05 °C 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 8.07 (s, 3H), 7.46 (d, 2H, J= 7.98 Hz), 7.10 (d, 2H, J= 7.98 Hz), 4.10 (q, 
2H, J= 7.15 Hz), 3.98 (s, 2H), 3.70 (s, 2H), 2.15 (s, 3H), 1.10 (t, 3H).  
                                                            
145  TLC conditions: Cyclohexane/ Ethyl Acetate = 80 /20 
Rf: 0.05 
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Ethyl 2-(2-mercapto-1H-imidazol-4-yl)acetate 
 
 
 
A solution of 10.1 g (31.82 mmol) of ethyl 4-amino-3-oxobutanoate p-toluenesulfonate 
in 17.3 mL of Water is refluxed; 5.27 g (54.26 mmol) of KNCS are slowly added to the 
mixture portionwise. 
The reaction is monitored by TLC146; at completion, the mixture is warmed to RT and 
the pH is moved to 5, adding NaHCO3.  
The suspension is cooled to 4°C, until the precipitation of a white solid is achieved; its 
filtration yields 1.84 g (9.88 mmol) of the desired product. 
 
 
Yield: 31.05 % 
 
Melting point: 152.18 °C 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 11.86 (s, 1 H), 11.75 (s, 1H), 6.63 (s, 1H), 4.07 (q, 2H, J= 7.16 Hz), 3.47 
(s, 2H), 1.17 (t, 3H, J= 7.16 Hz).  
                                                            
146  TLC conditions: DCM/ Methanol= 95/ 5 
Rf: 0.27 
FTase Inhibitors / Scaffolds synthesis                                               Experimental section 
209 
 
2-(2-mercapto-1H-imidazol-4-yl)acetic acid 
 
 
 
1.84 g (9.88 mmol) of ethyl 2-(2-mercapto-1H-imidazol-4-yl)acetate are dissolved in a 
mixture of 15 mL of Methanol and 8 mL of 2.5M of NaOH. 
The solution is refluxed for 1 hour, monitoring the progression by TLC147; at 
completion, the solvents are removed, the crude is resumed with Ethanol and acidified 
with an ethanolic H2SO4 solution. 
The suspension is then filtered and the solid is further crystallized from Isopropanol, 
yielding 0.750 g (4.74 mmol) of the desired product.  
 
 
Yield:48 % 
 
Melting point: 
 
 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 11.82 (bs, 1H), 11.70 (bs, 1H), 6.60 (s, 1H), 3.38 (s, 2H).  
                                                            
147  TLC conditions: DCM/ Methanol= 95/ 5 
Rf: 0.6 
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Methyl 5-bromo-4-oxo-pentanoate 
 
 
 
Br2 (17.70 mL, 344.47 mmol) is slowly dropped to a solution of levulinic acid (40.00 g, 
344.47 mmol) in Methanol (340 ml), at 3°C. 
The reaction is warmed to RT and monitored by TLC148. 
At completion, after 2 ½ days, the Methanol is removed, the residue is treated with 
140 mL of DCM and with 10% NaHCO3, neutralizing the aqueous pH.  
The two layers are discarded, the aqueous layer is extracted ones more with DCM, and 
the organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure. 
The residue is purified on silica gel, using Cyclohexane / Ethyl Acetate= 80 / 20 as 
elution solvent, yielding 36.76 g (175.85 mmol) of a colourless oil. 
 
 
Yield : 51.05 % 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 3.94 (s, 2H), 3.65 (s, 3H), 2.93 (t, 2H, J= 6.32 Hz), 2.63 (t, 2H, J= 6.32 Hz). 
                                                            
148 TLC conditions : Cyclohexane/ Ethyl Acetate = 80/ 20 
Rf: 0.36 
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Methyl-5-azido-4-oxo-pentanoate 
 
 
 
A solution of methyl-5-bromo-4-oxo-pentanoate (36.76 g, 175.85 mmol) in 70 mL of 
THF is slowly dropped, at 2°C, to a mixture of NaN3 (26.29 g, 404.45 mmol) in 40 mL 
of Water. 
The reaction is stirred at RT for 3 hours, monitoring the progression by TLC149. 
At completion, 80 mL of Ethyl Acetate are added to the mixture, the aqueous layer is 
extracted twice more with Ethyl Acetate, the organic phases are collected, washed with 
Water and brine, dried over Na2SO4, filtered and concentrated under vacuum, yielding 
27.73 g (162.03 mmol) of a yellow oil. 
 
 
Yield: 92.14 % 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 4.00 (s, 2H), 3.64 (s, 3H), 2.69 (m, 2H), 2.64 (m, 2H).  
                                                            
149 TLC conditions: Cyclohexane/ Ethyl Acetate= 80/20 
Rf= 0.32 
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Methyl-5-amino-4-oxo-pentanoate p-toluenesulfonate 
 
 
 
A solution of methyl 5-azido-4-oxo pentanoate (27.73 g, 162.03 mmol) and p-
toluenesulfonic acid (27.90 g, 162.03 mmol) in 200 mL of Methanol undergoes 
hydrogenolysis with Pd/C 10% at RT, the progression of the reaction is monitored by 
TLC150. 
At completion, after 24 hours, catalyst filtration and solvent removal give a residue 
that is further crystallized from Isopropanol, yielding 42.88 g (135.11 mmol) of a white 
solid.  
 
 
Yield: 83.38% 
 
 
Melting point= 130.43 °C 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 4.00 (s, 2H), 3.64 (s, 3H), 2.69 (m, 2H), 2.64 (m, 2H).  
                                                            
150  TLC conditions: Cyclohexane/ Ethyl Acetate = 80 /20 
Rf: 0.05 
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Methyl 3-(2-mercapto-1H-imidazol-4-yl)propanoate 
 
 
 
A solution of 42.88 g (135.11 mmol) of methyl 5-amino-4-oxopentanoate p-
toluenesulfonate in 80 mL of Water is refluxed; 22.32 g (229.72 mmol) of KNCS are 
slowly added to the mixture portionwise. 
The reaction is monitored by TLC151; at completion, the mixture is warmed to RT and 
the pH is moved to 5, adding NaHCO3.  
The suspension is cooled to 4°C, until the precipitation of a pale grey solid is achieved; 
its filtration yields 13.57 g (72.88 mmol) of the desired product. 
 
 
Yield: 53.94 % 
 
Melting point = 161.46 °C 
 
 
 
 
 
 
 
 
1H-NMR (D2O): 6.57 (s, 1H), 3.56 (s, 3H), 2.70 (m, 2H), 2.57 (m, 2H).  
                                                            
151  TLC conditions: DCM/ Methanol= 95/ 5 
Rf: 0.23 
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3-(2-mercapto-1H-imidazol-4-yl)propanoic acid 
 
 
 
13.57 g (72.88 mmol) of methyl 3-(2-mercapto-1H-imidazol-4-yl)propanoate are 
suspended in a mixture of 15 mL of Water and 40 mL of 4M NaOH. 
The solution is heated at 55°C for 2 hours, monitoring the progression by TLC152; at 
completion, the mixture is cooled to 4°C and acidified with HCl 10%, until the 
precipitation of a grey solid. 
The suspension is then filtered and the solid is further crystallized from Isopropanol, 
yielding 9.02 g (52.39 mmol) of the desired product.  
 
 
Yield: 71.88% 
 
Melting point: 203.14°C 
 
 
 
 
 
 
 
 
1H-NMR (D2O): 6.60 (s, 1H), 2.70 (t, 2H, J= 7.42 Hz), 2.58 (t, 2H, J= 7.42 Hz).  
                                                            
152  TLC conditions: DCM/ Methanol= 95/ 5 
Rf: 0.06 
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Ethyl 2-(2-mercaptothiazol-4-yl)acetate 
 
 
 
9.00 g of ethyl-4-chloro-3-oxo butanoate (54.81 mmol) are added dropwise to a 
solution of ammonium dithiocarbamate (6.03 g, 54.81 mmol) in 80 mL of water. 
The reaction mixture is refluxed overnight and monitored by TLC153; at completion, the 
suspension is warmed to RT, until the precipitation of a solid that is filtered and 
crystallized from Toluene, yielding 5.12 g (25.19 mmol) of the desired product. 
 
 
Yield: 45.95 % 
 
Melting point: 143.01 °C 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 6.46 (s, 1H), 4.23 (q, 2H, J= 3.30 Hz), 3.58 (s, 2H), 1.29 (t, 3H, J= 3.30 Hz). 
                                                            
153 TLC conditions: Cyclohexane/ Ethyl Acetate= 80/ 20 
Rf: 0.17 
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2-(2-mercaptothiazol-4-yl)acetic acid 
 
 
 
A solution of ethyl 2-(2-mercaptothiazol-4-yl)acetate (5.12 g, 25.19 mmol) in 25 mL of 
2.5M NaOH is heated at 55°C for 1 hour, monitoring the hydrolysis progression by 
TLC154. 
At completion, the reaction mixture is warmed to RT and then cooled to 4°C, before 
acidification with HCl 10% and formation of a precipitate. 
The suspension filtration yields 3.59 g (20.50 mmol) of a pale brown solid, 
corresponding to the desired product. 
 
 
Yield: 81.39 % 
 
Melting point: 165.88 °C 
 
 
 
 
 
 
 
 
 
 
1H-NMR (d6 DMSO): 6.70 (s, 1H), 3.52 (s, 2H), 3.29 (s, 1H).  
                                                            
154 Eluente : Cicloesano : Acetato di etile 70 : 30  Rf part = 0,17   Rf prod = 0,05               Evidenziatore : 
KMnO4 
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Ethyl 2-(2-(methylthio)thiazol-4-yl)acetate 
 
OCH2CH3N
S
HS
O
C7H9NO2S2
M.W.: 203,28
OCH2CH3N
S
H3CS
O
C8H11NO2S2
M.W.: 217,31
 
 
A solution of ethyl 2-(2-mercaptothiazol-4-yl)acetate (2.50 g, 12.30 mmol) in 20 mL of 
dry DME is added dropwise to a suspension of NaH (0.30 g, 12.30 mmol) in 10 mL of 
dry DME, under a nitrogen atmosphere. 
The mixture is stirred for 10 minutes and then a solution of methyl iodide (1.00 mL, 
14.80 mmol) is slowly dropped; the reaction is stirred RT and monitored by TLC155. 
At completion, 10 ml of Water and 20 ml of Ethyl Acetate are added, the two phases 
are separated and the aqueous layer is extracted twice with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduce pressure, yielding 2.48 g (11.41 mmol) of a pale yellow oil. 
 
 
Yield: 92.77 % 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.08 (s, 1H), 4.18 (q, 2H, J= 3.85 Hz), 3.78 (s, 2H), 2.68 (s, 3H), 1.24 (t, 3H, 
J= 3.85 Hz).  
                                                            
155  TLC conditions: Cyclohexane/ Ethyl Acetate= 70/ 30 
Rf: 0.50 
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2-(2-(methylthio)thiazol-4-yl)acetic acid 
 
 
 
2.48 g (11.41 mmol) of ethyl 2-(2-(methylthio)thiazol-4-yl)acetate are dissolved in 15 
mL of Methanol; 6 mL of NaOH 2.5 M are dropped and the resulting mixture is heated 
at 60°C for 18 hours. 
After completion of the reaction, followed by TLC156, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl, and then extracted three times with 15 mL of Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, obtaining a pale grey solid (0.64 g, 2.58 mmol), corresponding to 
the desired compound.  
 
 
Yield: 97.05 % 
 
Melting point: 122.01 °C 
 
 
 
 
 
 
 
1H-NMR (d6 DMSO): 7.34 (s, 1H), 3.65 (s, 2H), 2.64 (s, 3H).  
                                                            
156 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/ 30 
Rf: 0.10 
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Methyl 3-(2-mercaptothiazol-4-yl)propanoate 
 
 
 
13.05 g of methyl-5-bromo-4-oxo pentanoate (62.43 mmol) are added dropwise to a 
solution of ammonium dithiocarbamate (6.88 g, 62.43 mmol) in 60 mL of water. 
The reaction mixture is refluxed for 3 hours and monitored by TLC157; at completion, 
the suspension is warmed to RT, until the precipitation of a solid that is filtered and 
crystallized from Isopropyl ether, yielding 6.31 g (25.19 mmol) of a pale yellow solid, 
corresponding to the desired product. 
 
 
Yield: 49.71 % 
 
Melting point: 126.54 °C 
 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 11.80 (s, 1H), 6.28 (s, 1H), 3.71 (s, 3H), 2.84 (t, 2H, J= 6.60 Hz), 2.66 (t, 2H, 
J= 6.60 Hz).  
                                                            
157 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/ 30 
Rf: 0.25 
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3-(2-mercaptothiazol-4-yl)propanoic acid 
 
 
 
6.31 g (25.19 mmol) of methyl 3-(2-mercaptothiazol-4-yl)propanoate are dissolved in 
12.5 mL of NaOH 4 M; the resulting mixture is heated at 55°C for 1 hour. 
After completion of the reaction, followed by TLC158, the reaction mixture is acidified 
with 10% HCl, and then extracted three times with 10 mL of Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, obtaining a beige solid (4.35 g, 23.00 mmol), corresponding to the 
desired compound.  
 
 
Yield: 91.30 % 
 
Melting point: 191.92 °C 
 
 
 
 
 
 
 
 
1H-NMR (D2O): 6.57 (s, 1H), 2.78 (t, 2H, J= 7.15 Hz), 2.62 (t, 2H, J=7.15 Hz).  
                                                            
158 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/ 30 
Rf: 0.05 
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Methyl 3-(2-(methylthio)thiazol-4-yl)propanoate 
 
 
 
A solution of methyl 3-(2-mercaptothiazol-4-yl)propanoate (2.50 g, 12.30 mmol) in 20 
mL of DME/ THF =1/ 1 is added dropwise to a suspension of NaH (0.30 g, 12.30 
mmol) in 5 mL of dry DME, under a nitrogen atmosphere. 
The mixture is stirred for 10 minutes and then a solution of methyl iodide (1.00 mL, 
14.80 mmol) is slowly dropped; the reaction is stirred RT and monitored by TLC159. 
At completion, 20 ml of Water and 20 ml of Ethyl Acetate are added, the two phases 
are separated and the aqueous layer is extracted twice with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduce pressure, yielding 2.54 g (11.69 mmol) of a brown oil. 
 
 
Yield: 95.04 % 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 6.83 (s, 1H), 3.67 (s, 3H), 3.03 (t, 2H, J= 7.70 Hz), 2.73 (t, 2H, J= 7.70 Hz), 
2.66 (s, 3H).  
                                                            
159  TLC conditions: Cyclohexane/ Ethyl Acetate= 70/ 30 
Rf: 0.58 
FTase Inhibitors / Scaffolds synthesis                                               Experimental section 
222 
 
3-(2-(methylthio)thiazol-4-yl)propanoic acid 
 
 
 
2.54 g (11.69 mmol) of methyl 3-(2-(methylthio)thiazol-4-yl)propanoate are dissolved 
in 15 mL of Methanol; 7.9 mL of NaOH 2.5 M are dropped and the resulting mixture is 
stirred at RT for 18 hours. 
After completion of the reaction, followed by TLC160, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl, and then extracted three times with 15 mL of Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, obtaining a pale yellow solid (2.27 g, 11.17 mmol), corresponding 
to the desired compound.  
 
 
Yield: 95.43 % 
 
Melting point: 96.69°C 
 
 
 
 
 
 
1H-NMR (d6 DMSO): 12.14 (s, 1H), 7.18 (s, 1H), 2.85 (t, 2H, J= 7.43 Hz), 2.63 (s, 3H), 2.56 (t, 
2H, J= 7.43 Hz).  
                                                            
160 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/ 30 
Rf: 0.08 
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2-bromo-4-nitrobenzoic acid  
 
 
 
To a stirring solution of 2-bromo-4-nitro-toluene (30 g, 138.9 mmol) in a mixture of 
Pyridine/ Water 1:1 (300 mL), at 80°C, it is added solid KMNO4 (118.9g, 752.3 
mmol), in portions of 7 grams, during a period of 3 days. 
The progress and conclusion of the reaction is defined using NMR experiment. 
The heterogeneous mixture reaction is then cooled, the black solid is filtered and 
washed with Ethyl Acetate (50 mL); the filtered solution is acidified with HCl 37% and 
extracted three times with Ethyl Acetate (3*150 mL). 
The organic layers are combined, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue is crystallized from isopropyl ether, giving 25.6 g of a 
white solid, referring to the desired compound. 
 
 
Yield: 75% 
 
Melting Point: 165.08°C 
 
 
 
 
 
 
 
1H-NMR (d6DMSO): 14.07 (bs, 1H), 8.44 (d, 1H, J=2.2 Hz), 8.26 (dd, 1H, J=2.2 Hz, J=8.43 Hz), 
7.92 (d, 1H, J=8.43 Hz).  
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Methyl 2-bromo-4-nitrobenzoate 
 
 
 
2-bromo-4-nitrobenzoic acid (10.00 g, 40.65 mmol) is dissolved in 35 mL of Methanol, 
trimethyl orthoformate (7.56 mL, 69.13 mmol) is added and then 1 mL of 
concentrated H2SO4.is dropped to the reaction. 
The mixture is refluxed for 12 hours, monitoring the reaction progress by TLC161; the 
reaction is then cooled, till the desired product precipitate. 
The white solid is filtered, washed with fresh Methanol and dried, obtaining 9.40 g of 
methyl 2-bromo-4-nitrobenzoate. 
 
 
Yield: 89% 
 
Melting Point: 80.77°C 
 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 8.49 (d, 1H, J=2.2 Hz), 8.19 (dd, 1H, J=2.2 Hz, J=8.79 Hz), 7.91 (d, 1H, 
J=7.89Hz), 3.98 (s, 3H) 
. 
                                                            
161 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.56 
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Methyl 2'-methyl-5-nitro-[1,1'-biphenyl]-2-carboxylate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-nitrobenzoate (1.00 g, 3.85 mmol) in 
6 mL of Toluene, under a nitrogen atmosphere, Pd(PPh3)4 (0.44 g, 0.385 mmol) is 
added as solid. 
The solution is stirred for 10 minutes and then amounted firstly of a solution of K2CO3 
(1.60 g , 11.55 mmol) in 2 mL of Water and then of a solution of o-tolylboronic acid 
(0.63 g, 4.62 mmol) in 1 mL of Methanol. 
The reaction mixture is heated at 80°C for 18 hours and monitored by TLC162; at 
completion it is cooled to RT. 
The mixture is treated with Ethyl Acetate and brine, the organic phase is dried over 
Na2SO4, filtered and concentrated under reduced pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 90/ 10, yields 0.86 g (3.16 mmol) of the desired product, as yellow solid.  
 
 
Yield: 82% 
 
 
 
 
1H-NMR (CDCl3): 8.26 (dd, 1H, J=2.47 Hz, J=8.52 Hz), 8.15 (m, 2H), 7.26 (m, 3H), 7.07 (d, 1H, 
J=7.70 Hz), 3.65 (s, 3H), 2.13 (s, 3H).  
                                                            
162 TLC conditions: Cyclohexane/ Ethyl Acetate= 80/ 20 
Rf= 0.57 
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2'-methyl-5-nitro-[1,1'-biphenyl]-2-carboxylic acid 
 
 
 
0.86 g (3.16 mmol) of methyl 2'-methyl-5-nitro-[1,1'-biphenyl]-2-carboxylate are 
dissolved in 10 mL of Methanol; 2.5 mL of NaOH 2.5 M are dropped and the resulting 
mixture is stirred at RT for 18 hours. 
After completion of the reaction, followed by TLC163, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl, and then extracted three times with 10 mL of Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, obtaining a pale green solid (0.78 g, 3.03 mmol), corresponding to 
the desired compound.  
 
 
Yield: 96% 
 
 
Melting point: 166.30° C 
 
 
 
 
1H-NMR (CDCl3): 8.26 (dd, 1H, J=2.2 Hz, J=8.52 Hz), 8.14 (m, 2H), 7.27 (m, 3H), 7.07 (d, 1H, 
J=7.42 Hz), 2.09 (s, 3H).  
                                                            
163 TLC conditions: Cyclohexane/ Ethyl Acetate= 80/ 20 
Rf= 0.13 
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(S)-isopropyl 2-(2'-methyl-5-nitro-[1,1'-biphenyl]-2-
ylcarboxamido)-4-(methylthio)butanoate 
 
 
 
A solution of EDAC (0.69 g, 3.63 mmol) and DIPEA (0.63 mL, 3.63 mmol) in 5 mL of 
dry DMF is added dropwise to a solution of 2'-methyl-5-nitro-[1,1'-biphenyl]-2-carboxylic 
acid (0.78 g, 3.03 mmol), HOBT (0.49 g, 3.63 mmol) in 8 mL of dry DMF, under a 
nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.58 g, 3.03 mmol) in 5 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC164, 
the mixture is concentrated, resumed with Ethyl Acetate, washed with brine, dried over 
Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 70/30 as elution solvent, to give 1.23 g (2.85 mmol) of 
the desired product, as yellow oil. 
 
 
Yield: 94% 
 
 
1H-NMR (CDCl3): 8.27 (dd, 1H, J=2.48 Hz, J=8.53 Hz), 8.05 (m, 2H), 7.30 (m, 3H), 7.17 (d, 1H, 
J=6.61 Hz), 6.03 (d, 1H, J=7.43 Hz), 4.94 (m, 1H), 4.54 (m, 1H), 2.20 (s, 1H), 2.09 (s, 1H), 
2.01 (s, 3H), 1.85 (m, 1H), 1.60 (m, 1H), 1.41 (s, 3H), 1.18 (m, 6H).  
                                                            
164 TLC conditions: Cyclohexane/ Ethyl Acetate= 60/ 40 
Rf = 0.69 
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(S)-isopropyl 2-(5-amino-2'-methyl-[1,1'-biphenyl]-2-
ylcarboxamido)-4-(methylthio)butanoate 
 
 
1.23 g of (S)-isopropyl-2-(2'-methyl-5-nitro-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoate (2.85 mmol) are dissolved in 37 mL of Ethyl Acetate and 1 mL 
of Water.  
Stannous chloride (2.70 g, 14.25 mmol) is added and the mixture is refluxed for 3 
hours. 
After completion of the reaction, defined by TLC165, the mixture reaction is firstly 
cooled and poured into 100 mL of iced 5% NaHCO3, then it is filtered over Celite and 
the two layers are separated.  
The organic layer is washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure, giving 1.08 g (2.71 mmol) of a colourless oil. 
 
 
Yield: 95% 
 
 
 
 
1H-NMR (CDCl3): 7.90 (m, 1H), 7.28 (m, 3H), 7.15 (d, 1H, J= 7.88 Hz), 6.95 (d, 1H, J= 8.53 Hz), 
6.78 (s, 1H), 5.85 (m, 1H), 4.95 (m, 1H), 4.55 (m, 1H), 2.20 (s, 2H), 2.04 (s, 3H), 2.02 (s, 3H), 
1.80 (m, 1H), 1.57 (m, 1H), 1.20 (m, 6H).  
                                                            
165 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.35 
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(S)-isopropyl 2-(5-(2-(2-mercapto-1H-imidazol-4-
yl)acetamido)-2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-
4-(methylthio)butanoate 
 
 
A solution of EDAC (0.31 g, 1.60 mmol) and DIPEA (0.29 mL, 1.60 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of 2-(2-mercapto-1H-imidazol-4-yl)acetic acid 
(0.21 g, 1.33 mmol), HOBT (0.22 g, 1.60 mmol) in 3 mL of dry DMF, under a nitrogen 
atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then (S)-isopropyl-2-(5-amino-
2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate (0.53 g, 1.33 
mmol) in 3 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC166, 
the DMF is removed, the residue is resumed with Ethyl Acetate, washed with brine, 
dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using DCM/ 
Methanol= 95/ 5 as elution solvent, to give 0.29 g (0.53 mmol) of the desired product, 
as brown oil. 
 
Yield: 40% 
 
1H-NMR (d6DMSO): 11.87 (bs, 1H), 11.73 (bs, 1H), 10.23 (bs, 1H), 8.07 (d, 1H, J=7.15 Hz), 
7.61 (dd, 1H, J=3.30 Hz, J=5.50 Hz), 7.45 (m, 2H), 7.14 (m, 4H), 6.64 (s, 1H), 4.85 (m, 1H), 
4.19 (m, 1H), 3.51 (s, 2H), 2.12 (m, 1H), 2.09 (s, 3H), 1.94 (s, 3H), 1.75 (m, 2H), 1.21 (s, 1H), 
1.14 (m, 6H).  
                                                            
166 TLC conditions: DCM/ Methanol= 90/ 10 
Rf = 0.60 
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(S)-2-(5-(2-(2-mercapto-1H-imidazol-4-yl)acetamido)-2'-
methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoic acid 
 
 
0.29 g (0.53 mmol) of (S)-isopropyl 2-(5-(2-(2-mercapto-1H-imidazol-4-yl)acetamido)-2'-
methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate are dissolved in 5 mL 
of Methanol; 0.53 mL of NaOH 1 M are dropped and the resulting mixture is stirred at 
RT for 15 hours. 
After completion of the reaction, followed by TLC167, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic Acid, till a white solid starts precipitation. 
The filtration yields a sticky solid (0.26 g, 0.53 mmol), corresponding to the desired 
compound.  
 
 
Yield: quantitative 
 
 
 
 
1H-NMR (d6DMSO): 11.89 (bs, 1H), 11.74 (bs 1H), 10.28 (s, 1H), 7.81–7.77 (m, 1H), 7.60–
7.58 (m, 1H), 7.51–7.49 (m, 2H), 7.22–7.01 (m, 4 H), 6.60 (s, 1H), 4.18–4.10 (m, 1H), 3.76 
(s, 2H), 2.20–1.88 (m, 6H), 1.76–1.60 (m, 4H).  
                                                            
167 TLC conditions: DCM/ Methanol= 90/ 10 
Rf= basal 
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(S)-isopropyl 2-(5-(3-(2-mercapto-1H-imidazol-4-
yl)propanamido)-2'-methyl-[1,1'-biphenyl]-2-
ylcarboxamido)-4-(methylthio)butanoate 
 
 
A solution of EDAC (0.63 g, 3.28 mmol) and DIPEA (0.57 mL, 3.28 mmol) in 4 mL of 
dry DMF is added dropwise to a solution of 2-(2-mercapto-1H-imidazol-4-yl)propanoic 
acid (0.47 g, 2.73 mmol), HOBT (0.44 g, 3.28 mmol) in 5 mL of dry DMF, under a 
nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then (S)-isopropyl-2-(5-amino-
2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate (0.47 g, 2.73 
mmol) in 5 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC168, 
the DMF is removed, the residue is resumed with Ethyl Acetate, washed with brine, 
dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using DCM/ 
Methanol= 95/ 5 as elution solvent, to give 0.45 g (0.82 mmol) of the desired product, 
as pink oil. 
 
Yield: 30% 
 
1H-NMR (d6DMSO): 11.85 (bs, 1H), 11.61 (bs, 1H), 10.10 (bs, 1H), 8.02 (d, 1H, J=7.25 Hz), 
7.93 (d, 1H, J=8.25 Hz), 7.65 (d, 1H, J= 8.25 Hz), 7.45 (m, 2H), 7.16 (m, 3H), 6.48 (s, 1H), 
4.83 (m, 1H), 4.19 (m, 1H), 2.61 (m, 4H), 2.04 (m, 5H), 1.94 (s, 3H), 1.75 (m, 2H), 1.14 (m, 
6H).  
                                                            
168 TLC conditions: DCM/ Methanol= 95/ 5 
Rf = 0.13 
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(S)-2-(5-(3-(2-mercapto-1H-imidazol-4-yl)propanamido)-2'-
methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoic acid 
 
 
0.45 g (0.82 mmol) of (S)-isopropyl 2-(5-(3-(2-mercapto-1H-imidazol-4-
yl)propanamido)-2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate 
are dissolved in 5 mL of Methanol; 0.82 mL of NaOH 1 M are dropped and the 
resulting mixture is stirred at RT for 15 hours. 
After completion of the reaction, followed by TLC169, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic Acid, till a white solid starts precipitation. 
The filtration yields a sticky solid (0.42 g, 0.82 mmol), corresponding to the desired 
compound.  
 
 
Yield: quantitative 
 
 
 
 
1H-NMR (d6DMSO): 11.88 (bs, 1H), 11.64 (1H), 10.15 (s, 1H), 7.59–7.63 (m, 4H), 7.22–7.05 
(m, 4H), 6.49 (s, 1H), 4.10–3.98 (m, 1H), 2.66–2.58 (m, 4H), 2.20–1.88(m, 6H), 1.76–1.58 
(m, 4H).  
                                                            
169 TLC conditions: DCM/ Methanol= 95/ 5 
Rf= basal 
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(S)-isopropyl 2-(5-(2-(2-mercaptothiazol-4-yl)acetamido)-
2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoate 
 
 
 
A solution of EDAC (0.26 g, 1.36 mmol) and DIPEA (0.24 mL, 1.36 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of 2-(2-mercaptothiazol-4-yl)acetic acid (0.20 
g, 1.13 mmol), HOBT (0.18 g, 1.36 mmol) in 3 mL of dry DMF, under a nitrogen 
atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then (S)-isopropyl-2-(5-amino-
2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate (0.49 g, 1.13 
mmol) in 3 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC170, 
the DMF is removed, the residue is resumed with Ethyl Acetate, washed with brine, 
dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 1/ 1 as elution solvent, to give 0.29 g (0.52 mmol) of the 
desired product, as red oil. 
 
Yield: 46% 
 
 
1H-NMR (d6DMSO): 10.32 (bs, 1H), 8.08 (d, 1H, J=7.97 Hz), 7.62 (d, 1H, J=1.93 Hz), 7.52 (m, 
2H), 7.16 (m, 4H), 6.73 (s, 1H), 4.84 (m, 1H), 4.19 (m, 1H), 3.65 (s, 2H), 2.15 (m, 2H), 2.12 (s, 
3H), 1.94 (s, 3H), 1.76 (m, 2H), 1.14 (m, 6H).  
                                                            
170 TLC conditions: DCM/ Methanol= 95/ 5 
Rf = 0.30 
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(S)-2-(5-(2-(2-mercaptothiazol-4-yl)acetamido)-2'-methyl-
[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoic 
acid 
 
 
0.29 g (0.52 mmol) of (S)-isopropyl 2-(5-(2-(2-mercaptothiazol-4-yl)acetamido)-2'-
methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate are dissolved in 5 mL 
of Methanol; 0.52 mL of NaOH 1 M are dropped and the resulting mixture is stirred at 
RT for 18 hours. 
After completion of the reaction, followed by TLC171, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic Acid, till a white solid starts precipitation. 
The filtration yields a sticky solid (0.27 g, 0.52 mmol), corresponding to the desired 
compound.  
 
 
Yield: quantitative 
 
 
 
 
 
 
1H-NMR (d6DMSO): 10.35 (s, 1H), 7.62–7.51 (m, 2H), 7.42 (s, 1H), 7.19–7.03 (m, 4H), 6.63–
6.58 (m, 2H), 4.14 (m, 1H), 3.60 (s, 2H), 2.21–1.98 (m, 6H), 1.82–1.58 (m, 4H).  
                                                            
171 TLC conditions: DCM/ Methanol= 95/ 5 
Rf= basal 
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(S)-isopropyl 2-(5-(3-(2-mercaptothiazol-4-
yl)propanamido)-2'-methyl-[1,1'-biphenyl]-2-
ylcarboxamido)-4-(methylthio)butanoate 
 
 
 
A solution of EDAC (0.38 g, 1.98 mmol) and DIPEA (0.34 mL, 1.98 mmol) in 3 mL of 
dry DMF is added dropwise to a solution of 2-(2-mercaptothiazol-4-yl)propanoic acid 
(0.32 g, 1.65 mmol), HOBT (0.27 g, 1.98 mmol) in 5 mL of dry DMF, under a nitrogen 
atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then (S)-isopropyl-2-(5-amino-
2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate (0.66 g, 1.65 
mmol) in 3 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC172, 
the DMF is removed, the residue is resumed with Ethyl Acetate, washed with brine, 
dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 1/ 1 as elution solvent, to give 0.31 g (0.54 mmol) of the 
desired product, as yellow oil. 
 
Yield: 33% 
 
1H-NMR (d6DMSO): 10.16 (bs, 1H), 8.04 (d, 1H, J=6.87 Hz), 7.60 (dd, 1H, J=1.93 Hz, J=8.53 
Hz), 7.46 (m, 2H), 7.15 (m, 4H), 6.54 (s, 1H), 4.84 (m, 1H), 4.19 (m, 1H), 2.74 (m, 2H), 2.66 
(m, 2H), 2.10 (s, 3H), 2.06 (m, 1H), 1.98 (s, 3H), 1.75 (m, 2H), 1.14 (m, 6H).  
                                                            
172 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/ 1 
Rf = 0.15 
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(S)-2-(5-(3-(2-mercaptothiazol-4-yl)propanamido)-2'-
methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoic acid 
 
 
0.31 g (0.54 mmol) of (S)-isopropyl 2-(5-(3-(2-mercaptothiazol-4-yl)propanamido)-2'-
methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate are dissolved in 5 mL 
of Methanol; 0.54 mL of NaOH 1 M are dropped and the resulting mixture is stirred at 
RT for 18hours. 
After completion of the reaction, followed by TLC173, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic Acid, till a white solid starts precipitation. 
The filtration yields a sticky solid (0.29 g, 0.54 mmol), corresponding to the desired 
compound.  
 
 
Yield: quantitative 
 
 
 
 
1H-NMR (d6DMSO): 10.21 (s, 1H), 7.97–7.85 (m, 1H), 7.60–7.52 (m, 1H), 7.50–7.39 (m, 1H), 
7.22–7.01 (m, 4H), 6.54 (s, 1H), 6.22 (br s, 1H), 4.21–4.12 (m, 1H), 2.81–2.62 (m, 4H), 
2.16–1.63 (m, 10H).  
                                                            
173 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/ 1 
Rf= basal 
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(S)-isopropyl 2-(2'-methyl-5-(2-(2-(methylthio)thiazol-4-
yl)acetamido)-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoate 
 
 
A solution of EDAC (0.55 g, 2.86 mmol) and DIPEA (0.50 mL, 2.86 mmol) in 5 mL of 
dry DMF is added dropwise to a solution of 2-(2-(methylthio)thiazol-4-yl)acetic acid 
(0.45 g, 2.38 mmol), HOBT (0.38 g, 2.86 mmol) in 8 mL of dry DMF, under a nitrogen 
atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then (S)-isopropyl-2-(5-amino-
2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate (1.02 g, 2.38 
mmol) in 8 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC174, 
the DMF is removed, the residue is resumed with Ethyl Acetate, washed with brine, 
dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 1/ 1 as elution solvent, to give 0.30 g (0.52 mmol) of the 
desired product, as red oil. 
 
Yield: 22% 
 
 
1H-NMR (d6DMSO): 10.35 (bs, 1H), 8.08 (d, 1H, J=6.72 Hz), 7.62 (m, 1H), 7.49 (m, 2H), 7.36 
(m, 1H), 7.15 (m, 4H), 4.84 (m, 1H), 4.18 (m, 1H), 3.76 (s, 2H), 2.63 (s, 3H), 2.05 (s, 3H), 2.03 
(m, 2H), 2.02 (s, 3H), 1.75 (m, 2H), 1.14 (m, 6H).  
                                                            
174 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/ 1 
Rf = 0.29 
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(S)-2-(2'-methyl-5-(2-(2-(methylthio)thiazol-4-
yl)acetamido)-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoic acid 
 
 
0.30 g (0.52 mmol) of (S)-isopropyl 2-(2’-methyl-5-(2-(2-(methylthio)thiazol-4-
yl)acetamido)-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate are dissolved 
in 5 mL of Methanol; 0.52 mL of NaOH 1 M are dropped and the resulting mixture is 
stirred at RT for 18 hours. 
After completion of the reaction, followed by TLC175, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic Acid, till a white solid starts precipitation. 
The filtration yields a sticky solid (0.28 g, 0.52 mmol), corresponding to the desired 
compound.  
 
 
Yield: quantitative 
 
 
 
 
 
1H-NMR (d6DMSO): 10.38 (s, 1H), 7.78–7.68 (br s, 1H), 7.59–7.51 (m, 1H), 7.48–7.41 (m, 
1H), 7.36 (s, 1H), 7.18–7.03 (m, 4H), 4.09 (m, 1H), 3.76 (s, 2H), 2.63 (s, 3H), 2.20–1.98 (m, 
6H), 1.85–1.58 (m, 4H).  
                                                            
175 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/ 1 
Rf= basal 
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(S)-isopropyl 2-(2'-methyl-5-(3-(2-(methylthio)thiazol-4-
yl)propanamido)-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoate 
 
 
A solution of EDAC (0.42 g, 2.18 mmol) and DIPEA (0.38 mL, 2.18 mmol) in 5 mL of 
dry DMF is added dropwise to a solution of 3-(2-(methylthio)thiazol-4-yl)propanoic acid 
(0.37 g, 1.82 mmol), HOBT (0.30 g, 2.18 mmol) in 8 mL of dry DMF, under a nitrogen 
atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then (S)-isopropyl-2-(5-amino-
2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate (0.78 g, 1.82 
mmol) in 5 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC176, 
the DMF is removed, the residue is resumed with Ethyl Acetate, washed with brine, 
dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 60/ 40 as elution solvent, to give 0.16 g (0.27 mmol) of 
the desired product, as yellow oil. 
 
Yield: 15% 
 
 
1H-NMR (d6DMSO): 10.13 (bs, 1H), 8.03 (d, 1H, J=6.88 Hz), 7.61 (d, 1H, J=6.90 Hz), 7.46 (m, 
2H), 7.15 (m, 5H), 4.83 (m, 1H), 4.18 (m, 1H), 2.95 (t, 2H, J= 7.15 Hz), 2.66 (t, 2H, J= 7.15 
Hz), 2.62 (s, 3H), 2.07 (m, 8H), 1.74 (m, 2H), 1.15 (m, 6H).  
                                                            
176 TLC conditions: Cyclohexane/ Ethyl Acetate= 60/ 40 
Rf = 0.19 
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(S)-2-(2'-methyl-5-(3-(2-(methylthio)thiazol-4-
yl)propanamido)-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoic acid 
 
  
0.16 g (0.27 mmol) of (S)-isopropyl 2-(2’-methyl-5-(2-(3-(methylthio)thiazol-4-
yl)propanamido)-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate are 
dissolved in 5 mL of Methanol; 0.27 mL of NaOH 1 M are dropped and the resulting 
mixture is stirred at RT for 18 hours. 
After completion of the reaction, followed by TLC177, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic Acid, till a white solid starts precipitation. 
The filtration yields a sticky solid (0.15 g, 0.27 mmol), corresponding to the desired 
compound.  
 
 
Yield: quantitative 
 
 
 
 
1H-NMR (d6DMSO): 10.17 (s, 1H), 8.27 (s, 1H), 7.60–7.57 (m, 1H), 7.50–7.44 (m, 2H), 7.33 
(br s, 1H), 7.18–7.12 (m, 4H), 3.94–3.85 (m, 1H), 2.96–2.91 (m, 2H), 2.71–2.63 (m, 2H), 
2.62 (s, 3H), 2.10–1.91 (m, 6H), 1.70–1.58 (m, 4H). 
 
                                                            
177 TLC conditions: Cyclohexane/ Ethyl Acetate= 60/ 40 
Rf= basal 
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Isopropyl 2-(5-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-
4-(methylthio)butanoate 
 
H2N
C22H26N2O5S
M.W.: 430,52
O
N
H
OO
S
N
H
O
N
H
OO
S
O
O
O
C31H34N2O6S
M.W.: 562,68
 
 
A solution of ((S)-isopropyl-2-(5-amino-2'-methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoate (0.62 g, 1.56 mmol) and DIPEA (0.35 mL, 2.03 mmol) in 6 mL 
of DCM is stirred under a nitrogen atmosphere. 
The resulting mixture is cooled to 0°C and then amounted of a solution of 2,3-
dihydrobenzo[b][1,4]dioxine-2-carbonyl chloride (0.40 g, 2.03 mmol) in 3 mL of DCM. 
The reaction mixture is stirred at RT for 1 hour; after completion, monitored by TLC178, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated. 
The crude is purified on silica gel, using Cyclohexane/ Ethyl Acetate= 85/15 as elution 
solvent, obtaining 0.82 g (1.45 mmol) of the desired product, as sticky white solid.  
 
Yield: 93% 
 
 
 
 
1H-NMR (d6DMSO): 10.30 (bs, 1H), 8.16 (bs,1H), 7.70 (dd, 1H, J=2.2 Hz, J=8.53 Hz), 7.50 (m, 
2H), 6.99-7.19 (m, 5H), 6.87 (m, 1H), 4.99 (dd, 1H, J=2.75 Hz, J=5.5 Hz), 4.84 (m, 1H), 4.44 
(dd, 1H, J=2.75 Hz, J=11.55 Hz), 4.35 (dd, 1H, J=5.5 Hz , J=11.55 Hz ), 4.20 (m, 1H), 2.17 (m, 
2H), 1.94 (s, 3H), 1.76 (m, 2H), 1.14 (m, 6H).  
                                                            
178 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf = 0.44 
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2-(5-(2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamido)-2'-
methyl-[1,1'-biphenyl]-2-ylcarboxamido)-4-
(methylthio)butanoic acid 
 
H2N
C22H26N2O5S
M.W.: 430,52
O
N
H
OO
S
N
H
O
N
H
OHO
S
O
O
O
C28H28N2O6S
M.W.: 520,60
 
 
0.82 g of (2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamido)-2-
(thiophen-2-yl)benzamido)-4-(methylthio)butanoate (1.45 mmol) are dissolved in 10 
mL of Methanol; 1.45 mL of NaOH 1M are dropped and the resulting mixture is stirred 
at RT overnight. 
After completion of the reaction, followed by TLC179, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The solid filtration yields 0.53 g (1.02 mmol) of the final product, as a sticky solid. 
 
 
Yield: 70% 
 
 
 
 
1H-NMR (d6DMSO): 12.61 (bs, 1H), 10.30 (s,1H), 8.05 (bs, 1H), 7.70 (dd, 1H, J=2.2 Hz, J=8.26 
Hz), 7.51 (m, 2H), 7.00-7.53 (m, 4H), 6.86 (m, 3H), 4.99 (dd 1H, J=2.75 Hz, J=5.5 Hz), 4.44 
(dd, 1H, J=2.75 Hz, J=11.55 Hz), 4.35 (dd 3H, J=5.5 Hz, J=11.55 Hz), 4.21 (m, 1H), 2.14 (m, 
2H), 1.94 (s, 3H), 1.76 (m, 2H).  
                                                            
179 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf = basal 
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Methyl 4-nitro-2-(thiophen-2-yl)benzoate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-nitrobenzoate (1.00 g, 3.85 mmol) in 
5 mL of dry DMF, under a nitrogen atmosphere, Pd(PPh3)4 (0.44 g, 0.385 mmol) is 
added as solid. 
The solution is stirred for 10 minutes and then amounted of Na3PO4*12H2O (4.39 g , 
11.55 mmol) and of a solution of 2-thienylboronic acid (0.59 g, 4.62 mmol) in 5 mL of 
dry DMF. 
The reaction mixture is heated at 100°C for 18 hours, monitored by TLC180 and then 
concentrated.  
The crude is resumed with Ethyl Acetate, washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 78/24, yields 0.68 g (2.58 mmol) of the desired product, as yellow solid.  
 
Yield: 67% 
 
Melting point: 98.81° C 
 
 
1H-NMR (CDCl3): 8.35 (d, 1H, J=2.2 Hz), 8.22 (ddd, 1H, J=0.55 Hz, J=2.20 Hz, J=8.53 Hz), 
7.83 (d, 1H, J=8.53 Hz), 7.45 (ddd, 1H, J=0.55 Hz, J=1.38 Hz, J=4.95 Hz), 7.09-7.15 (m, 1H), 
3.80 (s, 3H).  
                                                            
180 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.49 
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4-nitro-2-(thiophen-2-yl)benzoic acid 
 
 
 
0.68 g of methyl 4-nitro-2-(thiophen-2-yl)benzoate (2.58 mmol) are dissolved in 10 mL 
of Methanol; 2 mL of NaOH 2.5 M are dropped and the resulting mixture is heated at 
60°C for 2 hours. 
After completion of the reaction, followed by TLC181, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl, and then extracted three times with 10 mL of Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, obtaining a yellow solid (0.64 g, 2.58 mmol), corresponding to the 
desired compound.  
 
 
Yield: quantitative 
 
 
Melting point: 136.19° C 
 
 
 
1H-NMR (CDCl3): 8.26 (d, 1H, J=0.83 Hz), 8.25 (m, 1H), 8.01 (d, 1H, J=8.52 Hz), 7.46 (m, 1H), 
7.20 (dd, 1H, J=0.83 Hz, J=2.75 Hz), 7.12 (dd, 1H, J=0.83 Hz, J=3.56 Hz). 
  
                                                            
181 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.26 
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(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(thiophen-2-
yl)benzamido)butanoate 
 
 
 
A solution of EDAC (0.59 g, 3.10 mmol) and DIPEA (0.54 mL, 3.10 mmol) in 2 mL of 
DCM is added dropwise to a solution of 4-nitro-2-(thiophen-2-yl)benzoic acid (0.64 g, 
2.58 mmol), HOBT (0.42 g, 3.10 mmol) in 3 mL of DCM, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.49 g, 2.58 mmol) in 3 mL of DCM is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC182, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 70/30 as elution solvent, to give 0.76 g (1.81 mmol) of 
the desired product, as yellow oil. 
 
Yield: 70% 
 
 
 
1H-NMR (CDCl3): 8.33 (d, 1H, J=1.1 Hz), 8.22 (dd, 1H, J=2.2 Hz, J=8.53 Hz), 7.76 (dd, 1H, 
J=1.1 Hz, J=8.53 Hz), 7.46 (dd, 1H, J=1.37 Hz, J=5.22 Hz), 7.27 (d, 1H, J=1.37 Hz), 7.12 (dd, 
1H, J=3.57 Hz, J=5.22 Hz), 6.33 (d, 1H, J=7.42 Hz), 5.02 (m, 1H), 4.72 (m, 1H), 2.24 (t, 2H, 
J=7.15 Hz), 2.06 (m, 1H), 2.04 (s, 3H), 1.91 (m, 1H), 1.26 (d, 3H, J=6.60 Hz), 1.24 (d, 3H, 
J=6.60 Hz).  
                                                            
182 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.54 
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(S)-isopropyl 2-(4-amino-2-(thiophen-2-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(thiophen-2-yl)benzamido)butanoate (0.76 g, 
1.81 mmol) is dissolved in 23 mL of Ethyl Acetate and 1 mL of Water. Stannous 
chloride (1.72 g, 9.05 mmol) is added and the mixture is refluxed for 3 hours. 
After completion of the reaction, defined by TLC183, the mixture reaction is firstly 
cooled and poured into 50 mL of iced 5% NaHCO3, then it is filtered over Celite and the 
two layers are separated.  
The organic layer is washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure, giving 0.61 g (1.56 mmol) of a colourless oil. 
 
 
Yield: 86% 
 
 
 
 
1H-NMR (CDCl3): 7.56 (dd, 1H, J=1.1 Hz, J=9.08 Hz), 7.35 (dd, 1H, J=1.1 Hz, J=4.96 Hz), 7.04-
7.12 (m, 1H), 6.66 (m, 2H), 6.08 (d, 1H, J=7.43 Hz), 4.98 (m, 1H), 4.63 (m, 1H), 3.90 (bs, 2H), 
2.23 (t, 2H, J=7.7 Hz), 2.04 (s, 3H), 2.02 (m, 1H), 1.80 (m, 1H), 1.23 (d, 3H, J=6.33 Hz), 1.21 
(d, 3H, J=6.05 Hz).  
                                                            
183 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.23 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(thiophen-2-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
A solution of EDAC (0.36 g, 1.87 mmol) and DIPEA (0.33 mL, 1.87 mmol) in 2 mL of 
DCM is added dropwise to a solution of (S)-isopropyl 2-(4-amino-2-(thiophen-2-
yl)benzamido)-4-(methylthio)butanoate (0.61 g, 1.56 mmol), HOBT (0.25 g, 1.87 
mmol) in 3 mL of DCM, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.30 g, 1.56 mmol) in 3 mL of DCM is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC184, 
the mixture is washed firstly with a solution of 10% NaHCO3, secondly with HCl 10 % 
and finally with brine.  
The organic phase is then dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 70/30 as elution solvent, to give 0.74 g (0.95 mmol) of 
the desired product, as yellow oil. 
 
Yield: 61% 
 
1H-NMR (CDCl3): 9.19 (s,1H), 7.57 (d, 1H, J=8.25 Hz), 7.48 (d, 1H, J=1.92 Hz), 7.23-7.36 (m, 
18H), 7.13 (dd, 1H, J=1.38 Hz, J=3.58 Hz), 7.06 (dd, 1H, J=4.58 Hz , J=5.23 Hz), 6.58 (s, 1H), 
6.16 (bs, 1H), 5.00 (m, 1H), 4.62 (m, 1H), 3.49 (s, 2H), 2.23 (t, 2H, J=7.7 Hz), 2.05 (m, 1H), 
2.04 (s, 3H), 1.90 (m, 1H), 1.24 (d, 3H, J=7.15 Hz), 1.22 (d, 3H, J=6.60 Hz).  
                                                            
184 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.24 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(thiophen-2-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
0.74 g (0.95 mmol) of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(thiophen-2-yl)benzamido)-4-(methylthio)butanoate are dissolved in 9 mL of DCM and 
then treated with 3 mL of Formic acid. 
The reaction is followed by TLC185, at completion the reaction mixture is slowly poured 
in 20 mL of 5% aqueous NaHCO3, the two layers are separated; the organic layer is 
washed with brine, dried over Na2SO4, filtered and concentrated under reduce 
pressure. 
The crude is purified on silica gel, using Ethyl Acetate as elution solvent, yielding 0.34 
g of the desired product (0.64 mmol), as sticky solid. 
 
 
Yield: 67%  
 
 
 
1H-NMR (CDCl3): 9.38 (s,1H), 7.59 (m, 3H), 7.36 (d, 1H, J=4.13 Hz), 7.14 (d, 1H, J=2.47 Hz), 
7.06 (m, 1H), 6.34 (s, 1H ), 6.21 (d, 1H, J= 7.7 Hz), 5.13 (bs, 2H), 4.98 (m, 1H), 4.65 (m, 1H), 
3.62 (s, 2H), 2.25 (m, 2H), 2.04 (s, 3H), 2.00 (m, 1H), 1.84 (m, 1H), 1.23 (d, 3H, J=6.33 Hz), 
1.21 (d, 3H, J=6.33 Hz).  
                                                            
185 TLC conditions: Ethyl Acetate= 100 % 
Rf = 0.23 
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(S)-2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(thiophen-2-
yl)benzamido)-4-(methylthio)butanoic acid 
 
 
 
0.34 g of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(thiophen-2-
yl)benzamido)-4-(methylthio)butanoate (0.64 mmol) are dissolved in 5 mL of Methanol; 
1.28 mL of NaOH 1M are dropped and the resulting mixture is heated at 50°C for 2 
hours. 
After completion of the reaction, followed by TLC186, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 0.31 g of the final product, as a sticky solid, in 
quantitative yield.  
 
 
Yield: quantitative 
 
 
 
 
1H-NMR (d6DMSO): 10.30 (S, 1H), 8.53 (d,1H, J= 7.7 Hz), 7.81 (s, 1H), 7.58 (d, 1H, J=8.35 
Hz), 7.53 (d, 1H, J = 4.95 Hz), 7.31 (d, 1H, J = 8.26 Hz) ,7.20 (d, 1H, J = 3.3 Hz), 7.00 (m, 2H), 
6.89 (s, 2H), 6.30 (s, 1H), 4.34 (m, 1H), 3.48 (s, 2H), 2.36 (m, 2H), 2.00 (s, 3H), 1.87 (m, 2H). 
  
                                                            
186 TLC conditions: Ethyl Acetate= 100% 
Rf = basal 
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(2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(thiophen-2-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
A solution of (S)-isopropyl 2-(4-amino-2-(thiophen-2-yl)benzamido)-4-
(methylthio)butanoate (0.61 g, 1.56 mmol) and DIPEA (0.30 mL, 1.72 mmol) in 8 mL 
of DCM is stirred under a nitrogen atmosphere. 
The resulting mixture is cooled to 0°C and then amounted of a solution of 2,3-
dihydrobenzo[b][1,4]dioxine-2-carbonyl chloride (0.34 g, 1.72 mmol) in 2 mL of DCM. 
The reaction mixture is stirred at RT for 2 hours; after completion, monitored by TLC187, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated. 
The crude is purified on silica gel, using Cyclohexane/ Ethyl Acetate= 75/25 as elution 
solvent, obtaining 0.73 g (1.31 mmol) of the desired product, as sticky white solid.  
 
Yield: 85% 
 
 
1H-NMR (CDCl3): 8.42 (s,1H), 7.67 (m, 3H), 7.37 (dd, 1H, J=1.1 Hz, J=4.13 Hz), 7.16 (dd, 1H, 
J=1.1 Hz, J=3.57 Hz), 7.02-7.08 (m, 2H), 6.91-6.95 (m, 3H), 6.21 (d, 1H, J=7.7 Hz), 5.00 (m, 
1H), 4.80 (dd, 1H, J=2.75 Hz, J=7.43 Hz), 4.68 (dd, 1H, J=5.23 Hz, J=7.16 Hz), 4.62 (dd, 1H, 
J=2.75 Hz , J=11.28 Hz), 4.26 (dd, 1H, J=7.43 Hz , J=11.26 Hz), 2.23 (t, 2H, J=7.7 Hz), 2.04 
(s, 3H), 2.01 (m, 1H), 1.87 (m, 1H), 1.24 (d, 3H, J=6.6 Hz), 1.22 (d, 3H, J=6.33 Hz). 
                                                            
187 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.44 
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(2S)-2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(thiophen-2-yl)benzamido)-4-
(methylthio)butanoic acid 
 
 
 
0.62 g of (2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamido)-2-
(thiophen-2-yl)benzamido)-4-(methylthio)butanoate (1.12 mmol) are dissolved in 5 mL 
of Methanol; 1.12 mL of NaOH 1M are dropped and the resulting mixture is stirred at 
RT overnight. 
After completion of the reaction, followed by TLC188, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 0.57 g of the final product, as a sticky solid, in 
quantitative yield.  
 
Yield: quantitative 
 
 
1H-NMR (d6DMSO): 10.39 (s,1H), 8.54 (d, 1H, J=1.1 Hz), 7.84 (dd, 1H, J=3.58 Hz, J=5.2 Hz), 
7.66 (dd, 1H, J=2.2 Hz, J=8.25 Hz), 7.54 (dd, 1H, J=1.1 Hz, J=5.23 Hz), 7.35 (d, 1H, , J=8.25 
Hz), 7.22 (dd, 1H, J=1.1 Hz, J=3.58 Hz), 7.01-7.04 (m, 2H), 6.84-6.91 (m, 3H), 5.00 (m, 1H), 
4.46 (dd, 1H, J=2.48 Hz, J=11.55 Hz), 4.31-4.44 (m, 3H), 2.35 (m, 2H), 2.00 (s, 3H), 1.91 (m, 
2H).  
                                                            
188 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= basal 
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Methyl 4-nitro-2-(thiophen-3-yl)benzoate 
 
Br
O2N
COOCH3
C8H6BrNO4
M.W.: 260,04
O2N
COOCH3
S
C12H9NO4S
M.W.: 263,27
 
 
To a sonicated solution of the methyl 2-bromo-4-nitrobenzoate (1.00 g, 3.85 mmol) in 
5 mL of dry DMF, under a nitrogen atmosphere, Pd(PPh3)4 (0.44 g, 0.385 mmol) is 
added as solid. 
The solution is stirred for 10 minutes and then amounted of Na3PO4*12H2O (4.39 g , 
11.55 mmol) and of a solution of 3-thienylboronic acid (0.59 g, 4.62 mmol) in 5 mL of 
dry DMF. 
The reaction mixture is heated at 120°C for 18 hours, monitored by TLC189 and then 
concentrated.  
The crude is resumed with Ethyl Acetate, washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 70/30, yields 0.64 g (2.42 mmol) of the desired product, as yellow solid.  
 
 
Yield: 63% 
 
Melting point: 112.93° C 
 
1H-NMR (CDCl3): 8.29 (d, 1H, J=2.2 Hz), 8.21 (dd, 1H, J=2.2 Hz, J=8.52 Hz), 7.87 (d, 1H, 
J=8.52 Hz), 7.42 (dd, 1H, J=3.03 Hz, J=4.95 Hz), 7.37 (dd, 1H, J=1.38 Hz, J=3.03 Hz), 7.12 
(dd, 1H, J=1.1 Hz, J=4.95 Hz), 3.77 (s, 3H).  
                                                            
189 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.60 
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4-nitro-2-(thiophen-3-yl)benzoic acid 
 
 
 
0.64 g of methyl 4-nitro-2-(thiophen-3-yl)benzoate (2.42 mmol) are dissolved in 10 mL 
of Methanol; 2 mL of NaOH 2.5 M are dropped and the resulting mixture is heated at 
60°C for 1 hour. 
After completion of the reaction, followed by TLC190, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl, and then extracted three times with 10 mL of Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, obtaining a yellow solid (0.60 g, 2.42 mmol), corresponding to the 
desired compound.  
 
 
Yield: quantitative 
 
Melting point: 159.28°C 
 
 
 
 
 
1H-NMR (CDCl3): 8.29 (d, 1H, J=2.47 Hz), 8.24 (dd, 1H, J= 2.47 Hz, J= 8.53 Hz), 8.03 (d, 1H, 
J=8.53 Hz), 7.40 (m, 2H), 7.16 (dd, 1H, J=2.75 Hz, J=3.85 Hz).  
                                                            
190 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.20 
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(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(thiophen-3-
yl)benzamido)butanoate 
 
 
 
A solution of EDAC (0.56 g, 2.90 mmol) and DIPEA (0.50 mL, 2.90 mmol) in 2 mL of 
DCM is added dropwise to a solution of 4-nitro-2-(thiophen-3-yl)benzoic acid (0.60 g, 
2.42 mmol), HOBT (0.39 g, 2.90 mmol) in 3 mL of DCM, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.46 g, 2.42 mmol) in 3 mL of DCM is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC191, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 75/25 as elution solvent, to give 0.84 g (1.98 mmol) of 
the desired product, as pale yellow oil. 
 
 
Yield: 82% 
 
 
 
1H-NMR (CDCl3): 8.29 (d, 1H, J=2.48 Hz), 8.22 (ddd, 1H, J=0.83 Hz, J=2.48 Hz, J=8.53 Hz), 
7.77 (d, 1H, J=8.53 Hz), 7.51 (m, 1H), 7.45 (ddd, 1H, J=0.82 H , J=3.02 Hz, J=4.95 Hz), 7.23 
(m, 2H), 6.23 (d, 1H, J=7.43 Hz), 5.01 (m, 1H), 4.68 (m, 1H), 2.22 (t, 2H, J=7.7 Hz), 2.07 (m, 
1H), 2.05 (s, 3H), 1.89 (m, 1H), 1.26 (d, 3H, J=6.33 Hz), 1.24 (d, 3H, J=6.33 Hz).  
                                                            
191 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.50 
FTase Inhibitors-Amidic series                                                           Experimental section 
255 
 
(S)-isopropyl 2-(4-amino-2-(thiophen-3-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(thiophen-3-yl)benzamido)butanoate (0.84 g, 
1.98 mmol) is dissolved in 13 mL of Ethyl Acetate and 1 mL of Water. Stannous 
chloride (1.69 g, 9.9 mmol)is added and the mixture is refluxed for 2 hours. 
After completion of the reaction, defined by TLC192, the mixture reaction is firstly 
cooled and poured into 50 mL of iced 5% NaHCO3, then it is filtered over Celite and the 
two layers are separated.  
The organic layer is washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure, giving 0.39 g (1.78 mmol) of a sticky oil. 
 
 
Yield: 90% 
 
 
 
 
1H-NMR (CDCl3): 7.59 (d, 1H, J=8.25 Hz), 7.37 (dd, 1H, J=3.03 Hz, J=4.95 Hz), 7.33 (dd, 1H, 
J=1.38 Hz, J=3.03 Hz), 7.12 (dd, 1H, J=1.38 Hz , J=4.95 Hz), 6.67 (dd, 1H, J=2.48 Hz, J=8.25 
Hz), 6.60 (d, 1H, J=2.48 Hz), 5.97 (d, 1H, J=7.42 Hz), 4.98 (m, 1H), 4.60 (m, 1H), 3.90 (bs, 
2H), 2.23 (t, 2H, J=7.7 Hz), 2.05 (s, 3H), 1.99 (m, 1H), 1.79 (m, 1H), 1.23 (d, 3H, J=6.33 Hz), 
1.21 (d, 3H, J=6.60 Hz).  
                                                            
192 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.22 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(thiophen-3-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
A solution of EDAC (0.41 g, 2.14 mmol) and DIPEA (0.37 mL, 2.14 mmol) in 2 mL of 
DCM is added dropwise to a solution of (S)-isopropyl 2-(4-amino-2-(thiophen-3-
yl)benzamido)-4-(methylthio)butanoate (0.39 g, 1.78 mmol), HOBT (0.29 g, 2.14 
mmol) in 3 mL of DCM, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.34 g, 1.78 mmol) in 3 mL of DCM is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC193, 
the mixture is washed firstly with a solution of 10% NaHCO3, secondly with HCl 10 % 
and finally with brine.  
The organic phase is then dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 70/30 as elution solvent, to give 0.99 g (1.28 mmol) of 
the desired product, as colourless oil. 
 
Yield: 72% 
 
1H-NMR (CDCl3): 9.19 (s,1H), 7.62 (d, 1H, J=8.25 Hz), 7.53 (d, 1H, J=2.92 Hz), 7.23-7.38 (m, 
18H), 7.15 (dd, 1H, J=1.1 Hz, J=4.68 Hz), 6.70 (bs, 1H), 6.18 (s, 1H), 6.05 (d, 1H, J= 7.97 Hz), 
4.99 (m, 1H), 4.63 (m, 1H), 3.54 (s, 2H), 2.23 (t, 2H, J=7.7 Hz), 2.04 (s, 3H), 2.00 (m, 1H), 
1.79 (m, 1H), 1.24 (d, 3H, J=7.53 Hz), 1.22 (d, 3H, J=6.33 Hz).  
                                                            
193 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.28 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(thiophen-3-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
0.99 g (1.28 mmol) of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(thiophen-3-yl)benzamido)-4-(methylthio)butanoate are dissolved in 6 mL of DCM and 
then treated with 2 mL of Formic acid. 
The reaction is followed by TLC194, at completion the reaction mixture is slowly poured 
in 20 mL of 5% aqueous NaHCO3, the two layers are separated; the organic layer is 
washed with brine, dried over Na2SO4, filtered and concentrated under reduce 
pressure. 
The crude is purified on silica gel, using Ethyl Acetate as elution solvent, yielding 0.44 
g of the desired product (0.82 mmol), as sticky solid. 
 
 
Yield: 64%  
 
 
 
1H-NMR (CDCl3): 9.34 (s,1H), 7.64 (d, 1H, J= 8.52 Hz), 7.58 (d, 1H, J=1.93 Hz), 7.53 (dd, 1H, 
J=1.93 Hz, J= 8.52 Hz), 7.37 (dd, 1H, J= 2.2 Hz, J= 3.03 Hz), 7.35 (dd, 1H, J= 3.03 Hz, J= 4.13 
Hz), 7.15 (dd, 1H, J= 2.2 Hz, J= 4.13 Hz), 6.34 (s, 1H ), 6.09 (d, 1H, J= 7.42 Hz), 5.01 (bs, 2H), 
4.98 (m, 1H), 4.63 (m, 1H), 3.62 (s, 2H), 2.23 (m, 2H), 2.05 (s, 3H), 1.98 (m, 1H), 1.79 (m, 
1H), 1.24 (d, 3H, J=7.15 Hz), 1.22 (d, 3H, J=6.6 Hz).  
                                                            
194 TLC conditions: Ethyl Acetate= 100 % 
Rf = 0.25 
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(S)-2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(thiophen-2-
yl)benzamido)-4-(methylthio)butanoic acid 
 
 
 
0.44 g of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(thiophen-3-
yl)benzamido)-4-(methylthio)butanoate (0.82 mmol) are dissolved in 5 mL of Methanol; 
1.64 mL of NaOH 1M are dropped and the resulting mixture is stirred at RT for 18 
hours. 
After completion of the reaction, followed by TLC195, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 0.40 g of the final product, as a sticky solid, in 
quantitative yield.  
 
 
Yield: quantitative 
 
 
 
1H-NMR (d6DMSO): 10.27 (s,1H), 8.51 (d, 1H, J= 7.7 Hz), 7.74 (d, 1H, J=1.92 Hz), 7.58 (dd, 
1H, J= 1.92 Hz, J=8.25 Hz), 7.51 (m, 1H), 7.33 (d, 1H, J= 8.25 Hz), 7.18 (dd, 1H, J= 1.1 Hz, J= 
6.31 Hz), 6.91 (m, 2H ), 6.31 (s, 1H), 4.36 (m, 1H), 3.48 (s, 2H), 3.35 (bs, 2H), 2.41 (m, 2H), 
2.01 (s, 3H), 1.88 (m, 2H).  
                                                            
195 TLC conditions: Ethyl Acetate= 100% 
Rf = basal 
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(2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(thiophen-3-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
A solution of (S)-isopropyl 2-(4-amino-2-(thiophen-3-yl)benzamido)-4-
(methylthio)butanoate (0.39 g, 1.78 mmol) and DIPEA (0.34 mL, 1.72 mmol) in 8 mL 
of DCM is stirred under a nitrogen atmosphere. 
The resulting mixture is cooled to 0°C and then amounted of a solution of 2,3-
dihydrobenzo[b][1,4]dioxine-2-carbonyl chloride (0.39 g, 1.96 mmol) in 2 mL of DCM. 
The reaction mixture is stirred at RT for 2 hours; after completion, monitored by TLC196, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated. 
The crude is purified on silica gel, using Cyclohexane/ Ethyl Acetate= 75/25 as elution 
solvent, obtaining 0.73 g (1.32 mmol) of the desired product, as sticky white solid.  
 
 
Yield: 74% 
 
 
1H-NMR (CDCl3): 8.38 (s,1H), 7.70 (d, 1H, J= 8.52 Hz), 7.69 (s, 1H), 7.59 (dd, 1H, J=2.2 Hz, 
J=8.52 Hz), 7.37-7.41 (m, 2H), 7.17 (dd, 1H, J= 0.83 Hz, J= 5.50 Hz), 6.91-7.06 (m, 3H), 6.09 
(d, 1H, J=7.42 Hz), 4.99 (m, 1H), 4.82 (dd, 1H, J=2.75 Hz, J=7.42 Hz), 4.60-4.65 (m, 2H), 4.27 
(ddd, 1H, J=1.38 Hz, J=7.7 Hz, J=11.55 Hz), 2.23 (t, 2H, J=7.7 Hz), 2.05 (s, 3H), 1.97 (m, 1H), 
1.83 (m, 1H), 1.24 (d, 3H, J=6.33 Hz), 1.22 (d, 3H, J=6.43 Hz).  
                                                            
196 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.43 
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(2S)-2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(thiophen-3-yl)benzamido)-4-
(methylthio)butanoic acid 
 
 
 
0.73 g of (2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamido)-2-
(thiophen-3-yl)benzamido)-4-(methylthio)butanoate (1.32 mmol) are dissolved in 5 mL 
of Methanol; 1.12 mL of NaOH 1M are dropped and the resulting mixture is stirred at 
RT overnight. 
After completion of the reaction, followed by TLC197, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 0.68 g of the final product, as a sticky solid, in 
quantitative yield.  
 
 
Yield: quantitative 
 
 
1H-NMR (d6DMSO): 10.31 (s,1H), 8.47 (d, 1H, J=7.7 Hz,), 7.77 (s,1H), 7.75 (d, 1H, J=9.08 Hz), 
7.64 (dd, 1H, J=2.2 Hz, J=8.52 Hz), 7.49-7.55 (m, 2H), 7.36 (d, 1H, , J=8.52 Hz), 7.20 (dd, 1H, 
J=0.83 Hz, J=4.95 Hz), 7.03 (dd, 1H, J= 1.93 Hz, J= 7.98 Hz), 6.85-6.90 (m, 3H), 5.00 (m, 1H), 
4.45 (dd, 1H, J=2.48 Hz, J=11.28 Hz), 4.32-4.38 (m, 3H), 2.37 (m, 2H), 2.04 (s, 3H), 2.1 (m, 
2H).  
                                                            
197 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = basal 
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Methyl 4-nitro-2-(furan-2-yl)benzoate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-nitrobenzoate (1.00 g, 3.85 mmol) in 
5 mL of dry THF, under a nitrogen atmosphere, Pd(PPh3)4 (0.44 g, 0.385 mmol) is 
added as solid. 
The solution is stirred for 10 minutes and then amounted of K2CO3 (1.60 g, 11.55 
mmol) and of a solution of 2-furanylboronic acid (0.47 g, 4.24 mmol) in 5 mL of dry 
THF. 
The reaction mixture is stirred at RT for 18 hours, monitoring the progression by TLC198 
and then concentrated.  
The crude is resumed with Ethyl Acetate, washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. 
Purification by chromatography on silica gel, through elution with Hexane/ Ethyl 
Acetate= 90/104, yields 0.70 g (2.85 mmol) of the desired product, as yellow solid.  
 
 
Yield: 74% 
 
Melting point: 67.73° C 
 
 
1H-NMR (CDCl3): 8.49 (d, 1H, J=2.2 Hz), 8.15 (dd, 1H, J=2.20 Hz, J=8.53 Hz), 7.74 (d, 1H, 
J=8.53 Hz), 7.55 (dd, 1H, J=0.83 Hz, J=1.93 Hz), 7.75 (dd, 1H, J=0.83 Hz, J=3.58 Hz), 3.91 (s, 
3H).  
                                                            
198 TLC conditions: Hexane/ Ethyl Acetate= 80/20 
Rf= 0.28 
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4-nitro-2-(furan-2-yl)benzoic acid 
 
 
 
0.70 g of methyl 4-nitro-2-(furan-2-yl)benzoate (2.85 mmol) are dissolved in 10 mL of 
Methanol; 2.3 mL of NaOH 2.5 M are dropped and the resulting mixture is stirred at RT 
for 18 hours. 
After completion of the reaction, followed by TLC199, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl, and then extracted three times with 10 mL of Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, obtaining a yellow solid (0.63 g, 2.68 mmol), corresponding to the 
desired compound.  
 
 
Yield: 94 % 
 
 
Melting point: 136.19° C 
 
 
 
 
1H-NMR (CDCl3): 8.51 (d, 1H, J=2.2 Hz), 8.20 (ddd, 1H, J=0.82 Hz, J=2.20 Hz, J=8.52 Hz), 
7.94 (d, 1H, J=8.52 Hz), 7.57 (dd, 1H, J=0.83 Hz, J=1.65 Hz), 6.86 (d, 1H, J=3.58 Hz), 6.56 
(ddd, 1H, J=0.83 Hz, J=1.65 Hz, J=3.58 Hz).  
                                                            
199 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.20 
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(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(furan-2-
yl)benzamido)butanoate 
 
 
 
A solution of EDAC (0.62 g, 3.22 mmol) and DIPEA (0.56 mL, 3.22 mmol) in 2 mL of 
DCM is added dropwise to a solution of 4-nitro-2-(furan-2-yl)benzoic acid (0.63 g, 2.68 
mmol), HOBT (0.44 g, 3.22 mmol) in 3 mL of DCM, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.51 g, 2.68 mmol) in 3 mL of DCM is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC200, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated.  
The crude product is treated with Isopropyl Ether, achieving 1.04 g (2.55 mmol) of the 
desired product, as white solid. 
 
Yield: 95% 
 
Melting point: 140.97°C 
 
 
 
 
1H-NMR (CDCl3): 8.53 (d, 1H, J=2.2 Hz), 8.13 (dd, 1H, J=2.2 Hz, J=8.25 Hz), 7.62 (dd, 1H, 
J=3.47 Hz, J=8.25 Hz), 7.55 (dd, 1H, J=0.82 Hz, J=2.92 Hz), 6.84 (dd, 1H, J=0.82 Hz, J= 3.67 
Hz), 6.50-6.55 (m, 2H), 5.08 (m, 1H), 4.86 (m, 1H), 2.51 (t, 2H, J=7.70 Hz), 2.18 (m, 1H), 2.09 
(s, 3H), 2.06 (m, 1H), 1.29 (d, 3H, J=6.33 Hz), 1.27 (d, 3H, J=6.60 Hz).  
                                                            
200 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.61 
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(S)-isopropyl 2-(4-amino-2-(furan-2-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(furan-2-yl)benzamido)butanoate (1.04 g, 2.55 
mmol) is dissolved in 30 mL of Ethyl Acetate. Stannous chloride (2.42 g, 12.75 mmol) 
is added and the mixture is refluxed for 3 hours. 
After completion of the reaction, defined by TLC201, the mixture reaction is firstly 
cooled and poured into 50 mL of iced 5% NaHCO3, then it is filtered over Celite and the 
two layers are separated.  
The organic layer is washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure, giving 0.84 g (2.22 mmol) of a colourless oil. 
 
 
Yield: 87 
 
 
 
 
 
1H-NMR (CDCl3): 7.47 (d, 1H, J=0.55), 7.40 (d, 1H, J=8.25 Hz), 6.86 (d, 2H, J= 2.20 Hz), 6.60-
6.64 (m, 2H), 6.45 (dd, 1H, J= 1.55 Hz, J= 4.4 Hz), 6.25 (d, 1H, J= 7.70 Hz), 5.04 (m, 1H), 
4.78 (m, 1H), 3.90 (bs, 2H), 2.48 (t, 2H, J=7.6 Hz), 2.13 (m, 1H), 2.08 (s, 3H), 1.99 (m, 1H), 
1.27 (d, 3H, J=6.05 Hz), 1.25 (d, 3H, J=5.78 Hz).  
                                                            
201 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.18 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(furan-2-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
A solution of EDAC (0.51 g, 2.66 mmol) and DIPEA (1.97 mL, 2.66 mmol) in 8 mL of 
dry DMF is added dropwise to a solution of (S)-isopropyl 2-(4-amino-2-(furan-2-
yl)benzamido)-4-(methylthio)butanoate (0.84 g, 2.22 mmol), HOBT (0.36 g, 2.66 
mmol) in 5 mL of dry DMF, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.42 g, 2.22 mmol) in 5 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC202, 
the solvents is removed; the residue is resumed with 20 mL of Ethyl Acetate, washed 
firstly with a solution of 10% NaHCO3, secondly with HCl 10 % and finally with brine.  
The organic phase is then dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 65/35 as elution solvent, to give 1.08 g (1.42 mmol) of 
the desired product, as yellow oil. 
 
Yield: 64% 
 
1H-NMR (CDCl3): 9.21 (s,1H), 7.69 (d, 1H, J=1.93 Hz), 7.44 (m, 2H), 7.22-7.36 (m, 15H), 6.65 
(m, 2H), 6.45 (dd, 1H, J=1.93 Hz, J=4.68 Hz), 6.32 (d, 1H, J=7.98 Hz), 6.19 (s, 1H), 5.05 (m, 
1H), 4.80 (m, 1H), 3.53 (s, 2H), 2.49 (t, 2H, J=6.86 Hz), 2.17 (m, 1H), 2.09 (s, 3H), 2.00 (m, 
1H), 1.28 (d, 3H, J=6.05 Hz), 1.26 (d, 3H, J=6.24 Hz).  
                                                            
202 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.48 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(furan-2-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
1.08 g (1.42 mmol) of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(furan-2-
yl)benzamido)-4-(methylthio)butanoate are dissolved in 12 mL of DCM and then 
treated with 4 mL of Formic acid. 
The reaction is followed by TLC203, at completion the reaction mixture is slowly poured 
in 20 mL of 5% aqueous NaHCO3, the two layers are separated; the organic layer is 
washed with brine, dried over Na2SO4, filtered and concentrated under reduce 
pressure. 
The crude is purified on silica gel, using Ethyl Acetate as elution solvent, yielding 0.29 
g of the desired product (0.57 mmol), as sticky solid. 
 
 
Yield: 40%  
 
 
 
 
1H-NMR (CDCl3): 9.37 (s,1H), 7.76 (d, 1H, J= 1.93 Hz), 7.53 (dd, 1H, J=1.93 Hz, J=8.53 Hz), 
7.46 (s, 1H), 7.43 (m, 1H), 6.65 (d, 1H, J= 3.3 Hz), 6.43 (m, 2H), 6.35 (s, 1H), 5.30 (bs, 2H), 
5.05 (m, 1H), 4.79 (m, 1H), 3.63 (s, 2H), 2.49 (t, 2H, J= 6.65 Hz), 2.17 (m, 1H), 2.09 (s, 3H), 
1.99 (m, 1H), 1.27 (d, 3H, J=6.33 Hz), 1.25 (d, 3H, J=5.75 Hz).  
                                                            
203 TLC conditions: Ethyl Acetate= 100 % 
Rf = 0.30 
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(S)-2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(furan-2-
yl)benzamido)-4-(methylthio)butanoic acid 
 
 
 
0.29 g of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(furan-2-
yl)benzamido)-4-(methylthio)butanoate (0.57 mmol) are dissolved in 5 mL of Methanol; 
0.57 mL of NaOH 1M are dropped and the resulting mixture is stirred at RT for 18 
hours. 
After completion of the reaction, followed by TLC204, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 0.27 g of the final product, as a sticky solid, in 
quantitative yield.  
 
 
Yield: quantitative 
 
 
 
 
1H-NMR (d6DMSO): 12.76 (bs, 1H), 10.28 (s, 1H), 8.65 (d, 1H, J= 7.65 Hz), 8.01 (d, 1H, J= 2.2 
Hz), 7.70 (d, 1H, J=1.61 Hz), 7.55 (dd, 1H, J= 2.2 Hz, J= 8.45 Hz), 7.27 (d, 1H, J= 8.45 Hz), 
6.89 (s, 1H ), 6.74 (d, 1H, J= 3.63 Hz), 6.50 (dd, 1H, J= 1.61 Hz, J= 3.63 Hz), 6.30 (s, 1H), 
4.44 (m, 1H), 3.48 (s, 2H), 2.46 (m, 2H), 2.04 (s, 3H), 1.96 (m, 2H).  
                                                            
204 TLC conditions: Ethyl Acetate= 100% 
Rf = basal 
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(2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(furan-2-yl)benzamido)-4-
(methylthio)butanoate 
 
H2N
O
N
H
O
S
O O
C19H24N2O3S2
M.W.: 376,42
N
H
O
N
H
O
S
O O
O
O
O
C28H30N2O7S
M.W.: 538,61
 
 
A solution of (S)-isopropyl 2-(4-amino-2-(furan-2-yl)benzamido)-4-(methylthio)butanoate 
(0.84 g, 2.22 mmol) and DIPEA (0.58 mL, 3.33 mmol) in 8 mL of dry THF is stirred 
under a nitrogen atmosphere. 
The resulting mixture is cooled to 0°C and then amounted of a solution of 2,3-
dihydrobenzo[b][1,4]dioxine-2-carbonyl chloride (0.66 g, 3.33 mmol) in 2 mL of dry 
THF. The reaction mixture is stirred at RT for 18 hours; after completion, monitored by 
TLC205, the mixture is concentrated. 
The residue is resumed with 20 mL of DCM, washed with brine, dried over Na2SO4, 
filtered and concentrated, obtaining 1.19 g (2.21 mmol) of the desired product, as 
sticky white solid.  
 
Yield: 99.8% 
 
 
1H-NMR (CDCl3): 8.41 (s,1H), 7.85 (s, 1H), 7.60 (dd, 1H, J= 2.2 Hz, J= 8.25 Hz), 7.50 (d, 1H, J= 
8.25 Hz), 7.48 (s, 1H), 7.06 (m, 1H), 6.94 (m, 3H), 6.71 (d, 1H, J= 3.58 Hz), 6.46 (dd, 1H, J= 
1.92 Hz, J= 3.58 Hz), 6.38 (d, 1H, J= 7.98 Hz), 5.05 (m, 1H), 4.81 (m, 1H), 4.63 (dd, 1H, J= 
2.75 Hz, J= 11.55 Hz), 4.26 (dd, 1H, J=7.70 Hz , J=11.55 Hz), 2.49 (t, 1H, J= 6.60 Hz), 2.18 
(m, 1H), 2.09 (s, 3H), 1.96 (m, 1H), 1.28 (d, 3H, J=6.05 Hz), 1.26 (d, 3H, J=6.60 Hz). 
                                                            
205 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.50 
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(2S)-2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(furan-2-yl)benzamido)-4-
(methylthio)butanoic acid 
 
N
H
O
N
H
O
S
O OH
O
O
O
C25H24N2O7S
M.W.: 496,53
N
H
O
N
H
O
S
O O
O
O
O
C28H30N2O7S
M.W.: 538,61
 
 
1.19 g of (2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamido)-2-(furan-
2-yl)benzamido)-4-(methylthio)butanoate (2.21 mmol) are dissolved in 10 mL of 
Methanol; 1.19 mL of NaOH 1M are dropped and the resulting mixture is stirred at RT 
overnight. 
After completion of the reaction, followed by TLC206, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 1.05 g (2.21 mmol) of the final product, as a sticky 
solid, in quantitative yield.  
 
 
Yield: 96% 
 
 
1H-NMR (d6DMSO): 12.72 (bs, 1H), 10.34 (bs,1H), 8.68 (d, 1H, J=7.25 Hz), 8.05 (s, 1H), 7.71 
(s, 1H), 7.61 (d, 1H, J=7.65 Hz), 7.30 (d, 1H, J=8.05 Hz), 7.04 (m, 1H), 6.87 (m, 3H), 6.75 (d, 
1H, J= 2.82 Hz), 6.51 (d, 1H, J= 1.21 Hz), 5.00 (m, 1H), 4.37-4.47 (m, 3H), 2.49 (m, 2H), 2.04 
(s, 3H), 1.97 (m, 2H).  
                                                            
206 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = basal 
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Methyl 4-nitro-2-(furan-3-yl)benzoate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-nitrobenzoate (1.00 g, 3.85 mmol) in 
8 mL of Toluene, under a nitrogen atmosphere, Pd(PPh3)4 (0.44 g, 0.385 mmol) is 
added as solid. 
The solution is stirred for 10 minutes and then amounted of Na2CO3 (1.22 g, 11.55 
mmol) in 2 mL of Water and of a solution of 3-furanylboronic acid (0.56 g, 5.00 mmol) 
in 1 mL of Methanol. 
The reaction mixture is heated at 120°C for 18 hours and monitored by TLC207. 
At completion, the mixture is treated with DCM and NaHCO3, the organic layer is 
washed with brine and dried over Na2SO4, filtered and concentrated under reduced 
pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 80/20, yields 0.76 g (3.08 mmol) of the desired product, as dense yellow oil.  
 
 
Yield: 80% 
 
 
 
 
1H-NMR (CDCl3): 8.26 (d, 1H, J=2.2 Hz), 8.18 (dd, 1H, J=2.2 Hz, J=8.53 Hz), 7.84 (d, 1H, 
J=8.53 Hz), 7.66 (dd, 1H, J=0.82 Hz, J=1.65 Hz), 7.50 (dd, 1H, J=1.38 Hz, J=1.65 Hz), 6.53 
(dd, 1H, J=0.82 Hz, J=1.38 Hz), 3.85 (s, 3H).  
                                                            
207 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.51 
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4-nitro-2-(furan-3-yl)benzoic acid 
 
O2N
COOH
O
O2N
COOCH3
O
C12H9NO5
M.W.: 247,20
C11H7NO5
M.W.: 233,18
 
 
0.76 g of methyl 4-nitro-2-(furan-3-yl)benzoate (3.08 mmol) are dissolved in 10 mL of 
Methanol; 1.5 mL of NaOH 1 M are dropped and the resulting mixture is heated at 
60°C for 2 hour. 
After completion of the reaction, followed by TLC208, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl, and then extracted three times with 10 mL of Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, obtaining a dense yellow oil (0.59 g, 2.52 mmol), corresponding to 
the desired compound.  
 
 
Yield: 82% 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 8.27 (m, 1H), 8.22 (dd, 1H, J= 2.2 Hz, J= 8.52 Hz), 8.03 (d, 1H, J=8.52 Hz), 
7.70 (m, 1H), 7.52 (m, 1H), 6.60 (m, 1H).  
                                                            
208 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.20 
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(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(furan-3-
yl)benzamido)butanoate 
 
 
 
A solution of EDAC (0.58 g, 3.02 mmol) and DIPEA (0.53 mL, 3.02 mmol) in 2 mL of 
DCM is added dropwise to a solution of 4-nitro-2-(furan-3-yl)benzoic acid (0.59 g, 2.52 
mmol), HOBT (0.41 g, 3.02 mmol) in 5 mL of DCM, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.48 g, 2.52 mmol) in 3 mL of DCM is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC209, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 80/20 as elution solvent, to give 0.77 g (1.89 mmol) of 
the desired product, as yellow oil. 
 
 
Yield: 75% 
 
 
 
1H-NMR (CDCl3): 8.27 (d, 1H, J=1.65 Hz), 8.19 (dd, 1H, J=2.2 Hz, J=8.25 Hz), 7.75 (dd, 1H, 
J=1.1 Hz, J=1.65 Hz), 7.71 (dd, 1H, J=2.85 Hz, J=8.25 Hz), 7.52 (dd, 1H, J=2.2 Hz, J=2.85 Hz), 
6.62 (dd, 1H, J=0.83 Hz, J=1.61 Hz), 6.41 (d, 1H, J=7.7 Hz), 5.06 (m, 1H), 4.87 (m, 1H), 2.37 
(t, 2H, J=7.7 Hz), 2.16 (m, 1H), 2.07 (s, 3H), 2.03 (m, 1H), 1.28 (d, 3H, J=6.60 Hz), 1.26 (d, 
3H, J=6.60 Hz).  
                                                            
209 TLC conditions: Cyclohexane/ Ethyl Acetate= 80/20 
Rf = 0.20 
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(S)-isopropyl 2-(4-amino-2-(furan-3-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(furan-3-yl)benzamido)butanoate (0.77 g, 1.89 
mmol) is dissolved in 23 mL of Ethyl Acetate; stannous chloride (1.79 g, 9.45 mmol) is 
added and the mixture is refluxed for 2 hours. 
After completion of the reaction, defined by TLC210, the mixture reaction is firstly 
cooled and poured into 50 mL of iced 5% NaHCO3, then it is filtered over Celite and the 
two layers are separated.  
The organic layer is washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure, giving 0.67 g (1.78 mmol) of yellow oil. 
 
 
Yield: 94% 
 
 
 
 
 
1H-NMR (CDCl3): 7.58 (m, 1H), 7.53 (dd, 1H, J=8.25 Hz), 7.45 (dd, 1H, J=1.38 Hz, 1.65 Hz), 
6.65 (dd, 1H, J= 2.47 Hz, J= 8.25 Hz), 6.61 (d, 1H, J=2.2 Hz), 6.52 (d, 1H, J= 1.65 Hz), 6.25 
(d, 1H, J= 7.70 Hz), 5.01 (m, 1H), 4.68 (m, 1H), 2.35 (m, 2H), 2.08 (m, 1H), 2.06 (s, 3H), 1.92 
(m, 1H), 1.25 (d, 3H, J=6.33 Hz), 1.23 (d, 3H, J=6.05 Hz).  
                                                            
210 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.19 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(furan-3-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
A solution of EDAC (0.41 g, 2.14 mmol) and DIPEA (0.37 mL, 2.14 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of (S)-isopropyl 2-(4-amino-2-(furan-3-
yl)benzamido)-4-(methylthio)butanoate (0.67 g, 1.78 mmol), HOBT (0.29 g, 2.14 
mmol) in 3 mL of dry DMF, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.34 g, 1.78 mmol) in 3 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC211, 
the mixture is concentrated, resumed with Ethyl Acetate, washed firstly with a solution 
of 10% NaHCO3, secondly with HCl 10 % and finally with brine.  
The organic phase is then dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 70/30 as elution solvent, to give 0.62 g (0.82 mmol) of 
the desired product, as colourless oil. 
 
Yield: 46% 
 
1H-NMR (CDCl3): 9.50 (bs,1H), 7.69 (m, 1H), 7.62 (m, 1H), 7.56 (m, 1H), 7.54 (m, 1H), 7.44 
(m, 1H), 7.26-7.31 (m, 16H), 6.55 (s, 1H), 6.27 (m, 2H), 5.03 (m, 1H), 4.71 (m, 1H), 3.68 (s, 
2H), 2.36 (t, 2H, J=6.33 Hz), 2.11 (m, 1H), 2.06 (s, 3H), 1.92 (m, 1H), 1.26 (d, 3H, J=6.05 Hz), 
1.24 (d, 3H, J=6.60 Hz).  
                                                            
211 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.48 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(furan-3-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
0.62 g (0.82 mmol) of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(furan-3-
yl)benzamido)-4-(methylthio)butanoate are dissolved in 6 mL of DCM and then treated 
with 2 mL of Formic acid. 
The reaction is followed by TLC212, at completion the reaction mixture is slowly poured 
in 20 mL of 5% aqueous NaHCO3, the two layers are separated; the organic layer is 
washed with brine, dried over Na2SO4, filtered and concentrated under reduce 
pressure. 
The crude is purified on silica gel, using Ethyl Acetate as elution solvent, yielding 0.31 
g of the desired product (0.61 mmol), as sticky solid. 
 
 
Yield: 74%  
 
 
 
 
1H-NMR (CDCl3): 9.34 (s,1H), 7.62 (s, 1H), 7.57 (dd, 1H, J=1.93 Hz, J=10.18 Hz), 7.49 (dd, 1H, 
J=1.93 Hz, J=8.25 Hz), 7.45 (dd, 1H, J=0.83 Hz, J=1.65 Hz), 7.10 (m, 1H), 6.55 (m, 1H ), 6.35-
6.37 (m, 2H), 5.30 (bs, 2H), 5.02 (m, 1H), 4.70 (m, 1H), 3.63 (s, 2H), 2.36 (t, 2H, J=7.7 Hz), 
2.08 (m, 1H), 2.06 (s, 3H), 1.95 (m, 1H), 1.25 (d, 3H, J=5.23 Hz), 1.23 (d, 3H, J=7.15 Hz). 
                                                            
212 TLC conditions: Ethyl Acetate= 100 % 
Rf = 0.24 
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(S)-2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(furan-2-
yl)benzamido)-4-(methylthio)butanoic acid 
 
 
 
0.31 g of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(furan-3-
yl)benzamido)-4-(methylthio)butanoate (0.61 mmol) are dissolved in 5 mL of Methanol; 
0.61 mL of NaOH 1M are dropped and the resulting mixture is stirred at RT for 18 
hours. 
After completion of the reaction, followed by TLC213, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 0.23 g (0.48 mmol) of the final product, as a sticky 
solid. 
 
 
Yield: 78% 
 
 
 
 
1H-NMR (d6DMSO): 12.83 (bs, 1H), 10.24 (s, 1H), 8.58 (d,1H, J=7.65 Hz), 7.83 (dd, 3H, 
J=0.80 Hz, J=1.61 Hz), 7.71 (d, 1H, J=2.01 Hz), 7.65 (dd, 1H, J=1.61 Hz, J=3.63 Hz), 7.56 (dd, 
1H, J=2.02 Hz, J=8.06 Hz), 7.30 (d, 1H, J=8.45 Hz), 7.05 (bs, 1H ), 6.89 (bs, 1H), 6.64 (s, 2H), 
6.30 (s, 1H), 4.40 (m, 1H), 3.48 (s, 2H), 2.49 (m, 2H), 2.03 (s, 3H), 1.90 (m, 2H).  
                                                            
213 TLC conditions: Ethyl Acetate= 100% 
Rf = basal 
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(2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(furan-3-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
A solution of (S)-isopropyl 2-(4-amino-2-(furan-3-yl)benzamido)-4-(methylthio)butanoate 
(0.67 g, 1.78 mmol) and DIPEA (0.40 mL, 2.31 mmol) in 8 mL of DCM is stirred under 
a nitrogen atmosphere. 
The resulting mixture is cooled to 0°C and then amounted of a solution of 2,3-
dihydrobenzo[b][1,4]dioxine-2-carbonyl chloride (0.46 g, 2.31 mmol) in 2 mL of DCM. 
The reaction mixture is stirred at RT for 2 hours; after completion, monitored by TLC214, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated. 
The crude is purified on silica gel, using Cyclohexane/ Ethyl Acetate= 70/30 as elution 
solvent, obtaining 0.42 g (0.78 mmol) of the desired product, as sticky white solid.  
 
 
Yield: 44% 
 
1H-NMR (CDCl3): 8.37 (s,1H), 7.55-7.66 (m, 4H), 7.46 (dd, 1H, J=1.65 Hz, J=1.95 Hz), 7.05 (m, 
1H), 6.92-6.96 (m, 3H), 6.57 (dd, 3H, J=0.55 Hz, J=1.65 Hz), 6.31 (d, 1H, J=7.7 Hz), 5.03 (m, 
1H), 4.82 (dd, 1H, J=2.75 Hz, J=7.43 Hz), 4.72 (dd, 1H, J=1.93 Hz, J=7.43 Hz), 4.63 (dd, 1H, 
J=2.75 Hz, J=9.55 Hz), 4.27 (dd, 1H, J=7.42 Hz, J=11.28 Hz), 2.37 (t, 2H, J=7.7 Hz), 2.12 (m, 
1H), 2.06 (s, 3H), 1.95 (m, 1H), 1.26 (d, 3H, J=6.33 Hz), 1.24 (d, 3H, J=6.33 Hz). 
                                                            
214 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.51 
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(2S)-2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(furan-3-yl)benzamido)-4-
(methylthio)butanoic acid 
 
 
 
0.42 g of (2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamido)-2-(furan-
3-yl)benzamido)-4-(methylthio)butanoate (0.78 mmol) are dissolved in 5 mL of 
Methanol; 0.78 mL of NaOH 1M are dropped and the resulting mixture is stirred at RT 
overnight. 
After completion of the reaction, followed by TLC215, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 0.39 g of the final product, as a sticky solid, in 
quantitative yield.  
 
 
Yield: quantitative 
 
 
1H-NMR (d6DMSO): 12.73 (bs, 1H), 10.27 (s,1H), 8.63 (d, 1H, J=6.65 Hz,), 7.84 (s, 1H), 7.76 
(d, 1H, J=1.61 Hz), 7.60-7.66 (m, 2H), 7.34 (dd, 1H, J=4.83 Hz, J=8.06 Hz), 6.84-7.04 (m, 4H), 
6.66 (d, 1H, J= 0.81 Hz), 4.99 (m, 1H), 4.42-4.48 (m, 3H), 2.46 (m, 2H), 2.03 (s, 3H), 1.97 (m, 
2H).  
                                                            
215 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = basal 
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Methyl 2-(naphthalen-1-yl)-4-nitrobenzoate 
 
Br
O2N
COOCH3
C8H6BrNO4
M.W.: 260,04
O2N
COOCH3
C18H13NO4
M.W.: 307,30
 
 
To a sonicated solution of the methyl 2-bromo-4-nitrobenzoate (1.00 g, 3.85 mmol) in 
8 mL of dry DMF, under a nitrogen atmosphere, Pd(PPh3)4 (0.44 g, 0.385 mmol) is 
added as solid. 
The solution is stirred for 10 minutes and then amounted of Na2CO3 (1.60 g, 11.55 
mmol) and of a solution of 1-naphtylboronic acid (0.79 g, 4.62 mmol) in 1 mL of dry 
DMF. 
The reaction mixture is heated at 110°C for 18 hours and monitored by TLC216. 
At completion, the solvent is removed and the residue resumed with Ethyl Acetate, 
washed with brine and dried over Na2SO4, filtered and concentrated under reduced 
pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 85/15, yields 1.15 g (3.73 mmol) of the desired product, as dense yellow oil.  
 
 
Yield: 97% 
 
 
 
1H-NMR (CDCl3): 8.36 (dd, 1H, J=1.1 Hz, J=8.53 Hz), 8.31 (dd, 1H, J=0.53 Hz,  J=1.1 Hz), 8.15 
(dd, 1H, J=0.53 Hz, J=8.53 Hz), 7.93 (dd, 2H, J=0.82 Hz, J=7.43 Hz), 7.33-7.57 (m, 5H), 3.41 
(s, 3H).  
                                                            
216 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.30 
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4-nitro-2-(naphtalen-3-yl)benzoic acid 
 
 
 
1.15 g of methyl 4-nitro-2-(naphtalen-1-yl)benzoate (3.73 mmol) are dissolved in 15 
mL of Methanol; 3 mL of NaOH 2.5 M are dropped and the resulting mixture is heated 
at 60°C for 3 hour. 
After completion of the reaction, followed by TLC217, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl, and then extracted three times with 15 mL of DCM. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, obtaining a dense yellow oil (0.96 g, 3.28 mmol), corresponding to 
the desired compound.  
 
 
Yield: 88% 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 8.33 (dd, 1H, J=2.2 Hz, J=8.53 Hz), 8.25 (d, 1H, J= 1.93 Hz), 8.17 (d, 1H, 
J=8.53 Hz), 7.91 (d, 2H, J=8.25 Hz), 7.50 (m, 2H), 7.29-7.42 (m, 3H).  
                                                            
217 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.30 
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(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(naphtalen-3-
yl)benzamido)butanoate 
 
 
 
A solution of EDAC (0.75 g, 3.94 mmol) and DIPEA (0.67 mL, 3.94 mmol) in 2 mL of 
DCM is added dropwise to a solution of 4-nitro-2-(naphtalen-1-yl)benzoic acid (0.96 g, 
3.28 mmol), HOBT (0.53 g, 3.94 mmol) in 5 mL of DCM, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.48 g, 2.52 mmol) in 2 mL of DCM is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC218, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 75/25 as elution solvent, to give 1.36 g (2.92 mmol) of 
the desired product, as yellow oil. 
 
 
Yield: 89% 
 
 
 
 
1H-NMR (CDCl3): 8.37 (dd, 1H, J=2.47 Hz, J=8.53 Hz), 8.30 (d, 1H, J=1.65 Hz), 8.15 (d, 1H, 
J=8.53 Hz), 7.93-8.00 (m, 2H), 7.42-7.66 (m, 5H), 5.98 (d, 1H, J=7.7 Hz), 4.86 (m, 1H), 4.36 
(m, 1H), 1.82 (s, 3H), 1.62 (m, 2H), 1.54 (m, 2H), 1.14 (m, 6H).  
                                                            
218 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf = 0.27 
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(S)-isopropyl 2-(4-amino-2-(naphtalen-3-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(naphtalen-1-yl)benzamido)butanoate (1.36 g, 
2.92 mmol) is dissolved in 40 mL of Ethyl Acetate; stannous chloride (2.77 g, 14.6 
mmol) is added and the mixture is refluxed for 5 hours. 
After completion of the reaction, defined by TLC219, the mixture reaction is firstly 
cooled and poured into 100 mL of iced 5% NaHCO3, then it is filtered over Celite and 
the two layers are separated.  
The organic layer is washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure, giving 1.21 g (2.77 mmol) of yellow oil. 
 
 
Yield: 95% 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.90 (m, 2H), 7.74 (dd, 1H, J=0.83 Hz, J=8.52 Hz), 7.36-7.60 (m, 5H), 6.76 
(m, 1H), 6.56 (dd, 1H, J= 0.55 Hz, J=2.2 Hz), 5.72 (d, 1H, J= 7.7 Hz), 4.89 (m, 1H), 4.34 (m, 
1H), 1.79 (s, 3H), 1.70 (m, 2H), 1.55 (m, 2H), 1.12 (m, 6H).  
                                                            
219 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.32 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(naphtalen-3-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
A solution of EDAC (0.64 g, 3.32 mmol) and DIPEA (0.43 mL, 3.32 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of (S)-isopropyl 2-(4-amino-2-(naphtalen-1-
yl)benzamido)-4-(methylthio)butanoate (1.21 g, 2.77 mmol), HOBT (0.45 g, 3.32 
mmol) in 3 mL of dry DMF, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.53 g, 2.77 mmol) in 3 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC220, 
the mixture is concentrated, resumed with Ethyl Acetate and washed with brine.  
The organic phase is then dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 63/37 as elution solvent, to give 1.64 g (2.00 mmol) of 
the desired product, as a dense yellow oil. 
 
Yield: 72% 
 
 
 
1H-NMR (CDCl3): 9.20 (s,1H), 7.94 (m, 3H), 7.16-7.62 (m, 20H), 6.81 (m, 1H), 6.58 (m, 1H), 
6.17 (s, 1H), 5.78 (d, 1H, J=7.70 Hz), 4.82 (m, 1H), 4.17 (m, 1H), 3.48 (s, 2H), 1.92 (s, 3H), 
1.65 (m, 2H), 1.41 (m, 2H), 1.12 (m, 6H).  
                                                            
220 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.36 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(naphtalen-3-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
1.64 g (2.00 mmol) of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(naphtalen-1-yl)benzamido)-4-(methylthio)butanoate are dissolved in 12 mL of DCM 
and then treated with 4 mL of Formic acid. 
The reaction is followed by TLC221, at completion the reaction mixture is slowly poured 
in 30 mL of 5% aqueous NaHCO3, the two layers are separated; the organic layer is 
washed with brine, dried over Na2SO4, filtered and concentrated under reduce 
pressure. 
The crude is purified on silica gel, using Ethyl Acetate as elution solvent, yielding 0.69 
g of the desired product (1.20 mmol), as sticky solid. 
 
 
Yield: 60%  
 
 
 
 
 
1H-NMR (CDCl3): 9.42 (d,1H, J=10.73 Hz), 8.02 (d, 3H, J=8.53 Hz), 7.89 (m, 2H), 7.77 (m, 1H), 
7.36-7.65 (m, 6H), 6.32 (s, 1H ), 5.84 (d, 1H, J= 7.7 Hz), 4.88 (m, 1H), 4.33 (m, 1H), 3.62 (s, 
2H), 1.88 (s, 3H), 1.72 (m, 2H), 1.34 (m, 2H), 1.14 (m, 6H).  
                                                            
221 TLC conditions: Ethyl Acetate= 100 % 
Rf = 0.42 
FTase Inhibitors-Amidic series                                                           Experimental section 
285 
 
(S)-2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(naphtalen-
2-yl)benzamido)-4-(methylthio)butanoic acid 
 
 
 
0.69 g of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(naphtalen-1-
yl)benzamido)-4-(methylthio)butanoate (1.20 mmol) are dissolved in 10 mL of 
Methanol; 1.20 mL of NaOH 1M are dropped and the resulting mixture is stirred at RT 
for 18 hours. 
After completion of the reaction, followed by TLC222, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 0.64 g (1.20 mmol) of the final product. 
 
 
Yield: Quantitative 
 
 
 
 
 
 
1H-NMR (d6DMSO): 12.66 (bs, 1H), 10.31 (bs,1H), 8.22 (d, 1H, J=8.45 Hz), 7.90 (m, 2H), 7.74 
(d, 1H, J=8.52 Hz), 7.30-7.60 (m, 7H), 6.88 (bs, 1H), 6.29 (s, 1H), 4.02 (m, 2H), 3.47 (s, 2H), 
2.04 (m, 1H), 1.82 (s, 3H), 1.76 (m, 1H), 1.64 (m, 1H), 1.51 (m, 1H.  
                                                            
222 TLC conditions: Ethyl Acetate= 100% 
Rf = basal 
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(2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(naphtalen-3-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
A solution of (S)-isopropyl 2-(4-amino-2-(naphtalen-1-yl)benzamido)-4-
(methylthio)butanoate (1.21 g, 2.77 mmol) and DIPEA (0.63 mL, 3.60 mmol) in 8 mL 
of DCM is stirred under a nitrogen atmosphere. 
The resulting mixture is cooled to 0°C and then amounted of a solution of 2,3-
dihydrobenzo[b][1,4]dioxine-2-carbonyl chloride (0.71 g, 3.60 mmol) in 2 mL of DCM. 
The reaction mixture is stirred at RT for 18 hours; after completion, monitored by 
TLC223, the mixture is washed with brine, dried over Na2SO4, filtered and concentrated. 
The crude is purified on silica gel, using Cyclohexane/ Ethyl Acetate= 70/30 as elution 
solvent, obtaining 1.16 g (1.94 mmol) of the desired product, as sticky white solid.  
 
 
Yield: 70% 
 
 
1H-NMR (CDCl3): 8.42 (m,2H), 8.08 (dd, 1H, J=2.65 Hz, J=8.53 Hz), 7.93 (m, 1H), 7.80 (m, 
1H), 7.48-7.64 (m, 4H), 7.42 (m, 1H), 6.89-7.03 (m, 4H), 5.84 (d, 1H, J=7.98 Hz), 4.79-4.89 
(m, 2H), 4.61 (m, 1H), 4.22-4.38 (m, 2H), 1.87 (s, 3H), 1.60 (m, 2H), 1.37 (m, 2H), 1.13 (m, 
6H).  
                                                            
223 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.55 
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(2S)-2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(napthalen-3-yl)benzamido)-4-
(methylthio)butanoic acid 
 
 
 
1.16 g of (2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamido)-2-
(naphtalen-1-yl)benzamido)-4-(methylthio)butanoate (1.94 mmol) are dissolved in 15 
mL of Methanol; 1.94 mL of NaOH 1M are dropped and the resulting mixture is stirred 
at RT overnight. 
After completion of the reaction, followed by TLC224, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid and extracted three times with Ethyl Acetate.  
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduce pressure, obtaining 0.93 g (1.67 mmol) of the final product, as a sticky solid.  
 
 
Yield: 86% 
 
 
 
1H-NMR (d6DMSO): 12.58 (bs, 1H), 10.35 (s,1H), 8.29 (d, 1H, J=7.76 Hz,), 7.79-7.86 (m, 3H), 
7.57-7.64 (m, 2H), 7.31-7.50 (m, 5H), 4.98 (m, 1H), 4.35-4.46 (m, 2H), 4.03 (m, 1H), 2.16 (m, 
2H), 2.05 (s, 3H), 1.85 (m, 2H).  
                                                            
224 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = basal 
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Methyl 2-(isoquinolin-4-yl)-4-nitrobenzoate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-nitrobenzoate (1.00 g, 3.85 mmol) in 
10 mL of Toluene, under a nitrogen atmosphere, Pd(PPh3)4 (0.44 g, 0.385 mmol) is 
added as solid. 
The solution is stirred for 10 minutes and then amounted of Na2CO3 (1.02 g, 9.63 
mmol) in 2.5 mL of Water and of a solution of 4-isoquinolynboronic acid (0.73 g, 4.24 
mmol) in 2.5 mL of Methanol. 
The reaction mixture is heated at 80°C for 18 hours and monitored by TLC225. 
At completion, the mixture is treated with Ethyl Acetate and NaCl 10%, the organic 
layer is washed with brine and dried over Na2SO4, filtered and concentrated under 
reduced pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 60/40, yields 0.66 g (2.16 mmol) of the desired product, as dense red oil.  
 
 
Yield: 56% 
 
 
 
1H-NMR (CDCl3): 9.32 (s, 1H), 8.40 (dd, 1H, J=3.58 Hz, J=8.53 Hz), 8.38 (s, 1H), 8.29 (dd, 1H, 
J=1.38 Hz, J=3.58 Hz), 8.23 (dd, 1H, J=1.38 Hz, J=8.53 Hz), 8.07 (m, 1H), 7.64-7.67 (m, 2H), 
7.42 (m, 1H).  
                                                            
225 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.25 
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4-nitro-2-(isoquinolin-4-yl)benzoic acid 
 
 
 
0.66 g of methyl 4-nitro-2-(isoquinolin-4-yl)benzoate (2.16 mmol) are dissolved in 10 
mL of Methanol; 1.3 mL of NaOH 1 M are dropped and the resulting mixture is stirred 
at RT for 18 hours. 
After completion of the reaction, followed by TLC226, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl, and then extracted three times with 10 mL of Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, obtaining a dense yellow oil (0.49 g, 1.68 mmol), corresponding to 
the desired compound.  
 
 
Yield: 78% 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 9.37 (s, 1H), 8.43 (dd, 1H, J= 2.48 Hz, J= 8.53 Hz), 8.38 (s, 1H), 8.18-8.23 
(m, 3H), 7.70-7.75 (m, 2H), 7.45 (m, 1H).  
                                                            
226 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.20 
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(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(isoquinolin-4-
yl)benzamido)butanoate 
 
 
 
A solution of EDAC (0.39 g, 2.02 mmol) and DIPEA (0.35 mL, 2.02 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of 4-nitro-2-(isoquinolin-4-yl) benzoic acid 
(0.49 g, 1.68 mmol), HOBT (0.27 g, 2.02 mmol) in 5 mL of dry DMF, under a nitrogen 
atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.32 g, 1.68 mmol) in 3 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC227, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 60/40 as elution solvent, to give 0.65 g (1.39 mmol) of 
the desired product, as yellow oil. 
 
Yield: 83% 
 
 
 
1H-NMR (CDCl3): 9.36 (d, 1H, J=2.48 Hz), 8.52 (d, 1H, J=15.4 Hz), 8.41 (m, 1H), 8.30 (d, 1H, 
J= 2.2 Hz), 7.99-8.12 (m, 2H), 7.68-7.74 (m, 2H), 7.50-7.57 (m, 2H), 6.17 (d, 1H, J=8.25 Hz), 
4.89 (m, 1H), 4.38 (m, 1H), 1.92 (s, 3H), 1.76 (m, 2H), 1.63 (m, 1H), 1.54 (m. 1H), 1.14 
(m,6H).  
                                                            
227 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.25 
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(S)-isopropyl 2-(4-amino-2-(isoquinolin-4-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
(S)-isopropyl 4-(methylthio)-2-(4-nitro-2-(isoquinolin-4-yl)benzamido)butanoate (0.65 g, 
1.39 mmol) is dissolved in 20 mL of Ethyl Acetate; stannous chloride (1.79 g, 9.45 
mmol) is added and the mixture is refluxed for 1 1/2 hours. 
After completion of the reaction, defined by TLC228, the mixture reaction is firstly 
cooled and poured into 50 mL of iced 5% NaHCO3, then it is filtered over Celite and the 
two layers are separated.  
The organic layer is washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure, giving 0.55 g (1.27 mmol) of dense white oil. 
 
 
Yield: 91% 
 
 
 
 
 
1H-NMR (CDCl3): 9.28 (d, 1H, J=6.33 Hz), 8.50 (s, 1H), 8.03 (m, 1H), 7.83 (d, 1H, J=8.53 Hz), 
7.62-7.74 (m, 3H), 6.80 (m, 1H), 6.59 (dd, 1H, J=1.1 Hz, J=2.2 Hz), 5.80 (d, 1H, J=7.7 Hz), 
4.86 (m, 1H), 4.34 (m, 1H), 4.10 (bs, 2H), 1.94 (s, 3H), 1.77 (m, 2H), 1.56 (m, 1H), 1.44 (m, 
1H), 1.14 (m, 6H).  
                                                            
228 TLC conditions: Ethyl Acetate= 100 % 
Rf= 0.30 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(isoquinolin-4-yl) benzamido)-4-(methylthio)butanoate 
 
 
 
A solution of EDAC (0.29 g, 1.52 mmol) and DIPEA (0.26 mL, 1.52 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of (S)-isopropyl 2-(4-amino-2-(isoquinolin-4-
yl)benzamido)-4-(methylthio)butanoate (0.55 g, 1.27 mmol), HOBT (0.21 g, 1.52 
mmol) in 2 mL of dry DMF, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.24 g, 1.27 mmol) in 2 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC229, 
the mixture is concentrated, resumed with Ethyl Acetate, washed firstly with a solution 
of 10% NaHCO3, secondly with HCl 10 % and finally with brine.  
The organic phase is then dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using Ethyl 
Acetate= 100% as elution solvent, to give 0.96 g (1.17 mmol) of the desired product, 
as sticky orange oil. 
 
Yield: 92% 
 
1H-NMR (CDCl3): 9.20 (m, 2H), 8.50 (s, 1H), 8.07 (m, 1H), 7.81 (d, 1H, J=8.25 Hz), 7.63 (m, 
2H), 7.45 (m, 2H), 7.18-7.38 (m, 15H), 6.54 (bs, 1H), 6.19 (s, 1H), 5.90 (d, 1H, J=7.43 Hz), 
4.82 (m, 1H), 4.35 (m, 1H), 3.54 (s, 2H), 1.84 (s, 3H), 1.78 (m, 2H), 1.56 (m, 2H), 1.12 (m, 
6H).  
                                                            
229 TLC conditions: Ethyl Acetate= 100% 
Rf = 0.50 
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(S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(isoquinolin-4-yl)benzamido)-4-(methylthio)butanoate 
 
 
 
0.96 g (1.12 mmol) of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-
(naphtalen-1-yl)benzamido)-4-(methylthio)butanoate are dissolved in 9 mL of DCM and 
then treated with 3 mL of Formic acid. 
The reaction is followed by TLC230, at completion the reaction mixture is slowly poured 
in 20 mL of 5% aqueous NaHCO3, the two layers are separated; the organic layer is 
washed with brine, dried over Na2SO4, filtered and concentrated under reduce 
pressure. 
The crude is purified on silica gel, using Ethyl Acetate as elution solvent, yielding 0.65 
g of the desired product (1.12 mmol), as sticky solid. 
 
 
Yield: Quantitative 
 
 
 
 
1H-NMR (CDCl3): 9.52 (d, 1H, J=4.13 Hz), 9.28 (d, 1H, J=6.05 Hz), 8.53 (s, 1H), 8.03 (m, 1H), 
7.91 (d, 1H, J=8.53 Hz), 7.81 (m, 1H), 7.51-7.67(m, 4H), 6.33 (s, 1H), 6.06 (d, 1H, J=7.43 Hz), 
5.21 (bs, 2H), 4.85 (m, 1H), 4.34 (m, 2H), 3.63 (s, 2H), 1.96 (m, 1H), 1.93 (s, 3H), 1.84 (m, 
1H), 1.52 (m, 2H), 1.14 (m, 6H).  
                                                            
230 TLC conditions: Ethyl Acetate/ Methanol= 80/ 25 
Rf = 0.55 
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(S)-2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(isoquinolin-
4-yl)benzamido)-4-(methylthio)butanoic acid 
 
 
 
0.65 g of (S)-isopropyl 2-(4-(2-(2-aminothiazol-4-yl)acetamido)-2-(isoquinolin-4-
yl)benzamido)-4-(methylthio)butanoate (1.12 mmol) are dissolved in 6 mL of Methanol; 
2.24 mL of NaOH 1M are dropped and the resulting mixture is stirred at RT for 18 
hours. 
After completion of the reaction, followed by TLC231, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid and extracted three times with Ethyl Acetate. 
The organic phases are collected, dried over Na2SO4, filtered and concentrated, 
yielding 0.53 g (1.00 mmol) of the final product, as a sticky solid. 
 
 
Yield: 89% 
 
 
 
 
1H-NMR (d6DMSO): 12.61 (bs, 1H), 10.43 (bs,1H), 9.27 (d, 1H, J=6.59 Hz), 8.26-8.39 (m, 4H), 
7.57-7.78 (m, 4H), 7.48 (m, 1H), 6.88 (bs, 2H), 6.30 (s, 1H), 3.84 (m, 1H), 3.48 (s, 2H), 1.90 
(m, 1H), 1.83 (s, 3H), 1.67 (m, 1H), 1.55 (m, 1H), 1.51 (m, 1H). 
  
                                                            
231 TLC conditions: Ethyl Acetate= 100% 
Rf = basal 
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(2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(isoquinolin-4-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
A solution of (S)-isopropyl 2-(4-amino-2-(isoquinolin-4-yl)benzamido)-4-
(methylthio)butanoate (0.55 g, 1.27 mmol) and DIPEA (0.33 mL, 1.91 mmol) in 7 mL 
of dry DMF is stirred under a nitrogen atmosphere. 
The resulting mixture is cooled to 0°C and then amounted of a solution of 2,3-
dihydrobenzo[b][1,4]dioxine-2-carbonyl chloride (0.38 g, 1.91 mmol) in 3 mL of dry 
DMF. 
The reaction mixture is stirred at RT for 2 hours; after completion, monitored by TLC232, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated. 
The crude is purified on silica gel, using a gradient of Cyclohexane/ Ethyl Acetate, from 
30% to 100% of Ethyl Acetate, as elution solvent, obtaining 0.67 g (1.12 mmol) of the 
desired product, as sticky white solid.  
 
Yield: 88% 
 
 
1H-NMR (CDCl3): 9.30 (d,1H, J=4.68 Hz), 8.50 (m, 2H), 7.91-8.05 (m, 2H), 7.85 (m, 1H), 7.58-
7.67 (m, 3H), 6.90-7.01 (m, 4H), 6.05 (d, 1H, J=7.7 Hz), 4.80-4.90 (m, 2H), 4.60 (d, 1H, 
J=11.56 Hz), 4.08-4.31 (m, 2H), 1.92 (s, 3H), 1.84 (m, 2H), 1.56 (m, 2H), 1.12 (m, 6H). 
                                                            
232 TLC conditions: Cyclohexane/ Ethyl Acetate= 30/70 
Rf = 0.21 
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(2S)-2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-
carboxamido)-2-(isoquinolin-4-yl)benzamido)-4-
(methylthio)butanoic acid 
 
 
 
0.67 g of (2S)-isopropyl 2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamido)-2-
(isoquinolin-4-yl)benzamido)-4-(methylthio)butanoate (1.12 mmol) are dissolved in 5 
mL of Methanol; 1.12 mL of NaOH 1M are dropped and the resulting mixture is stirred 
at RT overnight. 
After completion of the reaction, followed by TLC233, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 0.62 g of the final product, as a sticky white solid, in 
quantitative yield.  
 
 
Yield: quantitative 
 
 
1H-NMR (d6DMSO): 12.62 (bs, 1H), 10.41 (bs,1H), 9.27 (d, 1H, J=4.03 Hz,), 8.13-8.36 (m, 3H), 
7.86 (dd, 1H, J=1.82 Hz, J=8.06 Hz), 7.50-7.68 (m, 5H), 6.82-7.02 (m, 4H), 5.00 (d, 1H, 
J=2.56 Hz, J=5.5 Hz), 4.32-4.46 (m, 2H), 4.04 (m, 1H), 2.08 (m, 2H), 1.88 (s, 3H), 1.74 (m, 
2H). 
                                                            
233 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = basal 
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Methyl 4-amino-2-bromobenzoate 
 
 
 
Methyl 2-bromo-4-nitrobenzoate (10.00 g, 38.46 mmol) is dissolved in 300 mL of Ethyl 
Acetate and 1 mL of Water. Stannous chloride (36.46 g, 192.3 mmol)is added and the 
mixture is refluxed for 2 hours. 
After completion of the reaction, defined by TLC234, the mixture reaction is firstly 
cooled and poured into 600 mL of iced 5% NaHCO3, then it is filtered over Celite and 
the two layers are separated.  
The organic layer is washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure, giving 7.96 g of methyl 4-amino-2-bromobenzoate, as a white 
solid. 
 
 
Yield: 90% 
 
Melting Point: 81-83°C 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.76 (dd, 1H, J=0.83 Hz, J=8.53 Hz), 6.92 (d, 1H, J=0.83 Hz, J=2.48 Hz), 
6.56 (dd, 1H, J=2.48 Hz, J=8.53 Hz), 4.05 (bs, 2H), 3.86 (s, 3H). 
  
                                                            
234 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.45 
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Methyl 2-bromo-4-hydroxybenzoate 
 
 
 
Methyl 4-amino-2-bromobenzoate (1.00 g, 4.35 mmol) is suspended in 15 ml of H2SO4 
20% and then cooled to -15°C.  
To this mixture an iced solution of NaNO2 (0.33g, 4.79 mmol) in 1 mL of Water is 
slowly dropped; the reaction is maintained at -15°C for 30 minutes, then warmed to 
RT and kept at that temperature for 1 hour. 
The yellow solution is lastly heated at 60°C for 18 hours; the reaction is monitored by 
TLC235; when accomplished, it is cooled and extracted three times with 10 mL of Ethyl 
Acetate; the organic layers are collected, washed with brine, dried over Na2SO4, filtered 
and concentrated under reduced pressure. 
The crude is eventually purified by chromatography on silica gel; elution with 
Cyclohexane/ Ethyl Acetate= 65/35 yields 0.93 g (4.04 mmol) of the desired product, 
as yellow solid.  
 
 
Yield: 94% 
 
Melting Point: 152-155°C 
 
 
 
1H-NMR (CDCl3): 7.82 (d, 1H, J=8.53 Hz), 7.22 (dd, 1H, J=0.83 Hz, J=2.48 Hz), 6.82 (dd, 1H, 
J=2.48 Hz, J=8.53 Hz), 6.13 (bs, 1H), 3.90 (s, 3H).  
                                                            
235 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.54  
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Methyl 2-bromo-4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)benzoate 
 
 
 
To a suspension of K2CO3 (0.60 g, 4.33 mmol) in 2 mL of DMF, under a nitrogen 
atmosphere, is dropped a solution of methyl 2-bromo-4-hydroxybenzoate (1.00 g, 4.33 
mmol) in 5 mL of DMF.  
The reaction mixture is maintained at RT for 30 minutes and then the 2-
mesyloxymethylbenzodioxane (1.06 g, 4.33 mmol), dissolved  in 3 mL of DMF, is 
added in.   
The reaction, monitored by TLC236, is warmed at 60°C for 18 hours. 
After cooling, the mixture is concentrated and the residue resumed with Ethyl Acetate; 
the organic layer is washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure. 
The crude is purified by chromatography on silica gel; elution with Cyclohexane/ Ethyl 
Acetate= 80/20 yields 1.25 g (3.29 mmol) of the desired product, as yellow oil.  
 
 
Yield: 76% 
 
 
 
 
1H-NMR (CDCl3): 7.86 (d, 1H, J=8.8 Hz), 7.23 (dd, 1H, J=0.55 Hz, J=2.75 Hz), 6.85-6.93 (m, 
5H), 4.56 (m, 1H), 4.38 (dd, 1H, J=2.48 Hz, J=11.56 Hz), 4.16-4.30 (m, 3H), 3.90 (s, 3H). 
                                                            
236 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf= 0.44 
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Methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(thiophen-2-yl)benzoate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)benzoate (1.00 g, 2.64 mmol) in 5 mL of dry DMF, under a nitrogen 
atmosphere, Pd(PPh3)4 (0.31 g, 0.264 mmol) is added as solid. 
The solution is stirred for 10 minutes and then amounted of Na3PO4*12H2O (3.01 g , 
7.92 mmol) and of a solution of 2-thienylboronic acid (0.41 g, 3.17 mmol) in 5 mL of 
dry DMF. 
The reaction mixture is heated at 100°C for 18 hours, monitored by TLC237 and then 
concentrated.  
The crude is resumed with Ethyl Acetate, washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 80/20, yields 0.81 g (2.11 mmol) of the desired product, as yellow oil.  
 
Yield: 80% 
 
 
1H-NMR (CDCl3): 7.80 (d, 1H, J=8.8 Hz), 7.35 (dd, 1H, J=1.1 Hz, J=4.96 Hz), 7.00-7.06 (m, 
3H),6.85-6.96 (m, 5H), 4.58 (m, 1H), 4.39 (dd, 1H, J=2.47 Hz, J=11.55 Hz), 4.19-4.33 (m, 
3H), 3.71 (s, 3H).  
                                                            
237 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf= 0.45 
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4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-
(thiophen-2-yl)benzoic acid 
 
 
 
0.81 g of methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-(thiophen-2-
yl)benzoate (2.11 mmol) is dissolved in 10 mL of Methanol; 3.17 mL of NaOH 1M are 
dropped and the resulting mixture is heated at 60°C for 18 hours. 
After completion of the reaction, followed by TLC238, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether and 
then acidified with 10% HCl, till a sticky solid precipitate. 
The filtration yields 0.73 g (1.96 mmol) of the desired compound.  
 
 
Yield: 93% 
 
 
 
 
 
 
 
1H-NMR (CDCl3): 7.95 (d, 1H, J=8.53 Hz), 7.35 (dd, 1H, J=1.65 Hz, J=4.67 Hz), 6.85-7.26 (m, 
8H), 4.58 (m, 1H), 4.39 (dd, 1H, J=2.48 Hz, J=11.55 Hz), 4.20-4.34 (m, 3H).  
                                                            
238 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.40 
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(2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(thiophen-2-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
A solution of EDAC (0.45 g, 2.35 mmol) and DIPEA (0.41 mL, 2.35 mmol) in 2 mL of 
DCM is added dropwise to a solution of 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(thiophen-2-yl)benzoic acid (0.73 g, 1.96 mmol), HOBT (0.31 g, 2.35 
mmol) in 3 mL of DCM, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.37 g, 1.96 mmol) in 3 mL of DCM is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC239, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 70/30 as elution solvent, to give 0.88 g (1.63 mmol) of 
the desired product. 
 
Yield: 83% 
 
1H-NMR (CDCl3): 7.65 (dd, 1H, J=0.83 Hz, J=8.8 Hz), 7.37 (dd, 1H, J=1.1 Hz, J=5.22 Hz), 7.15 
(dd, 1H, J=1.1 Hz, J=3.58 Hz), 7.08 (dd, 1H, J=3.58 Hz, J=5.22 Hz), 6.84-6.98 (m, 6H), 6.15 
(d, 1H, J=7.7 Hz), 5.00 (m, 1H), 4.66 (m, 1H), 4.57 (m, 1H), 4.20-4.42 (m, 3H), 2.23 (t, 2H, 
J=7.7 Hz), 2.04 (s, 3H), 2.00-2.07 (m, 1H), 1.84 (m, 1H), 1.24 (d, 3H, J=6.6 Hz), 1.22 (d, 3H,. 
J=6.32 Hz).  
                                                            
239 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.54 
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(2S)-2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(thiophen-2-yl)benzamido)-4-(methylthio)butanoic acid 
 
 
 
0.88 g of (2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-
(thiophen-2-yl)benzamido)-4-(methylthio)butanoate (1.63 mmol) are dissolved in 10 
mL of Methanol; 1.63 mL of NaOH 1M are dropped and the resulting mixture is stirred 
RT for 18 hours 
After completion of the reaction, followed by TLC240, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl and then extracted three times with 10 mL of Ethyl Acetate. 
The filtration yields 0.81 g of the final product, as a sticky solid, in quantitative yield.  
 
Yield: quantitative 
 
 
 
 
 
1H-NMR (d6DMSO): 12.60 (bs, 1H), 8.54 (d, 1H, J=7.7 Hz), 7.54 (dd, 1H, J=1.1 Hz, J=5.14 
Hz),7.33 (d, 1H, J=9.16 Hz), 7.25 (dd, 1H, J=1.11 Hz, J=3.3 Hz), 7.03 (m, 3H), 6.81-6.92 (m, 
4H), 4.58 (m, 1H), 4.3-4.46 (m, 4H), 4.15 (m, 1H), 2.32-2.40 (m, 2H), 2.00 (s, 3H), 1.86-2.02 
(m, 2H).  
                                                            
240 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = basal 
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Methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(thiophen-3-yl)benzoate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)benzoate (1.00 g, 2.64 mmol) in 5 mL of dry DMF, under a nitrogen 
atmosphere, Pd(PPh3)4 (0.31 g, 0.264 mmol) is added as solid. 
The solution is stirred for 10 minutes and then amounted of Na3PO4*12H2O (3.01 g , 
7.92 mmol) and of a solution of 3-thienylboronic acid (0.41 g, 3.17 mmol) in 5 mL of 
dry DMF. 
The reaction mixture is heated at 100°C for 18 hours, monitored by TLC241 and then 
concentrated.  
The crude is resumed with Ethyl Acetate, washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 80/20, yields 0.84 g (2.19 mmol) of the desired product, as yellow oil.  
 
Yield: 83% 
 
 
1H-NMR (CDCl3): 7.85 (d, 1H, J=9.08 Hz), 7.32 (dd, 1H, J=0.82 Hz, J=4.95 Hz), 7.22 (dd, 1H, 
J=0.82 Hz, J=2.75 Hz), 7.06 (m, 1H), 6.85-6.95 (m, 6H), 4.59 (m, 1H), 4.40 (dd, 1H, J=2.2 Hz, 
J=11.55 Hz), 4.19-4.33 (m, 3H), 3.70 (s, 3H).  
                                                            
241 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf= 0.46 
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4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-
(thiophen-3-yl)benzoic acid 
 
 
 
0.84 g of methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-(thiophen-3-
yl)benzoate (2.19 mmol) is dissolved in 10 mL of Methanol; 5 mL of NaOH 4M are 
dropped and the resulting mixture is stirred RT for 18 hours. 
After completion of the reaction, followed by TLC242, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl and then extracted three times with Ethyl Acetate. 
The organic layers are collected, dried over Na2SO4, filtered and concentrated under 
reduced pressure, giving 0.80 g (2.19 mmol) of a white solid, corresponding to the 4-
((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-(thiophen-3-yl)benzoic acid. 
 
 
Yield: quantitative 
 
Melting point: 187-190°C 
 
 
1H-NMR (d6DMSO): 12.55 (bs, 1H), 7.69 (d, 1H, J=8.45 Hz), 7.50 (m, 2H), 7.11 (m, 1H), 7.00 ( 
m, 2H), 6.80-6.91 (m, 4H), 4.58 (m, 1H), 4.28-4.44 (dd, 3H), 4.14 (dd, 1H, J=6.85 Hz, 
J=11.27 Hz).  
                                                            
242 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.10 
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(2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(thiophen-3-yl)benzamido)-4-
(methylthio)butanoate 
 
 
A solution of EDAC (0.50 g, 2.63 mmol) and DIPEA (0.461 mL, 2.63 mmol) in 3 mL of 
DMF is added dropwise to a solution of 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(thiophen-3-yl)benzoic acid (0.80 g, 2.19 mmol), HOBT (0.36 g, 2.63 
mmol) in 4 mL of DMF, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.42 g, 2.19 mmol) in 3 mL of DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC243, 
the mixture is concentrated, resumed with 20 mL of Ethyl Acetate, washed with brine, 
dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 80/20 as elution solvent, to give 1.02 g (1.88 mmol) of 
the desired product, as a dense milky oil. 
 
Yield: 86% 
 
1H-NMR (CDCl3): 7.68 (d, 1H, J=8.25 Hz), 7.39 (m, 2H), 7.15 (ddd, 1H, J=0.83 Hz, J=1.65 Hz, 
J=4.68 Hz), 6.84-6.97 (m, 6H), 6.04 (d, 1H, J=7.7 Hz), 4.99 (m, 1H), 4.55-4.66 (m, 2H), 4.40 
(dd, 1H, J=2.48 Hz, J=11.55 Hz), 4.18-4.32 (m, 3H), 2.24 (t, 2H, J=7.7 Hz), 2.05 (s, 3H), 1.99 
(m, 1H), 1.82 (m, 1H), 1.24 (d, 3H, J=6.87 Hz), 1.22 (d, 3H, J=6.32 Hz).  
                                                            
243 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf = 0.30 
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(2S)-2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(thiophen-3-yl)benzamido)-4-(methylthio)butanoic acid 
 
 
 
1.02 g of (2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-
(thiophen-3-yl)benzamido)-4-(methylthio)butanoate (1.88 mmol) are dissolved in 10 
mL of Methanol; 1.88 mL of NaOH 1M are dropped and the resulting mixture is stirred 
RT for 18 hours 
After completion of the reaction, followed by TLC244, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl and then extracted three times with 10 mL of Ethyl Acetate. 
The filtration yields 0.94 g of the final product, as a sticky solid, in quantitative yield.  
 
 
Yield: quantitative 
 
 
 
1H-NMR (d6DMSO): 12.50 (bs, 1H), 8.50 (d, 1H, J=7.65 Hz), 7.63 (dd, 1H, J=1.61 Hz, J=3.22 
Hz), 7.49 (dd, 1H, J=3.22 Hz, J=5.23 Hz), 7.33 (d, 1H, J=8.45 Hz), 7.27 (dd, 1H, J=1.61 Hz, 
J=5.23 Hz), 7.08 (m, 1H), 7.00 (dd, 1H, J=2.01 Hz, J=8.45 Hz), 6.82-6.92 (m, 4H), 4.59 (m, 
1H), 4.4 (d, 1H, J=11.67 Hz), 4.31-4.37 (m, 3H), 4.15 (dd, 1H, J=7.25 Hz , J=11.67 Hz), 2.37-
2.43 (m, 2H), 2.00 (s, 3H), 1.86-2.02 (m, 2H).  
                                                            
244 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = basal 
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Methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(furan-2-yl)benzoate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)benzoate (1.00 g, 2.64 mmol) in 5 mL of dry THF, under a nitrogen 
atmosphere, Pd(PPh3)4 (0.31 g, 0.264 mmol) is added as solid. 
The solution is stirred for 10 minutes and then amounted of K2CO3 (1.09 g , 7.92 
mmol) in 1 mL of Water and of a solution of 2-furanylboronic acid (0.35 g, 3.17 mmol) 
in 5 mL of dry THF. 
The reaction mixture is stirred RT for 18 hours, monitored by TLC245 and then 
concentrated.  
The crude is resumed with Ethyl Acetate, washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 80/20, yields 0.92 g (2.51 mmol) of the desired product, as yellow oil.  
 
 
Yield: 95% 
 
1H-NMR (CDCl3): 7.72 (d, 1H, J=8.53 Hz), 7.49 (dd, 1H, J=0.83 Hz, J=1.93 Hz), 7.14 (dd, 1H, 
J=2.75 Hz), 6.85-6.94 (m, 5H), 6.59 (dd, 1H, J=0.83 Hz , J=3.58 Hz), 6.48 (dd, 1H, J=1.93 Hz , 
J=3.58 Hz),4.59 (m, 1H), 4.40 (dd, 1H, J=1.55 Hz, J=2.20 Hz), 4.32 (dd, 1H, J=4.95 Hz , 
J=9.90 Hz), 4.20-4.27 (m, 2H), 3.81 (s, 3H).  
                                                            
245 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf= 0.40 
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4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-(furan-
2-yl)benzoic acid 
 
 
 
0.92 g of methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-(furan-2-
yl)benzoate (2.51 mmol) is dissolved in 10 mL of Methanol; 4.22 mL of NaOH 1M are 
dropped and the resulting mixture is heated at 60°C for 6 hours. 
After completion of the reaction, followed by TLC246, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl and then extracted three times with Ethyl Acetate. 
The organic phases are sequentially collected, dried over Na2SO4, filtered and 
concentrated under pressure, giving the desired product as sticky yellow solid (0.74 g, 
2.10 mmol)  
 
 
Yield: 84% 
 
 
 
1H-NMR (d6DMSO): 7.73 (s, 1H), 7.61 (d, 1H, J=8.52 Hz), 7.18 (d, 1H, J=2.48 Hz), 7.03 (dd, 
1H, J=2.48 Hz, J=8.52 Hz), 6.82-6.92 (m, 5H), 6.77 (dd, 1H, J=0.83 Hz , J=1.38 Hz), 6.56 (dd, 
1H, J=1.38 Hz, J=3.08 Hz), 4.59 (m, 1H), 4.43 (dd, 1H, J=1.55 Hz, J=2.20 Hz), 4.34 (m, 2H), 
4.16 (dd, 1H, J=7.15 Hz, J=11.55 Hz).  
                                                            
246 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf =basal 
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(2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(furan-2-yl)benzamido)-4-
(methylthio)butanoate 
 
 
A solution of EDAC (0.48 g, 2.52 mmol) and DIPEA (0.44 mL, 2.52 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(furan-2-yl)benzoic acid (0.74 g, 2.10 mmol), HOBT (0.34 g, 2.52 mmol) 
in 3 mL of dry DMF, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.40 g, 2.10 mmol) in 3 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC247, 
the mixture is concentrated, resumed with Ethyl Acetate, washed with brine, dried over 
Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 70/30 as elution solvent, to give 0.79 g (1.51 mmol) of 
the desired product, as white dense oil. 
 
Yield: 72% 
 
1H-NMR (CDCl3): 7.48 (m, 2H), 7.18(d, 1H, J=2.48), 6.85-6.94 (m, 5H), 6.67 (dd, 1H, J=0.83 
Hz, J=3.62 Hz), 6.46 (dd, 1H, J=1.65 Hz, J=2.65 Hz), 6.32 (d, 1H, J=7.7 Hz), 5.05 (m, 1H), 
4.80 (ddd, 1H, J=4.95 Hz, J=7.15 Hz, J=7.7 Hz), 4.68 (m, 1H), 4.40 (dd, 1H, J=2.48 Hz, 
J=11.55 Hz), 4.19-4.34 (m, 3H), 2.49 (t, 2H, J=6.68 Hz), 2.19 (m, 1H), 2.09 (s, 3H), 2.03 (m, 
1H), 1.28 (d, 3H, J=6.05 Hz), 1.26 (d, 3H, J=6.05 Hz).  
                                                            
247 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf = 0.22 
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(2S)-2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(furan-2-yl)benzamido)-4-(methylthio)butanoic acid 
 
 
 
0.79 g of (2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-(furan-2-
yl)benzamido)-4-(methylthio)butanoate (1.51 mmol) are dissolved in 10 mL of 
Methanol; 1.27 mL of NaOH 1M are dropped and the resulting mixture is stirred RT for 
18 hours 
After completion of the reaction, followed by TLC248, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl and then extracted three times with 10 mL of Ethyl Acetate. 
The filtration yields 0.73 g (1.51 mmol) of the final product, as a pale pink sticky solid, 
in quantitative yield.  
 
 
Yield: quantitative 
 
 
 
1H-NMR (d6DMSO): 12.68 (bs, 1H), 8.62 (d, 1H, J=7.64 Hz), 7.68 (d, 1H, J=1.21 Hz), 7.27 (m, 
2H), 7.01 (dd, 1H, J=1.61 Hz, J=4.03 Hz), 6.81-6.99 (m, 5H), 6.51 (t, 1H, J=1.61 Hz ), 4.58 
(m, 1H), 4.42 (m, 2H), 4.31 (m, 2H), 4.15 (m, 1H), 2.47-2.54 (m, 2H), 2.04 (s, 3H), 1.95 (m, 
2H).  
                                                            
248 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf (starting compound)= 0.54 
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Methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(furan-3-yl)benzoate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)benzoate (1.00 g, 2.64 mmol) in 6 mL of Toluene, under a nitrogen 
atmosphere, Pd(PPh3)4 (0.31 g, 0.264 mmol) is added as solid. 
The solution is stirred for 10 minutes and then amounted of Na2CO3 (0.84 g , 7.92 
mmol) in 3 mL of Water and of a solution of 3-furanylboronic acid (0.35 g, 3.17 mmol) 
in 1.5 mL of Methanol. 
The reaction mixture is heated at 75°C for 18 hours, monitored by TLC249 and then 
cooled.  
The residue is treated with 20 mL of DCM and 15 mL of NaHCO3, the two layers are 
separated and the organic one washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 80/20, yields 0.69 g (1.87 mmol) of the desired product, as yellow oil.  
 
Yield: 71% 
 
1H-NMR (CDCl3): 7.96 (dd, 1H, J=1.65 Hz, J=9.8 Hz), 7.42 (dd, 1H, J=0.82 Hz , J=9.8 Hz), 6.82-
6.96 (m, 7H), 6.41 (d, 1H, J=0.82 Hz), 4.59 (m, 1H), 4.39 (dd, 1H, J=2.2 Hz, J=9.35 Hz), 4.19-
4.33 (m, 3H), 3.79 (s, 3H).  
                                                            
249 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf= 0.44 
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4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-(furan-
3-yl)benzoic acid 
 
 
 
0.69 g of methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-(furan-3-
yl)benzoate (1.87 mmol) is dissolved in 10 mL of Methanol; 7.48 mL of NaOH 1M are 
dropped and the resulting mixture is heated at 60°C for 18 hours. 
After completion of the reaction, followed by TLC250, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether and 
then acidified with 10% HCl, till a pale yellow solid precipitate. 
The filtration yields 0.73 g (1.96 mmol) of the desired compound.  
 
 
Yield: 85% 
 
Melting Point: 145-149°C 
 
 
 
 
1H-NMR (CDCl3): 8.04 (m, 1H), 7.56 (d, 1H, J=0.83 Hz),7.44 (t, 2H, J=1.65 Hz), 6.85-6.99 (m, 
5H), 6.52 (dd, 1H, J=0.83 Hz, J=1.65 Hz, ), 4.59 (m, 1H), 4.40 (dd, 1H, J=2.2 Hz, J=9.35 Hz), 
4.20-4.38 (m, 3H).  
                                                            
250 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf = 0.19 
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(2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(furan-3-yl)benzamido)-4-
(methylthio)butanoate 
 
 
A solution of EDAC (0.45 g, 2.35 mmol) and DIPEA (0.41 mL, 2.35 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(furan-3-yl)benzoic acid (0.73 g, 1.96 mmol), HOBT (0.31 g, 2.35 mmol) 
in 4 mL of DCM, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.37 g, 1.96 mmol) in 2 mL of DCM is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC251, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 70/30 as elution solvent, to give 0.69 g (1.31 mmol) of 
the desired product, as yellow oil. 
 
Yield: 67% 
 
1H-NMR (CDCl3): 7.79 (d, 1H, J=8.8 Hz ), 7.62 (s, 1H), 7.61 (d, 1H, J=1.1 Hz), 7.47 (t, 1H, 
J=1.65 Hz), 6.85-6.98 (m, 5H), 6.55 (dd, 1H, J=0.83 Hz, J=1.65 Hz), 6.27 (d, 1H, J=7.7 Hz), 
5.02 (m, 1H), 4.71 (dd, 1H, J=2.2 Hz, J=7.15 Hz), 4.58 (dd, 1H, J=1.65 Hz, J=4.95 Hz), 4.40 
(dd, 1H, J=2.47 Hz , J=11.55 Hz ), 4.17-4.32 (m, 2H), 2.39 (t, 2H, J=1.65 Hz), 2.07 (s, 3H), 
2.08 (m, 1H), 1.94 (m, 1H), 1.26 (d, 3H, J=6.33 Hz), 1.24(d, 3H,. J=6.33 Hz).  
                                                            
251 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf = 0.24 
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(2S)-2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(furan-3-yl)benzamido)-4-(methylthio)butanoic acid 
 
 
 
0.69 g of (2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-(furan-3-
yl)benzamido)-4-(methylthio)butanoate (1.31 mmol ) are dissolved in 10 mL of 
Methanol; 1.63 mL of NaOH 1M are dropped and the resulting mixture is stirred RT for 
18 hours 
After completion of the reaction, followed by TLC252, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl and then extracted three times with 10 mL of Ethyl Acetate. 
The filtration yields 0.79 g of the final product, as a sticky white solid, in quantitative 
yield.  
 
 
Yield: quantitative 
 
 
 
 
1H-NMR (d6DMSO): 12.67 (bs, 1H), 8.52 (d, 1H, J=7.65 Hz), 7.94 (s, 1H), 7.87 (d, 1H, J=8.85), 
7.64 (t, 1H, J=1.61 Hz), 7.30 (d, 1H, J=8.45 Hz), 6.78-7.08 (m, 6H), 4.58 (m, 1H), 4.35-4.51 
(m, 4H), 4.14 (m, 1H), 2.52 (m, 2H), 2.04 (s, 3H), 1.94 (m, 2H).  
                                                            
252 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf = basal 
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Methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(naphthalen-1-yl)benzoate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)benzoate (1.00 g, 2.64 mmol) in 5 mL of dry DMF, under a nitrogen 
atmosphere, Pd(PPh3)4 (0.31 g, 0.264 mmol) is added as solid. 
The solution is stirred for 10 minutes and then amounted of Na3PO4*12H2O (3.01 g , 
7.92 mmol) and of a solution of 1-naphtylboronic acid (0.41 g, 3.17 mmol) in 5 mL of 
dry DMF. 
The reaction mixture is heated at 100°C for 18 hours, monitored by TLC253 and then 
concentrated.  
The crude is resumed with Ethyl Acetate, washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 85/15, yields 1.02 g (2.35 mmol) of the desired product, as pale pink oil.  
 
 
Yield: 89% 
 
H-NMR (CDCl3): 8.08 (d, 1H, J=8.53 Hz), 7.87 (dd, 1H, J=7.88 Hz, J=8.52 Hz), 7.29-7.53 (m, 
5H), 7.06 (dd, 1H, J=2.75 Hz, J=8.80 Hz), 6.83-6.93 (m, 5H), 4.58 (m, 1H), 4.40 (dd, 1H, 
J=2.48 Hz, J=11.55 Hz), 4.20-4.30 (m, 3H), 3.37 (s, 3H).  
                                                            
253 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf= 0.45 
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4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-
(naphthalen-1-yl)benzoic acid 
 
 
 
1.02 g of methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-(naphthalen-1-
yl)benzoate (2.35 mmol) is dissolved in 10 mL of Methanol; 9.4 mL of NaOH 1M are 
dropped and the resulting mixture is heated at 60°C for 18 hours. 
After completion of the reaction, followed by TLC254, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl and then extracted three times with Ethyl Acetate.  
The organic layer is dried over Na2SO4, filtered and concentrated under reduced 
pressure, yielding 0.78 g (1.88 mmol) of the desired compound, as sticky solid.  
 
 
Yield: 80% 
 
 
 
 
 
1H-NMR (CDCl3): 8.08 (dd, 1H, J=0.83 Hz , J=8.81 Hz), 7.86 (dd, 1H, J=8.25 Hz, J=9.35 Hz), 
7.40-7.49 (m, 3H), 7.33 (dd, 1H, J=7.15 Hz, J=7.85 Hz), 7.25 (m, 1H), 6.82-6.90 (m, 5H), 4.56 
(m, 1H), 4.37 (dd, 1H, J=1.1 Hz, J=11.52 Hz), 4.09-4.35 (m, 3H).  
                                                            
254 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = 0.23 
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(2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(naphthalen-1-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
A solution of EDAC (0.43 g, 2.26 mmol) and DIPEA (0.39 mL, 2.26 mmol) in 2 mL of 
dry DMF is added dropwise to a solution of 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(naphtalen-1-yl)benzoic acid (0.78 g, 1.88 mmol), HOBT (0.30 g, 2.26 
mmol) in 3 mL of dry DMF, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.36 g, 1.88 mmol) in 3 mL of dry DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC255, 
the mixture is concentrated, resumed with 15 mL of Ethyl Acetate, washed with brine, 
dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 70/30 as elution solvent, to give 1.00 g (1.71 mmol) of 
the desired product, as colourless oil. 
 
Yield: 91% 
 
1H-NMR (CDCl3): 8.05 (d, 1H, J=8.53 Hz), 7.88-7.95 (m, 2H), 7.39-7.63 (m, 5H), 7.09 (m, 1H), 
6.83-6.92 (m, 5H), 5.81 (d, 1H, J=9.7 Hz), 4.85 (m, 1H), 4.58 (m, 1H), 4.19-4.41 (m, 4H), 1.81 
(s, 3H), 1.65 (m, 2H), 1.40 (m, 2H), 1.15 (d, 3H, J=6.33 Hz), 1.13(d, 3H,. J=6.05 Hz). 
                                                            
255 TLC conditions: Cyclohexane/ Ethyl Acetate= 70/30 
Rf = 0.27 
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(2S)-2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(naphthalen-1-yl)benzamido)-4-(methylthio)butanoic 
acid 
 
 
 
1.00 g of (2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-
(naphthalen-1-yl)benzamido)-4-(methylthio)butanoate (1.71 mmol) are dissolved in 10 
mL of Methanol; 3.42 mL of NaOH 1M are dropped and the resulting mixture is stirred 
RT for 3 hours 
After completion of the reaction, followed by TLC256, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with 10% HCl and then extracted three times with 10 mL of Ethyl Acetate. 
The filtration yields 0.93 g of the final product, as a colourless sticky solid, in 
quantitative yield.  
 
 
Yield: quantitative 
 
 
 
1H-NMR (d6DMSO): 12.51 (bs, 1H), 8.20 (d, 1H, J=8. Hz), 7.77-7.94 (m, 2H), 7.57-7.63 (m, 
2H), 7.33-7.50 (m, 4H), 7.14-7.19 (m, 1H), 6.80-6.92 (m, 4H), 4.57 (m, 1H), 4.32-4.43 (m, 
3H), 4.00-4.15 (m, 2H), 2.02 (m, 1H), 1.97 (m, 1H), 1.84 (s, 3H), 1.76 (m, 1H), 1.72 (m, 1H). 
                                                            
256 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = basal 
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Methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(isoquinolin-4-yl)benzoate 
 
 
 
To a sonicated solution of the methyl 2-bromo-4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)benzoate (1.00 g, 2.64 mmol) in 7.5 mL of Toluene/Methanol: 4/1, under 
a nitrogen atmosphere, Pd(PPh3)4 (0.31 g, 0.264 mmol) is added as solid. 
The solution is stirred for 10 minutes and then amounted of Na2CO3 (0.70 g , 6.6 
mmol) in 1.5 mL of Water and of solid 4-isoquinolineboronic acid (0.50 g, 2.90 mmol). 
The reaction mixture is heated at 80°C for 18 hours, monitored by TLC257 and, at 
completion, treated with Ethyl Acetate, washed with brine, dried over Na2SO4, filtered 
and concentrated under reduced pressure. 
Purification by chromatography on silica gel, through elution with Cyclohexane/ Ethyl 
Acetate= 60/40, yields 0.65 g (1.53 mmol) of the desired product, as yellow-red oil.  
 
 
Yield: 58% 
 
 
 
1H-NMR (CDCl3): 9.33 (s, 1H), 8.35 (s, 1H), 8.15 (d, 1H, J=9.08 Hz), 8.11 (m, 1H), 7.72 (m, 
2H), 7.53 (m, 1H), 7.12 (ddd, 1H, J=1.1 Hz, J=2.75 Hz, J=8.80 Hz), 6.83-6.91 (m, 5H), 4.60 
(m, 1H), 4.39 (dd, 1H, J=2.48 Hz, J=11.55 Hz), 4.21-4.36 (m, 3H), 3.44 (s, 3H).  
                                                            
257 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf= 0.24 
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4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-
(isoquinolin-4-yl)benzoic acid 
 
 
 
0.65 g (1.53 mmol) of methyl 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-
(isoquinolin-4-yl)benzoate is dissolved in 5 mL of Methanol; 3 mL of NaOH 2.5 M are 
dropped and the resulting mixture is heated at 60°C for 18 hours. 
After completion of the reaction, followed by TLC258, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether and 
then acidified with Formic acid, till a white solid precipitate. 
The filtration yields 0.38 g (0.92 mmol) of the desired compound.  
 
 
Yield: 60% 
 
Melting point: 235-238°C 
 
 
 
1H-NMR (d6DMSO): 9.24 (s, 1H), 8.26 (s, 1H), 8.12 (dd, 1H, J=4.02 Hz, J=5.32 Hz), 7.96 (d, 
1H, J=8.46 Hz), 7.62 (m, 2H), 7.43 (dd, 1H, J=2.82 Hz , J=8.46 Hz), 7.14 (dd, 1H, J=2.41 Hz, 
J=8.85 Hz), 6.79-6.88 (m, 5H), 4.56 (m, 1H), 4.24-4.42 (m, 3H), 4.08-4.14 (m, 1H), 4.11 (dd, 
1H, J=7.25 Hz, J=11.27 Hz).  
                                                            
258 TLC conditions: Cyclohexane/ Ethyl Acetate= 1/1 
Rf = basal 
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(2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(isoquinolin-4-yl)benzamido)-4-
(methylthio)butanoate 
 
 
 
A solution of EDAC (0.21 g, 1.11 mmol) and DIPEA (0.19 mL, 1.1 mmol) in 2 mL of 
DMF is added dropwise to a solution of 4-((2,3-dihydrobenzo[b][1,4]dioxin-2-
yl)methoxy)-2-(isoquinolin-4-yl)benzoic acid (0.38 g, 0.92 mmol), HOBT (0.15 g, 1.11 
mmol) in 3 mL of DMF, under a nitrogen atmosphere.  
The resulting mixture is stirred for 30 minutes at RT and then a solution of L-
Methionine isopropyl ester (0.18 g, 0.92 mmol) in 3 mL of DMF is dropped. 
The reaction mixture is stirred at RT overnight; after completion, monitored by TLC259, 
the mixture is washed with brine, dried over Na2SO4, filtered and concentrated.  
The crude product is purified by column chromatography on silica gel, using 
Cyclohexane/ Ethyl Acetate= 1/1 as elution solvent, to give 0.41 g (0.70 mmol) of the 
desired product. 
 
Yield: 76% 
 
1H-NMR (CDCl3): 9.32 (s, 1H), 8.50 (s, 1H), 8.07 (m, 1H), 7.89 (d, 1H, J=8.53 Hz), 7.57-7.72 
(m, 3H), 7.09-7.14 (m, 1H), 6.83-6.93 (m, 5H), 6.05 (d, 1H, J=7.43 Hz), 4.87 (m, 1H), 4.59 (m, 
1H), 4.21-4.42 (m, 5H), 2.04 (m, 2H), 1.94 (s, 3H), 1.58 (m, 2H), 1.16 (d, 3H, J=4.4 Hz), 1.14 
(d, 3H,. J=4.4 Hz).  
                                                            
259 TLC conditions: Cyclohexane/ Ethyl Acetate= 30/70 
Rf = 0.46 
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(2S)-2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-
2-(isoquinolin-4-yl)benzamido)-4-(methylthio)butanoic 
acid 
 
 
 
0.41 g of (2S)-isopropyl 2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)-2-( 
isoquinolin-4-yl)benzamido)-4-(methylthio)butanoate (0.70 mmol) are dissolved in 5 
mL of Methanol; 0.41 mL of NaOH 1M are dropped and the resulting mixture is stirred 
RT for 18 hours. 
After completion of the reaction, followed by TLC260, the Methanol is evaporated and 
the residue resumed with water; the aqueous layer is washed with Ethyl Ether, 
acidified with Formic acid till a white precipitate is formed. 
The filtration of the solid yields 0.38 g of the final product, as a white solid, in 
quantitative yield.  
 
Yield: quantitative 
 
Melting point: 117°C 
 
1H-NMR (d6DMSO): 12.57 (bs, 1H), 9.26 (s, 1H), 8.39 (m, 1H), 8.31 (s, 1H), 8.16 (m, 2H), 
7.49-7.67 (m, 4H), 7.21 (dd, 1H, J=2.42 Hz, J=8.46 Hz), 7.00 (dd, 1H, J=1.61 Hz , J=3.63 Hz), 
6.79-6.90 (m, 3H), 4.58 (m, 1H), 4.28-4.16 (m, 3H), 3.97-4.16 (m, 2H), 2.05 (m, 2H), 1.84 (s, 
3H); 1.66 (m, 2H).  
                                                            
260 TLC conditions: Cyclohexane/ Ethyl Acetate= 30/70 
Rf (starting compound)= basal 
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Ti auguro la FATICA 
che farà più grande la gioia che ogni sera proverai 
nel voltarti indietro a guardare il cammino percorso. 
Ti auguro il SOLE 
che scaldi ogni fibra del tuo corpo 
e ogni sospiro della tua anima. 
Ti auguro la PIOGGIA 
che rinfreschi e disseti l'arsura 
delle giornate troppo aride 
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che ti accarezzi con brezza leggera il viso 
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